

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
5 August 2004 (05.08.2004)

PCT

(10) International Publication Number  
**WO 2004/065401 A1**

(51) International Patent Classification<sup>7</sup>: **C07H 15/203**,  
15/26, 15/10, C07C 229/30, 237/16, C12P 19/44, A61K  
31/7032, A61P 31/00

(21) International Application Number:  
PCT/CA2004/000068

(22) International Filing Date: 21 January 2004 (21.01.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/441,123 21 January 2003 (21.01.2003) US  
60/469,810 13 May 2003 (13.05.2003) US  
60/491,516 1 August 2003 (01.08.2003) US  
60/494,568 13 August 2003 (13.08.2003) US

(71) Applicant (for all designated States except US): **ECOPIA BIOSCIENCES INC.** [CA/CA]; 7290 Frederick-Banting, Saint-Laurent, Québec H4S 2A1 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BACHMANN, Brian, O.** [US/US]; 2905 Snowden Rd., Nashville, TN 37204 (US). **MCALPINE, James, B.** [US/CA]; 40 Upper Trafalgar Place, Montreal, Québec H3H 1T3 (CA). **ZAZOPOULOS, Emmanuel** [CA/CA]; 455 Saint-Pierre, apt. 410, Montreal, Québec H2Y 2M8 (CA). **FARNET, Chris, M.** [US/CA]; 772 Bloomfield, Outremont, Québec H2V 3S3 (CA).

(74) Agent: **LOOPER, Ywe, J.**; 7290 Frederick-Banting, Saint-Laurent, Québec H4S 2A1 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to the identity of the inventor (Rule 4.17(i)) for all designations
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: POLYENE POLYKETIDES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS A PHARMACEUTICAL

(57) Abstract: This invention relates to a new class of polyene polyketides, their pharmaceutically acceptable salts and derivatives, and to methods for obtaining the compounds. One method of obtaining these compounds is by cultivation of novel strains of *Streptomyces aizunensis*; another method involves expression of biosynthetic pathway genes in transformed host cells. The present invention further relates to the novel strains of *Streptomyces aizunensis* used to produce these compounds, to the use of these compounds and their pharmaceutically acceptable salts and derivatives as pharmaceuticals, in particular to their use as inhibitors of fungal cell growth and cancer cell growth. The invention also relates to pharmaceutical compositions comprising these novel polyketides or a pharmaceutically acceptable salts or derivatives thereof. Finally, the invention relates to novel polynucleotide sequences and their encoded proteins, which are involved in the biosynthesis of these novel polyketides.



A1

WO 2004/065401

**TITLE OF INVENTION:** POLYENE POLYKETIDES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS A PHARMACEUTICAL

**RELATED APPLICATIONS:**

This application claims priority to U.S. Provisional Application 60/441,123 filed January 21, 2003; U.S. Provisional Application 60/494,568 filed August 13, 2003; U.S. Provisional Application 60/469,810 filed May 13, 2003; and U.S. Provisional 60/491,516 filed August 1, 2003.

**FIELD OF INVENTION:**

This invention relates to a new class of polyene polyketides, their pharmaceutically acceptable salts and derivatives, and to methods for their production. One method of obtaining these novel polyketides is by cultivation of novel strains of *Streptomyces aizunensis*; another method involves expression of the biosynthetic gene cluster of the invention in transformed host cells. The compounds may also be produced by known strains of certain bacteria. The invention also encompasses the novel strains of *Streptomyces aizunensis* which produce these compounds, as well as the gene cluster which directs the biosynthesis of these compounds. The invention also includes the use of these novel polyketides and their pharmaceutically acceptable salts and derivatives as pharmaceuticals, in particular, to their use as inhibitors of fungal and bacterial cell growth, inhibitors of cancer cell growth and for lowering serum cholesterol and other steroids. The invention also encompasses pharmaceutical compositions comprising these novel polyketides, or pharmaceutically acceptable salts or derivatives thereof.

**BACKGROUND:**

Actinomycetes comprise a family of bacteria that are abundant in soil and have generated significant commercial and scientific interest as a result of the large number of therapeutically useful antibiotics, antifungals, anticancer and cholesterol-lowering agents, produced as secondary metabolites by these bacteria. Many actinomycetes, particularly those of the *Streptomyces* genus,

have been extensively studied because of their ability to produce a notable diversity of biologically active metabolites. The intensive search for new natural products has led to the identification of new species of bacteria and the creation of improved strains.

Polyene polyketides are a group of natural products produced by actinomycetes that have generated significant commercial interest. For example Sakuda *et al.*, 1996 *J. of Chem. Soc., Perkin trans. 1*, 2315-19; and Sakuda *et al.*, *Tetrahedron Letters*, Vol 35, No. 16, 2777-2789 (1995) disclose the linear polyene linearmycin A produced by a *Streptomyces* sp. Sakuda *et al.* report that linearmycin A has shown both antifungal and antibacterial activity. Pawlak *et al.* *J of Antibiotics*, Vol. XXXIII No. 9, 989-997 disclose the polyene macrolide lienomycin produced by *Actinomyces diastatochromogenes*. Pawlak *et al.* report that lienomycin has shown antifungal, antibacterial and anti-tumor activity. Antifungal activity of polyene macrolides has also been correlated with hyperchlesterolemic effect (C.P. Schaffner, Polyene Microlides in Clinical Practice, in *Macrolide Antibiotics: Chemistry, biology and practice*, S. Omura, ed. Academic Press (1984), p. 491; C.P. Schaffner and H.W. Gordon, *Proc Natl. Acad. Sci. U.S.A.* **61**, 36 (1968)).

Polyketides have carbon chain backbones formed of two-carbon units through a series of condensations reactions and subsequent modifications. Type I polyketides are synthesized in nature by modular polyketide synthase (PKS) enzymes having a set of separate catalytic active sites for each cycle of carbon chain elongation and modification. Because of the multimodular nature of PKS proteins, much is known of the specificity and mechanism of the biosynthesis of polyketides.


Although many biologically active compounds have been identified, there remains the need to obtain novel naturally occurring compounds with enhanced properties. Current methods of obtaining such compounds include screening of natural isolates and chemical modification of existing compounds, both of which are costly and time consuming. Current screening methods are based on general biological properties of the compound, which require prior knowledge of the structure of the molecules. Methods for

chemically modifying known active compounds exist, but still suffer from practical limitations as to the type of compounds obtainable.

Thus, there exists a considerable need to obtain pharmaceutically active compounds in a cost-effective manner and with high yield. The present invention solves these problems by providing improved strains of *Streptomyces aizunensis* capable of producing potent new therapeutic compounds, as well as reagents (e.g. polynucleotides, vectors comprising the polynucleotides and host cells comprising the vectors) and methods to generate novel compounds by de novo biosynthesis rather than by chemical synthesis.

### SUMMARY OF THE INVENTION:

The present invention encompasses compounds of Formula I:




Formula I

and pharmaceutically acceptable salts thereof;


wherein,

A is selected from the group consisting of -NR<sup>1</sup>R<sup>2</sup>, -N=CR<sup>1</sup>R<sup>2</sup>,






$R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  are each independently selected from the group consisting of H,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{3-6}$  cycloalkyl,  $C_{2-6}$  heterocycloalkyl, aryl, heteroaryl and amino acid, wherein said alkyl, alkenyl, aryl and heteroaryl are optionally substituted with a group selected from halogen, OH,  $NO_2$ ,  $NH_2$  or aryl, said aryl being optionally further substituted with one or more groups independently selected from halogen, OH,  $NO_2$  or  $NH_2$ ;




wherein  $R^{10}$  is oxo or  $OR^{11}$ ;

wherein  $R^{11}$  is H or a heterocycloalkyl, the heterocycloalkyl being optionally substituted with 1-4 substituents selected from OX,  $C_{1-3}$  alkyl and  $-O-C(O)R^1$ , wherein X is H or, when there are at least two neighboring substituent groups that are OX, then the X can be a bond such that the two neighboring oxygen groups form a five-membered acetal ring of the formula:



independently selected from the group consisting of H,  $C_{1-6}$  alkyl, and  $C_{2-7}$  alkenyl;

D is selected from







,  $-NR^{12a}R^{12a}$ , and  $OR^{12}$ ,


wherein

$R^{12}$  is selected from H and  $C_{1-6}$  alkyl optionally substituted with 1 to 2 phenyl groups, wherein the phenyl group is optionally substituted with  $C_{1-6}$  alkyl or halo;

$R^{12a}$  and  $R^{12a}$  are each independently selected from H,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{3-6}$  cycloalkyl,  $C_{2-6}$  heterocycloalkyl, aryl, heteroaryl and amino acid, wherein said alkyl, alkenyl, aryl and heteroaryl are optionally substituted with a group selected from halogen, OH,  $NO_2$ ,  $NH_2$  or aryl, said aryl being optionally further substituted with one or more groups independently selected from halogen, OH,  $NO_2$  or  $NH_2$ ;





$X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$ ,  $X^5$ ,  $X^6$ ,  $X^7$ ,  $X^8$ ,  $X^9$ ,  $X^{12}$  and  $X^{13}$  are each independently selected from H,  $-C(O)-R^7$  and a bond such that when any of two neighboring  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$ ,  $X^5$ ,  $X^6$ ,  $X^7$ ,  $X^8$ ,  $X^9$ ,  $X^{12}$  and  $X^{13}$  is a bond then the two neighboring oxygen atoms and their attached carbon atoms together form a six-membered acetal ring of the formula:




$R^5$ ,  $R^6$  and  $R^7$  are each independently selected from H,  $C_{1-6}$  alkyl,  $C_{2-7}$  alkenyl;

$Y^1, Y^2, Y^3, Y^4, Y^5, Y^6, Y^7, Y^9, Y^{10}, Y^{11}, Y^{12}, Y^{13}$  and  $Y^{15}$  are each independently selected from the group consisting of ethene-1,2-diyl,

ethane-1,2-diyl and ; wherein said ethene-1,2-diyl and ethane-1,2-diyl groups are optionally substituted with a methyl group;




Z is selected from OH,  $NHR^8$ ,  and when the dotted line is a bond then Z is oxo, or  $NR^9$ ;

$R^8$  is selected from H,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl;

$R^9$  is  $C_{1-6}$  alkyl optionally substituted with aryl.

The invention is also directed to the Compound 2(a), a linear glycosylated polyketide with an amidohydroxycyclopentenone component, and pharmaceutically acceptable salts thereof:



#### Compound 2(a)

The systematic name for Compound 2(a) has been determined to be: 56-Amino-15,17,33,35,37,41,43,45,47,51,53-undecahydroxy-14,16,30-trimethyl-31-oxo-29-(3,4,5-trihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-hexapentaconta-2,4,6,8,12,18,20,22,24,26,38,48-dodecaenoic acid (2-hydroxy-5-oxo-cyclopent-1-enyl)-amide.

The invention encompasses pharmaceutical compositions of compounds of Formula I comprising, a therapeutically effective amount of the

compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In particular, the invention is directed to pharmaceutical compositions of compound 2(a) comprising, a therapeutically effective amount of the compound 2(a) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

The present invention is also directed to methods for producing the compound 2(a) and related compounds, including compounds of Formula I and Formula II as defined herein. Such methods comprise the steps of cultivating cells derived from a *Streptomyces aizunensis* strain, incubating said cultured cells aerobically in a growth medium for such time as is required for production of the desired compound, extracting said medium with a solvent such as methanol or ethanol and purifying the compound from the crude extract. The *Streptomyces aizunensis* strain which may be used in the methods of the invention may be NRRL B-11277 or a mutant thereof. A preferred strain of *Streptomyces aizunensis* useful in the methods of the invention is a mutant strain identified as [C03]023 (deposit accession number IDAC 070803-1); a most preferred strain of *Streptomyces aizunensis* useful in the methods of the invention is a mutant strain identified as [C03U03]023 (deposit accession number IDAC 231203-02). The invention also encompasses the *Streptomyces aizunensis* strains identified by deposit accession numbers IDAC 070803-1 and IDAC 231203-02.

The invention also includes methods of inhibiting fungal cell growth, which comprise contacting a fungal cell with a compound of Formula I, a compound of Formula II or compound 2(a), or a pharmaceutically acceptable salt thereof. In addition, the invention encompasses methods for treating a fungal infection in a mammal, which comprise administering to a mammal suffering from such an infection, a therapeutically effective amount of a compound of Formula I, a compound of Formula II or compound 2(a), or a pharmaceutically acceptable salt thereof. The methods of the invention are particularly useful for treating fungal infections or inhibiting the growth of fungal cells in mammals caused by *Candida albicans*. The invention also encompasses methods for treating or inhibiting other types of fungal infections in a subject, wherein said fungal infections include those caused by *Candida*

*sp.* such as *C. glabrata*, *C. lusitaniae*, *C. parapsilosis*, *C. krusei*, *C. tropicalis*, *S. cerevisiae*; *Aspergillus sp.* such as *A. fumigatus*, *A. niger*, *A. terreus*, *A. flavus*; *Fusarium spp.*; *Scedosporium spp.*; *Cryptococcus spp.*; *Mucor spp.*; *Histoplasma spp.*; *Trichosporon spp.*; and *Blaspomyces spp.* Such methods comprise administering to a subject suffering from the fungal infection, a therapeutically effective amount of a compound of Formula I, Formula II or compound 2(a), or a pharmaceutically acceptable salt thereof.

The invention also provides methods of inhibiting cancer cell growth, which comprise contacting said cancer cell with a compound of Formula I, Formula II or compound 2(a), or a pharmaceutically acceptable salt thereof. The invention further encompasses methods for treating cancer in a subject, comprising administering to said subject suffering from said cancer, a therapeutically effective amount of a compound of Formula I, Formula II or compound 2(a) or a pharmaceutically acceptable salt thereof. Examples of cancers that may be treated or inhibited according to the methods of the invention include leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer and breast cancer.

The present invention also provides the biosynthetic locus from *Streptomyces aizunensis* (NRRL B-11277) which biosynthetic locus is responsible for producing the compound of Formula 2(a). *Streptomyces aizunensis* was not previously reported to produce Compound 2(a). We have now discovered, in the *Streptomyces aizunensis* genome, the gene cluster responsible for the production of the Compound 2(a). Thus the invention provides polynucleotides and polypeptides useful in the production and engineering of compounds of Formula I and Compound 2(a). The invention also provides chemical modifications of compounds of Formula I and Compound 2(a).

In one aspect, the invention relates to the biosynthetic locus for production of a polyketide of Formula I and provides, in one embodiment, an isolated, purified or enriched nucleic acid for production of a polyketide of Formula I comprising a nucleic acid encoding at least one domain of the

polyketide synthase system formed by the polyketide synthases of SEQ ID NOS: 21, 23, 25, 27, 29, 31, 33, 35 and 37.

In a further embodiment, the nucleic acid encodes one or more domains of the polyketide synthase of SEQ ID NO: 21 and comprises a nucleic acid selected from the group consisting of: a) SEQ ID NO: 22; b) the nucleic acid of residues 169-354 of SEQ ID NO: 22, the nucleic acid of residues 421-1698 of SEQ ID NO: 22, the nucleic acid of residues 1789-3093 of SEQ ID NO: 22, the nucleic acid of residues 3910-4551 of SEQ ID NO: 22, the nucleic acid of residues 4807-4992 of SEQ ID NO: 22, the nucleic acid of residues 5068-6354 of SEQ ID NO: 22, the nucleic acid of residues 6403-7686 of SEQ ID NO: 22, the nucleic acid of residues 8497-9135 of SEQ ID NO: 22, the nucleic acid of residues 9388-9573 of SEQ ID NO: 22, the nucleic acid of residues 9643-10920 of SEQ ID NO: 22, the nucleic acid of residues 10978-12267 of SEQ ID NO: 22, the nucleic acid of residues 12304-12624 of SEQ ID NO: 22, the nucleic acid of residues 13834-14487 of SEQ ID NO: 22, the nucleic acid of residues 14731-14916 of SEQ ID NO: 22, the nucleic acid of residues 15019-16314 of SEQ ID NO: 22, the nucleic acid of residues 16378-17649 of SEQ ID NO: 22, the nucleic acid of residues 18439-19080 of SEQ ID NO: 22, the nucleic acid of residues 19330-19515 of SEQ ID NO: 22, the nucleic acid of residues 19585-20862 of SEQ ID NO: 22, the nucleic acid of residues 20935-22206 of SEQ ID NO: 22, the nucleic acid of residues 23107-23754 of SEQ ID NO: 22, the nucleic acid of residues 24004-24189 of SEQ ID NO: 22; c) a nucleic acid having at least 80% identity to a nucleic acid of a) or b); and d) a nucleic acid complementary to a nucleic acid of a), b) or c).

In another embodiment the nucleic acid encodes one or more domains of the polyketide synthase of SEQ ID NO: 23 and comprises a nucleic acid selected from the group consisting of: a) SEQ ID NO: 24; b) the nucleic acid of residues 109-1386 of SEQ ID NO: 24, the nucleic acid of residues 1477-2757 of SEQ ID NO: 24, the nucleic acid of residues 2794-3114 of SEQ ID NO: 24, the nucleic acid of residues 4231-4881 of SEQ ID NO: 24, the nucleic acid of residues 5116-5301 of SEQ ID NO: 24, the nucleic acid of residues 5380-6645 of SEQ ID NO: 24, the nucleic acid of residues 6694-7977 of SEQ ID

NO: 24, the nucleic acid of residues 8878-9519 of SEQ ID NO: 24, the nucleic acid of residues 9772-9957 of SEQ ID NO: 24; c) a nucleic acid having at least 80% identity to a nucleic acid of a) or b); and d) a nucleic acid complementary to a nucleic acid of a), b) or c).

In another embodiment the nucleic acid encodes one or more domains of the polyketide synthase of SEQ ID NO: 25 and comprises a nucleic acid selected from the group consisting of: a) SEQ ID NO: 26; b) the nucleic acid of residues 106-1383 of SEQ ID NO: 26, the nucleic acid of residues 1447-2721 of SEQ ID NO: 26, the nucleic acid of residues 2755-3081 of SEQ ID NO: 26, the nucleic acid of residues 4315-4965 of SEQ ID NO: 26, the nucleic acid of residues 5206-5391 of SEQ ID NO: 26, the nucleic acid of residues 5491-6768 of SEQ ID NO: 26, the nucleic acid of residues 6841-8142 of SEQ ID NO: 26, the nucleic acid of residues 8941-9582 of SEQ ID NO: 26, the nucleic acid of residues 9832-10017 of SEQ ID NO: 26, the nucleic acid of residues 10081-11358 of SEQ ID NO: 26, the nucleic acid of residues 11407-12675 of SEQ ID NO: 26, the nucleic acid of residues 13480-14118 of SEQ ID NO: 26, the nucleic acid of residues 14383-14568 of SEQ ID NO: 26, the nucleic acid of residues 14638-15912 of SEQ ID NO: 26, the nucleic acid of residues 15967-17244 of SEQ ID NO: 26, the nucleic acid of residues 17278-17598 of SEQ ID NO: 26, the nucleic acid of residues 18880-19530 of SEQ ID NO: 26, the nucleic acid of residues 19795-19980 of SEQ ID NO: 26; c) a nucleic acid having at least 80% identity to a nucleic acid of a) or b); and d) a nucleic acid complementary to a nucleic acid of a), b) or c).

In another embodiment the nucleic acid encodes one or more domains of the polyketide synthase of SEQ ID NO: 27 and comprises a nucleic acid selected from the group consisting of: a) SEQ ID NO: 28; b) the nucleic acid of residues 103-1380 of SEQ ID NO: 28, the nucleic acid of residues 1450-2760 of SEQ ID NO: 28, the nucleic acid of residues 3583-4218 of SEQ ID NO: 28, the nucleic acid of residues 4468-4653 of SEQ ID NO: 28; c) a nucleic acid having at least 80% identity to a nucleic acid of a) or b); and d) a nucleic acid complementary to a nucleic acid of a), b) or c).

In another embodiment the nucleic acid encodes one or more domains of the polyketide synthase of SEQ ID NO: 29 and comprises a nucleic acid

selected from the group consisting of: a) SEQ ID NO: 30; b) the nucleic acid of residues 103-1380 of SEQ ID NO: 30, the nucleic acid of residues 1459-2754 of SEQ ID NO: 30, the nucleic acid of residues 3655-4293 of SEQ ID NO: 30, the nucleic acid of residues 4540-4725 of SEQ ID NO: 30, the nucleic acid of residues 4804-6081 of SEQ ID NO: 30, the nucleic acid of residues 6136-7419 of SEQ ID NO: 30, the nucleic acid of residues 7456-7776 of SEQ ID NO: 30, the nucleic acid of residues 8938-9588 of SEQ ID NO: 30, the nucleic acid of residues 9832-10017 of SEQ ID NO: 30, the nucleic acid of residues 10087-11364 of SEQ ID NO: 30, the nucleic acid of residues 11428-12711 of SEQ ID NO: 30, the nucleic acid of residues 12745-13065 of SEQ ID NO: 30, the nucleic acid of residues 14278-14928 of SEQ ID NO: 30, the nucleic acid of residues 15187-15372 of SEQ ID NO: 30; c) a nucleic acid having at least 80% identity to a nucleic acid of a) or b); and d) a nucleic acid complementary to a nucleic acid of a), b) or c).

In another embodiment the nucleic acid encodes one or more domains of the polyketide synthase of SEQ ID NO: 31 and comprises a nucleic acid selected from the group consisting of: a) SEQ ID NO: 32; b) the nucleic acid of residues 103-1380 of SEQ ID NO: 32, the nucleic acid of residues 1438-2742 of SEQ ID NO: 32, the nucleic acid of residues 2776-3096 of SEQ ID NO: 32, the nucleic acid of residues 4267-4917 of SEQ ID NO: 32, the nucleic acid of residues 5209-5394 of SEQ ID NO: 32, the nucleic acid of residues 5464-6741 of SEQ ID NO: 32, the nucleic acid of residues 6787-8070 of SEQ ID NO: 32, the nucleic acid of residues 8107-8427 of SEQ ID NO: 32, the nucleic acid of residues 9562-10212 of SEQ ID NO: 32, the nucleic acid of residues 10447-10632 of SEQ ID NO: 32, the nucleic acid of residues 10702-11979 of SEQ ID NO: 32, the nucleic acid of residues 12049-13326 of SEQ ID NO: 32, the nucleic acid of residues 13366-13686 of SEQ ID NO: 32, the nucleic acid of residues 14932-15582 of SEQ ID NO: 32, the nucleic acid of residues 15853-16038 of SEQ ID NO: 32; c) a nucleic acid having at least 80% identity to a nucleic acid of a) or b); and d) a nucleic acid complementary to a nucleic acid of a), b) or c).

In another embodiment the nucleic acid encodes one or more domains of the polyketide synthase of SEQ ID NO: 33 and comprises a nucleic acid



selected from the group consisting of: a) SEQ ID NO: 34; b) the nucleic acid of residues 103-1380 of SEQ ID NO: 34, the nucleic acid of residues 1441-2751 of SEQ ID NO: 34, the nucleic acid of residues 3613-4248 of SEQ ID NO: 34, the nucleic acid of residues 4498-4683 of SEQ ID NO: 34, the nucleic acid of residues 4753-6030 of SEQ ID NO: 34, the nucleic acid of residues 6199-7515 of SEQ ID NO: 34, the nucleic acid of residues 8356-8994 of SEQ ID NO: 34, the nucleic acid of residues 9247-9432 of SEQ ID NO: 34; c) a nucleic acid having at least 80% identity to a nucleic acid of a) or b); and d) a nucleic acid complementary to a nucleic acid of a), b) or c).

In another embodiment the nucleic acid encodes one or more domains of the polyketide synthase of SEQ ID NO: 35 and comprises a nucleic acid selected from the group consisting of: a) SEQ ID NO: 36; b) the nucleic acid of residues 118-1395 of SEQ ID NO: 36, the nucleic acid of residues 1507-2823 of SEQ ID NO: 36, the nucleic acid of residues 2860-3180 of SEQ ID NO: 36, the nucleic acid of residues 4366-5016 of SEQ ID NO: 36, the nucleic acid of residues 5251-5436 of SEQ ID NO: 36, the nucleic acid of residues 5503-6780 of SEQ ID NO: 36, the nucleic acid of residues 6841-8154 of SEQ ID NO: 36, the nucleic acid of residues 8191-8511 of SEQ ID NO: 36, the nucleic acid of residues 9562-10638 of SEQ ID NO: 36, the nucleic acid of residues 10651-11301 of SEQ ID NO: 36, the nucleic acid of residues 11536-11721 of SEQ ID NO: 36, the nucleic acid of residues 11794-13071 of SEQ ID NO: 36, the nucleic acid of residues 13117-14409 of SEQ ID NO: 36, the nucleic acid of residues 14443-14763 of SEQ ID NO: 36, the nucleic acid of residues 15898-16548 of SEQ ID NO: 36, the nucleic acid of residues 16789-16974 of SEQ ID NO: 36, the nucleic acid of residues 17056-18333 of SEQ ID NO: 36, the nucleic acid of residues 18391-19671 of SEQ ID NO: 36, the nucleic acid of residues 19714-20034 of SEQ ID NO: 36, the nucleic acid of residues 21184-21834 of SEQ ID NO: 36, the nucleic acid of residues 22087-22272 of SEQ ID NO: 36; c) a nucleic acid having at least 80% identity to a nucleic acid of a) or b); and d) a nucleic acid complementary to a nucleic acid of a), b) or c).

In another embodiment the nucleic acid encodes one or more domains of the polyketide synthase of SEQ ID NO: 37 and comprises a nucleic acid

selected from the group consisting of: a) SEQ ID NO: 38; b) the nucleic acid of residues 100-1377 of SEQ ID NO: 38, the nucleic acid of residues 1504-2778 of SEQ ID NO: 38, the nucleic acid of residues 2812-3132 of SEQ ID NO: 38, the nucleic acid of residues 4258-4908 of SEQ ID NO: 38, the nucleic acid of residues 5143-5328 of SEQ ID NO: 38, the nucleic acid of residues 5395-6672 of SEQ ID NO: 38, the nucleic acid of residues 6739-8019 of SEQ ID NO: 38, the nucleic acid of residues 8056-8376 of SEQ ID NO: 38, the nucleic acid of residues 9607-10257 of SEQ ID NO: 38, the nucleic acid of residues 10537-10722 of SEQ ID NO: 38, the nucleic acid of residues 10945-11616 of SEQ ID NO: 38; c) a nucleic acid having at least 80% identical to a nucleic acid of a) or b); and d) a nucleic acid complementary to a nucleic acid of a), b) or c).

The invention also provides nucleic acids involved in the biosynthesis of a polyketide of Formula I other than those encoding a domain of the polyketide synthase system. In this embodiment, the invention provides an isolated, purified or enriched nucleic acid selected from the group consisting of: a) a nucleic acid of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 20, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76 and 78; b) a nucleic acid encoding a polypeptide of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 71, 73, 75 and 77; c) a nucleic acid having at least 75% identity to a nucleic acid of (a) or (b); and d) a nucleic acid complementary to a nucleic acid of (a), (b) or (c).

The invention further provides a nucleic acid that is hybridizable under stringent conditions to any one of the above nucleic acids and is substitutable for the nucleic acid to which it specifically hybridizes to direct the synthesis of a compound of Formula I. The invention further provides an isolated, purified or enriched nucleic acid comprising the sequence of at least two, preferably three, more preferably five, still more preferably 7 or more of the above nucleic acids.

The invention further provides an expression vector comprising any of the above nucleic acids. The invention further provides a host cell transformed with such an expression vector.

In a further aspect, the invention provides a gene cluster for production of a polyketide of Formula I. In one embodiment, the gene cluster may comprise at least ten, preferably twelve, more preferably fifteen, still more preferably twenty or more of the above nucleic acids. In a further embodiment, the gene cluster may include the nucleic acids of a cosmid selected from the cosmids deposited under IDAC accession nos. 250203-01, 250203-02, 250203-03, 250203-04, and 250203-05. In a further embodiment, the deposited cosmids are inserted into a prokaryotic host for expressing a product. The host may be *E. coli*, *Streptomyces lividans*, *Streptomyces griseofuscus*, *Streptomyces ambofaciens*, another species of *Actinomycetes*, or bacteria of the genus *Bacillus*, *Corynebacteria*, or *Thermoactinomyces*. In a further embodiment, the invention provides a nucleic acid which hybridizes under stringent hybridization conditions to the nucleic acids of the deposited cosmids and which encodes at least one protein involved in the biosynthesis of a polyene polyketide. In a further embodiment, the invention provides the isolated gene cluster from *Streptomyces aizunensis* encoding the biosynthetic pathway for the formation of compound 2(a), wherein said isolated gene cluster is the gene cluster formed by the deposited cosmids.

In another aspect, the invention relates to an isolated polypeptide for production of a polyketide of Formula I, and provides, in one embodiment, an amino acid sequence of a polyketide synthase domain of SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35 and SEQ ID NO: 37. The domain may be a  $\beta$ -ketoacyl synthase (KS) domain, an acyl carrier protein (ACP) domain, an acyl transferase (AT) domain, a ketoreductase (KR) domain, an enoyl reductase (ER) domain, a thioesterase (TE) domain or a dehydratase (DH) domain. In one embodiment, the domain is a KS domain and the amino acid comprises a sequence selected from the group consisting of the amino acid of residues 141 to 566 of SEQ ID NO: 21, residues 1690 to 2118 of SEQ ID NO: 21, residues 3215 to 3640 of SEQ ID NO: 21, residues 5007 to 5438 of SEQ ID NO: 21, residues 6529 to 6954 of SEQ ID NO: 21, residues 37 to 462 of SEQ ID NO: 23, residues 1794 to 2215 of SEQ ID NO: 23, residues 36 to 461 of SEQ ID NO: 25, residues 1831 to 2256 of SEQ ID NO: 25, residues

3361 to 3786 of SEQ ID NO: 25, residues 4880 to 5304 of SEQ ID NO: 25, residues 35 to 460 of SEQ ID NO: 27, residues 35 to 460 of SEQ ID NO: 29, residues 1602 to 2027 of SEQ ID NO: 29, residues 3363 to 3788 of SEQ ID NO: 29, residues 35 to 460 of SEQ ID NO: 31, residues 1822 to 2247 of SEQ ID NO: 31, residues 3568 to 3993 of SEQ ID NO: 31, residues 35 to 460 of SEQ ID NO: 33, residues 1585 to 2010 of SEQ ID NO: 33, residues 40 to 465 of SEQ ID NO: 35, residues 1835 to 2260 of SEQ ID NO: 35, residues 3932 to 4357 of SEQ ID NO: 35, residues 5686 to 6111 of SEQ ID NO: 35, residues 34 to 459 of SEQ ID NO: 37, residues 1799 to 2224 of SEQ ID NO: 37; and amino acid sequence having at least 75% identity to any one of the above amino acid residues.

In another embodiment, the domain is an ACP domain and the amino acid comprises a sequence selected from the group consisting of the amino acid of: residues 57 to 118 of SEQ ID NO: 21, residues 1603 to 1664 of SEQ ID NO: 21, residues 3130 to 3191 of SEQ ID NO: 21, residues 4911 to 4972 of SEQ ID NO: 21, residues 6444 to 6505 of SEQ ID NO: 21, residues 8002 to 8063 of SEQ ID NO: 21, residues 1706 to 1767 of SEQ ID NO: 23, residues 3258 to 3319 of SEQ ID NO: 23, residues 1736 to 1797 of SEQ ID NO: 25, residues 3278 to 3339 of SEQ ID NO: 25, residues 4795 to 4856 of SEQ ID NO: 25, residues 6599 to 6660 of SEQ ID NO: 25, residues 1490 to 1551 of SEQ ID NO: 27, residues 1514 to 1575 of SEQ ID NO: 29, residues 3278 to 3339 of SEQ ID NO: 29, residues 5060 to 5124 of SEQ ID NO: 29, residues 1737 to 1798 of SEQ ID NO: 31, residues 3483 to 3544 of SEQ ID NO: 31, residues 5285 to 5346 of SEQ ID NO: 31, residues 1500 to 1561 of SEQ ID NO: 33, residues 3083 to 3144 of SEQ ID NO: 33, residues 1751 to 1812 of SEQ ID NO: 35, residues 3846 to 3907 of SEQ ID NO: 35, residues 5597 to 5658 of SEQ ID NO: 35, residues 7363 to 7424 of SEQ ID NO: 35, residues 1715 to 1776 of SEQ ID NO: 37, residues 3513 to 3574 of SEQ ID NO: 37, and an amino acid sequence having at least 75% identity to any one of the above amino acid residues.

In another embodiment, the domain is a AT domain and the amino acid comprises a sequence selected from the group consisting of the amino acid of: residues 597 to 1013 of SEQ ID NO: 21, residues 2135 to 2562 of SEQ ID

NO: 21, residues 3660 to 4089 of SEQ ID NO: 21, residues 5460 to 5883 of SEQ ID NO: 21, residues 6979 to 7402 of SEQ ID NO: 21, residues 493 to 919 of SEQ ID NO: 23, residues 2232 to 2659 of SEQ ID NO: 23, residues 483 to 907 of SEQ ID NO: 25, residues 2281 to 2714 of SEQ ID NO: 25, residues 3803 to 4225 of SEQ ID NO: 25, residues 5323 to 5748 of SEQ ID NO: 25, residues 484 to 920 of SEQ ID NO: 27, residues 487 to 918 of SEQ ID NO: 29, residues 2046 to 2473 of SEQ ID NO: 29, residues 3810 to 4237 of SEQ ID NO: 29, residues 480 to 914 of SEQ ID NO: 31, residues 2263 to 2690 of SEQ ID NO: 31, residues 4017 to 4442 of SEQ ID NO: 31, residues 481 to 917 of SEQ ID NO: 33, residues 2067 to 2505 of SEQ ID NO: 33, residues 503 to 941 of SEQ ID NO: 35, residues 2281 to 2718 of SEQ ID NO: 35, residues 4373 to 4803 of SEQ ID NO: 35, residues 6131 to 6557 of SEQ ID NO: 35, residues 502 to 926 of SEQ ID NO: 37, residues 2247 to 2673 of SEQ ID NO: 37; and an amino acid sequence having at least 75% identity to any one of the above amino acid residues.

In another embodiment, the domain is a KR domain and the amino acid comprises a sequence selected from the group consisting of the amino acid of: residues 1304 to 1517 of SEQ ID NO: 21, residues 2833 to 3045 of SEQ ID NO: 21, residues 4612 to 4829 of SEQ ID NO: 21, residues 6147 to 6360 of SEQ ID NO: 21, residues 7703 to 7918 of SEQ ID NO: 21, residues 1411 to 1627 of SEQ ID NO: 23, residues 2960 to 3173 of SEQ ID NO: 23, residues 1439 to 1655 of SEQ ID NO: 25, residues 2981 to 3194 of SEQ ID NO: 25, residues 4494 to 4706 of SEQ ID NO: 25, residues 6294 to 6510 of SEQ ID NO: 25, residues 1195 to 1406 of SEQ ID NO: 27, residues 1219 to 1431 of SEQ ID NO: 29, residues 2980 to 3196 of SEQ ID NO: 29, residues 4760 to 4976 of SEQ ID NO: 29, residues 1423 to 1639 of SEQ ID NO: 31, residues 3188 to 3404 of SEQ ID NO: 31, residues 4978 to 5194 of SEQ ID NO: 31, residues 1205 to 1416 of SEQ ID NO: 33, residues 2786 to 2998 of SEQ ID NO: 33, residues 1456 to 1672 of SEQ ID NO: 35, residues 3551 to 3767 of SEQ ID NO: 35, residues 5300 to 5516 of SEQ ID NO: 35, residues 7062 to 7288 of SEQ ID NO: 35, residues 1420 to 1636 of SEQ ID NO: 37, residues 3203 to 3419 of SEQ ID NO: 37; and an amino acid sequence having at least 75% identity to any one of the above amino acid residues.

In another embodiment, the domain is a DH domain and the amino acid comprises a sequence selected from the group consisting of the amino acid of: residues 4102 to 4208 of SEQ ID NO: 21, residues 932 to 1038 of SEQ ID NO: 23, residues 919 to 1027 of SEQ ID NO: 25, residues 5761 to 5866 of SEQ ID NO: 25, residues 2486 to 2592 of SEQ ID NO: 29, residues 4249-4355 of SEQ ID NO: 29 residues 926 to 1032 of SEQ ID NO: 31, residues 2703 to 2809 of SEQ ID NO: 31, residues 4456 to 4562 of SEQ ID NO: 31, residues 954 to 1060 of SEQ ID NO: 35, residues 2731 to 2837 of SEQ ID NO: 35, residues 4815 to 4921 of SEQ ID NO: 35, residues 6572 to 6678 of SEQ ID NO: 35, residues 938 to 1044 of SEQ ID NO: 37; residues 2686 to 2792 of SEQ ID NO: 37; and an amino acid sequence having at least 75% identity to any one of the above amino acid residues.

In another embodiment, the domain is an ER domain and the amino acid comprises a sequence selected from the group consisting of the amino acid of: residues 3188 to 3546 of SEQ ID NO: 35 and any amino acid sequence having at least 75% identity to residues 3188 to 3546 of SEQ ID NO: 35.

In another embodiment, the domain is an TE domain and the amino acid comprises a sequence selected from the group consisting of the amino acid of: residues 3649 to 3872 of SEQ ID NO: 37, and any amino acid sequence having at least 75% identity to residues 3649 to 3872 of SEQ ID NO: 37.

In another embodiment, the invention provides a polypeptide involved in the biosynthesis of a polyketide of Formula I other than a polypeptide encoding a domain of the polyketide synthase system of the invention. In this embodiment, the invention provides an isolated polypeptide for the production of a polyketide of Formula I selected from the group consisting of: a) SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75 and 77; and b) a polypeptide which is at least 75% identical to SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75 and 77.

In another aspect, the invention provides a method of making a polypeptide having a sequence selected from the group consisting of SEQ ID

NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75 and 77 comprising the steps of: (a) introducing a nucleic acid encoding said polypeptide, said nucleic acid being operably linked to a promoter, into a bacterial host cell; and (b) culturing the transformed host cell under conditions which result in the expression of the polypeptide.

In another aspect the invention is drawn to a method for increasing the yield of the polyketides of the invention using the deposited cosmids of the nucleic acids described above, said method comprising the steps of transforming a prokaryotic host with cosmids or nucleic acids and culturing the transformed prokaryotic host under conditions which result in the expression of the polyketide.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1: Diagram of the biosynthetic locus for compound 2(a) from *Streptomyces aizunensis*. Also indicated are the positions of cosmids deposited under IIDAC accession numbers 250203-01, 250203-02, 250203-03, 250203-04 and 250203-05, which span the locus of compound 2(a).

Figure 2a-d: Multiple amino acid alignment comparing the 26 KS domains present in the polyketide synthase (PKS) for compound 2(a) (ORFs 10 to 18). The boundaries and key residues (highlighted in black) of the KS domains were chosen as described by Kakavas *et al.*, *J. Bacteriol.* 179, 7515-7522 (1997).

Figure 3a-d: Multiple amino acid alignment comparing the 26 AT domains present in the compound 2(a) PKS (ORFs 10 to 18). The boundaries and key residues (highlighted in black) of the AT domains were chosen as described by Kakavas *et al.*, *supra*.

Figure 4: Multiple amino acid alignment comparing the 15 DH domains present in the compound 2(a) PKS (ORFs 10, 11, 12, 14, 15, 17 and 18). The boundaries and key residues (highlighted in black) of the DH domains were chosen as described by Kakavas *et al. supra*. The inactive DH domains are highlighted.

Figure 5: Amino acid alignment comparing the ER domain present in the compound 2(a) PKS (ORF 17) with the ER domains from modules 5 and

15 in the nystatin biosynthetic locus as described by Brautaset *et al.*, *Chem. Biol.*, 7, 395-403 (2000). The boundaries and key residues (highlighted in black) of the ER domain were chosen as described by Kakavas *et al. supra*.

Figure 6a and 6b: Multiple amino acid alignment comparing the 26 KR domains present in the compound 2(a) PKS (ORFs 10 to 18). The boundaries and key residues (highlighted in black) of the KR domains were chosen as described by Kakavas *et al. supra*, and Fisher *et al. Structure Fold Des.* 8, 339-347 (2000). The inactive KR domain found in ORF 13/module 12 is highlighted.

Figure 7: Multiple amino acid alignment comparing the 27 ACP domains present in the compound 2(a) PKS (ORFs 10 to 18). The boundaries and key serine residues (highlighted in black) of the ACP domains were chosen as described by Kakavas *et al. supra*.

Figure 8: Amino acid alignment comparing the TE domain present in the compound 2(a) PKS (ORF 18) with the TE domain from module 7 in the nystatin biosynthetic locus as described by Brautaset *et al. supra*. The boundaries and key residues (highlighted in black) of the ER domain were chosen as described by Kakavas *et al. supra*.

In each of the clustal alignments (Figs 2 to 8) a line below the alignment is used to mark strongly conserved positions. In addition, three characters, namely \* (asterisk), : (colon) and . (period) are used, wherein "\*" indicates positions which have a single, fully conserved residue; ":" indicates that one of the following strong groups is fully conserved: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, and FYW; and "." indicates that one of the following weaker groups is fully conserved: CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, FVLIM, and HFY.

Figure 9: Phylogenetic analysis of the 26 AT domains present in the compound 2(a) PKS (ORFs 10 to 18) along with a malonyl-specific and a methylmalonyl-specific AT domain present in modules 3 and 11 respectively of the nystatin PKS system as described by Brautaset *et al. supra*.

Figure 10a to 10c: biosynthetic pathway for compound 2(a) polyketide core structure.



Figure 11a and 11b: biosynthetic pathways for compound 2(a) aminohydroxy-cyclopentenone (a) and deoxysugar (b) components.

Figures 12a to 12f: outline of strategies for the genetic modification of locus for compound 2(a) providing for variants that functionally modify compound 2(a).

Figure 13: shows the data for the compound of compound 2(a) obtained by electrospray mass spectrometry.

Figure 14: shows the data for the compound of compound 2(a) obtained by UV  $\lambda_{\max}$ .


Figure 15: shows the data obtained for the compound of compound 2(a) by NMR at 500 MHz dissolved in  $d_3$ -MeOH including proton 15 A, carbon 15 B, and multidimensional pulse sequences gDQCOSY, gHSQC, gHMBC, and TOCSY 15 C, 15D, 15E and 15F, respectively.


Figure 16: is a plot of the data from a study to evaluate the antifungal activity of compound 2(a) against *Candida albicans* in a mouse model as described in Example 5. Figure 16 depicts the percent survival versus days post-inoculation with compound 2(a) (3 mg/kg), compound 2(a) (1 mg/kg), Fungizone (0.25 mg/kg) and Fungizone (0.50 mg/kg).

Figure 17: proton-NMR (Figure 17A) and carbon-13 NMR (Figure 17B) spectral assignments for Compound 2(a) as discussed in Example 3.

## DETAILED DESCRIPTION OF THE INVENTION

The present invention encompasses compounds of Formula I, and pharmaceutically acceptable salts thereof:






Formula I

wherein,

A is selected from the group consisting of  $-NR^1R^2$ ,  $-N=CR^1R^2$ ,




$R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  are each independently selected from the group consisting of H,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{3-6}$  cycloalkyl,  $C_{2-6}$  heterocycloalkyl, aryl, heteroaryl and amino acid, wherein said alkyl, alkenyl, aryl and heteroaryl are optionally substituted with a group selected from halogen, OH,  $NO_2$ ,  $NH_2$  or aryl, said aryl being optionally further substituted with one or more groups independently selected from halogen, OH,  $NO_2$  or  $NH_2$ ;




wherein  $R^{10}$  is oxo or  $OR^{11}$ ;

wherein  $R^{11}$  is H or a heterocycloalkyl, the heterocycloalkyl being optionally substituted with 1-4 substituents selected from OX,  $C_{1-3}$  alkyl and  $-O-C(O)R^1$ , wherein X is H or, when there are at least two neighboring substituent groups that are OX, then the X can be a bond such that the two neighboring oxygen groups form a five-membered acetal ring of the formula:



; wherein  $R^5$  and  $R^6$  are each independently selected from the group consisting of H,  $C_{1-6}$  alkyl, and  $C_{2-7}$  alkenyl;







D is selected from: ,  $-NR^{12a}R^{12a}$ , and  $OR^{12}$ ,

wherein


$R^{12}$  is selected from H,  $C_{1-6}$  alkyl optionally substituted with 1 to 2 phenyl groups, wherein the phenyl group is optionally substituted with  $C_{1-6}$  alkyl and halo;

$R^{12a}$  and  $R^{12a}$  are each independently selected from H,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{3-6}$  cycloalkyl,  $C_{2-6}$  heterocycloalkyl, aryl, heteroaryl and amino acid, wherein said alkyl, alkenyl, aryl and heteroaryl are optionally substituted with a group selected from halogen, OH,  $NO_2$ ,  $NH_2$  or aryl, said aryl being optionally further substituted with one or more groups independently selected from halogen, OH,  $NO_2$  or  $NH_2$ ;






X<sup>1</sup>, X<sup>2</sup>, X<sup>3</sup>, X<sup>4</sup>, X<sup>5</sup>, X<sup>6</sup>, X<sup>7</sup>, X<sup>8</sup>, X<sup>9</sup>, X<sup>12</sup> and X<sup>13</sup> are each independently selected from H, -C(O)-R<sup>7</sup> and a bond such that when any of two neighboring X<sup>1</sup>, X<sup>2</sup>, X<sup>3</sup>, X<sup>4</sup>, X<sup>5</sup>, X<sup>6</sup>, X<sup>7</sup>, X<sup>8</sup>, X<sup>9</sup>, X<sup>12</sup> and X<sup>13</sup> is a bond then the two neighboring oxygen atoms and their attached carbon atoms together form a six-membered acetal ring of the formula:




R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> are each independently selected from H, C<sub>1-6</sub> alkyl, C<sub>2-7</sub> alkenyl;

Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup>, Y<sup>4</sup>, Y<sup>5</sup>, Y<sup>6</sup>, Y<sup>7</sup>, Y<sup>9</sup>, Y<sup>10</sup>, Y<sup>11</sup>, Y<sup>12</sup>, Y<sup>13</sup> and Y<sup>15</sup> are each independently selected from the group consisting of ethene-1,2-diyl,

ethane-1,2-diyl and , wherein said ethene-1,2-diyl and ethane-1,2-diyl groups are optionally substituted with a methyl group;



Z is selected from OH, NHR<sup>8</sup>,  and when the dotted line is a bond then Z is oxo, or NR<sup>9</sup>;


R<sup>8</sup> is selected from H, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl;

R<sup>9</sup> is C<sub>1-6</sub> alkyl optionally substituted with aryl.

In a first embodiment the invention provides compounds of Formula I wherein Z is oxo; and all other groups are as previously defined; or a pharmaceutically acceptable salt thereof.


Within this first embodiment Z is oxo, A is  $-NR^1R^2$ ; and all other groups are as previously defined; or a pharmaceutically acceptable salt thereof.

Further within this embodiment Z is oxo, A is  $-NR^1R^2$ ; and D is




; and all other groups are as previously defined; or a pharmaceutically acceptable salt thereof.

Within the first embodiment the invention provides compounds of Formula I wherein Z is oxo and A is




; and all other groups are as previously defined; or a pharmaceutically acceptable salt thereof.

Further within this embodiment Z is oxo and A is  $-NH-C(=O)-R^4$  and D is



; and all other groups are as previously defined; or a pharmaceutically acceptable salt thereof.


In a second embodiment the invention provides compounds of Formula I wherein B is




wherein  $R^{10}$  is oxo or  $OR^{11}$ ; and all other groups are as previously defined; or a pharmaceutically acceptable salt thereof.

Within this second embodiment  $R^{10}$  is  $OR^{11}$ , wherein  $R^{11}$  is a heterocycloalkyl, the heterocycloalkyl being optionally substituted with 1-4 substituents selected from OX,  $C_{1-3}$  alkyl and  $-O-C(O)R^1$ , wherein X is H or,

when there are at least two neighboring substituent groups that are OX, then the X can be a bond such that the two neighboring oxygen groups form a five-membered acetal ring of the formula:




Within this embodiment  $R^{11}$  is a heterocycloalkyl, the heterocycloalkyl being optionally substituted with 1-4 substituents selected from OX,  $C_{1-3}$  alkyl and  $-O-C(O)R^1$ , wherein X is H or, when there are at least two neighboring substituent groups that are OX, then the X can be a bond such that the two neighboring oxygen groups form a five-membered acetal ring of the formula:




and A is  $-NR^1R^2$ ; and all other groups are as previously defined; or a pharmaceutically acceptable salt thereof.

Further within this embodiment the invention provides compounds of Formula I, wherein  $R^{11}$  is a heterocycloalkyl, the heterocycloalkyl being optionally substituted with 1-4 substituents selected from OX,  $C_{1-3}$  alkyl and  $-O-C(O)R^1$ , wherein X is H or, when there are at least two neighboring substituent groups that are OX, then the X can be a bond such that the two neighboring oxygen groups form a five-membered acetal ring of the formula:




, A is  $-NR^1R^2$  and Z is oxo; and all other groups are as previously defined; or a pharmaceutically acceptable salt thereof.

Preferred compounds of the invention comprise compounds of Formula II:




Formula II

wherein  $A^1$  is  $-NH_2$ ,  $-N=CH-R^{13}$ , amino acid or  $-NH-R^{14}$ , wherein  $R^{13}$  is hydrogen or phenyl and  $R^{14}$  is selected from the group consisting of isopropyl, 1-(4-nitrophenyl)methyl, cyclohexyl, and wherein said amino acid is attached via its nitrogen atom;




and




wherein  $R^{15}$  is selected from the group consisting of methyl, isopropyl, phenyl, 4-nitrophenyl, 1-aminoethyl, 1-amino-1-(4-hydroxyphenyl)methyl, 1-amino-2-(4-hydroxyphenyl)ethyl, 1-amino-2-methylpropyl, 2-pyrrolidinyl and 1-amino-2-hydroxyethyl;


$Y^{20}$  is selected from the group consisting of ethene-1,2-diyl and




$Z^1$  is selected from the group consisting of:




,




,




,



and




$R^{20}$  is selected from the group consisting of hydrogen and



$Y^{30}$  is ethene-1,2-diyl or ethane-1,2-diyl; and


$D^1$  is hydroxy, methoxy or



and pharmaceutically acceptable salts thereof.

The present invention includes pharmaceutical compositions of the compounds of Formula II, said compositions comprising a therapeutically effective amount of the compound of Formula II or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Particularly preferred compounds of the present invention include those of Formula II












wherein  $A^1$  is amino ( $-NH_2$ ), and  $Y^{20}$ ,  $Z^1$ ,  $R^{20}$ ,  $Y^{30}$  and  $D^1$  are as defined in Table A below.


**Table A.** Compounds of Formula II wherein  $A^1$  is  $NH_2$

Compound	$Y^{20}$	$Z^1$	$R^{20}$	$Y^{30}$	$D^1$
2(a)	ethene-1,2-diyl		3,4,5-trihydroxy-6-methyl-tetrahydro-pyran-2-yl	ethane-1,2-diyl	



2(b)		"	"	"	"
2(c)	ethene-1,2-diyl		"	"	"
2(d)	"		"	"	"
2(e)	"		"	"	"
2(f)	"		"	"	"
2(g)	"		"	"	hydroxy
2(h)	"	"	"	"	methoxy
2(i)	"	"	hydrogen	"	
2(j)	"	"	"	"	hydroxy
2(k)	"	"	3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl	ethene-1,2-diyl	
2(l)	"		"	"	"


Additional preferred compounds of the invention include compounds of  
Formula II




Formula II

as set forth in Tables B and C below,

wherein Y<sup>20</sup> is ethene-1,2-diyl;



$Y^{30}$  is ethane-1,2-diyl; and














wherein  $A^1$  is  $-N=CH-R^{13}$  (Table B);  $-NH-R^{14}$  (Table C).

**Table B.** Compounds of Formula II wherein  $A^1$  is  $-N=CH-R^{13}$  and  $Y^{20}$ ,  $Z^1$ ,  $R^{20}$ ,  $Y^{30}$  and  $D^1$  are as defined above.

Compound	$R^{13}$
2(m)	$CH_3$
2(n)	phenyl


**Table C.** Compounds of Formula II wherein  $A^1$  is  $-NH-R^{14}$  and  $Y^{20}$ ,  $Z^1$ ,  $R^{20}$ ,  $Y^{30}$  and  $D^1$  are as defined above.

Compound	$R^{14}$	$R^{15}$
2(o)		NA*
2(p)	isopropyl	NA
2(q)	1-(4-nitrophenyl)methyl	NA
2(r)	cyclohexyl	NA
2(s)		$CH_3$
2(t)		isopropyl
2(u)		phenyl
2(v)		4-nitrophenyl
2(w)		1-aminoethyl
2(x)		1-amino-1-(4-hydroxyphenyl)methyl
2(y)		1-amino-2-(4-hydroxyphenyl)ethyl


		hydroxyphenyl)ethyl
2(z)		1-amino-2-methylpropyl
2(aa)		2-pyrrolidinyl
2(ab)		1-amino-2-hydroxyethyl

\*NA = not applicable


The compounds of Tables A, B and C are shown below.




Compound 2(a)




Compound 2(b)




Compound 2(c)




Compound 2(d)




Compound 2(e)




Compound 2(f)




Compound 2(g)




Compound 2(h)




Compound 2(i)




Compound 2(j)




Compound 2(k)




Compound 2(l)




Compound 2(m)




Compound 2(n)




Compound 2(o)




Compound 2(p)




Compound 2(q)




Compound 2(r)




Compound 2(s)




Compound 2(t)




Compound 2(u)




Compound 2(v)




Compound 2(w)




Compound 2(x)




Compound 2(y)



Compound 2(z)




Compound 2(aa)




Compound 2(ab)


The following bivalent moieties are referred to herein by the nomenclature as indicated below:




1-oxo-methylene-1,1-diyl




1-hydroxymethylene-1,1-diyl




1,3-dioxacyclopentane-2,2-diyl



(2-propylamino)methylene-1,1-diyl




1-benzyliminomethylene-1,1-diyl




oxirane-2,3-diyl.

The following monovalent moieties are referred to herein by the nomenclature as indicated:



(2-hydroxy-5-oxo-cyclopent-1-enyl)-amino



3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl.

The terms "polyketide" or "polyene polyketide" refer to a class of polyketide compounds defined by Formula I or II. A preferred polyketide of



the invention is the compound 2a, having the systematic name 56-Amino-15,17,33,35,37,41,43,45,47,51,53-undecahydroxy-14,16,30-trimethyl-31-oxo-29-(3,4,5-trihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-hexapentaconta-2,4,6,8,12,18,20,22,24,26,38,48-dodecaenoic acid (2-hydroxy-5-oxo-cyclopent-1-enyl)-amide. The term further includes compounds of this class that can be used as intermediates in chemical synthesis.

The terms "producer of compounds of Formula I" and "compounds of Formula I -producing organism" refer to a microorganism that carries genetic information necessary to produce a compound of Formula I, whether or not the organism is known to produce a compound of Formula I. The terms "producer of compounds of Formula II" and "compound of Formula II-producing organism" refer to a microorganism that carries genetic information necessary to produce a compound of Formula II, whether or not the organism is known to produce a compound of Formula II. The terms "producer of Compound 2(a)" and "Compound 2(a)-producing organism" refer to a microorganism that carries genetic information necessary to produce Compound 2(a), whether or not the organism is known to produce Compound 2(a). The term "polyketide producer" refer to a microorganism that carries genetic information necessary to produce a polyketide of Formula I or II. The terms apply equally to organisms in which the genetic information to produce the compound of Formula I or II or Compound 2(a) is found in the organism as it exists in its natural environment, and to organisms in which the genetic information is introduced by recombinant techniques. For the sake of particularity, specific organisms contemplated herein include organisms of the family *Micromonosporaceae*, of which preferred genera include *Micromonospora*, *Actinoplanes* and *Dactylosporangium*; the family *Streptomycetaceae*, of which preferred genera include *Streptomyces* and *Kitasatospora*; the family *Pseudonocardiaceae*, of which preferred genera are *Amycolatopsis* and *Saccharopolyspora*; and the family *Actinosynnemataceae*, of which preferred genera include *Saccharothrix* and *Actinosynnema*; however the terms are intended to encompass all organisms containing genetic information necessary to produce a compound of Formula I or II or Compound 2(a). Preferred producers of a compound of formula I or II or Compound 2(a)

include *Streptomyces aizunensis* (NRRL B-11277) and any mutant or improved strain of *Streptomyces aizunensis*, including strain [C03]023 (IDAC accession no. 070803-01) and strain [C03U03]023 (IDAC accession no. 231203-02).

The term "isolated" means that the material is removed from its original environment, e.g. the natural environment if it is naturally-occurring. For example, a naturally occurring polynucleotide or polypeptide present in a living organism is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment.

The term "purified" does not require absolute purity; rather, it is intended as a relative definition. Individual nucleic acids obtained from a library have been conventionally purified to electrophoretic homogeneity. The purified nucleic acids of the present invention have been purified from the remainder of the genomic DNA in the organism by at least  $10^4$  to  $10^6$  fold. However, the term "purified" also includes nucleic acids which have been purified from the remainder of the genomic DNA or from other sequences in a library or other environment by at least one order of magnitude, preferably two or three orders of magnitude, and more preferably four or five orders of magnitude.

"Recombinant" means that the nucleic acid is present in the cell with "backbone" nucleic acid, wherein the nucleic acid is not present with "backbone" nucleic acid in its natural environment. "Recombinant" can also be defined to mean that the nucleic acid is adjacent to "backbone" nucleic acid to which it is not adjacent in its natural environment. "Enriched" nucleic acids represent 5% or more of the number of nucleic acid inserts in a population of nucleic acid backbone molecules. "Backbone" molecules include nucleic acids such as expression vectors, self-replicating nucleic acids, viruses, integrating nucleic acids, and other vectors or nucleic acids used to maintain or manipulate a nucleic acid of interest. Preferably, the enriched nucleic acids

represent 15% or more, more preferably 50% or more, and most preferably 90% or more, of the number of nucleic acid inserts in the population of recombinant backbone molecules.

“Recombinant” polypeptides or proteins refer to polypeptides or proteins produced by recombinant DNA techniques, *i.e.* produced from cells transformed by an exogenous DNA construct encoding the desired polypeptide or protein. “Synthetic” polypeptides or proteins are those prepared by chemical synthesis.

The term “gene” means the segment of DNA involved in producing a polypeptide chain; it includes regions preceding and following the coding region (leader and trailer) as well as, where applicable, intervening regions (introns) between individual coding segments (exons).

The terms “gene locus,” “gene cluster,” and “biosynthetic locus” refer to a group of genes or variants thereof involved in the biosynthesis of the polyketide of Formula 2a. Genetic modification of gene locus, gene cluster or biosynthetic locus refers to any genetic recombinant techniques known in the art including mutagenesis, inactivation, or replacement of nucleic acids that can be applied to generate variants of the compounds of Formula 2a. Genetic modification of gene locus, gene cluster or biosynthetic locus refers to any genetic recombinant techniques known in the art including mutagenesis, inactivation, or replacement of nucleic acids that can be applied to generate genetic variants of compounds of Formula I.

A DNA or nucleotide “coding sequence” or “sequence encoding” a particular polypeptide or protein, is a DNA sequence which is transcribed and translated into a polypeptide or protein when placed under the control of appropriate regulatory sequences.

“Oligonucleotide” refers to a nucleic acid, generally of at least 10, preferably 15 and more preferably at least 20 nucleotides, preferably no more than 100 nucleotides, that are hybridizable to a genomic DNA molecule, a cDNA molecule, or an mRNA molecule encoding a gene, mRNA, cDNA or other nucleic acid of interest.

A promoter sequence is "operably linked to" a coding sequence recognized by RNA polymerase which initiates transcription at the promoter and transcribes the coding sequence into mRNA.

"Digestion" of DNA refers to enzymatic cleavage of the DNA with a restriction enzyme that acts only at certain sequences in the DNA. The various restriction enzymes used herein are commercially available and their reaction conditions, cofactors and other requirements were used as would be known to the ordinary skilled artisan. For analytical purposes, typically 1 µg of plasmid or DNA fragment is used with about 2 units of enzyme in about 20 µl of buffer solution. For the purpose of isolating DNA fragments for plasmid construction, typically 5 to 50 µg of DNA are digested with 20 to 250 units of enzyme in a larger volume. Appropriate buffers and substrate amounts for particular enzymes are specified by the manufacturer. Incubation times of about 1 hour at 37°C are ordinarily used, but may vary in accordance with the supplier's instructions. After digestion, gel electrophoresis may be performed to isolate the desired fragment.

As used herein and as known in the art, the term "identity" is the relationship between two or more polynucleotide sequences, as determined by comparing the sequences. Identity also means the degree of sequence relatedness between polynucleotide sequences, as determined by the match between strings of such sequences. Identity can be readily calculated (see, e.g., *Computation Molecular Biology*, Lesk, A.M., eds., Oxford University Press, New York (1998), and *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York (1993), both of which are incorporated by reference herein). While there exist a number of methods to measure identity between two polynucleotide sequences, the term is well known to skilled artisans (see, e.g., *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press (1987); and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M. Stockton Press, New York (1991)). Methods commonly employed to determine identity between sequences include, for example, those disclosed in Carillo, H., and Lipman, D., *SIAM J. Applied Math.* (1988) 48:1073. "Substantially identical," as used herein, means there is a very high degree of homology (preferably 100% sequence

identity) between subject polynucleotide sequences. However, polynucleotides having greater than 90%, or 95% sequence identity may be used in the present invention, and thus sequence variations that might be expected due to genetic mutation, strain polymorphism, or evolutionary divergence can be tolerated.

The biosynthetic locus for the production of the Compound 2(a) spans approximately 176,000 base pairs of DNA and encodes 38 proteins. More than 10 kilobases of DNA sequence were analyzed on each side of the locus and these regions were found to contain primary metabolic genes. The order and relative position of the 38 open reading frames representing the proteins of the biosynthetic locus for Compound 2(a) are provided in Figure 1. Referring to Figure 1, the genes involved in the biosynthesis of Compound 2(a) are contained within two contiguous nucleotide sequences (SEQ ID NOS: 1 and 18). The contiguous nucleotide sequences are arranged such that, as found within the compound 2(a) biosynthetic locus, the 3' end of the 11740 base pairs of DNA of contig 1 (SEQ ID NO: 1) is found adjacent to the 5' end of the 164,051 base pairs of DNA of contig 2 (SEQ ID NO: 18).

The nucleotide sequence and polypeptide sequences relating to the locus of compound 2(a) are provided in the sequence listing filed together with and forming part of this application. SEQ ID NO: 1 is the 11740 contiguous base pairs of contig 1 comprising eight open reading frames, namely ORF 1 to ORF 8 listed in SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15 and 17 respectively. The gene product of ORF 1 (SEQ ID NO: 2) is the 719 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 3 which is drawn from residues 418 to 2577 (sense strand) of contig 1 (SEQ ID NO: 1). The gene product of ORF 2 (SEQ ID NO: 4) is the 253 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 5 which is drawn from residues 3006 to 3767 (sense strand) of contig 1 (SEQ ID NO: 1). The gene product of ORF 3 (SEQ ID NO: 6) is the 956 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 7 which is drawn from residues 4016 to 6886 (sense strand) of contig 1 (SEQ ID NO: 1). The gene product of ORF 4 (SEQ ID NO: 8) is the 201 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 9 which is drawn from residues 7581 to 6976 (antisense strand) of contig 1 (SEQ ID

NO: 1). The gene product of ORF 5 (SEQ ID NO: 10) is the 416 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 11 which is drawn from residues 8848 to 7598 (antisense strand) of contig 1 (SEQ ID NO: 1). The gene product of ORF 6 (SEQ ID NO: 12) is the 186 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 13 which is drawn from residues 9053 to 9613 (sense strand) of contig 1 (SEQ ID NO: 1). The gene product of ORF 7 (SEQ ID NO: 14) is the 163 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 15 which is drawn from residues 9682 to 10173 (sense strand) of contig 1 (SEQ ID NO: 1). The gene product of ORF 8 (SEQ ID NO: 16) is the 514 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 17 which is drawn from residues 10170 to 11714 (sense strand) of contig 1 (SEQ ID NO: 1).

SEQ ID NO: 18 is the 164,051 contiguous base pairs of contig 2 comprising 30 ORFs, namely ORF 9 to ORF 38 listed in SEQ ID NOS: 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76 and 78 respectively. The gene product of ORF 9 (SEQ ID NO: 19) is the 367 amino acids deduced from the nucleic acids sequence of SEQ ID NO: 20 which is drawn from residues 1109 to 6 (antisense strand) of contig 2 (SEQ ID NO: 18). The gene product of ORF 10 (SEQ ID NO: 21) is the 8147 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 22 which is drawn from residues 1375 to 25818 (sense strand) of contig 2 (SEQ ID NO: 18). The gene product of ORF 11 (SEQ ID NO: 23) is the 3428 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 24 which is drawn from residues 25902 to 36188 (sense strand) of contig 2 (SEQ ID NO: 18). The gene product of ORF 12 (SEQ ID NO: 25) is the 6751 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 26 which is drawn from residues 36213 to 56468 (sense strand) of contig 2 (SEQ ID NO: 18). The gene product of ORF 13 (SEQ ID NO: 27) is the 1657 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 28 which is drawn from residues 56600 to 61573 (sense strand) of contig 2 (SEQ ID NO: 18). The gene product of ORF 14 (SEQ ID NO: 29) is the 5207 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 30 which is drawn from residues 61852 to 77475

(sense strand) of contig 2 (SEQ ID NO: 18). The gene product of ORF 15 (SEQ ID NO: 31) is the 5432 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 32 which is drawn from residues 77606 to 93904 (sense strand) of contig 2 (SEQ ID NO: 18). The gene product of ORF 16 (SEQ ID NO: 33) is the 3227 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 34 which is drawn from residues 94057 to 103740 (sense strand) of contig 2 (SEQ ID NO: 18). The gene product of ORF 17 (SEQ ID NO: 35) is the 7510 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 36 which is drawn from residues 103789 to 126321 (sense strand) of contig 2 (SEQ ID NO: 18). The gene product of ORF 18 (SEQ ID NO: 37) is the 3872 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 38 which is drawn from residues 126389 to 138007 (sense strand) of contig 2 (SEQ ID NO: 18). The gene product of ORF 19 (SEQ ID NO: 39) is the 338 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 40 which is drawn from residues 139079 to 138063 (antisense strand) of contig 2 (SEQ ID NO: 18). The gene product of ORF 20 (SEQ ID NO: 41) is the 283 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 42 which is drawn from residues 140117 to 139266 (antisense strand) of contig 2 (SEQ ID NO: 18). The gene product of ORF 21 (SEQ ID NO: 43) is the 329 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 44 which is drawn from residues 141103 to 140114 (antisense strand) of contig 2 (SEQ ID NO: 18). The gene product of ORF 22 (SEQ ID NO: 45) is the 317 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 46 which is drawn from residues 141483 to 142436 (sense strand) of contig 2 (SEQ ID NO: 18). The gene product of ORF 23 (SEQ ID NO: 47) is the 204 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 48 which is drawn from residues 142440 to 143054 (sense strand) of contig 2 (SEQ ID NO: 18). The gene product of ORF 24 (SEQ ID NO: 49) is the 328 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 50 which is drawn from residues 143133 to 144119 (sense strand) of contig 2 (SEQ ID NO: 18). The gene product of ORF 25 (SEQ ID NO: 51) is the 328 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 52 which is drawn from residues 144116 to 145102

(sense strand) of contig 2 (SEQ ID NO: 18). The gene product of ORF 26 (SEQ ID NO: 53) is the 214 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 54 which is drawn from residues 145099 to 145743 (sense strand) of contig 2 (SEQ ID NO: 18). The gene product of ORF 27 (SEQ ID NO: 55) is the 470 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 56 which is drawn from residues 145818 to 147230 (sense strand) of contig 2 (SEQ ID NO: 18). The gene product of ORF 28 (SEQ ID NO: 57) is the 553 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 58 which is drawn from residues 148967 to 147306 (antisense strand) of contig 2 (SEQ ID NO: 18). The gene product of ORF 29 (SEQ ID NO: 59) is the 231 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 60 which is drawn from residues 149871 to 149176 (antisense strand) of contig 2 (SEQ ID NO: 18). The gene product of ORF 30 (SEQ ID NO: 61) is the 306 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 62 which is drawn from residues 150788 to 149868 (antisense strand) of contig 2 (SEQ ID NO: 18). The gene product of ORF 31 (SEQ ID NO: 63) is the 998 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 64 which is drawn from residues 153765 to 150769 (antisense strand) of contig 2 (SEQ ID NO: 18). The gene product of ORF 32 (SEQ ID NO: 65) is the 518 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 66 which is drawn from residues 154485 to 156041 (sense strand) of contig 2 (SEQ ID NO: 18). The gene product of ORF 33 (SEQ ID NO: 67) is the 329 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 68 which is drawn from residues 156075 to 157064 (sense strand) of contig 2 (SEQ ID NO: 18). The gene product of ORF 34 (SEQ ID NO: 69) is the 521 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 70 which is drawn from residues 157308 to 158873 (sense strand) of contig 2 (SEQ ID NO: 18). The gene product of ORF 35 (SEQ ID NO: 71) is the 410 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 72 which is drawn from residues 158970 to 160202 (sense strand) of contig 2 (SEQ ID NO: 18). The gene product of ORF 36 (SEQ ID NO: 73) is the 506 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 74 which is drawn from residues 160199 to 161719



(sense strand) of contig 2 (SEQ ID NO: 18). The gene product of ORF 37 (SEQ ID NO: 75) is the 217 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 76 which is drawn from residues 161924 to 162577 (sense strand) of contig 2 (SEQ ID NO: 18). The gene product of ORF 38 (SEQ ID NO: 77) is the 442 amino acids deduced from the nucleic acid sequence of SEQ ID NO: 78 which is drawn from residues 162723 to 164051 (sense strand) of contig 2 (SEQ ID NO: 18).

Some open reading frames listed herein initiate with non-standard initiation codons (e.g. GTG – Valine or CTG - Leucine) rather than the standard initiation codon ATG, namely ORFs 3, 5, 6, 9, 11, 13, 21, 22, 23, 24, 27, 34, 36 and 37 (SEQ ID NOS: 7, 11, 13, 20, 24, 28, 44, 46, 48, 50, 56, 70, 74 and 76). All ORFs are listed with the appropriate M, V or L amino acids at the amino-terminal position to indicate the specificity of the first codon of the ORF. It is expected, however, that in all cases the biosynthesized protein will contain a methionine residue, and more specifically a formylmethionine residue, at the amino terminal position, in keeping with the widely accepted principle that protein synthesis in bacteria initiates with methionine (formylmethionine) even when the encoding gene specifies a non-standard initiation codon (e.g. Stryer, Biochemistry 3<sup>rd</sup> edition, 1998, W.H. Freeman and Co., New York, pp. 752-754).

Five *E. coli* DH10B deposits, each harbouring a cosmid clone of a partial biosynthetic locus for compound 2(a) from *Streptomyces aizunensis* (NRRL B-11277) and together spanning the full locus were deposited with the International Depositary Authority of Canada, Bureau of Microbiology, Health Canada, 1015 Arlington Street, Winnipeg, Manitoba, Canada R3E 3R2 on February 25, 2003 and were assigned deposit accession numbers IDAC 250203-01, IDAC 250203-02, IDAC 250203-03, IDAC 250203-04 and IDAC 250203-05 respectively. The sequence of the polynucleotides comprised in the deposited strains, as well as the amino acid sequence of any polypeptide encoded thereby are controlling in the event of any conflict with any description of sequences herein.

A natural mutant of *Streptomyces aizunensis* (NRRL B-11277), referred to as strain [C03]023 producing Compound 2(a) and used to produce the

compounds of Formula I and Formula II was deposited with the International Depositary Authority of Canada, Bureau of Microbiology, Health Canada, 1015 Arlington Street, Winnipeg, Manitoba, Canada R3E 3R2 on August 7, 2003 and was assigned deposit accession number IDAC 070803-1.

Another mutant of *Streptomyces aizunensis* (NRRL B-11277), referred to as strain [C03U03]023 producing Compound 2(a) and used to produce the compounds of Formula I and Formula II was deposited with the International Depositary Authority of Canada, Bureau of Microbiology, Health Canada, 1015 Arlington Street, Winnipeg, Manitoba, Canada R3E 3R2 on December 23, 2003 and was assigned deposit accession number IDAC 231203-02.

The deposited cosmids and strains [C03]023 and [C03U03]023 (the deposited stains) have been made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for Purposes of Patent Procedure. The deposited strains will be irrevocably and without restriction or condition released to the public upon the issuance of a patent. The deposited strains are provided merely as convenience to those skilled in the art and are not an admission that a deposit is required for enablement. A license may be required to make, use or sell the deposited strains, and compounds derived there from, and no such license is hereby granted.

The order and relative position of the 38 open reading frames representing the proteins of the biosynthetic locus for compound 2(a) (compound 2(a) ORFs) are illustrated schematically in Figure 1. The top line in Figure 1 provides a scale in base pairs. The gray bars depict the two DNA contigs that cover the compound 2(a) locus. The empty arrows represent the 38 open reading frames of the compound 2(a) biosynthetic locus. The black arrows represent the five deposited cosmid clones covering the entire compound 2(a) locus.

One aspect of the present invention is an isolated, purified, or enriched nucleic acid comprising one of the sequences of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, the sequences complementary thereto, or a fragment comprising at least 100, 200, 300, 400, 500, 600, 700, 800 or more consecutive bases of one of the sequences of

SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78 or the sequences complementary thereto. The isolated, purified or enriched nucleic acids may comprise DNA, including cDNA, genomic DNA, and synthetic DNA. The DNA may be double stranded or single stranded, and if single stranded may be the coding (sense) or non-coding (anti-sense) strand. Alternatively, the isolated, purified or enriched nucleic acids may comprise RNA.

As discussed in more detail below, the isolated, purified or enriched nucleic acids of one of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78 may be used to prepare one of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, respectively, or fragments comprising at least 50, 75, 100, 200, 300, 500 or more consecutive amino acids of one of the polypeptides of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77.

Accordingly, another aspect of the present invention is an isolated, purified or enriched nucleic acid which encodes one of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77 or fragments comprising at least 50, 75, 100, 150, 200, 300 or more consecutive amino acids of one of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77. The coding sequences of these nucleic acids may be identical to one of the coding sequences of one of the nucleic acids of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78 or a fragment thereof, or may be different coding sequences which encode one of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77 or fragments comprising at least 50,

75, 100, 150, 200, 300 consecutive amino acids of one of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77 as a result of the redundancy or degeneracy of the genetic code. The genetic code is well known to those of skill in the art and can be obtained, for example, from Stryer, *Biochemistry*, 3<sup>rd</sup> edition, W. H. Freeman & Co., New York.

The isolated, purified or enriched nucleic acid which encodes one of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77 may include, but is not limited to: (1) only the coding sequences of one of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78; (2) the coding sequences of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78 and additional coding sequences, such as leader sequences or proprotein; and (3) the coding sequences of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78 and non-coding sequences, such as non-coding sequences 5' and/or 3' of the coding sequence. Thus, as used herein, the term "polynucleotide encoding a polypeptide" encompasses a polynucleotide that includes only coding sequence for the polypeptide as well as a polynucleotide that includes additional coding and/or non-coding sequence.

The invention relates to polynucleotides based on SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78 but having polynucleotide changes that are "silent", for example changes which do not alter the amino acid sequence encoded by the polynucleotides of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78. The invention also relates to polynucleotides which have nucleotide changes which result in amino acid substitutions, additions, deletions, fusions and

truncations of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77. Such nucleotide changes may be introduced using techniques such as site directed mutagenesis, random chemical mutagenesis, exonuclease III deletion, and other recombinant DNA techniques.

The isolated, purified or enriched nucleic acids of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, the sequences complementary thereto, or a fragment comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400 or 500 consecutive bases of one of the sequence of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, or the sequences complementary thereto may be used as probes to identify and isolate DNAs encoding the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77 respectively. In such procedures, a genomic DNA library is constructed from a sample microorganism or a sample containing a microorganism capable of producing a polypeptide. The genomic DNA library is then contacted with a probe comprising a coding sequence or a fragment of the coding sequence, encoding one of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, or a fragment thereof under conditions which permit the probe to specifically hybridize to sequences complementary thereto. In a preferred embodiment, the probe is an oligonucleotide of about 10 to about 30 nucleotides in length designed based on a nucleic acid of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76 or 78. Genomic DNA clones which hybridize to the probe are then detected and isolated. Procedures for preparing and identifying DNA clones of interest are disclosed in Ausubel *et al.*, Current Protocols in Molecular Biology, John Wiley 503 Sons, Inc. 1997; and Sambrook *et al.*, Molecular Cloning: A Laboratory

Manual 2d Ed., Cold Spring Harbor Laboratory Press, 1989. In another embodiment, the probe is a restriction fragment or a PCR amplified nucleic acid derived from SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78.

The isolated, purified or enriched nucleic acids of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, the sequences complementary thereto, or a fragment comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400 or 500 consecutive bases of one of the sequences of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, or the sequences complementary thereto may be used as probes to identify and isolate related nucleic acids. In some embodiments, the related nucleic acids may be genomic DNAs (or cDNAs) from potential polyketide producers. In such procedures, a nucleic acid sample containing nucleic acids from a potential polyketide producer is contacted with the probe under conditions that permit the probe to specifically hybridize to related sequences. The nucleic acid sample may be a genomic DNA (or cDNA) library from the potential polyketide-producer. Hybridization of the probe to nucleic acids is then detected using any of the methods described above.

Hybridization may be carried out under conditions of low stringency, moderate stringency or high stringency. As an example of nucleic acid hybridization, a polymer membrane containing immobilized denatured nucleic acids is first prehybridized for 30 minutes at 45 °C in a solution consisting of 0.9 M NaCl, 50 mM NaH<sub>2</sub>PO<sub>4</sub>, pH 7.0, 5.0 mM Na<sub>2</sub>EDTA, 0.5% SDS, 10X Denhardt's, and 0.5 mg/ml polyriboadenylic acid. Approximately 2 x 10<sup>7</sup> cpm (specific activity 4-9 x 10<sup>8</sup> cpm/ug) of <sup>32</sup>P end-labeled oligonucleotide probe are then added to the solution. After 12-16 hours of incubation, the membrane is washed for 30 minutes at room temperature in 1X SET (150 mM NaCl, 20 mM Tris hydrochloride, pH 7.8, 1 mM Na<sub>2</sub>EDTA) containing 0.5% SDS, followed by a 30 minute wash in fresh 1X SET at T<sub>m</sub>-10°C for the

oligonucleotide probe where  $T_m$  is the melting temperature. The membrane is then exposed to autoradiographic film for detection of hybridization signals.

By varying the stringency of the hybridization conditions used to identify nucleic acids, such as genomic DNAs or cDNAs, which hybridize to the detectable probe, nucleic acids having different levels of homology to the probe can be identified and isolated. Stringency may be varied by conducting the hybridization at varying temperatures below the melting temperatures of the probes. The melting temperature of the probe may be calculated using the following formulas:

For oligonucleotide probes between 14 and 70 nucleotides in length the melting temperature ( $T_m$ ) in degrees Celcius may be calculated using the formula:  $T_m = 81.5 + 16.6(\log [Na+]) + 0.41(\text{fraction G+C}) - (600/N)$  where N is the length of the oligonucleotide.

If the hybridization is carried out in a solution containing formamide, the melting temperature may be calculated using the equation  $T_m = 81.5 + 16.6(\log [Na+]) + 0.41(\text{fraction G+C}) - (0.63\% \text{ formamide}) - (600/N)$  where N is the length of the probe.

Prehybridization may be carried out in 6X SSC, 5X Denhardt's reagent, 0.5% SDS, 0.1 mg/ml denatured fragmented salmon sperm DNA or 6X SSC, 5X Denhardt's reagent, 0.5% SDS, 0.1 mg/ml denatured fragmented salmon sperm DNA, 50% formamide. The composition of the SSC and Denhardt's solutions are listed in Sambrook et al., *supra*.

Hybridization is conducted by adding the detectable probe to the hybridization solutions listed above. Where the probe comprises double stranded DNA, it is denatured by incubating at elevated temperatures and quickly cooling before addition to the hybridization solution. It may also be desirable to similarly denature single stranded probes to eliminate or diminish formation of secondary structures or oligomerization. The filter is contacted with the hybridization solution for a sufficient period of time to allow the probe to hybridize to cDNAs or genomic DNAs containing sequences complementary thereto or homologous thereto. For probes over 200 nucleotides in length, the hybridization may be carried out at 15-25 °C below the  $T_m$ . For shorter probes, such as oligonucleotide probes, the hybridization

may be conducted at 5-10 °C below the  $T_m$ . Preferably, the hybridization is conducted in 6X SSC, for shorter probes. Preferably, the hybridization is conducted in 50% formamide containing solutions, for longer probes. All the foregoing hybridizations would be considered to be examples of hybridization performed under conditions of high stringency.

Following hybridization, the filter is washed for at least 15 minutes in 2X SSC, 0.1% SDS at room temperature or higher, depending on the desired stringency. The filter is then washed with 0.1X SSC, 0.5% SDS at room temperature (again) for 30 minutes to 1 hour. Nucleic acids which have hybridized to the probe are identified by conventional autoradiography and non-radioactive detection methods.

The above procedure may be modified to identify nucleic acids having decreasing levels of homology to the probe sequence. For example, to obtain nucleic acids of decreasing homology to the detectable probe, less stringent conditions may be used. For example, the hybridization temperature may be decreased in increments of 5 °C from 68 °C to 42 °C in a hybridization buffer having a  $Na^+$  concentration of approximately 1M. Following hybridization, the filter may be washed with 2X SSC, 0.5% SDS at the temperature of hybridization. These conditions are considered to be "moderate stringency" conditions above 50°C and "low stringency" conditions below 50°C. A specific example of "moderate stringency" hybridization conditions is when the above hybridization is conducted at 55°C. A specific example of "low stringency" hybridization conditions is when the above hybridization is conducted at 45°C.

Alternatively, the hybridization may be carried out in buffers, such as 6X SSC, containing formamide at a temperature of 42 °C. In this case, the concentration of formamide in the hybridization buffer may be reduced in 5% increments from 50% to 0% to identify clones having decreasing levels of homology to the probe. Following hybridization, the filter may be washed with 6X SSC, 0.5% SDS at 50 °C. These conditions are considered to be "moderate stringency" conditions above 25% formamide and "low stringency" conditions below 25% formamide. A specific example of "moderate stringency" hybridization conditions is when the above hybridization is conducted at 30% formamide. A specific example of "low stringency"



hybridization conditions is when the above hybridization is conducted at 10% formamide. Nucleic acids which have hybridized to the probe are identified by conventional autoradiography and non-radioactive detection methods.

The preceding methods may be used to isolate nucleic acids having at least 97%, at least 95%, at least 90%, at least 85%, at least 80%, or at least 70% sequence identity to a nucleic acid sequence selected from the group consisting of the sequences of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, fragments comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive bases thereof, and the sequences complementary thereto. The isolated nucleic acid may have a coding sequence that is a naturally occurring allelic variant of one of the coding sequences described herein. Such allelic variant may have a substitution, deletion or addition of one or more nucleotides when compared to the nucleic acids of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 17, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, or the sequences complementary thereto.

Additionally, the above procedures may be used to isolate nucleic acids which encode polypeptides having at least 99%, at least 95%, at least 90%, at least 85%, at least 80%, or at least 70% identity to a polypeptide having the sequence of one of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77 or fragments comprising at least 50, 75, 100, 150, 200, 300 consecutive amino acids thereof as determined using the BLASTP version 2.2.2 algorithm with default parameters.

Another aspect of the present invention is an isolated or purified polypeptide comprising the sequence of one of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77 or fragments comprising at least 50, 75, 100, 150, 200 or 300 consecutive amino acids thereof. As discussed herein, such polypeptides may be obtained by inserting a nucleic acid encoding the polypeptide into a vector such that the coding sequence is operably linked to a sequence capable of driving the expression of the

encoded polypeptide in a suitable host cell. For example, the expression vector may comprise a promoter, a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for modulating expression levels, an origin of replication and a selectable marker.

Promoters suitable for expressing the polypeptide or fragment thereof in bacteria include the *E.coli lac* or *trp* promoters, the *lacI* promoter, the *lacZ* promoter, the T3 promoter, the T7 promoter, the *gpt* promoter, the lambda  $P_R$  promoter, the lambda  $P_L$  promoter, promoters from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), and the acid phosphatase promoter. Fungal promoters include the  $\alpha$  factor promoter. Eukaryotic promoters include the CMV immediate early promoter, the HSV thymidine kinase promoter, heat shock promoters, the early and late SV40 promoter, LTRs from retroviruses, and the mouse metallothionein-I promoter. Other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses may also be used.

Mammalian expression vectors may also comprise an origin of replication, any necessary ribosome binding sites, a polyadenylation site, splice donors and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. In some embodiments, DNA sequences derived from the SV40 splice and polyadenylation sites may be used to provide the required nontranscribed genetic elements.

Vectors for expressing the polypeptide or fragment thereof in eukaryotic cells may also contain enhancers to increase expression levels. Enhancers are cis-acting elements of DNA, usually from about 10 to about 300-bp in length that act on a promoter to increase its transcription. Examples include the SV40 enhancer on the late side of the replication origin bp 100 to 270, the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and the adenovirus enhancers.

In addition, the expression vectors preferably contain one or more selectable marker genes to permit selection of host cells containing the vector. Examples of selectable markers that may be used include genes encoding dihydrofolate reductase or genes conferring neomycin resistance for

eukaryotic cell culture, genes conferring tetracycline or ampicillin resistance in *E. coli*, and the *S. cerevisiae* TRP1 gene.

In some embodiments, the nucleic acid encoding one of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77 or fragments comprising at least 50, 75, 100, 150, 200 or 300 consecutive amino acids thereof is assembled in appropriate phase with a leader sequence capable of directing secretion of the translated polypeptides or fragments thereof. Optionally, the nucleic acid can encode a fusion polypeptide in which one of the polypeptide of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77 or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof is fused to heterologous peptides or polypeptides, such as N-terminal identification peptides which impart desired characteristics such as increased stability or simplified purification or detection.

The appropriate DNA sequence may be inserted into the vector by a variety of procedures. In general, the DNA sequence is ligated to the desired position in the vector following digestion of the insert and the vector with appropriate restriction endonucleases. Alternatively, appropriate restriction enzyme sites can be engineered into a DNA sequence by PCR. A variety of cloning techniques are disclosed in Ausbel *et al.* Current Protocols in Molecular Biology, John Wiley 503 Sons, Inc. 1997 and Sambrook *et al.*, Molecular Cloning: A Laboratory Manual 2d Ed., Cold Spring Harbour Laboratory Press, 1989. Such procedures and others are deemed to be within the scope of those skilled in the art.

The vector may be, for example, in the form of a plasmid, a viral particle, or a phage. Other vectors include derivatives of chromosomal, nonchromosomal and synthetic DNA sequences, viruses, bacterial plasmids, phage DNA, baculovirus, yeast plasmids, vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies. A variety of cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook *et al.*,

Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989).

Particular bacterial vectors which may be used include the commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017), pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden), pGEM1 (Promega Biotec, Madison, WI, USA) pQE70, pQE60, pQE-9 (Qiagen), pD10, phiX174, pBluescript™ II KS, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene), ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia), pKK232-8 and pCM7. Particular eukaryotic vectors include pSV2CAT, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPV, pMSG, and pSVL (Pharmacia). However, any other vector may be used as long as it is replicable and stable in the host cell.

The host cell may be any of the host cells familiar to those skilled in the art, including prokaryotic cells or eukaryotic cells. As representative examples of appropriate hosts, there may be mentioned: bacteria cells, such as *E. coli*, *Streptomyces lividans*, *Streptomyces griseofuscus*, *Streptomyces ambofaciens*, *Bacillus subtilis*, *Salmonella typhimurium* and various species within the genera *Pseudomonas*, *Streptomyces*, *Bacillus*, and *Staphylococcus*, fungal cells, such as yeast, insect cells such as *Drosophila* S2 and *Spodoptera Sf9*, animal cells such as CHO, COS or Bowes melanoma, and adenoviruses. The selection of an appropriate host is within the abilities of those skilled in the art.

The vector may be introduced into the host cells using any of a variety of techniques, including electroporation transformation, transfection, transduction, viral infection, gene guns, or Ti-mediated gene transfer. Where appropriate, the engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the genes of the present invention. Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter may be induced by appropriate means (e.g., temperature shift or chemical induction) and the cells may be cultured for an additional period to allow them to produce the desired polypeptide or fragment thereof.

Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract is retained for further purification. Microbial cells employed for expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents. Such methods are well known to those skilled in the art. The expressed polypeptide or fragment thereof can be recovered and purified from recombinant cell cultures by methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Protein refolding steps can be used, as necessary, in completing configuration of the polypeptide. If desired, high performance liquid chromatography (HPLC) can be employed for final purification steps.

Various mammalian cell culture systems can also be employed to express recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts (described by Gluzman, Cell, 23:175(1981)), and other cell lines capable of expressing proteins from a compatible vector, such as the C127, 3T3, CHO, HeLa and BHK cell lines. The constructs in host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence. Polypeptides of the invention may or may not also include an initial methionine amino acid residue.

Alternatively, the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77 or fragments comprising at least 50, 75, 100, 150, 200 or 300 consecutive amino acids thereof can be synthetically produced by conventional peptide synthesizers. In other embodiments, fragments or portions of the polynucleotides may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, the fragments may be employed as intermediates for producing the full-length polypeptides.

Cell-free translation systems can also be employed to produce one of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77 or fragments comprising at least 50, 75, 100, 150, 200 or 300 consecutive amino acids thereof using mRNAs transcribed from a DNA construct comprising a promoter operably linked to a nucleic acid encoding the polypeptide or fragment thereof. In some embodiments, the DNA construct may be linearized prior to conducting an *in vitro* transcription reaction. The transcribed mRNA is then incubated with an appropriate cell-free translation extract, such as a rabbit reticulocyte extract, to produce the desired polypeptide or fragment thereof.

The present invention also relates to variants of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77 or fragments comprising at least 50, 75, 100, 150, 200 or 300 consecutive amino acids thereof. The term "variant" includes derivatives or analogs of these polypeptides. In particular, the variants may differ in amino acid sequence from the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77 by one or more substitutions, additions, deletions, fusions and truncations, which may be present in any combination.

The variants may be naturally occurring or created *in vitro*. In particular, such variants may be created using genetic engineering techniques such as site directed mutagenesis, random chemical mutagenesis, exonuclease III deletion procedures, and standard cloning techniques. Alternatively, such variants, fragments, analogs, or derivatives may be created using chemical synthesis or modification procedures.

Other methods of making variants are also familiar to those skilled in the art. These include procedures in which nucleic acid sequences obtained from natural isolates are modified to generate nucleic acids that encode polypeptides having characteristics which enhance their value in industrial or laboratory applications. In such procedures, a large number of variant sequences having one or more nucleotide differences with respect to the

sequence obtained from the natural isolate are generated and characterized. Preferably, these nucleotide differences result in amino acid changes with respect to the polypeptides encoded by the nucleic acids from the natural isolates.

For example, variants may be created using error prone PCR. In error prone PCR, DNA amplification is performed under conditions where the fidelity of the DNA polymerase is low, such that a high rate of point mutation is obtained along the entire length of the PCR product. Error prone PCR is described in Leung, D.W., *et al.*, *Technique*, 1:11-15 (1989) and Caldwell, R. C. & Joyce G.F., *PCR Methods Applic.*, 2:28-33 (1992). Variants may also be created using site directed mutagenesis to generate site-specific mutations in any cloned DNA segment of interest. Oligonucleotide mutagenesis is described in Reidhaar-Olson, J.F. & Sauer, R.T., *et al.*, *Science*, 241:53-57 (1988). Variants may also be created using directed evolution strategies such as those described in US patent nos. 6,361,974 and 6,372,497. The variants of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75 and 77 may be variants in which one or more of the amino acid residues of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75 or 77 are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code.

Conservative substitutions are those that substitute a given amino acid in a polypeptide by another amino acid of like characteristics. Typically seen as conservative substitutions are the following replacements: replacements of an aliphatic amino acid such as Ala, Val, Leu and Ile with another aliphatic amino acid; replacement of a Ser with a Thr or vice versa; replacement of an acidic residue such as Asp or Glu with another acidic residue; replacement of a residue bearing an amide group, such as Asn or Gln, with another residue bearing an amide group; exchange of a basic residue such as Lys or Arg with

another basic residue; and replacement of an aromatic residue such as Phe or Tyr with another aromatic residue.

Other variants are those in which one or more of the amino acid residues of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77 include a substituent group. Still other variants are those in which the polypeptide is associated with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol). Additional variants are those in which additional amino acids are fused to the polypeptide, such as leader sequence, a secretory sequence, a proprotein sequence or a sequence that facilitates purification, enrichment, or stabilization of the polypeptide.

In some embodiments, the fragments, derivatives and analogs retain the same biological function or activity as the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77. In other embodiments, the fragment, derivative or analogue includes a fused heterologous sequence that facilitates purification, enrichment, detection, stabilization or secretion of the polypeptide that can be enzymatically cleaved, in whole or in part, away from the fragment, derivative or analogue.

Another aspect of the present invention are polypeptides or fragments thereof which have at least 70%, at least 80%, at least 85%, at least 90%, or more than 95% identity to one of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75 and 77 or a fragment comprising at least 50, 75, 100, 150, 200 or 300 consecutive amino acids thereof. It will be appreciated that amino acid "identity" includes conservative substitutions such as those described above.

The polypeptides or fragments having homology to one of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77 or a fragment comprising at least 50, 75, 100, 150, 200 or 300



consecutive amino acids thereof may be obtained by isolating the nucleic acids encoding them using the techniques described above.

Alternatively, the homologous polypeptides or fragments may be obtained through biochemical enrichment or purification procedures. The sequence of potentially homologous polypeptides or fragments may be determined by proteolytic digestion, gel electrophoresis and/or microsequencing. The sequence of the prospective homologous polypeptide or fragment can be compared to one of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77 or a fragment comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof.

The polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77 or fragments, derivatives or analogs thereof comprising at least 40, 50, 75, 100, 150, 200 or 300 consecutive amino acids thereof invention may be used in a variety of applications. For example, the polypeptides or fragments, derivatives or analogs thereof may be used to catalyze biochemical reactions as described elsewhere in the specification.

The polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77 or fragments, derivatives or analogues thereof comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof, may also be used to generate antibodies which bind specifically to the polypeptides or fragments, derivatives or analogues. The antibodies generated from SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77 may be used to determine whether a biological sample contains *Streptomyces aizunensis* or a related microorganism.

In such procedures, a biological sample is contacted with an antibody capable of specifically binding to one of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45,

47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77 or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof. The ability of the biological sample to bind to the antibody is then determined. For example, binding may be determined by labeling the antibody with a detectable label such as a fluorescent agent, an enzymatic label, or a radioisotope. Alternatively, binding of the antibody to the sample may be detected using a secondary antibody having such a detectable label thereon. A variety of assay protocols which may be used to detect the presence of a polyketide-producer or of *Streptomyces aizunensis* or of polypeptides related to SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77 in a sample are familiar to those skilled in the art. Particular assays include ELISA assays, sandwich assays, radioimmunoassays, and Western Blots. Alternatively, antibodies generated from SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77 may be used to determine whether a biological sample contains related polypeptides that may be involved in the biosynthesis of polyketides.

Polyclonal antibodies generated against the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77 or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof can be obtained by direct injection of the polypeptides into an animal or by administering the polypeptides to an animal, preferably a nonhuman. The antibody so obtained will then bind the polypeptide itself. In this manner, even a sequence encoding only a fragment of the polypeptide can be used to generate antibodies that may bind to the whole native polypeptide. Such antibodies can then be used to isolate the polypeptide from cells expressing that polypeptide.

For preparation of monoclonal antibodies, any technique that provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kholer and Milstein, 1975, Nature, 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor et

al., 1983, Immunology Today 4:72), and the EBV-hybridoma technique (Cole, et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96).

Techniques described for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce single chain antibodies to the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77 or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof. Alternatively, transgenic mice may be used to express humanized antibodies to these polypeptides or fragments thereof.

Antibodies generated against the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77 or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof may be used in screening for similar polypeptides from a sample containing organisms or cell-free extracts thereof. In such techniques, polypeptides from the sample are contacted with the antibodies and those polypeptides which specifically bind the antibody are detected. Any of the procedures described above may be used to detect antibody binding. One such screening assay is described in "Methods for measuring Cellulase Activities", Methods in Enzymology, Vol 160, pp. 87-116.

In order to identify the function of the genes in the compound 2(a) locus, ORFs 1 to 38 were compared, using the BLASTP version 2.2.1 algorithm with the default parameters, to sequences in the National Center for Biotechnology Information (NCBI) nonredundant protein database and the DECIPHER<sup>®</sup> database of microbial genes, pathways and natural products (Ecopia BioSciences Inc. St.-Laurent, QC, Canada).

The accession numbers of the top GenBank hits of this Blast analysis are presented in Table 1 along with the corresponding E values. The E value relates the expected number of chance alignments with an alignment score at least equal to the observed alignment score. An E value of 0.00 indicates a perfect homolog. The E values are calculated as described in Altschul *et al.* *J.*

*Mol. Biol.*, 215, 403-410 (1990). The E value assists in the determination of whether two sequences display sufficient similarity to justify an inference of homology.

Table 1

ORF	Family	#aa	GenBank homology	probability	% identity	% similarity	proposed function of GenBank match
1		719	T35189.719aa	1E-200	556/705 (78.7%)	582/705 (82.55%)	helicase, Streptomyces coelicolor
			BAC17778.1,688aa	1E-165	340/700 (48.57%)	407/700 (58.14%)	helicase, Corynebacterium efficiens
			NP_600121.1,683aa	1E-161	334/701 (47.65%)	412/701 (58.77%)	helicase, Corynebacterium glutamicum
2	TESA	253	BAB69315.1,255aa	2E-82	142/243 (58.44%)	185/243 (76.13%)	thioesterase, Streptomyces avermitilis
			CAC20922.1,255aa	3E-78	145/247 (58.7%)	180/247 (72.87%)	PimI thioesterase, Streptomyces natalensis
			AAF71777.1,251aa	2E-73	135/244 (55.33%)	173/244 (70.9%)	NysE thioesterase, Streptomyces noursei
3	REGD	956	AAC68887.1,928aa	1E-132	336/959 (35.04%)	472/959 (49.22%)	transcriptional activator, Streptomyces venezuelae
			AAM88362.1,945aa	1E-131	331/957 (34.59%)	468/957 (48.9%)	NbmM regulator, Streptomyces narbonensis
			BAA84600.1,949aa	1E-127	339/965 (35.13%)	451/965 (46.74%)	response regulator, Streptomyces avermitilis
4	RREB	201	NP_629592.1,224aa	8E-49	106/204 (51.96%)	140/204 (68.63%)	response regulator, Streptomyces coelicolor
			CAA74720.1,217aa	8E-47	100/202 (49.5%)	138/202 (68.32%)	response regulator, Streptomyces reticuli
			NP_642485.1,213aa	1E-43	96/201 (47.76%)	132/201 (65.67%)	regulator, Xanthomonas axonopodis
5	SPKK	416	NP_628447.1,428aa	7E-39	116/312 (37.18%)	163/312 (52.24%)	kinase, Streptomyces coelicolor
			CAA74719.1,398aa	2E-37	113/304 (37.17%)	157/304 (51.64%)	kinase, Streptomyces reticuli
			CAC32293.1,404aa	6E-37	109/267 (40.82%)	139/267 (52.06%)	kinase, Streptomyces coelicolor
6	UNEW	186	NP_628531.1,185aa	0.002	30/102 (29.41%)	50/102 (49.02%)	membrane protein, Streptomyces coelicolor
7	UNFI	163	CAB10923.1,177aa	2E-27	67/162 (41.36%)	97/162 (59.88%)	hypothetical protein, Mycobacterium tuberculosis
			ZP_00059442.1,172aa	4E-24	66/177 (37.29%)	98/177 (55.37%)	hypothetical protein, Thermobifida fusca
			NP_644099.1,158aa	1E-08	35/107 (32.71%)	58/107 (54.21%)	hypothetical protein, Xanthomonas axonopodis
8	UNEX	514	E70508.487aa	4E-41	145/494 (29.35%)	210/494 (42.51%)	hypothetical protein, Mycobacterium tuberculosis
			ZP_00059443.1,554aa	5E-39	155/516 (30.04%)	216/516 (41.86%)	hypothetical protein, Thermobifida fusca
			NP_280206.1,514aa	1E-07	107/475 (22.53%)	169/475 (35.58%)	hypothetical protein, Halobacterium sp.
9	GTFA	367	AAM94798.1,376aa	4E-69	155/370 (41.89%)	205/370 (55.41%)	CaG3 glycosyltransferase, Micromonospora echinospora
			CAC16413.2,382aa	2E-60	150/373 (40.21%)	187/373 (50.13%)	glycosyltransferase, Streptomyces olivaceus
			AAF01811.1,390aa	5E-54	138/374 (36.9%)	179/374 (47.86%)	glycosyl transferase, Streptomyces nogalater

10	PKSH	8147	AAG23263.1,4928aa BAB69303.1,6048aa AAF71766.1,9477aa	1E-200 1E-200 1E-200	2487/5027 (49.47%) 2452/4407 (55.64%) 2489/4970 (50.08%)	3043/5027 (60.53%) 2853/4407 (64.74%) 3044/4970 (61.25%)	polyketide synthase, Saccharopolyspora spinosa polyketide synthase, Streptomyces avermitilis NysI polyketide synthase, Streptomyces noursei
11	PKSH	3428	AAF71766.1,9477aa AAK73501.1,9510aa CAC20921.1,9507aa	1E-200 1E-200 1E-200	1763/3432 (51.37%) 1738/3394 (51.21%) 1729/3385 (51.08%)	2086/3432 (60.78%) 2065/3394 (60.84%) 2050/3385 (60.56%)	NysI polyketide synthase, Streptomyces noursei AmphI polyketide synthase, Streptomyces nodosus PimS2 polyketide synthase, Streptomyces natalensis
12	PKSH	6751	AAF71766.1,9477aa AAK73501.1,9510aa CAC20921.1,9507aa	1E-200 1E-200 1E-200	2992/5949 (50.29%) 2961/5904 (50.15%) 2962/5917 (50.06%)	3662/5949 (61.56%) 3650/5904 (61.82%) 3652/5917 (61.72%)	NysI polyketide synthase, Streptomyces noursei AmphI polyketide synthase, Streptomyces nodosus PimS2 polyketide synthase, Streptomyces natalensis
13	PKSH	1657	AAF71775.1,3192aa BAB69196.1,3613aa AAG23266.1,3170aa	1E-200 1E-200 1E-200	781/1553 (50.29%) 775/1562 (49.62%) 775/1572 (49.3%)	938/1553 (60.4%) 936/1562 (59.92%) 941/1572 (59.86%)	NysB polyketide synthase, Streptomyces noursei polyketide synthase, Streptomyces avermitilis polyketide synthase, Saccharopolyspora spinosa
14	PKSH	5207	BAB69303.1,6048aa CAC20931.1,6797aa AAK73514.1,10917aa	1E-200 1E-200 1E-200	2713/5239 (51.78%) 2651/5183 (51.15%) 2047/4174 (49.04%)	3215/5239 (61.37%) 3187/5183 (61.49%) 2494/4174 (59.75%)	polyketide synthase, Streptomyces avermitilis PimS1 polyketide synthase, Streptomyces natalensis AmphC polyketide synthase, Streptomyces nodosus
15	PKSH	5432	AAK73514.1,10917aa AAF71776.1,11096aa CAC20931.1,6797aa	1E-200 1E-200 1E-200	2814/5447 (51.66%) 2836/5548 (51.12%) 2824/5426 (52.05%)	3377/5447 (62%) 3375/5548 (60.83%) 3378/5426 (62.26%)	AmphC polyketide synthase, Streptomyces nodosus NysC polyketide synthase, Streptomyces noursei PimS1 polyketide synthase, Streptomyces natalensis
16	PKSH	3227	AAF71775.1,3192aa	1E-200	1628/3207 (50.76%)	1957/3207 (61.02%)	NysB polyketide synthase, Streptomyces noursei

			AAF82408.1,4150aa	1E-200	1643/3237 (50.76%)	1957/3237 (60.46%)	deoxyvoleandolide synthase, Streptomyces antibioticus
			BAB69307.1,3352aa	1E-200	1612/3170 (50.85%)	1948/3170 (61.45%)	polyketide synthase, Streptomyces avermitilis
17	PKSH	7510	AAK73502.1,5644aa	1E-200	2761/5719 (48.28%)	3366/5719 (58.86%)	AmphJ polyketide synthase, Streptomyces nodosus
			AAF71776.1,11096aa	1E-200	2313/4464 (51.81%)	2755/4464 (61.72%)	NysC polyketide synthase, Streptomyces noursei
			CAA60460.1,8563aa	1E-200	2448/5643 (43.38%)	3074/5643 (54.47%)	polyketide synthase, Streptomyces hygroscopicus
18	PKSH	3872	AAK73514.1,10917aa	1E-200	1913/3588 (53.32%)	2273/3588 (63.35%)	AmphC polyketide synthase, Streptomyces nodosus
			AAF71776.1,11096aa	1E-200	1907/3684 (51.76%)	2280/3684 (61.89%)	NysC polyketide synthase, Streptomyces noursei
			CAC20931.1,6797aa	1E-200	1879/3564 (52.72%)	2241/3564 (62.88%)	PimS1 polyketide synthase, Streptomyces natalensis
19	AYTF	338	D83961,313aa	1E-09	72/294 (24.49%)	118/294 (40.14%)	malonyl CoA-ACP transacylase, Bacillus halodurans
			AAL20123.1,309aa	1E-08	73/303 (24.09%)	120/303 (39.6%)	malonyl-CoA-ACP transacylase, Salmonella typhimurium
			AAK60008.1,316aa	1E-07	74/286 (25.87%)	110/286 (38.46%)	malonyl-CoA-ACP transacylase, Streptomyces aureofaciens
20	MEAY	283	AD2333,275aa	6E-11	60/220 (27.27%)	97/220 (44.09%)	hypothetical protein, Nostoc sp.
			S76277,294aa	2E-08	70/255 (27.45%)	112/255 (43.92%)	hypothetical protein, Synechocystis sp.
			ZP_00019722.1,251aa	6E-08	56/224 (25%)	99/224 (44.2%)	hypothetical protein, Chloroflexus aurantiacus
21	ABCD	329	ZP_00080468.1,308aa	1E-54	142/334 (42.51%)	176/334 (52.69%)	hypothetical protein, Geobacter metallireducens
			D72257,327aa	5E-52	131/330 (39.7%)	186/330 (56.36%)	hypothetical protein, Thermotoga maritima
			NP_578312.1,321aa	5E-49	121/327 (37%)	176/327 (53.82%)	daunorubicin resistance protein, Pyrococcus furiosus
22	DEPL	317	CAA07388.1,305aa	4E-73	152/290 (52.41%)	173/290 (59.66%)	StrL, Streptomyces glaucescens
			AAF59936.1,294aa	5E-65	139/285 (48.77%)	165/285 (57.89%)	4-ketoreductase, Streptomyces antibioticus
			AAF01815.1,291aa	8E-63	136/289 (47.06%)	161/289 (55.71%)	dTDP-4-dehydrohamnose reductase, Streptomyces nogalater
23	EPIM	204	CAA44442,200aa	1E-56	108/195 (55.38%)	137/195 (70.26%)	epimerase, Streptomyces griseus

			CAA55578.1,200aa	2E-55	108/191 (56.54%)	129/191 (67.54%)	epimerase, Streptomyces glaucescens
			AAG29805.1,198aa	1E-51	104/188 (55.32%)	121/188 (64.36%)	epimerase, Streptomyces rishirensis
24	NUTA	328	CAA68514.1,355aa	1E-125	215/328 (65.55%)	263/328 (80.18%)	sugaractivating enzyme, Streptomyces griseus
			BAC55207.1,350aa	1E-122	217/328 (66.16%)	261/328 (79.57%)	glucose-1-phosphate thymidyltransferase, Streptomyces sp.
			AAF59934.1,356aa	1E-119	214/329 (65.05%)	260/329 (79.03%)	dTDP-D-glucose synthase, Streptomyces antibioticus
25	DEPA	328	NP_625052.1,324aa	1E-108	201/318 (63.21%)	218/318 (68.55%)	putative dehydratase, Streptomyces coelicolor
			CAA07755.1,331aa	1E-107	200/317 (63.09%)	218/317 (68.77%)	dTDP-glucose 4,6-dehydratase, Streptomyces argillaceus
			AAF82605.1,317aa	1E-105	191/318 (60.06%)	214/318 (67.3%)	dTDP-glucose 4,6-dehydratase, Streptomyces rimosus
26	TESA	214	BAB69315.1,255aa	7E-22	74/239 (30.96%)	97/239 (40.59%)	thioesterase, Streptomyces avermitilis
			T17413,281aa	3E-17	73/242 (30.17%)	95/242 (39.26%)	thioesterase, Streptomyces venezuelae
			AAC01736.1,254aa	3E-15	61/225 (27.11%)	88/225 (39.11%)	thioesterase, Amycolatopsis mediterranei
27	CALB	470	ZP_00025699.1,510aa	1E-27	116/466 (24.89%)	188/466 (40.34%)	hypothetical protein, Ralstonia metallidurans
			ZP_00006768.1,501aa	5E-22	125/474 (26.37%)	192/474 (40.51%)	hypothetical protein, Rhodobacter sphaeroides
			G87227,548aa	1e-20	120/495 (24.24%)	195/495 (39.39%)	acyl-CoA synthase, Mycobacterium leprae
28	TMOA	553	CAB76876.1,565aa	1E-200	318/522 (60.92%)	383/522 (73.37%)	amino oxidase, Streptomyces coelicolor
			ZP_00086824.1,560aa	1E-172	280/521 (53.74%)	369/521 (70.83%)	hypothetical protein, Pseudomonas fluorescens
			ZP_00126831.1,559aa	1E-171	280/521 (53.74%)	370/521 (71.02%)	tryptophan monooxygenase, Pseudomonas syringae
29	PPTF	231	CAA19952.1,226aa	3E-50	115/226 (50.88%)	132/226 (58.41%)	hypothetical protein, Streptomyces coelicolor
			AAG43513.1,246aa	1E-43	105/228 (46.05%)	127/228 (55.7%)	phosphopantetheinyl transferase, Streptomyces verticillus
			BAA22407.1,208aa	5E-36	91/214 (42.52%)	109/214 (50.93%)	hypothetical protein, Streptomyces sp.
30	UNAK	306	CAA19951.1,295aa	2E-97	169/275 (61.45%)	195/275 (70.91%)	hypothetical protein, Streptomyces coelicolor
			AAL15596.1,293aa	1E-91	163/269 (60.59%)	190/269 (70.63%)	Sim18, Streptomyces antibioticus
			NP_217311.1,324aa	8E-89	159/276 (57.61%)	187/276 (67.75%)	hypothetical protein, Mycobacterium tuberculosis
31	REGD	998	AAC68887.1,928aa	1E-113	331/1014 (32.64%)	445/1014 (43.89%)	transcriptional activator, Streptomyces venezuelae



			AAM88362.1,945aa	1E-110	323/1007 (32.08%)	438/1007 (43.5%)	NbmM regulator, Streptomyces narbonensis
			AAC38065.1,948aa	1E-105	322/1019 (31.6%)	427/1019 (41.9%)	regulatory protein, Streptomyces hygroscopicus
32	CTFC	518	NP_629669.1,527aa	1E-200	461/516 (89.34%)	487/516 (94.38%)	carboxyl transferase, Streptomyces coelicolor
			AAK06793.1,528aa	1E-200	423/510 (82.94%)	464/510 (90.98%)	putative decarboxylase, Streptomyces antibioticus
			AAD13544.1,524aa	1E-200	411/511 (80.43%)	450/511 (88.06%)	decarboxylase, Streptomyces cyanogenus
33	ADHY	329	CAD55203.1,322aa	1E-140	240/314 (76.43%)	273/314 (86.94%)	putative agmatinase, Streptomyces coelicolor
			ZP_00057179.1,324aa	1E-128	216/312 (69.23%)	260/312 (83.33%)	hypothetical protein, Thermobifida fusca
			BAB96819.1,353aa	1E-119	206/307 (67.1%)	252/307 (82.08%)	guanidinobutyrase, Arthrobacter sp.
34	ADSN	521	AAG29784.1,529aa	6E-86	189/512 (36.91%)	255/512 (49.8%)	ligase, Streptomyces rishirensis
			AAN65228.1,527aa	1E-81	183/512 (35.74%)	252/512 (49.22%)	amide synthetase, Streptomyces roseochromogenes
			AAG34183.1,519aa	3E-74	186/515 (36.12%)	248/515 (48.16%)	aminocoumarin ligase, Streptomyces antibioticus
35	AYTP	410	NP_697353.1,425aa	1E-104	193/385 (50.13%)	252/385 (65.45%)	5-aminolevulinic acid synthase, Brucella suis
			AAL52785.1,425aa	1E-103	192/385 (49.87%)	250/385 (64.94%)	5-aminolevulinic acid synthase, Brucella melitensis
			BAB52860.1,425aa	1E-102	191/385 (49.61%)	249/385 (64.68%)	5-aminolevulinic acid synthase, Mesorhizobium loti
36	CALB	506	CAB89029.1,511aa	1E-134	256/505 (50.69%)	319/505 (63.17%)	long-chain-fatty-acid-CoA ligase, Streptomyces coelicolor
			ZP_00059397.1,557aa	1E-122	241/505 (47.72%)	315/505 (62.38%)	hypothetical protein, Thermobifida fusca
			ZP_00105928.1,513aa	7E-78	185/501 (36.93%)	260/501 (51.9%)	hypothetical protein, Nostoc punctiforme
37		217	NP_635504.1,210aa	6E-11	54/139 (38.85%)	77/139 (55.4%)	regulatory protein, Xanthomonas campestris
			BAB84309.1,221aa	6E-11	66/221 (29.86%)	101/221 (45.7%)	response regulator, Halomonas halodenitrificans
			NP_631750.1,226aa	8E-11	71/218 (32.57%)	99/218 (45.41%)	response regulator, Streptomyces coelicolor
38		442	CAA18514.534aa	1E-116	206/359 (57.38%)	251/359 (69.92%)	hypothetical protein, Streptomyces coelicolor
			ZP_00058746.1,366aa	7E-19	98/358 (27.37%)	145/358 (40.5%)	hypothetical protein, Thermobifida fusca
			AAK47101.352aa	3E-08	85/357 (23.81%)	130/357 (36.42%)	hypothetical protein, Mycobacterium tuberculosis

The gene product of each of ORFs 1-38 in the compound 2(a) locus is assigned a protein family based on sequence similarity to the structure of known proteins as determined in Table 1. A putative function is attributed to each gene product of the compound 2(a) locus biosynthetic locus based on the known function of members of the respective protein families. Each protein family is referred to by a four-letter designation used throughout the description and figures. For example, members of protein family ABCD including the gene product of ORF 21 (SEQ ID NO: 43) are transmembrane transporters; members of protein family ADHY including the gene product ORF 33 (SEQ ID NO: 67) are amidinohydrolases; members of protein family ADSN including the gene product of ORF 34 (SEQ ID NO: 69) are adenylation/condensing enzymes; members of protein families AYTF and AYTP including ORFs 19 and 35 (SEQ ID NOS: 39 and 71) are acyltransferases; members of protein family CALB are acyl CoA ligases including ORF 27 and 36 (SEQ ID NO: 55 and 73); members of protein family CTFC including ORF 32 (SEQ ID NO: 65) are carboxyltransferase/decarboxylases; members of protein families DEPA and DEPL including ORFs 25 and 22 (SEQ ID NOS: 51 and 45) are dehydratase/epimerases; members of protein family EPIM including ORF 23 (SEQ ID NO: 47) are epimerises; members of protein family GTFA including ORF 9 (SEQ ID NO: 19) are glycosyl transferases; members of protein family MEAY including ORF 20 (SEQ ID NO: 41) are membrane proteins; members of protein family NUTA including ORF 24 (SEQ ID NO: 49) are nucleotidyltransferases; members of protein family PKSH including ORFs 10, 11, 12, 13, 14, 15, 16, 17 and 18 (SEQ ID NOS: 21, 23, 25, 27, 29, 31, 33, 35 and 37) are polyketide synthase, type I proteins; members of PPTF protein family including ORF 29 (SEQ ID NO: 59) are phosphopantetheinyl transferases; members of protein family REGD including ORFs 3 and 31 (SEQ ID NOS: 6 and 63) are transcriptional regulators; members of protein family RREB including ORF 4 (SEQ ID NO: 8) are response regulators; members of protein family SPKK including ORF 5 (SEQ ID NO: 10) are sensory protein kinases; members of protein family TESA including ORFs 2 and 26 (SEQ ID NOS: 4 and 53) are thioesterases; and members of protein family TMOA including ORF 28 (SEQ ID NO: 57) are monooxygenases. A

more detailed description of the function of each protein family is provided in Table 2. The correlation between structure and function for each protein family is provided in Table 2.

**Table 2**

Protein Family	Function
ABCD	ABC transporter; ATP-binding cassette transmembrane transporter; includes proteins with similarity to Mdr proteins of mammalian tumor cells that confer resistance to chemotherapeutic agents.
ADHY	amidinohydrolase; agmatine ureohydrolase; hydrolyzes linear amidines; requires manganese for catalysis and contains a conserved His important for catalytic function
ADSN	Adenylating/condensing synthase; amide synthase; enzymes able to activate substrates as acyl adenylates and subsequently transfer the acyl group to an amino group of the acceptor molecule
AYTF	acyltransferase; acyl CoA-acyl carrier protein transacylase; includes malonyl CoA-ACP transacylases
AYTP	acyltransferase; pyridoxal phosphate-dependent; includes 5-aminolevulinate synthase, a glycyl transferase that condenses glycine and succinyl-CoA.
CALB	acyl CoA ligase; shows similarity to plant coumarate CoA ligases, other aryl CoA ligases, yeast CoA synthetase and aminocoumarin ligases.
CTFC	carboxyltransferase/decarboxylase; carboxyltransferase component of acetyl-CoA carboxylase, generally a 2 subunit component, this family consists of a fusion of the beta and alpha subunits (beta-alpha).
DEPA	dehydratase/epimerase; dTDP-glucose 4,6-dehydratases, catalyze the second step in 6-deoxyhexose biosynthesis.
DEPL	dehydratase/epimerase; similar to StrL dTDP-dihydrostreptose synthase; OleU 4-ketoreductase; SnogC putative dTDP-4-dehydrorhamnose reductase
EPIM	epimerase; NDP-hexose epimerase; TDP-4-ketohexose- 3,5-epimerases, convert TDP-4-keto-6-deoxy-D-glucose to TDP-4-keto-6-deoxy-L-mannose (TDP-4-keto-L-rhamnose).
GTFA	glycosyl transferase.
MEAY	membrane protein; putative transporter, permease
NUTA	nucleotidyltransferase; dNDP-glucose synthase; alpha-D-glucose-1-phosphate thymidyltransferase; catalyze the first step in 6-deoxyhexose biosynthesis.
PKSH	polyketide synthase, type I.
PPTF	phosphopantetheinyl transferases, required for activation of both PKSs and NRPSs from inactive apo forms to active holo forms.
REGD	transcriptional regulator
RREB	response regulator; similar to response regulators that are known to bind DNA and act as transcriptional activators
SPKK	sensory protein kinase.
TESA	thioesterase.
TMOA	monooxygenase; strong similarity to plasmid-encoded tryptophan-2-monooxygenases.

UNAK	unknown; homolog of <i>S. coelicolor</i> hypothetical protein
UNEW	unknown; similar to putative integral membrane protein in <i>S. coelicolor</i>
UNEX	unknown; domain homology to many bacterial putative membrane proteins; contain so-called "bacterial membrane flanked domains" found in an uncharacterised family of membrane proteins that have one to three copies of the domain flanked by transmembrane helices.
UNFI	unknown; similar to putative membrane proteins

Biosynthesis of Compound 2(a) involves the multimodular type I polyketide synthase system (PKS) of ORFs 10 to 18 (SEQ ID NOS: 21, 23, 25, 27, 29, 31, 33, 35 and 37) illustrated in Figure 1. Type I PKSs are large modular proteins that condense acyl thioester units in a sequential manner. PKS systems consist of one or more polyfunctional polypeptides each of which is made up of modules. Each type I PKS module contains three domains; a  $\beta$ -ketoacyl protein synthase (KS), an acyltransferase (AT) and an acyl carrier protein (ACP). Domains conferring additional enzymatic activities such as ketoreductase (KR), dehydratase (DH) and enoylreductase (ER) can also be found in the PKS modules. These additional domains result in various degrees of reduction of the  $\beta$ -keto groups of the growing polyketide chain. Each module is responsible for one round of condensation and reduction of the  $\beta$ -ketoacyl units. There is a direct correlation between the number of modules and the length of the polyketide chain as well as between the domain composition of the modules and the degree of reduction of the polyketide product. The final polyketide product is released from the PKS protein through the action of a thioesterase domain found in the ultimate module of the PKS system. The genetic organization of most type I PKS enzymes is colinear with the order of biochemical reactions giving rise to the polyketide chain. One skilled in the art will readily understand that these features allow prediction of polyketide core structure based on the architecture of the PKS modules found in a given biosynthetic pathway [Hopwood, *Chem. Rev.*, 97:2465-2497 (1997)].

The compound 2(a) locus PKS system is composed of ORFs 10 to 18 (SEQ ID NOS: 21, 23, 25, 27, 29, 31, 33, 35 and 37) and comprises a total of 27 modules described in Table 3. The first module contains only an ACP domain and corresponds to the loading module (module 0) whereas each of the remaining 26 modules contain domains KS, AT and ACP in various

combinations with KR, DH and ER domains. The thioesterase domain present in ORF 18/module 26 indicates that this module is the ultimate one in the biosynthesis of the polyketide chain. Dehydratase domains in modules 6 and 11 as well as ketoreductase domain in module 12 appear to be inactive due to the presence of non-conservative amino acid residues in highly conserved regions important for catalysis.

**Table 3****compound 2(a) locus PKS domain coordinates**

ORF no.	SEQ ID NO Amino acid/ Nucleic acid	Amino Acid Residue	Nucleic Acid	Homology	Module no.
10	21/22	57-118	169-354	ACP	0
	21/22	141-566	421-1698	KS	1
	21/22	597-1031	1789-3093	AT	
	21/22	1304-1517	3910-4551	KR	
	21/22	1603-1664	4807-4992	ACP	
	21/22	1690-2118	5068-6354	KS	2
	21/22	2135-2562	6403-7686	AT	
	21/22	2833-3045	8497-9135	KR	
	21/22	3130-3191	9388-9573	ACP	
	21/22	3215-3640	9643-10920	KS	3
	21/22	3660-4089	10978-12267	AT	
	21/22	4102-4208	12304-12624	DH	
	21/22	4612-4829	13834-14487	KR	
	21/22	4911-4972	14731-14916	ACP	4
	21/22	5007-5438	15019-16314	KS	
	21/22	5460-5883	16378-17649	AT	
	21/22	6147-6360	18439-19080	KR	
	21/22	6444-6505	19330-19515	ACP	5
	21/22	6529-6954	19585-20862	KS	
	21/22	6979-7402	20935-22206	AT	
	21/22	7703-7918	23107-23754	KR	
	21/22	8002-8063	24004-24189	ACP	6
11	23/24	37-462	109-1386	KS	
	23/24	493-919	1477-2757	AT	
	23/24	932-1038	2794-3114	DH*	
	23/24	1411-1672	4231-4881	KR	

	23/24	1706-1767	5116-5301	ACP	
	23/24	1794-2215	5380-6645	KS	
	23/24	2232-2659	6694-7977	AT	7
	23/24	2960-3173	8878-9519	KR	
	23/24	3258-3319	9772-9957	ACP	
12	25/26	36-461	106-1383	KS	
	25/26	483-907	1447-2721	AT	
	25/26	919-1027	2755-3081	DH	8
	25/26	1439-1655	4315-4965	KR	
	25/26	1736-1797	5206-5391	ACP	
	25/26	1831-2256	5491-6768	KS	
	25/26	2281-2714	6841-8142	AT	9
	25/26	2981-3194	8941-9582	KR	
	25/26	3287-3339	9832-10017	ACP	
	25/26	3361-3786	10081-11358	KS	
	25/26	3803-4225	11407-12675	AT	
	25/26	4494-4706	13480-14118	KR	10
	25/26	4795-4856	14383-14568	ACP	
	25/26	4880-5304	14638-15912	KS	
	25/26	5323-5748	15967-17244	AT	
	25/26	5761-5866	17278-17598	DH*	11
	25/26	6294-6510	18880-19530	KR	
	25/26	6599-6660	19795-19980	ACP	
13	27/28	35-460	103-1380	KS	
	27/28	484-920	1450-2760	AT	12
	27/28	1195-1406	3583-4218	KR*	
	27/28	1490-1551	4468-4653	ACP	
14	29/30	35-460	103-1380	KS	
	29/30	487-918	1459-2754	AT	13
	29/30	1219-1431	3655-4293	KR	
	29/30	1514-1575	4540-4725	ACP	
	29/30	1602-2027	4804-6081	KS	
	29/30	2046-2473	6136-7419	AT	
	29/30	2486-2592	7456-7776	DH	14
	29/30	2980-3196	8938-9588	KR	
	29/30	3287-3339	9832-10017	ACP	
	29/30	3363-3788	10087-11364	KS	
	29/30	3810-4237	11428-12711	AT	
	29/30	4249-4355	12745-13065	DH	15
	29/30	4760-4976	14278-14928	KR	
	29/30	5060-5124	15187-15372	ACP	

15	31/32	35-460	103-1380	KS	16
	31/32	480-914	1438-2742	AT	
	31/32	926-1032	2776-3096	DH	
	31/32	1423-1639	4267-4917	KR	
	31/32	1737-1798	5209-5394	ACP	
	31/32	1822-2247	5464-6741	KS	17
	31/32	2263-2690	6787-8070	AT	
	31/32	2703-2809	8107-8427	DH	
	31/32	3188-3404	9562-10212	KR	
	31/32	3483-3544	10447-10632	ACP	
	31/32	3568-3993	10702-11979	KS	18
	31/32	4017-4442	12049-13326	AT	
	31/32	4456-4562	13366-13686	DH	
	31/32	4978-5194	14932-15582	KR	
	31/32	5285-5346	15853-16038	ACP	
16	33/34	35-460	103-1380	KS	19
	33/34	481-917	1441-2751	AT	
	33/34	1205-1416	3613-4248	KR	
	33/34	1500-1561	4498-4683	ACP	
	33/34	1585-2010	4753-6030	KS	20
	33/34	2067-2505	6199-7515	AT	
	33/34	2786-2998	8356-8994	KR	
	33/34	3083-3144	9247-9432	ACP	
17	35/36	40-465	118-1395	KS	21
	35/36	503-941	1507-2823	AT	
	35/36	954-1060	2860-3180	DH	
	35/36	1456-1672	4366-5016	KR	
	35/36	1751-1812	5251-5436	ACP	
	35/36	1835-2260	5503-6780	KS	22
	35/36	2281-2718	6841-8154	AT	
	35/36	2731-2837	8191-8511	DH	
	35/36	3188-3546	9562-10638	ER	
	35/36	3551-3767	10651-11301	KR	
	35/36	3846-3907	11536-11721	ACP	
	35/36	3932-4357	11794-13071	KS	23
	35/36	4373-4803	13117-14409	AT	
	35/36	4815-4921	14443-14763	DH	
	35/36	5300-5516	15898-16548	KR	
	35/36	5597-5658	16789-16974	ACP	
	35/36	5686-6111	17056-18333	KS	
	35/36	6131-6557	18391-19671	AT	

	35/36	6572-6678	19714-20034	DH	24
	35/36	7062-7288	21184-21834	KR	
	35/36	7363-7424	22087-22272	ACP	
18	37/38	34-459	100-1377	KS	25
	37/38	502-926	1504-2778	AT	
	37/38	938-1044	2812-3132	DH	
	37/38	1420-1636	4258-4908	KR	
	37/38	1715-1776	5143-5328	ACP	
	37/38	1799-2224	5395-6672	KS	26
	37/38	2247-2673	6739-8019	AT	
	37/38	2686-2792	8056-8376	DH	
	37/38	3203-3419	9607-10257	KR	
	37/38	3513-3574	10537-10722	ACP	
	37/38	3649-3872	10945-11616	TE	

One skilled in the art would understand that all KS domains are functional as the multiple amino acid alignment of KS domains present in the compound 2(a) locus PKS system (Figure 2) shows an overall similarity of domains and conservation of amino acid residues and domain regions important for activity. Similarly, multiple amino acid alignment of AT domains (Figure 3), ER domains (Figure 5), ACP domains (Figure 7) and TE domains (Figure 8) show an overall similarity of related domains and a high conservation of protein regions and of amino acid residues important for catalytic activity. The domains that occur only once in the compound 2(a) locus PKS, namely the enoylreductase (ER) domain in ORF 17 (SEQ ID NO: 35) and the thioesterase (TE) domain in ORF 18 (SEQ ID NO: 37) are compared to prototypical domains from the nystatin type I polyketide system (Figures 5 and 8) (see Brauteset *et al.*, *supra*).

Comparison of DH domains found in the compound 2(a) locus PKS indicates a high conservation of amino acid residues important for catalytic activity (Figure 4). However, two DH domains are inactive as they contain non-conservative amino acid substitutions in a region of high sequence conservation. As highlighted in Figure 4, the DH domain of module 6 in ORF 11 (SEQ ID NO: 23) and the DH domain of module 11 in ORF 12 (SEQ ID



NO: 25) contain substitutions of charged amino acids arginine and glutamic acid respectively for non-charged aliphatic amino acids.

Comparison of KR domains found in the compound 2(a) locus PKS system also displays a conservation of active sites and amino acid residues important for catalysis with the exception of the KR domain of module 12 found in ORF 13 (SEQ ID NO: 27). Figure 6 shows the presence in that module of a substitution of a glutamine (Q) for a highly conserved tyrosine (Y) amino acid residue. This non-conservative amino acid substitution results in the inactivation of the enzymatic activity of the KR domain of module 12 in ORF 13 (SEQ ID NO: 27) (ORF13\_pKR01).

Phylogenetic analysis of the compound 2(a) locus PKS AT domains was conducted to assess the nature of the  $\beta$ -keto acyl units that are incorporated in the growing polyketide chain. The compound 2(a) locus PKS AT domains were compared to two domains, AAF71779mod03 and AAF71766mod11, derived from the nystatin PKS system [Brautaset, *supra*] and specifying the incorporation of malonyl-CoA and methylmalonyl-CoA respectively. Figure 9 shows the phylogenetic relatedness of the various AT domains indicating that, in the compound 2(a) locus PKS, ORF 13 (SEQ ID NO: 27) module 12 as well as ORF 16 (SEQ ID NO: 33) modules 19 and 20 incorporate methylmalonate in the polyketide chain whereas all remaining AT domains incorporate malonate extender  $\beta$ -keto acyl units.

Domain analysis of the compound 2(a) locus PKS system provides clear indication as to synthesis of the polyketide core structure. While not intending to be limited to any particular mode of action or biosynthetic scheme, the nature and organization of the compound 2(a) locus PKS modules can explain the synthesis of Compound 2(a). Figure 10 highlights schematically a series of reactions catalyzed by the polyketide synthase system based on the correlation between the deduced domain architecture and the polyketide core of the compounds 2(a). Type I PKS domains and the reactions they carry out are well known to those skilled in the art and well documented in the literature; see for example, Hopwood, *supra*.

A biosynthetic pathway for the production of the  $\gamma$ -aminobutyryl-CoA starter unit is also shown. The gene product of ORF 28 (SEQ ID NO: 57), a

member of protein family TMOA, catalyzes the decarboxylative oxidation of arginine forming 4-guanidinobutanamide. The gene product of ORF 33 (SEQ ID NO: 67), a member of protein family ADHY, catalyzes hydrolysis of the amidino group forming  $\gamma$ -aminobutanamide that is further activated by either ORF 27 or 36 (SEQ ID NOS: 55 and 73 respectively), both members of protein family CALB, to give  $\gamma$ -aminobutyryl-CoA (Figure 10a). The gene product of ORF 19 (SEQ ID NO: 39), a member of protein family AYTF, loads this unusual extender unit onto the ACP domain of the loading module (module 0) of ORF 10 (SEQ ID NO: 21), a member of protein family PKSH, as illustrated in Figure 10b. The polyketide chain continues to grow by the sequential condensation of malonyl-CoA and methylmalonyl-CoA extender units that are further reduced by specific domains to various degrees. Dehydratase domains found in module 6 of ORF 11 (SEQ ID NO: 23) and module 11 of ORF 12 (SEQ ID NO: 25) as well as the ketoreductase domain found in module 12 of ORF 13 (SEQ ID NO: 27) are inactive and consequently do not catalyze their respective reductive reactions. The mature polyketide chain is then released through the action of the thioesterase domain found in module 26 of ORF 18 (SEQ ID NO: 37), a member of protein family PKSH as illustrated in Figure 10b. The polyketide core structure expected from the architecture of the PKS domains of the compound 2(a) locus is entirely consistent with the polyketide portion of the compound 2(a).

The compound 2(a) locus contains genes involved in the synthesis of two other components found in the chemical structure of the compound 2(a) locus. Figure 11a illustrates a biosynthetic pathway for the production of the aminohydroxy-cyclopentenone moiety found in the compound 2(a) locus. The gene product of ORF 35 (SEQ ID NO: 71), a member of protein family AYTP, condenses glycine with succinyl-CoA forming 5-aminolevulinate. This intermediate is further activated through the action of either the gene products of ORF 27 or 36 (SEQ ID NOS: 55 and 73 respectively), both members of protein family CALB, forming 5-aminolevulinate-CoA that may spontaneously cyclize to produce aminohydroxycyclopentenone. This moiety is subsequently condensed to the activated carboxy terminus of the polyketide chain through

the action of the gene product of ORF 34 (SEQ ID NO: 69), a member of protein family ADSN as illustrated in Figure 10c.

Figure 11b depicts the biosynthetic pathway of the deoxysugar component of Compound 2(a). The gene product of ORF 24 (SEQ ID NO: 49), a member of protein family NUTA, activates D-glucose forming dNDP-D-glucose that is subsequently dehydrated through the action of the gene product of ORF 25 (SEQ ID NO: 51), a member of protein family DEPA, forming dNDP-4-keto-4, 6-dideoxy-D-glucose. The gene product of ORF 22 (SEQ ID NO: 45), a member of protein family DEPL, further reduces this intermediate forming dNDP-D-fucose that is subsequently epimerized by the gene product of ORF 23 (SEQ ID NO: 47), a member of protein family EPIM, producing dNDP-L-rhamnose.

The final deoxysugar moiety is transferred onto a hydroxyl group of the polyketide core structure through the action of a glycosyltransferase, i.e. the gene product of ORF 9 (SEQ ID NO: 19), a member of protein family GTFA, as illustrated in Figure 10c. Figure 10c proposes one scheme in regard to timing of the reactions catalyzed by the gene product of ORF 34 (SEQ ID NO: 69), a member of protein family CALB, and by the gene product of ORF 9 (SEQ ID NO: 19), a member of protein family GTFA. However, it will be readily understood that the invention does not reside in the actual timing and order of the reactions as depicted in Figure 10c.

Additional proteins forming the compound 2(a) locus include the gene product of ORF 2 (SEQ ID NO: 4) and a member of protein family TESA which is expected to having polyketide-priming editing functions; the gene products of ORFs 3, 4, 5 and 31 (SEQ ID NOS: 6, 8, 10 and 63), members of protein families REGD, RREB, SPKK and REGD respectively, are expected to regulate synthesis of Compound 2(a); the gene products of ORFs 6 and 21 (SEQ ID NOS: 12 and 43), members of protein families UNEW and ABCD respectively, are involved in transmembrane transport; and the gene product of ORF 29 (SEQ ID NO: 59), a member of protein family PPTF, activates ACP domains through phosphopantetheinylation.

Structural modification of compound of Formula I and Formula II and Compound 2(a) are attained by the genetic modifications of the compound 2(a) locus. Genetic modifications of PKS biosynthetic loci are well known in

the art. The WO 01/34816 patent publication teaches the construction of a library of structural variants of the macrolide polyketide rapamycin derived from the genetic modification of genes in the locus that directs rapamycin synthesis. The genetic modifications taught, include gene inactivation, gene insertion and gene replacement. These modifications, both individually and in combination at different positions within the rapamycin locus, resulted in alteration of polyketide starter units, chain length and hydroxyl stereospecificities in rapamycin. Similarly, McDaniel *et.al.* [Proc Natl Acad Sci USA, 1999, 96:18646-51] generated a library of over 50 derivatives of the macrolide antibiotic erythromycin using a combination of genetic modifications including gene inactivation, macrolide chain length and hydroxyl stereospecificity modifications of the erythromycin biosynthesis genes.

The elucidation of the nucleic acid sequences that encodes the biosynthesis of Compound 2a provides the biological tools to enable one skilled in the art to genetically modify the biosynthetic pathway to generate variants of the Compound 2a. In particular, Type I PKS systems may be manipulated by changing the number of modules, their specificities towards carboxylic acids, and by inactivating or inserting domains with reductive activities (Katz, Chem. Rev. v. 97, 2557-2575, 1997). Thus, the polyketide synthase system of Compound 2(a) may be engineered by modifying, adding, or deleting domains, or replacing them with those taken from other Type I PKS enzymes. Compounds of Formula I may be produced using a modified PKS system created based on the polyketide synthase system for the production of Compound 2a. Preferred modified PKS systems are those wherein a KS, AT, KR, DH or ER domain has been inactivated or deleted.

In one aspect, the invention is directed to preparation of a polyketide of Formula I or II resulting from a modified polyketide synthase system, which modification include deletions, mutagenesis, inactivation or replacement of one or more of the domains of the invention. The modified polyketide synthase system produces compounds of Formula I that may differ from the compound of Formula 2a in size, degree of saturation and oxidation. In another aspect, the invention is directed to compounds of Formula I or II produced by genetic modification of the polyketide synthase system for the compound 2(a) locus.

The compounds of this invention may be formulated into pharmaceutical compositions comprised of compounds of Formula I in combination with a pharmaceutically acceptable carrier.

The compounds of this invention are useful in treating bacterial infections, fungal infections and cancer.

Molecular terms, when used in this application, have their common meaning unless otherwise specified.

The term alkyl refers to a linear or branched hydrocarbon group. Examples of alkyl groups include, without limitation, methyl, ethyl, n-propyl, isopropyl, n-butyl, pentyl, hexyl, heptyl, cyclopentyl, cyclohexyl, cyclohexymethyl, and the like. Alkyl groups may optionally be substituted with one or more substituents selected from acyl, amino, acylamino, acyloxy, carboalkoxy, carboxy, carboxyamido, cyano, halo, hydroxyl, nitro, thio, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkoxy, aryloxy, sulfinyl, sulfonyl, oxo, guanidino and formyl.

The term alkenyl refers to a linear, branched or cyclic hydrocarbon group containing at least one carbon-carbon double bond. Examples of alkenyl groups include, without limitation, vinyl, 1-propene-2-yl, 1-butene-4-yl, 2-butene-4-yl, 1-pentene-5-yl and the like. Alkenyl groups may optionally be substituted with one or more substituents selected from acyl, amino, acylamino, acyloxy, carboalkoxy, carboxy, carboxyamido, cyano, halo, hydroxyl, nitro, thio, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkoxy, aryloxy, sulfinyl, sulfonyl, formyl, oxo and guanidino. The double bond portion(s) of the unsaturated hydrocarbon chain may be either in the cis or trans configuration.

The term cycloalkyl or cycloalkyl ring refers to a saturated or partially unsaturated carbocyclic ring in a single or fused carbocyclic ring system having from three to fifteen ring members. Examples of cycloalkyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclohexyl, and cycloheptyl. Cycloalkyl groups may optionally be substituted with one or more substituents selected from acyl, amino, acylamino, acyloxy, carboalkoxy, carboxy, carboxyamido, cyano, halo, hydroxyl, nitro, thio, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkoxy, aryloxy, sulfinyl, sulfonyl and formyl.

The term heterocycloalkyl, heterocyclic or heterocycloalkyl ring refers to a saturated or partially unsaturated ring containing one to four hetero atoms or hetero groups selected from O, N, NH, NR<sup>x</sup>, PO<sub>2</sub>, S, SO or SO<sub>2</sub> in a single or fused heterocyclic ring system having from three to fifteen ring members. Examples of heterocycloalkyl groups include, without limitation, morpholinyl, piperidinyl, and pyrrolidinyl. Heterocycloalkyl groups may optionally be substituted with one or more substituents selected from acyl, amino, acylamino, acyloxy, oxo, thiocarbonyl, imino, carboalkoxy, carboxy, carboxyamido, cyano, halo, hydroxyl, nitro, thio, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkoxy, aryloxy, sulfinyl, sulfonyl and formyl.

The term amino acid refers to a natural amino acid, a synthetic amino acid or a synthetic derivative of a natural amino acid. Examples of natural amino acids include, but are not limited to alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine.

The term halo is defined as a bromine, chlorine, fluorine or iodine atom.

The term aryl or aryl ring refers to an aromatic group comprising a single or fused ring system, having from five to fifteen ring members. Examples of aryl groups include, without limitation, phenyl, naphthyl, biphenyl, terphenyl. Aryl groups may optionally be substituted with one or more substituent group selected from acyl, amino, acylamino, acyloxy, azido, alkythio, carboalkoxy, carboxy, carboxyamido, cyano, halo, hydroxyl, nitro, thio, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkoxy, aryloxy, sulfinyl, sulfonyl and formyl.

The term heteroaryl or heteroaryl ring refers to an aromatic group comprising a single or fused ring system, having from five to fifteen ring members and containing at least one hetero atom such as O, N, S, SO and SO<sub>2</sub>. Examples of heteroaryl groups include, without limitation, pyridinyl, thiazolyl, thiadiazoyl, isoquinolinyl, pyrazolyl, oxazolyl, oxadiazoyl, triazolyl, and pyrrolyl groups. Heteroaryl groups may optionally be substituted with one or more substituent groups selected from acyl, amino, acylamino, acyloxy, carboalkoxy, carboxy, carboxyamido, cyano, halo, hydroxyl, nitro, thio,

thiocarbonyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkoxy, aryloxy, sulfinyl, sulfonyl, and formyl.

As used herein, the term "treatment" refers to the application or administration of a therapeutic agent to a patient, or application or administration of a therapeutic agent to an isolated tissue or cell line from a patient, who has a disorder, e.g., a disease or condition, a symptom of disease, or a predisposition toward a disease, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect the disease, the symptoms of disease, or the predisposition toward disease.

As used herein, a "pharmaceutical composition" comprises a pharmacologically effective amount of a farnesyl dibenzodiazepinone and a pharmaceutically acceptable carrier. As used herein, "pharmacologically effective amount," "therapeutically effective amount" or simply "effective amount" refers to that amount of a farnesyl dibenzodiazepinone effective to produce the intended pharmacological, therapeutic or preventive result. For example, if a given clinical treatment is considered effective when there is at least a 25% reduction in a measurable parameter associated with a disease or disorder, a therapeutically effective amount of a drug for the treatment of that disease or disorder is the amount necessary to effect at least a 25% reduction in that parameter.

The term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent. Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The term specifically excludes cell culture medium. For drugs administered orally, pharmaceutically acceptable carriers include, but are not limited to pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while corn starch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as

glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract.

Pharmaceutically acceptable salts include acid addition salts and base addition salts. The nature of the salt is not critical, provided that it is pharmaceutically-acceptable. Without being limited, examples of acid addition salts include hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulphuric, phosphoric, formic, acetic, citric, tartaric, succinic, oxalic, malic, glutamic, propionic, glycolic, gluconic, maleic, embonic (pamoic), methanesulfonic, ethanesulfonic, 2-hydroxyethanesulfonic, pantothenic, benzenesulfonic, toluenesulfonic, sulfanilic, mesylic, cyclohexylaminosulfonic, stearic, algenic,  $\beta$ -hydroxybutyric, malonic, galactantic, galacturonic acid and the like. Suitable pharmaceutically-acceptable base addition salts of compounds of the invention include, but are not limited to, metallic salts made from aluminium, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine, lysine, procaine and the like. Additional examples of pharmaceutically acceptable salts are listed in *Journal of Pharmaceutical Sciences*, 1977, 66:2. All of these salts may be prepared by conventional means from the corresponding compounds of Formula I by treating with the appropriate acid or base.

The compounds of the present invention can possess one or more asymmetric carbon atoms and can exist as optical isomers forming mixtures of racemic or non-racemic compounds. The compounds of the present invention are useful as a single isomer or as a mixture of stereochemical isomeric forms. Diastereoisomers, i.e., nonsuperimposable stereochemical isomers, can be separated by conventional means such as chromatography, distillation, crystallization and sublimation. The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes.

The invention embraces isolated compounds. An isolated compound refers to a compound which represents at least 10%, 20%, 50% and 80% of the compound of the present invention present in a mixture, provided that the mixture comprising the compound of the invention has demonstrable (i.e. statistically significant) biological activity including antibacterial, antifungal or



anticancer activity when tested in conventional biological assays known to a person skilled in the art.

The compounds of the present invention, or pharmaceutically acceptable salts thereof, can be formulated for oral, intravenous, intramuscular, subcutaneous, topical or parenteral administration for the therapeutic or prophylactic treatment of diseases, particularly bacterial and fungal infections. For oral or parental administration, compounds of the present invention can be mixed with conventional pharmaceutical carriers and excipients and used in the form of tablets, capsules, elixirs, suspensions, syrups, wafers and the like. The compositions comprising a compound of this present invention will contain from about 0.1% to about 99.9%, about 5% to about 95%, about 10% to about 80% or about 15% to about 60% by weight of the active compound.

The pharmaceutical preparations disclosed herein are prepared in accordance with standard procedures and are administered at dosages that are selected to reduce, prevent, or eliminate bacterial and fungal infection or the cancer (See, e.g., Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA and Goodman and Gilman's the Pharmaceutical Basis of Therapeutics, Pergamon Press, New York, NY, the contents of which are incorporated herein by reference, for a general description of the methods for administering various antimicrobial agents for human therapy). The compositions of the present invention can be delivered using controlled (e.g., capsules) or sustained release delivery systems (e.g., bioerodable matrices). Exemplary delayed release delivery systems for drug delivery that are suitable for administration of the compositions of the invention (preferably of Formula I) are described in U.S. Patent Nos 4,452,775 (issued to Kent), 5,239,660 (issued to Leonard), 3,854,480 (issued to Zaffaroni).

The pharmaceutically-acceptable compositions of the present invention comprise one or more compounds of the present invention in association with one or more non-toxic, pharmaceutically-acceptable carriers and/or diluents and/or adjuvants and/or excipients, collectively referred to herein as "carrier" materials, and if desired other active ingredients. The compositions may contain common carriers and excipients, such as corn starch or gelatin,

lactose, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride and alginic acid. The compositions may contain crosarmellose sodium, microcrystalline cellulose, sodium starch glycolate and alginic acid.

Lubricants that can be used include magnesium stearate or other metallic stearates, stearic acid, silicon fluid, talc, waxes, oils and colloidal silica.

Flavouring agents such as peppermint, oil of wintergreen, cherry flavouring or the like can also be used. It may also be desirable to add a coloring agent to make the dosage form more esthetic in appearance or to help identify the product comprising a compound of the present invention.

For oral administration, the pharmaceutical compositions are in the form of, for example, a tablet, capsule, suspension or liquid. For oral use, solid formulations such as tablets and capsules are particularly useful. Sustained released or enterically coated preparations may also be devised. Tablet binders that can be included are acacia, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone (Providone), hydroxypropyl methylcellulose, sucrose, starch and ethylcellulose. For pediatric and geriatric applications, suspension, syrups and chewable tablets are especially suitable. The pharmaceutical composition is preferably made in the form of a dosage unit containing a therapeutically-effective amount of the active ingredient. Examples of such dosage units are tablets and capsules. For therapeutic purposes, the tablets and capsules can contain, in addition to the active ingredient, conventional carriers such as binding agents, for example, acacia gum, gelatin, polyvinylpyrrolidone, sorbitol, or tragacanth; fillers, for example, calcium phosphate, glycine, lactose, maize-starch, sorbitol, or sucrose; lubricants, for example, magnesium stearate, polyethylene glycol, silica or talc; disintegrants, for example, potato starch, flavoring or coloring agents, or acceptable wetting agents. Oral liquid preparations generally are in the form of aqueous or oily solutions, suspensions, emulsions, syrups or elixirs may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous agents, preservatives, coloring agents and flavoring agents. Examples of additives for liquid preparations include acacia, almond

oil, ethyl alcohol, fractionated coconut oil, gelatin, glucose syrup, glycerin, hydrogenated edible fats, lecithin, methyl cellulose, methyl or propyl *para*-hydroxybenzoate, propylene glycol, sorbitol, or sorbic acid.

For intravenous (IV) use, compounds of the present invention can be dissolved or suspended in any of the commonly used intravenous fluids and administered by infusion. Intravenous fluids include, without limitation, physiological saline or Ringer's solution.

Formulations for parental administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions or suspensions can be prepared from sterile powders or granules having one or more of the carriers mentioned for use in the formulations for oral administration. The compounds can be dissolved in polyethylene glycol, propylene glycol, ethanol, corn oil, benzyl alcohol, sodium chloride, and/or various buffers.

For intramuscular preparations, a sterile formulation of compounds of the present invention or suitable soluble salts forming the compound, can be dissolved and administered in a pharmaceutical diluent such as Water-for-Injection (WFI), physiological saline or 5% glucose. A suitable insoluble form of the compound may be prepared and administered as a suspension in an aqueous base or a pharmaceutically acceptable oil base, e.g. an ester of a long chain fatty acid such as ethyl oleate.

For topical use the compounds of present invention can also be prepared in suitable forms to be applied to the skin, or mucus membranes of the nose and throat, and can take the form of creams, ointments, liquid sprays or inhalants, lozenges, or throat paints. Such topical formulations further can include chemical compounds such as dimethylsulfoxide (DMSO) to facilitate surface penetration of the active ingredient.

For application to the eyes or ears, the compounds of the present invention can be presented in liquid or semi-liquid form formulated in hydrophobic or hydrophilic bases as ointments, creams, lotions, paints or powders.

For rectal administration the compounds of the present invention can be administered in the form of suppositories admixed with conventional carriers such as cocoa butter, wax or other glyceride.

Alternatively, the compound of the present invention can be in powder form for reconstitution in the appropriate pharmaceutically acceptable carrier at the time of delivery. In another embodiment, the unit dosage form of the compound can be a solution of the compound or a salt thereof in a suitable diluent in sterile, hermetically sealed ampoules.

The amount of the compound of the present invention in a unit dosage comprises a therapeutically-effective amount of at least one active compound of the present invention which may vary depending on the recipient subject, route and frequency of administration. A recipient subject refers to a plant, a cell culture or an animal such as an ovine or a mammal including a human.

According to this aspect of the present invention, the novel compositions disclosed herein are placed in a pharmaceutically acceptable carrier and are delivered to a recipient subject (including a human subject) in accordance with known methods of drug delivery. In general, the methods of the invention for delivering the compositions of the invention in vivo utilize art-recognized protocols for delivering the agent with the only substantial procedural modification being the substitution of the compounds of the present invention for the drugs in the art-recognized protocols.

Likewise, the methods for using the claimed composition for treating cells in culture, for example, to eliminate or reduce the level of bacterial or fungal contamination of a cell culture, utilize art-recognized protocols for treating cell cultures with antibacterial or antifungal agent(s) with the only substantial procedural modification being the substitution of the compounds of the present invention for the agents used in the art-recognized protocols.

The compounds of the present invention provide a method for treating bacterial infections, fungal infections and pre-cancerous or cancerous conditions. As used herein the term unit dosage refers to a quantity of a therapeutically-effective amount of a compound of the present invention that elicits a desired therapeutic response. As used herein the phrase therapeutically-effective amount means an amount of a compound of the present invention that prevents the onset, alleviates the symptoms, or stops the progression of a bacterial infection, fungal infection or pre-cancerous or cancerous condition. The term treating is defined as administering, to a subject, a therapeutically-effective amount of at least one compound of the

present invention, both to prevent the occurrence of a bacterial or fungal infection or pre-cancer or cancer condition, or to control or eliminate a bacterial or fungal infection or pre-cancer or cancer condition. The term desired therapeutic response refers to treating a recipient subject with a compound of the present invention such that a bacterial or fungal infection or pre-cancer or cancer condition is reversed, arrested or prevented in a recipient subject.

The compounds of the present invention can be administered as a single daily dose or in multiple doses per day. The treatment regime may require administration over extended periods of time, e.g., for several days or for from two to four weeks. The amount per administered dose or the total amount administered will depend on such factors as the nature and severity of the infection, the age and general health of the recipient subject, the tolerance of the recipient subject to the compound and the type of the bacterial or fungal infection, or type of cancer.

A compound according to this invention may also be administered in the diet or feed of a patient or animal. The diet for animals can be normal foodstuffs to which the compound can be added or it can be added to a premix.

The compounds of the present invention may be taken in combination, together or separately with any known clinically approved antibiotic, anti-fungal or anti-cancer to treat a recipient subject in need of such treatment.

Compounds of Formula I are obtained biosynthetically by culturing *Actinomycetes* species in growth media described in Table 4, at temperatures between 24<sup>0</sup> C – 34<sup>0</sup> C and with shaking to aerate of the culture medium for 3 to 40 days. The compounds of Formula I are extracted and isolated from the bacterial culture by methods known to a skilled person including centrifugation, chromatography, adsorption, filtration, extraction or other methods of separation.

The compounds of Formula I may be biosynthesized by various microorganisms. Microorganisms that may synthesize the compounds of the present invention include but are not limited to bacteria of the order Actinomycetales, also referred to as actinomycetes. Non-limiting examples of members belonging to the genera of Actinomycetes include *Nocardia*,

*Geodermatophilus*, *Actinoplanes*, *Micromonospora*, *Nocardioides*, *Saccharothrix*, *Amycolatopsis*, *Kutzneria*, *Saccharomonospora*, *Saccharopolyspora*, *Kitasatospora*, *Streptomyces*, *Microbispora*, *Streptosporangium*, *Actinomadura*. The taxonomy of actinomycetes is complex and reference is made to Goodfellow (1989) Suprageneric classification of actinomycetes, *Bergey's Manual of Systematic Bacteriology*, Vol. 4, Williams and Wilkins, Baltimore, pp 2322-2339, and to Embley and Stackebrandt, (1994), and *The molecular phylogeny and systematics of the actinomycetes*, *Annu. Rev. Microbiol.* 48, 257-289 (1994), for genera that may synthesize the compounds of the invention, incorporated herein in their entirety by reference.

Microorganisms biosynthetically producing compounds of Formula I are cultivated in culture media containing known nutritional sources for actinomycetes having assimilable sources of carbon, nitrogen plus optional inorganic salts and other known growth factors at a pH of about 6 to about 9, non-limiting examples of growth media are provided in Table 4 below. Microorganisms are cultivated at incubation temperatures of about 20° C to about 40° C for about 3 to about 40 days.

**Table 4.** Examples of Growth Media for Production of Compounds of Formula

I

Component	VA	QB	GA* <sup>4</sup>	MA	NA	KH	OA	HA	RM	EA	KA	CA
pH* <sup>5</sup>	7	7.2		7.5	7	7	7		6.85	7	5.7	7
Glucose	50	12	10			10	10	10	10	5	10	10
Sucrose			103					340	100			
Lactose										50		
Cane molasses					10							15
Soluble starch		10		25								
Potato dextrin						20						40
Corn steep										5		
Corn steep		5					3				10	
Dried yeast				2							5	
Yeast extract			5			5	3	3	5			
Malt extract							3	3				
Pharmamedia™		10										
Glycerol					20		5			15	5	
NA-Amine A						5						10
Soybean				15							10	
Soybean flour	30									10		
Beef extract							3					
Bacto-peptone					1			5		5		
MgSO <sub>4</sub> ·7H <sub>2</sub> O										0.5		1
MgCl <sub>2</sub> ·6H <sub>2</sub> O			10.12									
CaCO <sub>3</sub>	6			4	4	1	2			3	2	2
NaCl	5			5							5	
(NH <sub>4</sub> ) <sub>2</sub> SO <sub>4</sub>	3			2						2		
K <sub>2</sub> SO <sub>4</sub>			0.25						0.25			
MnCl <sub>2</sub> ·4H <sub>2</sub> O										0.1		
MgCl <sub>2</sub> ·6H <sub>2</sub> O								1	10			
FeCl <sub>2</sub> ·4H <sub>2</sub> O										0.1		
ZnCl <sub>2</sub>										0.1		
Thiamine							0.1					
Casamino acid			0.1		5				0.1			
Proflo oil		4										
MOPS									21			
Trace element solution * <sup>3</sup> ml/L									2			

Unless otherwise indicated all the ingredients are in gm/L.

\*<sup>3</sup> Trace elements solution contains: ZnCl<sub>2</sub> 40 mg; Fe Cl<sub>3</sub> 6H<sub>2</sub>O (200 mg); CuCl<sub>2</sub> 2H<sub>2</sub>O (10 mg); MnCl<sub>2</sub>·4H<sub>2</sub>O; Na<sub>2</sub>B<sub>4</sub>O<sub>7</sub>·10H<sub>2</sub>O (10mg); (NH<sub>4</sub>)<sub>6</sub> Mo<sub>7</sub>O<sub>24</sub>·4H<sub>2</sub>O (10 mg) per litre.

\*<sup>4</sup> Dissolve components in 800 ml water and autoclave, later add: 10 ml KH<sub>2</sub>PO<sub>4</sub> (0.5% solution); 80 ml CaCl<sub>2</sub>·2H<sub>2</sub>O (3.68 % solution); 15 ml L-proline (20% solution); 100 ml TES buffer ( 5.73% solution, pH 7.2); 5 ml NaOH (1N solution), and 2 ml of trace elements solution.

\*<sup>5</sup> The pH is to be adjusted as marked prior to the addition of CaCO<sub>3</sub> in those media containing it.

The culture media inoculated with the microorganisms which biosynthetically produce compounds of Formula I, may be aerated by incubating the inoculated culture media with agitation, for example shaking on a rotary shaker, or a shaking water bath. Aeration may also be achieved by the injection of air, oxygen or an appropriate gaseous mixture to the inoculated culture media during incubation.

After cultivation and production of compounds of Formula I, the compounds can be extracted and isolated from the cultivated culture media by techniques known to a skilled person in the art and/or disclosed herein, including for example centrifugation, chromatography, adsorption. For example, the cultivated culture media can be mixed with a suitable organic solvent such as n-butanol, n-butyl acetate and 4-methyl-2-pentanone, the organic layer can be separated for example, by centrifugation followed by the removal of the solvent, by evaporation to dryness or by evaporation to dryness under vacuum. The resulting residue can optionally be reconstituted with for example water, ethanol, ethyl acetate, methanol or a mixture thereof, and re-extracted with a suitable organic solvent such as hexane, carbon tetrachloride, methylene chloride or a mixture thereof. After removal of the solvent, the compound of Formula I can be further purified by the use of standard techniques such as chromatography.

The compounds of Formula I that are biosynthesized by microorganisms may optionally be subjected to random and/or directed chemical modifications to form compounds that are derivatives or structural analogs of compounds of Formula I. Derivatives or structural analogs of compounds of Formula I having similar functional activities are within the scope of the present invention. Compounds of Formula I may optionally be modified using methods known in the art and described herein.

Unless otherwise indicated, all numbers expressing quantities of ingredients and properties such as molecular weight, reaction conditions,  $IC_{50}$  and so forth used in the specification and claims are to be understood as being modified in all instances by the term "about". Accordingly, unless indicated to the contrary, the numerical parameters set forth in the present specification and attached claims are approximations. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the



scope of the claims, each numerical parameter should at least be construed in light of the number of significant figures and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set in the examples, Tables and Figures are reported as precisely as possible. Any numerical values may inherently contain certain errors resulting from variations in experiments, testing measurements, statistical analyses and such.

The compounds of Formula I, Formula II and compound 2(a) may optionally be chemically modified using methods known in the art and described herein.

The compounds of the invention are made by biofermentation and well-known chemical schemes. The schemes described herein are exemplary, any chemical synthetic process known to a person skilled in the art providing the structures described herein, may be used and are therefore comprised in the present invention.


#### **SCHEME 1            Acylation Reactions**

EDC = 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide


Protective groups include N-benzyloxycarbonyl (CBZ), N-butoxycarbonyl (BOC), N-fluoren-9-ylmethoxycarbonyl (Fmoc)


R<sup>x</sup> represents C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, aryl or heteroaryl

AA represents a naturally occurring amino acid


**Scheme 2. Aminations/reductive aminations of terminal nitrogen**

$\text{R}^1$  as previously defined




**Scheme 3. Olefin reactions****Scheme 4. Ketone reactions**


$R^1$  and  $R^8$  are as previously defined.



**Scheme 5. O- Reactions**

$R^1$ ,  $R^5$  and  $R^6$  are as previously defined.



**Scheme 6. Hydrolysis/Esterification**

Scheme 1 is used to obtain Compounds 2(m), 2(n), 2(o), 2(p), 2(q), 2(r), 2(s), 2(t), 2(u), 2(v), 2(w), 2(x), 2(y), 2(z), 2(aa), and 2(ab) from Compound 2(a).

Scheme 3 is used to obtain Compound 2(b) from Compound 2(a).

Scheme 4 is used to obtain Compounds 2(c), 2(d), 2(e) and 2(f) from Compound 2(a).

Scheme 6 is used to obtain Compounds 2(g), 2(h), 2(i) and 2(j) from Compound 2(a).

The features of the invention are further described below by way of examples and are not to be construed as limiting in their scope.

**Example 1 Production of Compound 2(a) by Fermentation**

Example 1(A): Preparation of Strain [C03U03]023

Strain [C03]023: *Streptomyces aizunensis* NRRL B-11277 was plated on three tomato paste oatmeal agar (ATCC medium 1360) plates for sporulation at 28 °C. The plates were incubated for a period of 5-7 days, after which spores were collected from each plate into 5 ml sterile distilled water, spun down by centrifugation at 5000 rpm (10 min), and dispersed in 20 ml sterile water. After a second centrifugation under the same conditions the pellet was resuspended in 10 ml sterile distilled water. A series of ten-fold dilutions of the original spore suspension were prepared and 0.5 ml aliquots plated on tomato paste-oat meal agar until sporulation occurred (5-7 days). Each individual clone from the plates with single well-isolated colonies (generated from  $10^{-8}$  to  $10^{-10}$  dilutions of the spore suspension) was chosen and transferred to one plate of tomato paste-oat meal agar to generate spores for storage. Each clone was grown in 25x150 mm glass tubes for its production of Compound 2(a). A total of 385 clones were tested for production levels of Compound 2(a). Clone [C03]023 showed a production of 3 times better than the wild-type strain. This clone was chosen, stored, and used for mutagenesis.

Strain [C03U03]023: An aqueous spore suspension of [C03]023 was mutagenized by UV radiation (254 nm) at different energy levels (expressed as mJoules per surface area). Clone [C03U03]023 obtained at 0.4 mJ/1 cm<sup>2</sup> showed slightly more than three times better production than the parent clone [C03]023. Production of Compound 2(a) by the new clone has been consistently reproducible both in shaken flask (500 ml medium QB or VA in 2-L baffled flasks) and in 100-L fermentors with medium VA.

Example 1(B) Activation of lyophilized sample of Strain [C03U03]023

Strain [C03U03]023 was provided as a lyophilized pellet. The lyophilized sample was opened under aseptic conditions, and 0.3-0.5 ml of medium ITSB was added to the sample to make a cell suspension. The cell suspension was transferred to 25 ml of medium ITSB (described below) in a 125-ml flask to form a liquid culture. The liquid culture was incubated at 28 °C

for 3-5 days until visible growth occurred. Purity of the culture was tested by streaking a loop on ISP2 agar plate.

Example 1(C): Preparation and Storage of glycerol stocks of Strain [C03U03]023

Strain [C03U03]023 was grown for 7-10 days at 28°C on several tomato paste-oat meal agar plates. Surface growth was collected from each plate into 5 ml sterile distilled water, spun down by centrifugation at 5000 rpm (10 min), and dispersed in 10 ml sterile water. After a second centrifugation under the same conditions the pellet was resuspended in 2 ml sterile 25% glycerol and 0.5-ml aliquots were stored at -80 °C in screw-capped vials. In addition to the glycerol stocks, the collected cell mass could be resuspended in 15% sterile skim milk and dispensed in 0.5-ml aliquots into glass ampoules and lyophilized following standard procedures.

Example 1(D): Preparation of Seed Culture

A vial containing frozen mycelia prepared as described in Example 1(C) was taken out of freezer and kept on dry ice. Under aseptic conditions, a loopfull of the frozen culture was taken and streaked on the surface of tomato paste-oat meal agar plate and incubated at 28°C until vegetative mycelium appeared (5-7 days). In order to start the seed culture, 2-3 loopfull of the surface growth obtained from the tomato paste-oat meal agar plate was transferred to a 1.5-ml Eppendorf tube containing 300 µl of medium ITSB. The mycelium with agar fragments was homogenized, and 1 ml of medium ITSB was added to the suspension. The content was used to inoculate two 125-ml flasks containing 25 ml of sterile medium ITSB. The flasks were incubated at 28°C for 65-70 hours in a rotary shaker at 250 rpm. This seed culture was then used to inoculate production medium QB or VA.

Example 1(E): Production of Compound 2(a) by Fermentation

A sample of the seed culture prepared as described in Example 1(D) above was checked microscopically for any possible contamination. A sample of the seed culture was then streaked onto one ISP2 plate (control plate) and incubated at 28 °C. From the seed culture under aseptic conditions, 10 ml was

taken and used to inoculate each 2 Liter baffled flask containing 500 ml of sterile medium QB or VA. The fermentation batches were incubated aerobically with shaking (250 rpm) at 28°C for a period of 7 days. After 3-5 days of incubation the control plate was checked for purity of the culture.

The compositions of the growth media used in Examples 1(A) – 1(E) are given below. Note that either of Production media QB or VA may be used in the production of Compound 2(a); however, production medium VA is preferred when conducting the fermentation on a large scale.

Seed Medium ITSB:

Trypticase Soy Broth	(Difco)	30 g
Yeast extract	(Sigma)	3 g
MgSO <sub>4</sub>	(Sigma)	2 g
Glucose	(Sigma)	5 g
Maltose	(Sigma)	4 g
Distilled water		1 L

Production Medium VA

Glucose	50g
Soybean Flour	30g
CaCO <sub>3</sub>	6g
NaCl	5g
(NH <sub>4</sub> ) <sub>2</sub> SO <sub>4</sub>	3g
Distilled water	1L

Production Medium QB:

Soluble starch	(Sigma)	10 g
Glucose	(Sigma)	12 g
Pharmamedia	(Traders protein)	10 g
Corn steep liquor	(Sigma)	5 g
Proflo oil	(Traders Protein)	4 mL *
Distilled water		1 L

\* Adjust pH to 7.2, then add Proflo oil

Tomato paste Oatmeal Agar:



Baby Oatmeal Food (Heinz)	20 g
Tomato Paste	20 g
Agar	15 g
Tap water	1 L
pH 7.0	

The production of Compound 2(a) may also be carried out in the production media having the compositions as indicated in Table 4, *supra*, in order of preference.

### **Example 2 Isolation of Compound 2(a)**

Thirty minutes prior to harvest of Compound 2(a) from the fermentation broth of the baffled flasks of Example 1E, regenerated, water-washed, Diaion HP-20® in a quantity of wet-packed volume equal to 12% of the initial fermentation beer volume was added to the whole fermentation broth of Example 1E and modest agitation was continued for 30 minutes. At harvest the fermentation broth from 2 x 500 ml flasks was centrifuged and the supernatant was decanted from the resin and mycelia pellet. The pellet was resuspended in 15% MeOH in water (half the original fermentation beer volume), agitated mildly and recentrifuged, and the supernatant was decanted from the residue. The residue was washed a second time in the same manner with another 15% MeOH in water, followed by a single final wash with methanol: water (7:3 v/v) (half the original fermentation beer volume) to obtain a well-washed residue. The well-washed mycelia:resin residue was extracted three times with 100% ethanol, each extract being at 20% original beer volume. The three extracts were combined and concentrated under vacuum on a rotary evaporator, to dryness.

The three extracts (representing material from 2 x 500 ml flasks) were combined, filtered on paper and concentrated under vacuo to remove organic solvents. The resulting semi-solid residue (aqueous suspension) of crude Compound 2(a) represented greater than 90% of the respective compounds produced and was about 25% pure. The aqueous suspension was freeze-dried overnight to give 460 mg of a dark brown solid. The solid was stirred

with 10 ml of methanol and centrifuged for 2 minutes to remove insoluble matter.

The semi-solid residue of crude Compound 2(a) was then purified using a Waters Xterra® preparative MS C-18 column with 10  $\mu$ m packing of dimensions 19 mm diameter x 150 mm length, using the following gradient table (Table 5) from 5mM aqueous ammonium bicarbonate to acetonitrile.

**Table 5:**

Time (min)	% Aqueous	% Acetonitrile
0	70	30
5	45	55
10	70	30


The eluate was monitored at 390 nm, a single run was loaded with 23 mg of crude residue in 0.5 ml of methanol, and a conservative cut of the peak eluting at 3.4 minutes afforded compound 2(a). Nineteen runs were conducted to yield 33 mg of product with about 95% purity.

### **Example 3 Structural Determination of Compound 2(a)**

The structure of compound 2(a) was determined by a combination of genomic information and spectroscopic data, including Mass, UV, and NMR spectroscopy. The Mass was determined by electrospray mass spectrometry to be 1297 (Figure 13) and the UV  $\lambda_{\text{max}}$  were found to be 319, 333, 350 (Figure 14). The NMR data were collected at 500 MHz with the compound 2(a) dissolved in MeOH-*d*<sub>4</sub>, and included proton (Figure 15A), carbon-13 (Figure 15B), and multidimensional pulse sequences gDQCOSY, gHSQC, gHMBC, and TOCSY (Figures 15C, 15 D, 15E and 15F, respectively).

*Streptomyces aizunensis* NRRL B-11277 was grown on oat meal agar plates for 5-7 days. The surface growth was collected and washed with water, and DNA was extracted following standard procedures (T. Kiesser *et al.* Practical *Streptomyces* Genetics, The John Innes Foundation, Norwich, UK, 2000). The genomic library was produced in cosmid and plasmid vectors, and the genome was scanned for the presence of gene sequence tags (GSTs) related to the biosynthesis of secondary metabolites as described in E. Zazopoulos *et al.*, Nature Biotechnology 21:187-190 (2003). The GSTs

were used to isolate cosmids containing the compound 2(a) locus. The PKS system found within the compound 2(a) locus was determined to contain 9 PKS genes containing 27 modules. (The analysis of this PKS system is fully described elsewhere herein; see, e.g., Table III and accompanying text). Full analysis of the PKS and associated genes led to the prediction of a structure of Formula 1 below.



The position of the glycosidic linkage to the sugar moiety could not be determined by the genomic analysis; however, the positioning of the aminohydroxycyclopentenone unit was determined by analogy with its placement in other actinomycete metabolites (Colabomycin A from *Streptomyces griseoflavus* Tue 2880, J. Antibiot. 1988, 41, 1178-85, 1186-1195 or Enopeptin-A from *Streptomyces griseus*, Osada et al., J. Antibiot. 44, 1463-6 1991).

To obtain expression of these genes, and the end product of this biosynthesis pathway, *S. aizunensis* NRRL B-11277 was grown in several different media designed for the production of secondary metabolites in shaken flasks. At harvest the broth was diluted with an equal volume of methanol to induce cell lysis, and the diluted, clarified broth was concentrated 10 fold. An aliquot (50  $\mu$ L) from the concentrate from each medium was chromatographed on a Waters Xterra C-18 HPLC column (19 x 150 mm) at a flow rate of 1 mL/min and monitored by diode array detector (DAD) UV and positive and negative ion MS. Fractions (800  $\mu$ L) were collected and tested for antimicrobial activity against a panel of indicator strains. From the extracts of several different media, HPLC fractions in the number 39 to 45 region exhibited strong activity against *Candida albicans* and this correlated with a UV absorption  $\lambda_{\text{max}}$  319, 333, and 351 nm, and with strong MS peaks at m/z 1298 (positive ion mode) and 1296 (negative ion mode). These physical characteristics were entirely consistent with a metabolite of formula 1.

A high yielding medium was chosen and the organism was regrown on a 2-liter scale. The compound 2(a) was extracted from the mycelial pellet with methanol and acetone, and from the broth with Diaion HP-20<sup>®</sup> resin, from which it was recovered with methanol after the resin had been washed with methanol/water 3:2. The crude extracts were purified by HPLC on a Waters Xterra C-18 column (19 x 150 mm) using an aqueous (5 mM ammonium bicarbonate) / acetonitrile gradient.

Compound 2(a), a yellow solid of MW 1297 Da ( $C_{70}H_{108}N_2O_{20}$  requires 1296.75)  $\lambda_{max}$  319, 334, and 351 nm was the subject of a series of 1D and 2D NMR measurements including a CMR,  $^1H$ -NMR, gDQCOSY, gHSQC, gHMBC, TOCSY, gHSQCTOXY, and several 1D TOCSY experiments. See Figures 15A – 15E. Analysis of these spectra led to the assignments shown for compound 2(a) in Figure 17. Although considerable overlap of signals rendered unambiguous assignments of all of the signals to specific protons and carbons impractical, those that could be made unambiguously confirmed the structure predicted from the genomics. A major cross peak in the gHMBC spectrum between the well separated proton resonance at 4.01 ppm and the anomeric carbon at 102.6 ppm placed the sugar as shown, as this proton falls within a 14 carbon section of the major chain with fully assigned carbon and proton signals. A well resolved carbon spectrum with high signal to noise ratio showed that the unassigned methylene carbons were at 42.0, 45.3, 45.4 and 46.6 ppm. Analysis by gHSQC indicates that these were attached to protons at 2.24, 1.62, 1.50 and 1.68, and 1.55 ppm respectively. Similarly the unassigned carbinols at 66.2, 66.2 (resolved), 67.2 and 69.0 ppm attached to protons at 4.06, 4.08, 4.22 and 3.89 ppm respectively and the unassigned olefinic carbons at 129.1, 131.0, 131.9, 133.3, 133.7, 134.3, 134.8, 136.5, and 138.0 ppm attached to protons at 5.72, 5.72, 6.28, 6.25, 6.28, 6.25, 6.19, 5.53, and 5.86 respectively. The aminohydroxycyclopentenone signals were not straightforward and reflected the tautomeric equilibrium of this moiety. The upfield methylene signal and the downfield carbonyl signals were only 10% of the intensity of those from the other tautomer. The signal from C-1 of this moiety was not detected, a phenomenon which has been previously ascribed to tautomerization for the same structural unit. See, He, H.; Shen, B.; Korshalla, J.; Siegel, M.M.; Carter, G.T. *J. Antibiot.* 2000, 53, 191~195.

#### **Example 4 Minimal Inhibitory Concentration (MIC) Determination for Compound 2(a)**

The MIC determination for fungal and bacterial organisms was performed using the broth microdilution assay adapted from National Committee for Clinical Laboratory Standards (NCCLS) M27-A (Vol. 17 No. 9, 1997), Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard guidelines: M23-A: Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard, vol. 22, No. 16.

#### **Materials:**

- 1) Overnight broth cultures of bacterial and fungal strains to be tested;
- 2) Stock solution of Compound 2(a) at 3.2 mg/ml in DMSO;
- 3) Standard 96 well round-bottom plates, sterile;
- 4) Cation adjusted Mueller-Hinton broth, or Brain Heart Infusion broth (for antibacterial testing);
- 5) Morpholinepropanesulfonic acid (MOPS)-buffered RPMI-1640 medium (for antifungal testing);
- 6) Sterile isotonic saline (0.85%);
- 7) McFarland 0.5 Barium Sulfate Turbidity Standard at 100 X 3.2mg/ml.

Test compound preparation: The test article was prepared as 100x stock solutions in DMSO, with concentrations ranging from 3.2 mg/ml to 0.0625 mg/ml (a two-fold dilution series over 10 points). The first dilution (3.2mg/ml) was prepared by resuspending 0.5 mg of each test article in 156.25  $\mu$ l of DMSO. The stock is then serially diluted by two-fold increments to obtain the desired concentration range.

Inoculum preparation: For fungal strains, the inoculum was prepared as follows. From an overnight culture in Yeast Media broth, cell density was

adjusted in 0.85% saline to 0.5 McFarland. This procedure yielded a stock suspension of about  $5 \times 10^6$  cells/ml. Following thorough vortexing, a working suspension was prepared by diluting the stock 1:50 in RPMI 1640, and then further diluting it 1:20 with RPMI 1640 to obtain the 2x test inoculum (about  $5 \times 10^3$  cells/ml). For filamentous fungi, the inoculum was prepared as follows. From a spore suspension kept at 4°C, an appropriate dilution in 0.85% saline was made to obtain a final optical density 600 between 0.09-0.11. A working suspension was then prepared by diluting the spore suspension 50 times in RPMI to obtain the 2x test inoculum (about  $1 \times 10^5$  CFU/ml).

MIC Determination: The 100X test article solutions were diluted 50 times in RPMI 1640, MH or BHI media and dispensed in a 96 well plate, one concentration per column, 10 columns in total. The 11th column contained RPMI 1640 with 1% DMSO with cells, the 12th column contained 100 µl of RPMI 1640 alone.

50 µl of the final cell dilution (yeast, filamentous fungi or bacteria) of each indicator strain was added to each corresponding well of the microplate containing 50 µl of diluted drug or media alone. Assay plates were incubated at 35°C for up to 72 hrs. MIC readings were determined at 24 and 48 hrs for the *Candida* and *Aspergillus* species, and at 48 and 72 hrs for *Cryptococcus neoformans*. MIC readout for each indicator was determined as the lowest concentration of test compound resulting in total absence of growth.

**Table 6:** MIC ( $\mu\text{g/ml}$ ) for Compound 2(a) for various strains of yeast and fungi

	MIC ( $\mu\text{g/ml}$ )	
<u>Yeasts and filamentous fungi</u>	24 hrs	48 hrs
<i>Candida albicans</i> ATCC 10231	4	4
<i>Candida krusei</i> LSPQ 0309	8	8
<i>Candida glabrata</i> LSPQ 0250	4	8
<i>Candida lusitanae</i> ATCC 200953	4	4
<i>Saccharomyces cerevisiae</i> ATCC 9763	4	4
<i>Cryptococcus neoformans</i> ATCC 32045	2*	4**
<i>Aspergillus flavus</i> ATCC 204304	4	8
<i>Aspergillus fumigatus</i> ATCC 204305	16	16

\* 48 hrs reading; \*\* 72 hrs reading

#### **Example 5. In vitro activity of compound 2(a) against *Aspergillus* species**

To determine the antifungal activity of compound 2(a) against *Aspergillus* species (*A. fumigatus* and *A. flavus*) a disk diffusion assay was used to determine the minimum effective concentration (MEC) as described by Wong GK, Griffith S, Kojima I and Demain AL. Antifungal activities of rapamycin and its derivatives, prolylrapamycin, 32-desmethyrapamycin, and 32-desmethoxyrapamycin. J. Antibiotics, 51(5): 487-491, 1998. Such assay is commonly used to reveal activity of antifungal drugs against filamentous fungi such as *Aspergillus* sp. (Arikan S, Yurdakul P, Hascelik G. Comparison of two methods and three end points in determination of in vitro activity of micafungin against *Aspergillus* spp. *Antimicrobial Agents and Chemotherapy* 47(8): 2640-2643, 2003).

Preparation of the inoculum: After spreading on YM agar (in cell culture flasks), *Aspergillus* strains (*A. flavus* – ATCC 204304 and *A. fumigatus* - LSPQ 204305) were left sporulating for 4 to 5 days at 35°C. After the addition

of 10 to 20 ml of saline solution (0.85% NaCl), spores were collected by gently rubbing the surface of the conidiophores with a disposable inoculation loop. *Aspergillus* spore suspensions, kept at 4°C, were used as the inoculum for the disc assays.

Preparation of the disks : Stock solutions (5 mg/ml) in methanol and dilutions (0.25, 0.5, 1.0, 2.5, 5.0, 7.5, 10.0 and 50.0 µg/ml), prepared by serial dilutions of stock solution in methanol were prepared for the test article and each of the control compounds. Itraconazole and caspofungin were used as positive controls while fluconazole or DMSO alone were used as negative controls. Drug-containing disks were prepared by spotting of 10 µl of the proper drug solution (or methanol as control) onto filter disks that were then allowed to air-dry.

Agar plate preparation: *Aspergillus* spore suspensions were adjusted to about 81% of transmittance at 530 nm in saline solution. 200 µl of the adjusted inoculum was then mixed with 50 ml of melted 0.8% YM agar (cooled to ~50°C), mixed thoroughly and poured in a 150 mm Petri dish. Once the agar was set, the prepared filters were loaded onto the plates, which were incubated at 35°C. The zone of inhibition (ZOI) of fungal growth was measured after 24 hours of incubation.

Results: Data presented in Table 7 show the lowest concentration (MEC) inducing inhibition of the fungal growth and the corresponding ZOI obtained at this concentration for compound 2(a) and the controls. Results demonstrated that compound 2(a) was active against *Aspergillus fumigatus* and *Aspergillus flavus*. Similar effect was obtained for itraconazole and caspofungin while fluconazole was inactive.



**Table 7**

	<i>Aspergillus fumigatus</i>		<i>Aspergillus flavus</i>	
	MEC ( $\mu\text{g/ml}$ )	ZOI (mm)	MEC ( $\mu\text{g/ml}$ )	ZOI (mm)
Methanol	0	0	0	0
Compound 2(a)	2.5	2.7	2.5	2.7
itraconazole	1.0	1.7	0.5	1.7
caspofungin	2.5	0.7	2.5	0.7
fluconazole	0	0	0	0

MEC : mimimum effective concentration

ZOI : zone of inhibition of fungal growth calculated for each MEC

#### **Example 6. Evaluation of Antifungal Activity of Compound 2(a) in a Mouse Model of Disseminated Candidiasis**

Compound 2(a) was provided as a dry powder with an estimated purity of 95+%. Fungizone (amphotericin B desoxycholate, to be used as a comparator), was also provided as a dry powder with an estimated purity of 95+%. The compound 2(a) and Fungizone were stored as dry powders at  $-80^{\circ}\text{C}$  until the day of administration.

Female mice (species *Mus musculus*, strain CD-1, Charles River) with body weight range of 22-24 g were used in the study. The animals were observed for 3 days before treatment. All animal experiments were performed at the Ste-Justine Hospital (Montreal, Quebec) according to ethical guidelines of animal experimentation of the ethical committee of the hospital. During the study, dead or apparently sick animals were promptly removed and sick mice were euthanized upon removal from the cage.

The animals were maintained in rooms under controlled conditions of temperature ( $23\pm 2^{\circ}\text{C}$ ), humidity ( $45\pm 5\%$ ), photoperiodicity (12 hrs light / 12 hrs dark) and air exchange. The animals were housed in polycarbonate cages (4/single cage) equipped to provide food and water. Sterile wood

shavings were used for animal bedding and the bedding was replaced every other day. Food (Harlam Tecklab, Canada) and autoclaved tap water was provided *ab libitum*, the food being placed in the metal lid on top of the cage. Water bottles were equipped with rubber stoppers and sipper tubes and were cleaned, sterilized and replaced once a week.

Six groups of mice (10 mice per group) were infected intravenously with  $3 \times 10^6$  CFU of *C. albicans* SC5314 as previously described (see Dubois, N., et al., *Microbiology* 1998, 144: 2299-2310). Twenty-four hours after infection, each individual group of mice was treated with Compound 2(a) (1 or 3 mg/kg i.p.), Fungizone (0.25, 0.5 or 1 mg/kg i.p.) as comparitor, or sham-treated with sterile water containing 5% dextrose and 3% DMSO. Each animal received 100  $\mu$ l of test solution.

The treatment regimen was repeated once daily for a total of 4 days. The mice were observed twice daily for signs of morbidity over 21 days. Moribund animals were scored as non-survivors and euthanized by CO<sub>2</sub> inhalation. The Kaplan and Meier product limit estimate was used to analyze survival data and plot the survival function.

**Table 8:** Survival Rates Over Time After Inoculation with Compound 2(a) and Fungizone

Groups	Treatment	Dose (mg/kg)	Median survival
1	Vehicle	-	5 days
2	Compound 2(a)	1.0	8.5 days
3	Compound 2(a)	3.0	20 days
4	Fungizone	0.25	>21 days
5	Fungizone	0.5	>21 days
6	Fungizone	1.0	>21 days

As indicated in Table 8, compound 2(a) has *in vivo* antifungal activity similar to a dose of 0.25 mg/kg of Fungizone and increases 4-fold the median survival time of infected mice.

The data (percent survival versus days post-inoculation) was plotted; the resulting graph is shown in Figure 16.

#### **Example 7. In Vitro Antitumor activity of Compound 2(a)**

In vitro antiproliferative study of Compound 2a was performed by the National Cancer Institute (National Institutes of Health, Bethesda, Maryland, USA) against a panel of cancer cell lines in order to determine the concentrations needed to obtain a 50% inhibition of cell proliferation ( $IC_{50}$ ). The operation of this unique screen utilizes 60 different human tumor cell lines, representing leukemia, melanoma, and cancers of the lung, colon, brain, ovary, breast prostate and kidney. Compound 2(a) was provided as a lyophilized powder with an estimated purity of 90+%. The compound was stored at -20°C until day of use.

The human tumor cell lines of the cancer-screening panel were grown in RPMI 1640 medium containing 5% fetal bovine serum and 2 mM L-glutamine. For a typical screening experiment, cells were inoculated into 96 well microtiter plates in 100  $\mu$ l at plating densities ranging from 5000 to 40,000 cells/well depending on the doubling time of individual cell lines (Table 8). After cell inoculation, the microtiter plates were incubated at 37 °C, under 5% CO<sub>2</sub>, 95% air and 100% relative humidity for 24 hours prior to addition of the experimental drugs.

After 24 hours, two plates of each cell line were fixed *in situ* with TCA, to represent a measurement of the cell population for each cell line at the time of drug addition (T<sub>z</sub>). Compound 2(a) was solubilized in dimethyl sulfoxide at 400-fold the desired final maximum test concentration and stored frozen prior to use. At the time of drug addition, an aliquot of frozen concentrate was thawed and diluted to twice the desired final maximum test concentration with complete medium containing 50  $\mu$ g/ml gentamicin. Additional four, serial dilutions were made to provide a total of five drug concentrations plus control. Aliquots of 100  $\mu$ l of these different drug dilutions were added to the appropriate microtiter wells already containing 100  $\mu$ l of medium, resulting in the required final drug concentrations ( $2.5 \times 10^{-5}$  M to  $2.5 \times 10^{-9}$  M).

Following drug addition, the plates were incubated for an additional 48 hours at 37°C, 5 % CO<sub>2</sub>, 95 % air, and 100 % relative humidity. For adherent

cells, the assay was terminated by the addition of cold TCA. Cells were fixed *in situ* by the gentle addition of 50  $\mu$ l of cold 50 % (w/v) TCA (final concentration, 10 % TCA) and incubation for 60 minutes at 4°C. The supernatant was discarded, and the plates were washed five times with tap water and air-dried. Sulforhodamine B (SRB) solution (100  $\mu$ l) at 0.4 % (w/v) in 1 % acetic acid was added to each well, and plates were incubated for 10 minutes at room temperature. After staining, unbound dye was removed by washing five times with 1 % acetic acid and the plates were air-dried. Bound stain was subsequently solubilized with 10 mM trizma base, and the absorbance was read on an automated plate reader at a wavelength of 515 nm. For suspension cells, the methodology was the same except that the assay was terminated by fixing settled cells at the bottom of the wells by gently adding 50  $\mu$ l of 80 % TCA (final concentration, 16 % TCA).

The growth inhibitory power of compound 2(a) was measured by NCI utilizing the GI<sub>50</sub> value, rather than the classical IC<sub>50</sub> value. The GI<sub>50</sub> value emphasizes the correction for the cell count at time zero and, using the seven absorbance measurements [time zero (Tz), control growth (C), and the test growth in the presence of drug at each of the five concentration levels (Ti)], GI<sub>50</sub> is calculated as  $[(Ti - Tz) / (C - Tz) \times 100 = -50]$ , which is the drug concentration resulting in a 50% reduction in the net protein increase (as measured by SRB staining) in control cells during the drug incubation. The GI<sub>50</sub> values for compound 2(a) for the various cell lines tested are presented in Table 9 below.

**Table 9: NCI Developmental Therapeutics Program In-Vitro Testing Results for Compound 2(a)**


Cell Line	Panel name	Inoculation density (no. of cells per well)	GI <sub>50</sub> ( $\times 10^{-6}$ , unless otherwise indicated)
K-562	Leukemia	5000	9.18
MOLT-4	Leukemia	30,000	5.57
A549/ATCC	Non-small cell lung cancer	7500	4.09

EKVX	Non-small cell lung cancer	20,000	5.87
HOP-62	Non-small cell lung cancer	10,000	6.83
HOP-92	Non-small cell lung cancer	20,000	$9.77 \times 10^{-8}$
NCI-H226	Non-small cell lung cancer	20,000	3.10
NCI-H23	Non-small cell lung cancer	20,000	4.25
NCI-H322M	Non-small cell lung cancer	20,000	3.48
NCI-H460	Non-small cell lung cancer	7500	3.83
NCI-H522	Non-small cell lung cancer	20,000	2.80
COLO 205	Colon cancer	15,000	5.00
HCC-2998	Colon cancer	15,000	$6.03 \times 10^{-8}$
HCT-116	Colon cancer	5000	4.18
HCT-15	Colon cancer	10,000	3.25
HT29	Colon cancer	5000	6.36
KM12	Colon cancer	15,000	2.76
SW-620	Colon cancer	10,000	5.35
SF-268	CNS cancer	15,000	3.64
SF-295	CNS cancer	10,000	3.91
SNB-19	CNS cancer	15,000	5.58
SNB-75	CNS cancer	20,000	3.87
U251	CNS cancer	7500	3.65
LOX IMVI	Melanoma	7500	3.73
MALME-3M	Melanoma	20,000	2.40
M14	Melanoma	15,000	4.15
SK-MEL-2	Melanoma	20,000	4.34
SK-MEL-28	Melanoma	10,000	6.75
SK-MEL-5	Melanoma	10,000	4.16
UACC-257	Melanoma	20,000	3.74
UACC-62	Melanoma	10,000	2.68
IGROV1	Ovarian cancer	10,000	2.95
OVCAR-3	Ovarian cancer	10,000	3.40
OVCAR-4	Ovarian cancer	15,000	4.48
OVCAR-5	Ovarian cancer	20,000	4.00
OVCAR-8	Ovarian cancer	10,000	4.34
SK-OV-3	Ovarian cancer	20,000	7.94
786-0	Renal cancer	10,000	3.07

A498	Renal cancer	25,000	4.82
ACHN	Renal cancer	10,000	2.96
CAKI-1	Renal cancer	10,000	2.99
RXF 393	Renal cancer	15,000	1.20
SN12C	Renal cancer	15,000	$1.38 \times 10^{-7}$
TK-10	Renal cancer	15,000	3.32
UO-31	Renal cancer	15,000	3.65
PC-3	Prostate cancer	7500	2.66
DU-145	Prostate cancer	10,000	3.78
MCF7	Breast cancer	10,000	4.22
NCI/ADR-RES	Breast cancer	15,000	4.76
MDA-MB-	Breast cancer	20,000	3.38
MDA-MB-435	Breast cancer	15,000	3.26
BT-549	Breast cancer	20,000	4.59
T-47D	Breast cancer	20,000	6.00

The results indicate that compound 2(a) is effective against all the human tumor cell lines that have been assayed in the NCI screening panel suggesting a broad anticancer activity against several types of human cancer. In fact, the GI50 calculated for all cell lines was lower than  $10 \times 10^{-6}$  M, a significant level of pharmacological activity for anticancer drugs, and in some cases reached the nanomolar or picomolar level (SN12C/renal carcinoma; HOP92/non-small cell lung carcinoma; HCC2998/colon carcinoma).

#### **Example 8    Activation of inactive domains in the polyketide synthase system**



The gene cluster encoding the Compound 2(a) derived from *Streptomyces aizunensis* strain NRRL B-11277 is genetically modified to reactivate the ketoreductase (KR) domain, which is encoded in the ORF 13 module 12. This modification results in the conversion of the central carbonyl group adjacent to the sugar molecule of Compound 2(a), to a hydroxyl group (as shown in Figure 12a).

In the compound 2(a) locus, the KR domain present in ORF 13, module 12 is inactive. To provide for the compound of Example 7 the KR domain is reactivated or swapped for an active KR domain. Reactivation of the KR domain requires diagnosis of the integrity of critical active site residues necessary for a functional KR domain. The active site residues can be divided into those required for co-enzyme activation of the KR enzyme and those for catalysis. Experiments identifying the specific residues for ketoreductase activity [Ried *et. al.* Biochemistry 2003, 42:72-79; Udo *et.al.*, Biochemistry, 1997, 36:34-40] reveal that functional KR coenzyme binding site residues include glycine (G), glycine (G), glycine (G), alanine (A) and the functional KR active site residues include serine (S), tyrosine (Y) and asparagine (N). These residues are highlighted in Figures 6a and 6b. The sequence of the KR domain in the compound 2(a) locus shows that the coenzyme active site residues are glycine (G), glycine (G), glycine (G), alanine (A) indicating that this site is indeed active. However, the amino acid residues found in the KR site responsible for catalytic activity are serine (S), glutamine (Q) and asparagine (N) indicating that the catalytic site is likely to be inactive. This observation is confirmed by the fact compound 2(a) contains a carbonyl group at that specific position (Figure 10, module 12). Modification of the codon encoding glutamine to a codon encoding tyrosine provides for an active site residue required for functional ketoreduction of PKS monomers. This results in an altered nucleic acid sequence of the compound 2(a) locus used to modify a suitable host cell to produce the compound 2(a) variant of Example 7 as shown in Figure 12a.

The modification of glutamine to tyrosine may be introduced using a mismatched primer that hybridizes to the native nucleotide sequence at a temperature below the melting temperature of the mismatched duplex. The primer is kept specific by keeping primer length and base composition within narrow limits and keeping the mutant base centrally located as described in Zoller and Smith' Methods in Enzymol. (1983) 100:468. Primer extension is achieved using DNA polymerase. The product is cloned and positive clones containing the mutated DNA, derived by segregation of the primer extended strand, are selected. Selection is made using the mutant primer as a

hybridization probe (Dalbie-McFarland et al Proc. Natl. Acad Sci. USA (1982) 79:6409).


Another method to generate the compound of Example 7 involves swapping the inactive ketoreductase domain from the gene locus of the compound 2(a) (ORF 13 module 12) with an active ketoreductase domain from the same or different locus. Example of domains within the same locus suitable for swapping include the active ketoreductases that occur in the modules that encode the incorporation of methyl malonate extender units, namely ORF 16 modules 19 or 20. Swapping of acyltransferase domains between PKS loci has been demonstrated by Oliynyk *et.al.* Chem Biol, 1996, 3(10):833-9, wherein the gene encoding the acyltransferase domain in 6-deoxyerythronolide (DEBS) module 1 is swapped with the gene encoding the rapamycin module 2 acyltransferase resulting in the synthesis of novel triketides since the two acyltransferases had different acyl specificities. In Hans *et.al.* J Am Chem Soc, 2003, 125(18):5366-74, the kinetic aspects of product formation as a consequence of acyltransferase domain swaps is taught.

Swapping of domains is achieved using techniques developed by Kao *et.al.* Science, 1994, 265:509-512. The genetic strategy utilizes derivatives of pMAK705 to permit in vivo recombination between a temperature sensitive donor plasmid and a recipient shuttle vector by means of a double recombination event in *E.coli*. An Amp<sup>R</sup> Tc<sup>R</sup> recipient subclone of the regions flanking the domain to be swapped is made, pCK5, containing 1kb of flanking sequence from either flank. Endonuclease restriction sites are introduced at the boundaries of the domain, *Pst*I at 3' end of the left flank and *Xba*I at the 5' end of the right flank. Subclones pCK6 Cm<sup>R</sup> of the domains to be swapped are generated and endonuclease restriction sites are introduced into the boundaries of the domain. The restriction site *Pst*I is introduced at the 5' boundary of the KR domain and an *Xba*I site at the 3' boundary of the domain. Restriction sites are introduced into subclones by PCR mutagenesis. The fragment containing the domain is excised and ligated into the temperature sensitive Cm<sup>R</sup> donor plasmid, pCK6. The recipient plasmid is generated by in vivo recombination of the plasmid in the host strain using the selection method



outlined by Kao *et.al.*, *supra*. After selection recombinant strains are produced with the domain of interest replacing the original domain.

**Example 9 Inactivation of functional domains within the polyketide synthase system**




The gene locus encoding Compound 2(a) derived from a *Streptomyces aizunensis* strain is genetically modified to inactivate the enoyl reductase (ER) domain in the ORF 17 module 22. Inactivation of this domain abolishes the conversion the double bond to the single bond between the acyl units incorporated by modules 21 and 22 of Compound 2(a) (as shown in Figure 12e).

Generating the compound of Example 8 is achieved through insertional inactivation by double crossover techniques developed by Oh and Chater, 1997, *Journal of Bacteriology* 179:122-127. Examples of insertional inactivation of genes involved in polyketide biosynthesis in *Streptomyces* are well known in the art. Arrowsmith *et.al.*, 1992, *Mol Gen Genet* 234:254-264, used these techniques to identify the role of a cassette of secondary metabolic genes in the production of monensin by *Streptomyces cinnamomensis*. Paradkar, *et.al.*, 2001, *Appl Environ Microbiol* 67:2292-7, inactivated the *lat* gene encoding for lysine aminotransferase to disrupt the first step in the cephamycin pathway to block production of cephamycin C in *Streptomyces clavuligerus*. Similarly, these authors inactivated the *cvm1* gene involved in late stage antipodal clavam synthesis.

Methods used to inactivate domains in polyketide systems include domain swapping as described in Example 7 as well as targeted disruption by insertional gene inactivation. For this, a replicative plasmid-mediated homologous recombination is applied to *Streptomyces aizunensis*. Plasmids for homologous recombination are constructed by cloning a kanamycin resistance marker between the left and right flanking regions of the genes to be modified. Such a construct is cloned into a delivery plasmid that is marked with thiostrepton resistance producing a disruption plasmid. This plasmid is


introduced into *Streptomyces aizunensis* by either PEG-mediated protoplast transformation, by electroporation or by natural infection with a phage (Keiser *et al* (2000) Practical Streptomyces genetics, John Innes Foundation, Norwich). The spores from individual transformants or transconjugants are cultured on non-selective plates to induce recombination. The cycle is repeated three times to enhance the opportunity for recombination. Crossovers yielding targeted gene recombinants are then selected and screened using kanamycin and thiostrepton for single crossovers and kanamycin for double crossovers. Replica plating and southern hybridization are used to confirm the double crossover inactivation (Keiser *et al* (2000) *supra*).

#### **Example 10 Inactivation of the glycosyltransferase activity**




Inactivation of the glycosyltransferase gene (GTFA) encoding ORF 9 of the compound 2(a) locus (as shown in Figure 12b) provides for the compound of this example. The inactivation of the GTFA disrupts the transfer of the sugar moiety onto the backbone of Compound 2(a). The absence of the sugar moiety results in a non-glycosylated form of Compound 2(a). Insertional inactivation of GTFA genes in polyketide biosynthesis in *Streptomyces* is known in the art. Blanco *et.al.*, 2000, Mol Gen Genet 262:991-1000, identified two genes of the mithramycin biosynthetic gene cluster as glycosyltransferases by the production of a non-glycosylated mithramycin upon inactivation of these genes. A similar observation was made by Chen *et.al.*, Gene, 2001, 263:255-64 investigating genes responsible for glycosylation in the biosynthetic pathways encoding pikromycin, narbomycin, methymycin and neomethymycin.

Targeted inactivation of the glycosyltransferase activity is achieved using the method of insertional gene disruption as described in Example 8.


**Example 11 Elimination of the aminohydroxycyclopentenone unit**

Elimination of the terminal aminohydroxycyclopentenone unit may be accomplished by inactivation of any one of the following three ORFs of the compound 2(a) locus. First, disruption of ORF 35 results in the inactivation of the acyltransferase (AYTP) activity (as shown in Figure 12c) that abolishes condensation of succinyl-CoA and glycine to form 5-aminolevulinate. Second, disruption of ORF 36 results in the inactivation of acyl CoA ligase (CALB) preventing the conversion of 5-aminolevulinate to 5-aminolevulinate-CoA which cyclizes to form aminohydroxycyclopentenone. Third, disruption of ORF 34 (ADSN) prevents transfer of the aminohydroxycyclopentenone unit to the polyketide chain. Thus, the compound of Example 10 is provided by genetically modifying at least one of ORFs 34, 35 and 36. Methods used for insertional inactivation of all three genes are described in Example 9.

**Example 12 Replacement of the terminal amine group with a guanidino group**

The replacement of the terminal amine with a guanidino group may be accomplished by the insertional inactivation of ORF 33 (ADHY) using the methods described in Example 9. The inactivation of ORF 33 ADHY (as shown in Figure 12d) disrupts the synthesis of gamma-amino butanamide leading to the accumulation of 4-guanidino butanamide. The accumulated 4-guanidino butanamide is converted by ORF 27 CALB to 4-guanidino butyryl-CoA which is then attached onto the polyketide synthase enzyme (ORF 10, module 0 as shown in Figure 10b) through the action of ORF 19 (AYTF).


**Example 13: Synthesis of Compound 2(b) by epoxidation of Compound 2(a)**




Compound 2(b)

To a mixture of Compound 2(a) dissolved in tetrahydrofuran (THF) is added 1 equivalent of *meta*-chloroperbenzoic acid. The reaction is cooled in an ice bath and stirred at 0 °C for 1-2 hours. The reaction mixture is then evaporated to dryness, re-dissolved in methanol and subjected to liquid chromatography on a column of Sephadex LH-20 to isolate the Compound 2(b).

The epoxide group of Compound 2(b) may be hydrolyzed by treatment of Compound 2(b) with small quantity of aqueous hydrochloric acid (1.0 N), thereby forming the corresponding diol of the formula:




**Example 14: Synthesis of Compound 2(c) by Reduction of 31-oxo group**



Compound 2(c)

A solution of Compound 2(a) in acetonitrile is treated with 1.5 equivalents of NaCNBH<sub>3</sub>. The reaction is stirred at room temperature for 1 hour. The reaction mixture is then concentrated to dryness and then taken up into methanol. The mixture is filtered and the filtrate is subjected to liquid chromatography on a column of Sephadex LH-20 to isolate the Compound 2(c). Alternatively, the reduction of the oxo group at the 31-position may be done using lithium borohydride (LiBH<sub>4</sub>).

**Example 15: Synthesis of Compound 2(d) by addition of acetal ring at the 31-position**




Compound 2(d)

A solution of Compound 2(a) in tetrahydrofuran is treated with 3 equivalents of 2,2-dimethyl-1,3-dioxacyclopentane in the presence of a trace amount of toluene sulfonic acid. The reaction is stirred overnight at room temperature, evaporated to dryness and taken up into dry THF, followed by purification by liquid chromatography on a column of Sephadex LH-20. The 2,2-dimethyl-1,3-dioxacyclopentane may be synthesized by reaction of acetone with ethylene glycol in the presence of a trace of toluene sulfonic acid, over molecular sieves to remove water.

Alternatively, the addition of an acetal ring at the 31-position may be accomplished by reaction of Compound 2(a) with an excess of ethylene glycol in the presence of a trace of toluene sulfonic acid. The reaction may be conducted over molecular sieves to remove water.


**Example 16: Synthesis of Compound 2(e)**




Compound 2(e)

To a solution of Compound 2(a) in benzene or toluene is added 10 equivalents of benzylamine. The reaction is stirred at room temperature overnight. The reaction may be conducted over molecular sieves to remove water; alternatively, the water may be removed under reflux as an azeotrope with benzene or toluene using a Dean-Stark trap. The reaction mixture is concentrated under vacuum and residual reagent is removed by high vacuum at room temperature overnight.

The carbon-nitrogen double bond of Compound 2(e) may be reduced to the amine by reaction of Compound 2(e) with  $\text{NaCNBH}_3$  or  $\text{LiBH}_4$  (1.5 equivalents) in acetonitrile, to form a compound of the structure:



### **Example 17: Synthesis of Compound 2(f)**




Compound 2(f)

To a solution of one equivalent of Compound 2(a) in acetonitrile is added ten equivalents of isobutylamine. The reaction is stirred at room temperature for two hours. Benzene (1/10 volume) is added and the mixture is concentrated to dryness under vacuum on a rotary evaporator.

The Schiff base is then treated with  $\text{NaCNBH}_3$  or  $\text{LiBH}_4$  (1.5 equivalents) in acetonitrile, to reduce the carbon-nitrogen double bond of the imine to the amine, to form the compound 2(f).

### **Example 18: Synthesis of Compound 2(g)**




Compound 2(g)

Compound 2(g) may be synthesized biosynthetically as described in Example 9. Alternatively, Compound 2(g) may be prepared by hydrolysis of Compound 2(a). This is accomplished by treatment of Compound 2(a) in diethylether/THF with Meerwein's reagent (triethyloxonium tetrafluoroborate) for two hours at room temperature followed by cooling to  $-20\text{ }^{\circ}\text{C}$  and dropwise addition of aqueous acetic acid in THF. The reaction mixture is stirred for 20 minutes during which time it is allowed to come to room temperature. The mixture is then diluted with water (2 volumes) and HP-20 polystyrene resin is

added. The mixture is stirred for 30 minutes, filtered, the resin is washed well with water, and the product is eluted with 100% ethanol. The elutes are concentrated under vacuum to give compound 2(g).


**Example 19: Synthesis of Compound 2(h)**



Compound 2(h)

To a solution of 0.1 equivalents of Compound 2(g) in methanol is added 0.5 equivalents of diazomethane in diethyl ether. The reaction mixture is allowed to stand at room temperature overnight, and then the solvent is removed under vacuum to give compound 2(h).


**Example 20: Synthesis of Compound 2(i)**



Compound 2(i)


A solution of Compound 2(a) in methanol is treated with an equal volume of 0.1N HCl, and the reaction mixture is stirred overnight at room temperature. The mixture is then diluted with water (2 volumes) and HP-20 polystyrene resin is added. The mixture is stirred for 30 minutes, filtered, the resin is washed well with water, and the product is eluted with 100% ethanol. The elutes are concentrated under vacuum to give compound 2(i).

**Example 21: Synthesis of Compound 2(j)**




Compound 2(j)

Compound 2(j) is prepared by hydrolysis of compound 2(g). The hydrolysis may be carried out in the same way that compound 2(a) is hydrolysed to compound 2(i) as described in Example 19 above.

**Example 22: Synthesis of Compound 2(k)**


Compound 2(k)

Compound 2(k) is prepared biosynthetically by inactivation of the enoyl reductase as described in Example 8.

**Example 23: Synthesis of Compound 2(l)**

Compound 2(l)

A solution of Compound 2(k) in acetonitrile is treated with 1.5 equivalents of NaCNBH<sub>3</sub>. The reaction is stirred at room temperature for 1 hour. The reaction mixture is then concentrated to dryness and then taken up into methanol. The mixture is filtered and the filtrate is subjected to liquid chromatography on a column of Sephadex LH-20 to isolate the Compound 2(l). Alternatively, the reduction of the oxo group at the 31-position may be done using lithium borohydride (LiBH<sub>4</sub>).

**Example 24: Synthesis of Compound 2(m)**


Compound 2(m)

A solution of 10 equivalents of Compound 2(a) in acetonitrile is treated with one equivalent of acetaldehyde. The reaction is stirred at room temperature for two hours. Benzene (1/10 volume) is added and the mixture is concentrated to dryness under vacuum on a rotary evaporator to give the compound 2(m).



Compound 2(m) may be treated with  $\text{NaCNBH}_3$  or  $\text{LiBH}_4$  (1.5 equivalents) in acetonitrile, to reduce the carbon-nitrogen double bond of the imine to the amine.

**Example 25: Synthesis of Compound 2(n)**




Compound 2(n)

A solution of 10 equivalents of Compound 2(a) in acetonitrile is treated with one equivalent of benzaldehyde. The reaction is stirred at room temperature for two hours. Benzene (1/10 volume) is added and the mixture is concentrated to dryness under vacuum on a rotary evaporator to give the compound 2(n).


Compound 2(n) may be treated with  $\text{NaCNBH}_3$  or  $\text{LiBH}_4$  (1.5 equivalents) in acetonitrile, to reduce the carbon-nitrogen double bond of the imine to the amine.

**Example 26: Synthesis of Compound 2(o)**



Compound 2(o)


A solution of Compound 2(a) in tetrahydrofuran is treated with one equivalent of cyanamide. The reaction mixture is stirred at room temperature overnight. Solvent is removed from the reaction mixture under vacuum to give compound 2(o).

**Example 27: Synthesis of Compound 2(p)**

Compound 2(p)

To a solution of 10 equivalents of Compound 2(a) in acetonitrile is added 1 equivalent of acetone. The reaction is stirred at room temperature for two hours. Benzene (1/10 volume) is added and the mixture is concentrated to dryness under vacuum on a rotary evaporator.


The resulting Schiff base imine is then treated with  $\text{NaCNBH}_3$  or  $\text{LiBH}_4$  (1.5 equivalents) in acetonitrile, to reduce the carbon-nitrogen double bond of the imine to the amine, to form the compound 2(p).

**Example 28: Synthesis of Compound 2(q)**

Compound 2(q)

To a solution of 10 equivalents of Compound 2(a) in acetonitrile is added 1 equivalent of 4-nitrobenzaldehyde. The reaction is stirred at room temperature for two hours. Benzene (1/10 volume) is added and the mixture is concentrated to dryness under vacuum on a rotary evaporator.

The resulting Schiff base imine is then treated with  $\text{NaCNBH}_3$  or  $\text{LiBH}_4$  (1.5 equivalents) in acetonitrile, to reduce the carbon-nitrogen double bond of the imine to the amine, to form the compound 2(q).


**Example 29: Synthesis of Compound 2(r)**

Compound 2(r)

To a solution of 10 equivalents of Compound 2(a) in acetonitrile is added 1 equivalent of cyclohexylformaldehyde. The reaction is stirred at room temperature for two hours. Benzene (1/10 volume) is added and the mixture is concentrated to dryness under vacuum on a rotary evaporator.

The resulting Schiff base imine is then treated with  $\text{NaCNBH}_3$  or  $\text{LiBH}_4$  (1.5 equivalents) in acetonitrile, to reduce the carbon-nitrogen double bond of the imine to the amine, to form the compound 2(r).


### **Example 30: Synthesis of Compound 2(s)**



Compound 2(s)


To a solution of Compound 2(a) in tetrahydrofuran is added one equivalent of acetic anhydride and two equivalents of triethylamine. The reaction is stirred at room temperature for two hours. The mixture is then diluted with water (2 volumes) and HP-20 polystyrene resin is added. The mixture is stirred for 30 minutes, filtered, the resin is washed well with water, and the product is eluted with 100% ethanol. The elutes are concentrated under vacuum to give compound 2(s).

### **Example 31: Synthesis of Compound 2(t)**




Compound 2(t)

To a solution of Compound 2(a) in is added one equivalent of isobutyryl anhydride and two equivalents of triethylamine. The reaction is stirred at room temperature for two hours. The mixture is then diluted with water (2 volumes) and HP-20 polystyrene resin is added. The mixture is stirred for 30 minutes, filtered, the resin is washed well with water, and the product is eluted with 100% ethanol. The elutes are concentrated under vacuum to give compound 2(t).

**Example 32: Synthesis of Compound 2(u)**


Compound 2(u)

To a solution of Compound 2(a) in is added one equivalent of benzoic anhydride and two equivalents of triethylamine. The reaction is stirred at room temperature for two hours. The mixture is then diluted with water (2 volumes) and HP-20 polystyrene resin is added. The mixture is stirred for 30 minutes, filtered, the resin is washed well with water, and the product is eluted with 100% ethanol. The elutes are concentrated under vacuum to give compound 2(u).

**Example 33: Synthesis of Compound 2(v)**

Compound 2(v)


To a solution of Compound 2(a) in is added one equivalent of p-nitrobenzoic anhydride and two equivalents of triethylamine. The reaction is stirred at room temperature for two hours. The mixture is then diluted with water (2 volumes) and HP-20 polystyrene resin is added. The mixture is stirred for 30 minutes, filtered, the resin is washed well with water, and the product is eluted with 100% ethanol. The elutes are concentrated under vacuum to give compound 2(v).

**Example 34: Synthesis of Compound 2(w)**

Compound 2(w)


A solution of Compound 2(a) is reacted with 1 equivalent of N-protected alanine active ester. The amino group of alanine is protected by reacting alanine with DCC (dicyclohexyldicarbodiimide) or EDC (1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide) and the carboxylic acid group is converted to an active ester such as an N-hydroxysuccinimide ester. The N-protected active ester is added to Compound 2(a) in an inert solvent such as tetrahydrofuran. The mixture is warmed under reflux for one hour. The mixture is then diluted with water (2 volumes) and HP-20 polystyrene resin is added. The mixture is stirred for 30 minutes, filtered, the resin is washed well with water, and the product is eluted with 100% ethanol. The elutes are concentrated under vacuum to give compound 2(w).

**Example 35: Synthesis of Compound 2(x)**




Compound 2(x)

A solution of Compound 2(a) is reacted with 1 equivalent of N-protected *para*-hydroxyphenyl glycine active ester. The amino group of the *para*-hydroxyphenyl glycine is protected by reacting alanine with DCC (dicyclohexyldicarbodiimide) or EDC (1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide) and the carboxylic acid group is converted to an active ester such as an N-hydroxysuccinimide ester. The N-protected active ester is added to Compound 2(a) in an inert solvent such as tetrahydrofuran. The mixture is warmed under reflux for one hour. The mixture is then diluted with water (2 volumes) and HP-20 polystyrene resin is added. The mixture is stirred for 30 minutes, filtered, the resin is washed well with water, and the product is eluted with 100% ethanol. The elutes are concentrated under vacuum to give compound 2(x).

**Example 36: Synthesis of Compound 2(y)**

Compound 2(y)

A solution of Compound 2(a) is reacted with 1 equivalent of N-protected tyrosine active ester. The amino group of tyrosine is protected by reacting alanine with DCC (dicyclohexyldicarbodiimide) or EDC (1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide) and the carboxylic acid group is converted to an active ester such as an N-hydroxysuccinimide ester. The N-protected active ester is added to Compound 2(a) in an inert solvent such as tetrahydrofuran. The mixture is warmed under reflux for one hour. The mixture is then diluted with water (2 volumes) and HP-20 polystyrene resin is added. The mixture is stirred for 30 minutes, filtered, the resin is washed well with water, and the product is eluted with 100% ethanol. The elutes are concentrated under vacuum to give compound 2(y).


**Example 37: Synthesis of Compound 2(z)**

Compound 2(z)

A solution of Compound 2(a) is reacted with 1 equivalent of N-protected valine active ester. The amino group of valine is protected by reacting alanine with DCC (dicyclohexyldicarbodiimide) or EDC (1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide) and the carboxylic acid group is converted to an active ester such as an N-hydroxysuccinimide ester. The N-protected active ester is added to Compound 2(a) in an inert solvent such as tetrahydrofuran. The mixture is warmed under reflux for one hour. The mixture is then diluted with water (2 volumes) and HP-20 polystyrene resin is added. The mixture is stirred for 30 minutes, filtered, the resin is washed well

with water, and the product is eluted with 100% ethanol. The elutes are concentrated under vacuum to give compound 2(z).


**Example 38: Synthesis of Compound 2(aa)**



Compound 2(aa)

A solution of Compound 2(a) is reacted with 1 equivalent of N-protected proline active ester. The amino group of proline is protected by reacting alanine with DCC (dicyclohexyldicarbodiimide) or EDC (1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide) and the carboxylic acid group is converted to an active ester such as an N-hydroxysuccinimide ester. The N-protected active ester is added to Compound 2(a) in an inert solvent such as tetrahydrofuran. The mixture is warmed under reflux for one hour. The mixture is then diluted with water (2 volumes) and HP-20 polystyrene resin is added. The mixture is stirred for 30 minutes, filtered, the resin is washed well with water, and the product is eluted with 100% ethanol. The elutes are concentrated under vacuum to give compound 2(aa).

**Example 39: Synthesis of Compound 2(ab)**



Compound 2(ab)

A solution of Compound 2(a) is reacted with 1 equivalent of N-protected serine active ester. The amino group of serine is protected by reacting alanine with DCC (dicyclohexyldicarbodiimide) or EDC (1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide) and the carboxylic acid group is converted to an active ester such as an N-hydroxysuccinimide ester. The N-protected active ester is added to Compound 2(a) in an inert solvent such as tetrahydrofuran. The mixture is warmed under reflux for one hour. The mixture is then diluted with water (2 volumes) and HP-20 polystyrene resin is

added. The mixture is stirred for 30 minutes, filtered, the resin is washed well with water, and the product is eluted with 100% ethanol. The elutes are concentrated under vacuum to give compound 2(ab).

**Example 40: Compound 2(a) for the treatment of cardiovascular disorders**

Polyene compounds are not generally absorbed from the gastrointestinal tract and exhibit hypocholesterolemic properties by binding cholesterol in the gastrointestinal tract following oral administration. The hypocholesterolemic properties of polyene compounds was first demonstrated by studies in dogs (Schaffner, C.P. and Gordon H.W. The hypocholesterolemic activity of orally administered polyene macrolides. P.N.A.S. 61:36-41, 1968.). In another study with chickens, small amounts of polyene compounds in the diet led to the inhibition of enterohepatic cholesterol circulation, increased fecal lipid excretion and reduced atherogenesis (Fisher, H., Griminger P. and Siller W. Effect of candicidin on plasma cholesterol and avian atherosclerosis. Proceedings of the Society for Experimental Biology and Medicine, 145: 836-839, 1974). The beneficial effects of orally administered polyene compounds on cholesterol-lipid metabolism is not species-dependent as it was demonstrated in several species including humans, rats, dogs and chickens (Pagliano FM, Correction of hyperdyslipidemia using polyene-structure substances. Controlled clinical trial. Arch Sci Med (Torino). 136: 303-308, 1979; Barbaro A. and Casella G. Action of a polyene macrolide on hyperdislipidaemic disorders. Archivio per Scienze Mediche 137: 211-216, 1980; Singhal, A.K., Mosbach, E.H. and Schaffner, C.P. Effect of candicidin on cholesterol and bile acid metabolism in the rat. Lipids, 16: 423-426, 1981.).


The therapeutic potential of compound 2(a) for the treatment of cardiovascular disorders such as high cholesterol, dyslipidemia and atherosclerosis is demonstrated by measuring the effects of oral administration of compound 2(a) to rabbits. New Zealand rabbits are maintained under controlled light and temperature conditions and fed for several weeks with two different diets: normal rabbit chow (control) and a diet



containing 0.5 to 1% cholesterol to induce hypercholesterolemia. Rabbits are administered compound 2(a) (3, 10, 30 mg/kg) or vehicle by oral gavage daily for up to one month. Food intake and rabbit weight is measured daily for the duration of the experiment. Blood samples to measure cholesterol, lipoproteins and triglycerides are collected through a catheter inserted in the ear artery in the beginning and at the end of the experiment as well as every 4 days for the duration of the experiment. Serum cholesterol, lipoproteins and triglycerides are measured by enzymatic assays employing commercial kits as specified by the manufacturer (Sigma Chemical Co) and as described in Staprans I, Pan X-M, Rapp JH, Feingold KR. Oxidized cholesterol in the diet accelerates the development of aortic atherosclerosis in cholesterol-fed rabbits. *Arteriosclerosis, Thrombosis and Vascular Biology*, 18: 977-983, 1998. At the end of the experiment, after collecting the final blood sample, animals are anesthetized and the descending aorta is exposed, excised and processed for histological examination following fixation in formalin. Briefly, paraffin longitudinal or cross sections (five micron) are stained with Sudan black (dying lipids) and counterstained with Masson trichrome. Morphometric quantitative determination of the area of the intima, media and adventitia layers is performed by image analysis. Lipid deposition in the aorta is determined by evaluation of the percentage of the aorta covered by lesions visualized by fat staining. Arterial concentration of cholesterol is measured after extraction of lipids as described in Thiery J, Nebendahl K, Rapp K, Kluge R, Teupser D and Seidel D. Low atherosclerotic response of a strain of rabbits to diet-induced hypercholesterolemia. *Arteriosclerosis, Thrombosis and Vascular Biology*, 15: 1181-1188, 1995.

What is Claimed is:

1. A compound of Formula I,




Formula I

or a pharmaceutically acceptable salt thereof;


wherein,

A is selected from the group consisting of  $-NR^1R^2$ ,  $-N=CR^1R^2$ ,



$R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  are each independently selected from the group consisting of H,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{3-6}$  cycloalkyl,  $C_{2-6}$  heterocycloalkyl, aryl, heteroaryl and amino acid, wherein said alkyl, alkenyl, aryl and heteroaryl groups are optionally substituted with a group selected from halogen, OH,  $NO_2$ ,  $NH_2$  or aryl, said aryl being optionally further substituted with one or more groups independently selected from halogen, OH,  $NO_2$  or  $NH_2$ ;


B is selected from: ethene-1,2-diyl or




wherein  $R^{10}$  is oxo or  $OR^{11}$ ;

wherein  $R^{11}$  is H or a heterocycloalkyl, the heterocycloalkyl being optionally substituted with 1-4 substituents selected from OX,  $C_{1-3}$  alkyl and  $-O-C(O)R^1$ , wherein X is H or, when there are at least two neighboring

substituent groups that are OX, then the X can be a bond such that the two neighboring oxygen groups form a five-membered acetal ring of the formula:







; wherein  $R^5$  and  $R^6$  are each independently selected from the group consisting of H,  $C_{1-6}$  alkyl, and  $C_{2-7}$  alkenyl;




D is selected from: ,  $-NR^{12a}R^{12a}$ , and  $OR^{12}$ , wherein

$R^{12}$  is selected from H,  $C_{1-6}$  alkyl optionally substituted with 1 to 2 phenyl groups, wherein the phenyl group is optionally substituted with  $C_{1-6}$  alkyl or halo;

$R^{12a}$  and  $R^{12a}$  are each independently selected from H,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{3-6}$  cycloalkyl,  $C_{2-6}$  heterocycloalkyl, aryl, heteroaryl and amino acid, wherein said alkyl, alkenyl, aryl and heteroaryl are optionally substituted with a group selected from halogen, OH,  $NO_2$ ,  $NH_2$  or aryl, said aryl being optionally further substituted with one or more groups independently selected from halogen, OH,  $NO_2$  or  $NH_2$ ;





$X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{12}$  and  $X^{13}$  is each independently selected from H,  $-C(O)-R^7$  and a bond such that when any of two neighboring  $X^1, X^2, X^3, X^4, X^5, X^6, X^7, X^8, X^9, X^{12}$  and  $X^{13}$  is a bond then the two neighboring oxygen atoms and their attached carbon atoms together form a six-membered acetal ring of the formula:



wherein R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> are each independently selected from H, C<sub>1</sub>-<sub>6</sub> alkyl, C<sub>2</sub>-<sub>7</sub> alkenyl;

$Y^1, Y^2, Y^3, Y^4, Y^5, Y^6, Y^7, Y^9, Y^{10}, Y^{11}, Y^{12}, Y^{13}$  and  $Y^{15}$  are each independently selected from the group consisting of ethene-1,2-diyl,



ethane-1,2-diyl and , wherein said ethene-1,2-diyl and ethane-1,2-diyl groups are optionally substituted with a methyl group;





Z is selected from OH,  $\text{NHR}^8$ , and  ~~$\text{NR}^8$~~  and when the dotted line is a bond then Z is oxo, or  $\text{NR}^9$ ;

R<sup>8</sup> is independently selected from H, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl;


R<sup>9</sup> is C<sub>1-6</sub> alkyl optionally substituted with aryl.

2. The compound of claim 1, wherein Z is oxo, or a pharmaceutically acceptable salt thereof.



3. The compound of claim 1 or 2, wherein D is , or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1,2 or 3, wherein B is




or a

5. The compound of claim any one of claims 1 to 4, wherein A is - $\text{NR}^1\text{R}^2$ , or a pharmaceutically acceptable salt thereof.


6. The compound of claim 4, wherein A is  $-\text{NH}-\text{C}(=\text{O})-\text{R}^4$  or a pharmaceutically acceptable salt thereof.

7. The compound of any one of claims 1, 2, 4, 5 or 6, wherein D is




, or a pharmaceutically acceptable salt thereof.

8. A compound of the fomula:




Compound 2(a)

9. A compound of the formula II:




Formula II

wherein  $\text{A}^1$  is  $-\text{NH}_2$ ,  $-\text{N}=\text{CH}-\text{R}^{13}$ , amino acid or  $-\text{NH}-\text{R}^{14}$ , wherein  $\text{R}^{13}$  is hydrogen or phenyl and  $\text{R}^{14}$  is selected from the group consisting of isopropyl, 1-(4-nitrophenyl)methyl, cyclohexyl, and wherein said amino acid is attached via its nitrogen atom;





wherein  $R^{15}$  is selected from the group consisting of methyl, isopropyl, phenyl, 4-nitrophenyl, 1-aminoethyl, 1-amino-1-(4-hydroxyphenyl)methyl, 1-amino-2-(4-hydroxyphenyl)ethyl, 1-amino-2-methylpropyl, 2-pyrrolidinyl and 1-amino-2-hydroxyethyl;


$Y^{20}$  is selected from the group consisting of ethene-1,2-diyl and



$Z^1$  is selected from the group consisting of:




$R^{20}$  is selected from the group consisting of hydrogen and



$Y^{30}$  is ethene-1,2-diyl or ethane-1,2-diyl; and


$D^1$  is hydroxy, methoxy or

138




and pharmaceutically acceptable salts thereof.


10. A compound selected from the group consisting of:




Compound 2(b)




Compound 2(c)




Compound 2(d)




Compound 2(e)




Compound 2(f)




Compound 2(g)




Compound 2(h)




Compound 2(i)




Compound 2(j)



Compound 2(k)




Compound 2(l)




Compound 2(m)







Compound 2(n)




Compound 2(o)




Compound 2(p)




Compound 2(q)




Compound 2(r)




Compound 2(s)




Compound 2(t)




Compound 2(u)




Compound 2(v)




Compound 2(w)




Compound 2(x)




Compound 2(y)



Compound 2(z)



Compound 2(aa)



Compound 2(ab)

11. A method for producing the compound of claim 8, comprising the steps of cultivating cells derived from a *Streptomyces aizunensis* strain, incubating said cultured cells aerobically in a growth medium for such time as is required for production of said compound of claim 8, extracting said medium with a solvent and purifying the compound of claim 8 from the crude extract.

12. The method of claim 11 wherein said *Streptomyces aizunensis* strain is NRRL B-11277 or a mutant thereof.

13. The method of claim 12 wherein said mutant is strain [C03]023 (deposit accession number IDAC 070803-1) or [C03U03]023 (deposit accession number IDAC 231203-02).

14. The strain of *Streptomyces aizunensis* identified by deposit accession number IDAC 070803-1.

15. The strain of *Streptomyces aizunensis* identified by deposit accession number IDAC 231203-02.

16. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of claims 1 to 10, and a pharmaceutically acceptable carrier.

17. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 8, and a pharmaceutically acceptable carrier.

18. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 9, and a pharmaceutically acceptable carrier.

19. A method of treating a fungal infection in a mammal, comprising administering to said mammal suffering from said infection, a therapeutically effective amount of a compound of any one of claims 1 to 10.

20. The method of claim 19 wherein said fungal infection is caused by *Candida albicans*.

21. The method of claim 19 wherein said fungal infection is caused by a *Candida sp.*, wherein said *Candida sp.* is selected from the group consisting of *C. glabrata*, *C. lusitaniae*, *C. parapsilosis*, *C. krusei* and *C. tropicalis*.

22. The method of claim 19 wherein said fungal infection is caused by an *Aspergillus sp.*, wherein said *Aspergillus sp.* is selected from the group consisting of *A. fumigatus*, *A. niger*, *A. terreus* and *A. flavus*.

23. The method of claim 19 wherein said fungal infection is caused by *Fusarium spp.*; *Scedosporium spp.*; *Cryptococcus spp.*; *Mucor spp.*; *Histoplasma spp.*; *Trichosporon spp.*; *Blaspomyces spp.*; or *S. cerevisiae*.

24. A method of treating a fungal infection in a subject, comprising administering to said subject suffering from said infection, a therapeutically effective amount of a compound of any one of claims 1 to 10.

25. The method of claim 24 wherein said fungal infection is caused by a fungus selected from the group consisting of *Candida albicans*, *Candida sp.*, *Aspergillus sp.*, *Fusarium spp.*, *Scedosporium spp.*, *Cryptococcus spp.*, *Mucor spp.*, *Histoplasma spp.*, *Trichosporon spp.*, *Blaspomyces spp.*, and *S. cerevisiae*.

26. The method of claim 24 wherein said *Candida sp.* is selected from the group consisting of *C. glabrata*, *C. lusitaniae*, *C. parapsilosis*, *C. krusei* and *C. tropicalis*.


27. The method of claim 24 wherein said *Aspergillus sp.* is selected from the group consisting of *A. fumigatus*, *A. niger*, *A. terreus* and *A. flavus*.

28. A method of treating cancer in a subject, comprising administering to said subject suffering from said cancer, a therapeutically effective amount of a compound of any one of claims 1 to 10.

29. The method of claim 28, wherein said cancer is selected from the group consisting of leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer and breast cancer.

Figure 1

# Gene Cluster for Production of Compound 2(a)



## Figure 2a

[illegible]

## Figure 2b

```

ORF10_pKS01    GAETQEYGPRLQ-----DATDGFEGYLVGTGNAASVASGRIAYTFGFEGPTVTVDTACSS
ORF10_pKS02    GTNGQDYLSLVVTREGDG---LDGLEGHVGTGNAASVVSGRLSYVFGLEGPAITVDTACSS
ORF10_pKS03    GTNGQDYLSLITRESE-----GLEGHLGTGNAAGSVMSGRVSYVLGLEGPAVTVDTACSS
ORF10_pKS04    GVMYHDYVTGIGDGGSAVELPEGVEGYLGTGNAAGSIASGRIAYTFGLEGPAVTVDTACSS
ORF10_pKS05    GTNGQDYGAMLQTIPTD-----GIEGFLGTGNAASVVSGRLSYAFGLEGPAVTVDTACSA
ORF11_pKS01    GAGAMGYGADLKEA-----PEGLEGLLLTGGATSVLSGRVSYVFGLEGPAATVDTACSS
ORF11_pKS02    GAAYSGYDAQLEQSG-----VDGVLGHVMTGNAAGSVMSGRVSYALFLEGPAVTVDTACSS
ORF12_pKS01    GASANAYGAGSHDL-----PDGVEGHLTGTASSVLSGRLAYVFGLEGPAATIDTACSS
ORF12_pKS02    GSNAQDYQLWLNDAD-----GLEGHLGTGNAASVVSGRLSYTFGLEGPAVTVDTACSS
ORF12_pKS03    GTNGQDYLSVLLEEPE-----GLEGHLGTGNAASVVSGRLSYVFGLEGPAVTVDTACSS
ORF12_pKS04    GTNGQDYLSVLVNSAD-----GGDGMSTGNSASVVSGRLSYVFGLEGPAVTVDTACSA
ORF13_pKS01    GINGSDYLTPLLEAAE-----DYAGHLGTGNAASSVMSGRLSYTFGLEGPAVTVDTACSA
ORF14_pKS01    GTSNHDYLSALLSS-----SENVEGYLGTGNAASVASGRLSYTFGLEGPAVTVDTACSS
ORF14_pKS02    GTNGQDYLVNLAAPD-----GVEGFLGTGNAASVVSGRVSYVLGLEGPAVTVDTACSS
ORF14_pKS03    GVMYHDYGARLH-----AVPDGVEGYLGTGSSSSIVSGRVAYTFGLEGPAVTVDTACSS
ORF15_pKS01    GLMYHDYAARLF-----SVPEEIEGFLGNGSSGSIASGRIAYTLGLEGPAVTVDTACSS
ORF15_pKS02    GVMYHDYAALLE-----RSKDGADGSLGSGSTGSIASGRVSYTFGLEGPAVTIDTACSS
ORF15_pKS03    GVMYHDYASRLT-----ALPEGVEGFLGTGNAASVISGRLSYAFGLEGPAITVDTACSS
ORF16_pKS01    GVMYHDYTARLD-----SVPEGVEGFLGTGSSGSIASGRVAYTFGLEGPAVTVDTACSS
ORF16_pKS02    GTNGSDYSNLVRAGAD-----GLEGHLATGNAAGSVVSGRLSYTFGLEGPAVTVDTACSA
ORF17_pKS01    GTNGQDYPELLREVPK-----GVEGYLLTGNAAASVVSGRISYTFGLEGPAVTVDTACSA
ORF17_pKS02    GVMYHDYLTRLP-----AVPEGLEGYLTGTAGSVASGRISYTFGLEGPAVTVDTACSS
ORF17_pKS03    GQMHN DYVSRLN-----TVPEGVEGYLGTGSSSSIASGRVSYTFDFEGPAVTVDTACSS
ORF17_pKS04    GIMYHDYATRIT-----SVPDGVGYLGTGNSGSIASGRVSYAFGLEGPAVTVDTACSS
ORF18_pKS01    GVMYHDYASRLR-----AVPEEVEGYLGTGSSSSIASGRVSYTFGLEGPALTVDTACSS
ORF18_pKS02    GVMYNDYGTLLH-----RAPEGLEGYMGTSSSGVSASGRVSYTFGLEGPAVTVDTACSS
*      *      *      *      *      *      *      *      *      *      *      *      *      *      *      *

```

```

ORF10_pKS01    SLAALHLAVQALRTGECSLALAGGVAVMASPGSFVSFSRQRLAPDGRCKPFAAAADGTG
ORF10_pKS02    SLVALHLAVQALRQGECTLALAGGVVMSTPDAFVDFSRQRLAEDGRKAFASAADGTG
ORF10_pKS03    SLVALHWAIQALRQGECSMALAGGVVMSTPENFVDFSRQRLAEDGRKAFASAADGTG
ORF10_pKS04    SLVALHWAIQALRSGECSMALAGGVAVMATPETFVDFSRQRLSADGRCKSFASAADGTG
ORF10_pKS05    SLVALHWAVQALRSGECSLALAGGVVMSSPGAYIDFSRQRLAEDGRKAFASAADGTG
ORF11_pKS01    SLVALHLATQALRQRECSLALVGGVCMPSPDVFVEFSRQRLSPDGRCKSFASAADGTG
ORF11_pKS02    SLVALHWAIQALRNGECSLALAGGVVMSTPGTFSEFSQOGLSPDGRCKAFASAADGTG
ORF12_pKS01    SSVLHMAVQALRQGECSLALAAGVTVLAGPDVFVEFSRQRLSPDGRCKSFASAADGTG
ORF12_pKS02    SLVTLHLAAQALRRGECSMALAGAVTIMSTPGAFTEFSRQRLAEDGRKAFASAADGTG
ORF12_pKS03    SLVALHWAIQALRNGECSLALAGGVVMSTPGTFIEFSRQRLAEDGRKAFASAADGTG
ORF12_pKS04    SLVALHLAVQALRNGECSLALAGGVVMSTPGAFAEFSRQRLAEDGRKAFASAADGTG
ORF13_pKS01    SLVALHLAVQALRAGECSLAVAGGVHVMSTPGLFVEFSKQRLSTDGRCKAFASAADGTG
ORF14_pKS01    SSVLHHLAVQALRNGECSLALAGGATLMSAPGTFIDYSKQRLATDGRCKAFSPADAGTG
ORF14_pKS02    SLVALHWAIQALRQGECSMALAGGVVMSTPASFIDFSRQRLAEDGRKAFASAADGTG
ORF14_pKS03    SLVALHLAAQALRNGECSLALAGGVVMFTPGTFIEFSRQRLAEDGRCKSFASAADGTG
ORF15_pKS01    SLVAVHLAAQALRNGECSLALAGGVVMSTPGTFTEFSRQRLAEDGRCKSFASAADGTG
ORF15_pKS02    SLVALHMAIQALRTGECMDALAGGVVMATPGTFIGFSRQRLSADGRCKAFSADADGTG
ORF15_pKS03    SLVALHLAVQALRNGECSLALAGGVVMATPAAFVEFSRQRLAEDGRCKAFSADADGTG
ORF16_pKS01    SLVTLHLAVQALRAGECSMALAGGVVMATPATFTEFSRQRLAPDGRCKPFAAAADGTG
ORF16_pKS02    SLVALHLAVQALRSGECSLALAGGVVMSTPGTFIEFSRQRLSTDGRCKAFSSADAGTG
ORF17_pKS01    SLVALHLAVQALRNDECSLALAGGVVMSSPRAVFQFSRQRLAPDGRCKPFADGADGTG
ORF17_pKS02    SLVALHLAAQALRNGECSMALAGGVVMSTPDTFIDFSRQRLSGNGRCKSFADADGTG
ORF17_pKS03    SLVALHLAAQALRNGECSLALAGGVTIITPDVFTEFSRQRLASDGRCKPFAEADGTG
ORF17_pKS04    SLVALHWAIQALRNGECSMALAGGVVMSTPGTFTEFSRQRLAEDGRKAFASAADGTG
ORF18_pKS01    SLVTLHLAMQALRKGECSLALAGGVVMATPGTFTEFSRQRLSFDGRCKSFADADGTG
ORF18_pKS02    SLVTLHLAVQALRNGECSLALAGGVVMATPGTFVAFSRQRLASDGRCKPFAAAADGTG
*      *      *      *      *      *      *      *      *      *      *      *      *      *      *      *

```



### Figure 2c

ORF10\_pks01 WGEGVGMLLVERLSDARAKGHRILAVVRGSAINQDGASNGLTAPSGPSQQRVIRQALANA  
ORF10\_pks02 WGEGVGMLLVERLSDARRNGHPVLAVVRGSAINQDGASNGLTAPNGPSQQRVIRQALAGA  
ORF10\_pks03 WGEGVGMLLVERLSDARRNGHPVLAVVRGSAINQDGASNGLTAPNGPSQQRVIRQALASA  
ORF10\_pks04 WAEGAGMLLVERLSDAERNGHQVLAIVVRGSAINQDGASNGLTAPNGPSQQRVIRQALASA  
ORF10\_pks05 WGEGVGMLLVERLSDARRNGHPVLAVVRGSAINQDGASNGLTAPNGPSQQRVIRQALANA  
ORF11\_pks01 WSEGVGILLVERLSDARRNGHPVLAVVRGSAVNQDGASNGLTAPNGPAQQRVIRQALENA  
ORF11\_pks02 WGEGVGMLLVERLSDARRNGHPVLAVVRGSAVNQDGASNGLTAPNGPSQQRVIRQALASA  
ORF12\_pks01 WSEGAGVLLVERLSDARRNGHHILAVVRGSAVNQDGASNGLTAPNGPAQQKVIRQALESA  
ORF12\_pks02 WSEGVGILLVERLSDARRNGHPVLAVVRGTAVNQDGASNGLTAPNGPSQQRVIRREALADA  
ORF12\_pks03 WGEGVGMLLVERLSDAERNGHQVLAIVVRGSAINQDGASNGLTAPNGPSQQRVIRQALASA  
ORF12\_pks04 WGEGVGMLLVERLSDARRNGHPVLAVVRGSAVNQDGASNGLTAPNGPSQQRVIRQALASA  
ORF13\_pks01 PAEGVGILLERLSDARKNGRPVLAVVRGSAVNQDGASNGLTAPNGPSQQRVIRQALANA  
ORF14\_pks01 LAEGVGILLVERLSDARRKGHPVLAVVRGTAVNQDGASNGLTAPNGPSQQRVIRQALANA  
ORF14\_pks02 WGEGVGILLVERLSDAQRNGHPVLAVVRGSAINQDGASNGLTAPNGPSQQRVIRQALASG  
ORF14\_pks03 WGEAGMLLLERLSDARRNGHPVLAVVRGSAVNQDGASNGLTAPNGPSQQRVIRQALANA  
ORF15\_pks01 WGEAGMVLVERLSEARRNGHPVLAVVRGSAVNQDGASGLTAPNGPSQQRVIRQALAGA  
ORF15\_pks02 WGEGVGMLLVERLSDARRNGHPVLAVVRGSAINQDGASNGLTAPNGPSQQRVIRQALASA  
ORF15\_pks03 WSEGAGVLLVERLSDARRNGHPVLAVVRGSAINQDGASNGLTAPNGPSQQRVIRQALASA  
ORF16\_pks01 WGEGVGMLLVERLSDAQRNGHPILAVVRGSAINQDGASNGLTAPNGPSQQRVIRQALANA  
ORF16\_pks02 PAEGVGILLVERLSDARRNGHPILAVVRGSAINQDGASNGLTAPNGPSQQRVIRQALANA  
ORF17\_pks01 WGEGVGMLLVERLSDARRNGHPVLAVVRGSAINQDGASNGLTAPNGPSQQRVIRQALANA  
ORF17\_pks02 WAEGAGMILVERLSDARRNGHQLAVVRGTAVNQDGASNGLTAPNGPSQQRVIRQALANA  
ORF17\_pks03 WGEGVGMLLVERLSDARRNGHQLAVVRGTAVNQDGASNGLTAPNGPSQQRVIRQALANA  
ORF17\_pks04 WAEGAGMLLVERLSEARAKGHPVLAVVRGSAINQDGASNGLTAPNGPSQQRVIRQALAGA  
ORF18\_pks01 WAEGAGMLLVERLSDARKNGHTVLAVVRGSAVNQDGASNGLTAPNGPSQQRVIRQALADA  
ORF18\_pks02 WGEGVGMLLVERLSDARAKGHPVLAVVRGSAINQDGASNGLTAPNGPSQQRVIRQALASA  
\* \* \* \* \*

```

ORF10_pKS01      GLSAAEVDVVEAHGTTGTRLGDPPIEAQALLATYGQEHTEDDRPLWLGLSKSNIGHTQAAAGV
ORF10_pKS02      GLSAADVDAVEAHGTTGTRLGDPPIEAQALLATYGQGRPADRPLWLGLSVKSNIGHTQAAAGV
ORF10_pKS03      GLSAAADVVDVEAHGTTGTKLGDPPIEAQALLATYGQDRPAGRPLWLGLSIKSNIGHTQAAAGV
ORF10_pKS04      DLSAADDIDAVEAHGTTGTRLGDPPIEAQALLATYGREREAGRPLWLGLSKSNIGHTQAAAGV
ORF10_pKS05      GLSAAEVDAVEAHGTTGTRLGDPPIEVQALLATYGREREADQPLWLGLSIKSNIGHTQAAAGV
ORF11_pKS01      RLSAAEVDVVEAHGTTGTTLGDPPIEAQALLATYGQDRPEGRPLRLGLSLKSNIGHTQAAAGV
ORF11_pKS02      GLSAAADVVDVEAHGTTGTKLGDPPIEAQALLATYGQDRPDGRPLWLGLSIKSNIGHTQAAAGV
ORF12_pKS01      RLTPADIDAVEAHGTTGTTLGDPPIEAQALLATYGQRTDGRPLWLGLSLKSNLIGHTQNAAGV
ORF12_pKS02      GLSAAEVDAVEAHGTTGTTLGDPPIEAQALLATYGQGRPDDQPLWLGLSVKSNIGHTQAVAGA
ORF12_pKS03      GLSAADVDAVEAHGTTGTTLGDPPIEAQALLATYGQDRPADRPLQLGLSIKSNIGHTQAAAGV
ORF12_pKS04      GLAPGDIDAVEAHGTTGTKLGDPPIEAQALLATYGQDRPADRPLQLGLSIKSNIGHTQAAAGV
ORF13_pKS01      RLSTDQVDVVEAHGTTGTSLGDPIEAQALIATYGQDRPADQPLLLGLSVKSNIGHTQAAAGV
ORF14_pKS01      RLTPDQVDAVEAHGTTGTLGDPIEAQALIATYGQDRPDGRPLWLGLSLKTNIGHTQAAAGV
ORF14_pKS02      GLTTMDVDVEAHGTTGTKLGDPPIEAQALLATYGQDRPEGRPLLLGLSIKSNLIGHTQAAAGV
ORF14_pKS03      GVAAGHVDAVEAHGTTGTTLGDPPIEAQALLATYGQEHTEDDRPLWLGLSVKSNIGHTQAAAGV
ORF15_pKS01      RLSATQVDVAEAGHGTGTTLGDPPIEAQALLATYGQDRPDGRPLWLGLSIKSNMIGHTQAAAGI
ORF15_pKS02      GLSAAEVDAVEAHGTTGTTLGDPPIEAQALLATYGREHTEDSPWLWLGLSIKSNMIGHTQAAAGV
ORF15_pKS03      GLSAAADVVDVEAHGTTGTTLGDPPIEAQALLATYGQEHTEDEQPLLLGLSIKSNFIGHTQAAAGV
ORF16_pKS01      RLSAADVDVVEAHGTTGTTLGDPPIEAQALLATYGQDRPAGRPLLLGLSIKSNIGHTQAAAGV
ORF16_pKS02      RLSAADVDVVEAHGTTGTTLGDPPIEAQALLATYGQDRPAGRPLLLGLSIKSNIGHTQAAAGV
ORF17_pKS01      GLTPAQVDVVEAHGTTGTTLGDPPIEAQALLATYGQNRPEGRPLWLGLSVKSNIGHTQAAAGV
ORF17_pKS02      GLTTAEVDVVEAHGTTGTTLGDPPIEAQALLATYGQDRPAGSPLWLGLSIKSNIGHTQAAAGA
ORF17_pKS03      GLTAAEVDVAEAGHGTGTRLGDPPIEAQALLATYGQDRPEGPSPLWLGLSIKSNFIGHTQAAAGV
ORF17_pKS04      RLTSQIDVVEAHGTTGTTLGDPPIEAQALLATYGREREADQPLWLGLSIKSNMIGHTQAAAGV
ORF18_pKS01      RLTAADVVDVEAHGTTGTTLGDPPIEAQALLATYGREHTEDSPWLWLGLSVKSNLIGHTQAAAGV
ORF18_pKS02      GLSAAADVVDVEAHGTTGTTLGDPPIEAQALLATYGQEHTEDDSPWLWLGLSIKSNFIGHTQAAAGV

```



## Figure 3a

```

ORF10_pat01 VLLPWALSAKTPEALRAQAR-----RLGTLIAAQP--HVTPL---DIGHSLATTRGRF
ORF10_pat02 SVLPLLLISAKSDAGLRAQSE-----QLATHLVGNP--DVPIG---DIAYSLTTGRSGL
ORF10_pat03 LPLPYVLSAKSPEALRAQAS-----VLRTHLEATD--HNGPG--SDDLAFSLATARAHL
ORF10_pat04 PVVPWVLSGKGEEALRAQAR-----QLQSYVLRAP--ELRPV---DIAGSLAVGRASF
ORF10_pat05 GVMFWTLSAKSEALRVQAE-----RLRTRIA-----SDPLLQPVVDVAYSLATSRAAL
ORF11_pat01 AVLFWTLSGRSTAALRAQAA-----RLLTQGGQDG--ATEFGRPLDIGYSLATTRAAL
ORF11_pat02 GTVPYVLSAKSSDALRAQAR-----QLLAVVEAAE--SPRVA---DLAYSLATSRAGL
ORF12_pat01 KALPWLLSAKGRDALRDRAA-----QLLAYAEEHP--DLRPV---DIAGSLAVGRPSF
ORF12_pat02 PVLPLLVSGRTPALRAQAERLRPAATALATGTVTNSG--ALEAL---DLGYSLATSRAAL
ORF12_pat03 DFVPLMLSAKSDVALRAQAA-----SLRARLIAAP--DMRLS---DVGSTLTTRGSFAF
ORF12_pat04 AVSAWPLAGKTEAGLREQAE-----RLLAHIDAHS--ELR---PVDVGHSLATGRAAF
ORF13_pat01 -VVPWVLSGKSAGALRAQAE-----RLSGFLAGASAVDVPSV--DVGWSSLASSRAGL
ORF14_pat01 GALPVVLSGRTEPALRAQAA-----ALHAHLAAHP--GLGIA---DLAFSQALTRAAL
ORF14_pat02 GPQFWLLSAKTRDALHDQAR-----RLHAHAELNP--ELSPA---DLGLSLAAGRSFAF
ORF14_pat03 SSVPLIVSARGEDALRAQAR-----RLHAHVHADP--GLRAV---DLGLSLATSRAGL
ORF15_pat01 VPPLWTLSSAKSPAALRAQAG-----KLHAHLTAHP--GLRPG---DIAHSLAVGRTRDF
ORF15_pat02 SALPLQLAGRSAAALSAQAR-----ALSAHLT-----AHPDVPLADLAYSLATSRATF
ORF15_pat03 GSLFWLLSAKGADALRDQAA-----RLRAHAIGHP--ELSLA---DIGYALATSRTAL
ORF16_pat01 -VVPWVLSGKSAGALRAQAE-----RLSGWLAGASAAGVASV--DVGWSSLASSRAGL
ORF16_pat02 -VLPWTLTAKTEKALQGQAE-----RLLTQLT--TRSDLRLV--DVGHSLATTRTAL
ORF17_pat01 GPVPVLSVSGQSDAALRAQAE-----RLAAHLRAHPGLGADTGTLTDLGFSLATSRSSL
ORF17_pat02 TPLPFALSGRTPAALRAQAA-----RLIGHLAPRP--EAAPA---DVALSLATTRTAL
ORF17_pat03 AALPWNLSARTPDALRAQGE-----RLLSHLETHCE--THPETVLADIGHSLTTGRALF
ORF17_pat04 RVLFPVLSAKSAGALRGQAV-----RLKAHVEASP--EVSGAGAVDVAYSLATRRAVF
ORF18_pat01 PVLFPWPVSARTEALHAQAE-----RLLAHVR-----TNPDAQAPVGVALSLATGRAAL
ORF18_pat02 RVLFPVLSAKSAGALRGQAV-----RLKAHVEASP--EVSGAGAADVAYSLATRRAVF
      : : : . * : . * : : : : * :

```

```

ORF10_pat01 EQRAIVLGDD---REAFLDALHALAEGN-----DTPSVVQGAA--APGKLAFLFTGCG
ORF10_pat02 ETRAILVGADN--RTGLAALALRSLAAGE-----QAPGLVQGTV--TEGGLAFLFTGCG
ORF10_pat03 EHRVAVLT--ADD--PQEFREALARLADGD-----PSPRITTGAV--SDGRTAFLEFTGCG
ORF10_pat04 EDRAAVV--AAD--REGLLAALALADGG-----SATGAVEGSA--VGGKLAFLFTGCG
ORF10_pat05 ERRAVVVATE---RDEFLAGLKALASGQ-----PAPGLVQGR--VTEGGLAFLFTGCG
ORF11_pat01 EHRVAVLL--GRT--EDDFAAALSALAEGA-----ESAGLVQGRV--TEGGLAFLFTGCG
ORF11_pat02 DHRAALVADD---RENLTRALAALAAGE-----QVPGLVRGTA--TGGLLAFLFTGCG
ORF12_pat01 EDRAAVV--AAD--REGLLAGLAALADGG-----SATGLVKGSSQLVGKLAFLFTGCG
ORF12_pat02 EHRVAVLIGTPSD--GQALASRLDALAAGE-----QVPGLVQGT--SGGGLAFLFTGCG
ORF12_pat03 ERRAALV--AGG--REGLLAGLEALADGG-----SAAGLVEGSP--VSGKLAFLFTGCG
ORF12_pat04 DHRAVLVAGDD---RSEFRRALAALASGE-----SVAQVVQGIARPDQVAFLEFTGCG
ORF13_pat01 EHRVAVLG-----DHAAGVAVASGV-----MAAGVVTGSV--VGGKTAFFVFPQCG
ORF14_pat01 DRRRAAVVADD---RDALLAGLAALAEGR-----PSADVVEGSA--TDGKLAFLFTGCG
ORF14_pat02 ERRAAVI--AAD--RDGLLAGLAALADGG-----AAAGLVEGSP--VAGKLAFLFTGCG
ORF14_pat03 EQRAALVAGD---RAELLRGLDALARGE-----DTAGLVRGTA--REGQVAFLEFTGCG
ORF15_pat01 EHRVAVLT--SADG--PVGLVRALALADSAPEDTAPADRAPGVTRGRP--VAGKLAFLFTGCG
ORF15_pat02 DHRAVLVATEGTTAATAVTALDALADRR-----TAPGLVRGTASKGRTAFLEFTGCG
ORF15_pat03 DRRRAAVVAGD---REEFLAGLAALAEGA-----TAAGLVEGSP--AGGKLAFLFTGCG
ORF16_pat01 EHRVAVLG-----DHAAGVGAVASGV-----MAAGVVTGSV--VGGKTAFFVFPQCG
ORF16_pat02 DQRAVLIGRDRP---DYLGAALTALAAGD-----TSPLLVOGAV--VGGKTAFFVFPQCG
ORF17_pat01 DRRVAVLFGDR---DSLADLSALAEGE-----QPAGPVLGAV--GEGKTAFLFTGCG
ORF17_pat02 DRRRAVIAHD---RTELLAGLTALAEGH-----DSARLVQHTA--ADGRTAILFTGCG
ORF17_pat03 EHRATVVAGD---RDGFRAGLAALAEGR-----TAAGLIQSSSTGGRTAFLEFTGCG
ORF17_pat04 DHRAVVVAGD---REELLRLSAAVESEG-----AAAGVTRGAVG--GKKLAFLFTGCG
ORF18_pat01 EHRVAVVATD---RETALADLAALASGE-----TSARVVLGEPGARGKTAFLFTGCG
ORF18_pat02 DHRAVVVAGD---REELLRALAAVESEG-----TAAGVTRGTAG--GKKLAFLFTGCG
      : ** : : : : : : : : : : : :

```

## Figure 3b

	M1
ORF10_pat01	SQRLGMGRELYETHPVFADALDDACWYLDQLELPL--LDVLFADGSEPAALLHQYTAYT
ORF10_pat02	SQRLGMGRELYETYPVFADALDAVCARM--LEVPL--RDVLFAGY----AGLLDETAYT
ORF10_pat03	SQRLGMGRELYEAYPVFADALDAVCAHVDHLEVL--KDVLFAGD----AGLLDQYTAYT
ORF10_pat04	SQRLGMGRELYEAYPVFAEALDAVCAR----LELPL--KDVLFAGD----AGLLDETAYT
ORF10_pat05	SQRLGMGRELYETYPVFADALDAVCVR----LELPL--MDVLFAGTE----RDALDETGYT
ORF11_pat01	SQRLGMGRELYEAYPVFADALDAVCAR----LELPL--KDVLFAGD----AGLLDETAYT
ORF11_pat02	SQRLGMGRELYETYPVFARALDAV----DARLELPM--KEVLFAGD----ADLLNETAHT
ORF12_pat01	SQRLGMGRELYETYPVFAQALDAVCER----LELPL--KNVLFAGTD----SAALDETSYT
ORF12_pat02	SQRLGMGRELYETYPVFAEALDAVCAR----LELPL--KEVLFAGD----GAALDQYTAYT
ORF12_pat03	SQRLGMGRELYEAYPVFADALDAVCVR----LELPL--MDVLFAGD----AGLLNETAYT
ORF12_pat04	SQRLGMGRELYETYPVFADALDAVCAR----LELPL--KDVLFAGD----ADRLNETAYT
ORF13_pat01	SQWVGMAVGLLDSSPVFAARVEECAKALEPFTDWSL--VDVLRGVEG--APSLERVDVV
ORF14_pat01	SQRPGMGRELYATYPVFAQALDAVCER----LELPL--KDVLFAGTDGAA--GAALDETAYT
ORF14_pat02	SQRLGMGRELYDTPVFADALDAVCAHVDHLEVL--KDVLFAGD----TGLLDQYTAYT
ORF14_pat03	SQRPGMGRELYDAHPVFADALDEICGELDRHLEVL--KGVLFATE----GDLIHQYTAYT
ORF15_pat01	SQRLGMGRELYETYPVFAQALDAVCERLN--LEVPL--RDVLFAGD----AGLLDQTYT
ORF15_pat02	SQRLGMGRELYEAYPVFARALDAVCDR----LELPL--KDVLFAGTD----AGLLNETVYT
ORF15_pat03	SQRLAMGRELYSAHPVFARALDAVCDG--LALDVPL--KQVLFAGSD----ADLLDRTAYT
ORF16_pat01	SQWVGMAVGLLDSSPVFAARVDECAKALEPFTDWSL--VDVLRGVEG--APSLERVDVV
ORF16_pat02	SQWVGMAVALLDASPVFAARVDECAKALEPFTDWSL--RDVLRGVTG--APSLDRVDVV
ORF17_pat01	SQRLGMGRELYATHPGFARALDEVRAELDQHLEPL--FDVLFAGGTPEADLLDETAYT
ORF17_pat02	SQRPGMGRELYETYPFAEALDAVCAELDPHLEQPL--KEVLFATD----GDLNRTGRT
ORF17_pat03	SQRLGMGRELYEAYPVFARALDEVCA--LELPLPLKDVLFAGTD----TGLLNETAYT
ORF17_pat04	SQRLGMGRELYETYPVFARALDAACAR----LELPL--KDALFGTD----AGLLGETAYT
ORF18_pat01	SQRLGMGRELYEYYPVFADALDAVCAR----LELPL--KDVLFAGD----ARLLDETAYT
ORF18_pat02	SQRLGMGRELYETYPVFARALDAACAG----LELPL--KDALFGAD----AGLLDETAYT
	** . * * * * : : : . * : . . .

```

ORF10_pat01      LPAG-GVMIALQASEDEVLPLLT----DRVSIAAINGPQAVVIAGDEDAAAAIAETFOQA
ORF10_pat02      LPGG-GVMIAVQAPAEVLPLLT----ERVSIAAINGPQSVVIAGDEADAVAIVESFTG-
ORF10_pat03      LPTG-GVMIAVQASEDEVLPLLT----DRVSIAAINGPQSVVIAGDEADAVAIAESFTD-
ORF10_pat04      LPAG-GVMIAVQASEDEVLPLLT----DRVSIAAINGPRSVVIAGDEADAVAIVESFTG-
ORF10_pat05      LPTG-GVMIAVQASEAEVLPLLT----ERVSIAAINGPQSVVIAGDEADAVALVESFTG-
ORF11_pat01      LPAG-GVMIAVQASEAEVLPLLT----DRVSIAAINGPQSVVIAGDEADAVAIAGSFAD-
ORF11_pat02      LPTG-GVMIAVQASEDEVLPLLT----GOVSIAAINGPQSVVIAGDEADAVAIAESFTD-
ORF12_pat01      LPGG-GVMIAVQASEDEVLPLLT----DRVSIAAINGPQSVVIAGDEADAVAIAESFAD-
ORF12_pat02      LPGG-GVMIAVQASEDEVLPLLT----DRVSIAAINGPQSVVIAGDEADAVAIAESFTG-
ORF12_pat03      LPAG-GVMIAVQASEDEVLPLLT----DRVSIAAINGPQSVVIAGDEADAVAIVESFTG-
ORF12_pat04      LPTG-GVMIAVQASEAEVLPLLT----ERVSIAAINGPQSVVIAGDEADAVAIVDAFND-
ORF13_pat01      VLAGLGGMVSVPLPAKAVRELIAPWGEGRISVAAVNGPSSVVVSGEAAALDELLVSCSE
ORF14_pat01      LPTG-GVMIAVEASEDEVLPLLT----DWVSIAAVNGPRSVVVAGDEDAAVAIAEFAAQ
ORF14_pat02      LPTG-GVMIAVQASEDEVLPLLT----DRVSIAAINGPQSVVIAGDEADAVAIAESFTG-
ORF14_pat03      LPTG-GVMIAVQASEDEVLPLLT----DRVSIAAINGPQSVVIAGDEADAVAIAESFTD-
ORF15_pat01      LPGG-GVMIAVQASEDEVLPLLT----DRVSIAAINGPQSVVIAGDEADAVAIAESFAD-
ORF15_pat02      LPGG-GVMIAVQASEAEVLPLLT----DRVSIAAINGPRSVVIAGDEADAVAIVESFTD-
ORF15_pat03      LPTG-GVMIAVEASEDEVLPLLT----DRVSIAAINGPQSVVIAGDEADAVAIAESFTG-
ORF16_pat01      VLAGLGGMVSVPLPAKAVRELIAPWGEGRISVAAVNGPSSVVVSGEAAALDEMLASCSE
ORF16_pat02      VLAGLGGMVSVLPAKAVRELIAPWGEDRISVAAVNGPSSVVVSGETAALDELLASCESD
ORF17_pat01      LPAD-GAMIAVEATEDEVAPLLT----GRVSIAAVNGPRSVVVSGDEDAATALAETLRAR
ORF17_pat02      LPEG-GAMIALTATEDEVLPLLAGH--EDRIGIAAVNSASSVVISGEEGLALEIAAEFERR
ORF17_pat03      LPGG-GVMIAVQASEGEVLPLLT----DRVSIAAINGPQSVVIAGDEADAVAIVESFS-
ORF17_pat04      LPTG-GVMIAVQASEAEVLPLLT----DRVSIAAINGPQSVVIAGDEADAVAIVESFSG-
ORF18_pat01      LPAG-GVMIAVQASEDEVLPLLT----ARVSIAAINGPQSVVIAGDEADAVAIVESFTG-
ORF18_pat02      LPTG-GVMIAVQASEDEVLPLLT----DRVSIAAINGPQSVVIAGDEADAVAIVESFSG-

```

```

ORF10_pat01 GRKTKRLTVSHAFHS PHMDAMLEEFRLVAQVLDYAKPTLPVVSLLTGTATPAELATPAY
ORF10_pat02 -RKS KRLTVSHAFHS PHMDGMLD FRAVAEGLSYEAPRIPVVS NLTGALVS-DEMGSAEF
ORF10_pat03 -RKS KRLTVSHAFHS PHMDGMLDAFREIAEGLSYEPSRIPVVS NLTGALVS-DEMGSAEF
ORF10_pat04 -RKS KRLTVSHAFHS PHMDGMLD FRAVAEGLSYEAPRIPVVS NLTGTLVT-DEMGSAEF
ORF10_pat05 -RKS KRLTVSHAFHS PHMDGMLADFRKVAEGLSYEAPRIPVVS NLTGALVT-DEMGSAEF
ORF11_pat01 -RKS KRLTVSHAFHS PHMDGMLD FRLVAEGLSYEAPRIPVVS NLTGALVS-DEMGSAEF
ORF11_pat02 -RKS KRLTVSHAFHS PHMDGMLADFRKVAEGLVYENPRIPVVS NLTGTLVT-DEMASDF
ORF12_pat01 -RKS KRLTVSHAFHS PHMDGMLD FRVVAEGLSYEAPRIPVVS NLTGALVS-DEMGSAEF
ORF12_pat02 -RKS KHLAVSHAFHS PHMDGMLD FRAVAEGLSYEAPRIAVVS NLTGALVS-DEMGSAEF
ORF12_pat03 -RKS KRLSVSHAFHS PHMDGMLD FRVVAEGLSYDAPRIPVVS NLTGALVT-DEMGSAEF
ORF12_pat04 -RKS KRLAVSHAFHS PHMDGMLADFRKVAEELS YEAPRIPVVS NLTGALVT-DEMGSAEF
ORF13_pat01 GVRAKRIADVYASHSAQVELLREELAE LLAPIVPRAAEVPFLSTVTGEWVRGPELDGG-Y
ORF14_pat01 GRKTKRLTVSHAFHS PHMDGMLDAFRTVAQGLSYGTFRIPVVS NLTGALVT-DEMGSAEF
ORF14_pat02 -RKS KRLTVSHAFHS PHMDGMLD FRAVAEGLSYEAPRIPVVS NLTGALIS-DEMGSAEF
ORF14_pat03 -RKS KRLTVSHAFHS PHMDGMLADFRKVAEGLVYENPRIPVVS NLTGALVT-DEMGSAEF
ORF15_pat01 -RKS KRLTVSHAFHS PHMDAMLEDFRAVAEGLSYEAPRIPVVS NLTGALVS-DEMGSAEF
ORF15_pat02 -RKS KRLTVSHAFHS PHMDGMLDAFREIAEGLSYEAPRIPVVS NLTGALVS-DEMGSAEF
ORF15_pat03 -RKS KRLTVSHAFHS PHMDGMLDAFREVAEGLSYGTFPLIPVVS SHLTGTLVT-DEMRSDF
ORF16_pat01 GVRAKRIADVYASHSAQVELLREELAE LLAPIVPRAAEVPFLSTVTGEWVRGPELDAG-Y
ORF16_pat02 GVRAKRIADVYASHSAQVELLREELAE LLAPIVPRAAEVPFLSTVTGEWVRGPELDGG-Y
ORF17_pat01 GRRTKRLTVSHAFHS PLMDGMLDAFREVAESVAYAPPVPIVVS NLTGASVTAEEICAADY
ORF17_pat02 GRRTKRLTVSHAFHS PLMDGMLDAFREVAESLTYRAPAIPVVS TLLTGTGTVAG-DELRTAEH
ORF17_pat03 -RKS KRLTVSHAFHS PHMDGMLD DFRVAEGLSYGAPRIPVVS NLTGALVS-DEMGSAEF
ORF17_pat04 -RKS KRLTVSHAFHS PHMDGMLAGFRKVAESLS YEAPRIPVVS NLTGALVT-DEMGSAEF
ORF18_pat01 -RKS KRLTVSHAFHS PHMDGMLD FRVVAEGLSYEAPRIPVVS NLTGALVS-DEMGSAEF
ORF18_pat02 -RKS KRLTVSHAFHS PHMDGMLAGFRKVAESLS YEAPRIPVVS NLTGALVT-DEMGSAEF

```

### Figure 3d

```

ORF10_pat01      WVRHV RDAVRYLDGVR TLHQRGVRT FLELGPDAVL TAMAQDCVDP----QGAAFPALR
ORF10_pat02      WVRHV REAVRFLDGM RVLEAAGV TTYVELGPGGVL SALAQECVSG----DGAAFPVPLR
ORF10_pat03      WVRHV REAVRFLDGIR TLEAAGV TKYVELGPDGVL SAMAQDCVSG----EGSVFIPVLR
ORF10_pat04      WVRHV REAVRFLDGI RALEAAGV TTYVELGPGGVL SALAQECVSG----DGAAFPVPLR
ORF10_pat05      WVRHV REAVRFLDGT RTLEALGV TTYVELGPDGVL SAMAQECVTG----EDSVFVPVLR
ORF11_pat01      WVRHV REAVRFLDGI RTLEAAGV TKYVELGPDGVL SAMAQDCVSG----EGSVFIPVLR
ORF11_pat02      WVRHV REAVRFLDGI RALESRGV TTYIELGPDGVL SAMAQDCLTAGTG-TGTAIFAPVLR
ORF12_pat01      WVRHV RETVRFLDGI RTLEAAGV TKYVELGPDGVL SALAQDCVSG----EDSVFIPVLR
ORF12_pat02      WVRHV REAVRFLDGI RALEAAGV TTYVELGPGGVL SALAQECVSG----DGAAFPVPLR
ORF12_pat03      WVRHV REAVRFLDGI RALEAAGV TTYVELGPDGVL SAMAQECVTE----GGAAFPVPLR
ORF12_pat04      WVRHV REAVRFLDGI RALEAAGV TTYVELGPDGVL SAMAQECVTG----EGAAFPVPLR
ORF13_pat01      WFO NLRRTV ELEEAT RTLLEQGFGVFV ESSPHPVLSVGMQETVEDAG---REAAVLGSLR
ORF14_pat01      WVRHV REAVRFLDGI RWLESRGV TTYIELGPGGVL SALGQDCQTATG--PRAAFLPALR
ORF14_pat02      WVRHV REAVRFLDGI RTLEAAGV TKYVELGPDGVL SAMAQDCVSG----EGSVFIPVLR
ORF14_pat03      WVRHV REAVRFLDGI RALEAAGV TTHIELGPDGVL CAMAQECVSG----EDTVFVPVLR
ORF15_pat01      WVRHV RETVRFLDGI RALTERNV VHFVELGPDAVL SAMAQDCPSA----DTAAFPVPLR
ORF15_pat02      WVRHV REAVRFLDGI HALEAAGV TTYVELGPDGVL SAMAQECVTG----EDSVFVPVLR
ORF15_pat03      WVRHV REAVRFLDGI RTLEDAGV TTYIELGPGGVL SAMGQSCVTR----DDAAFLPALR
ORF16_pat01      WFO NLRRTV ELEEAT RTLLEQGFGVFV ESSPHPVLSVGMQETVEDAG---REAAVLGSLR
ORF16_pat02      WFO NLRRTV ELEEAT RTLLEQGFGVFV ESSPHPVLTMGVQETVEDAG---RDAAVLGSLR
ORF17_pat01      WVRHV REAVRFLDGI VRKLSAQGV TTFVEVGP GGVL TALAQECVTG----QDAVFPVPLR
ORF17_pat02      WVSHV REAVRFLDGI RTLDAEHV TTYIELGPGQGVLSGLGRDCLTDPADPADTAVFVPALR
ORF17_pat03      WVRHV REAVRFLDGI RALEAAGV TTYIELGPDGIL SAMAQECITG----EGAAFPVPLR
ORF17_pat04      WVRHV REAVRFLDGI RTLEAAGV ATYVELGPDGVL SAMAQDCVTG----EGAAFPALR
ORF18_pat01      WVRHV REAVRFLDGI RALEAAGV TTYVELGPDGVL SAMAQACVTG----ENSVFVPVLR
ORF18_pat02      WVRHV REAVRFLDGI RALEAAGV TAYVELGPDGVL SALAQECVTG----EGAAFPALR
*      *      *      *      *      *      *      *      *      *      *      *

```

```

ORF10_pat01      SGRPEAATVLNAVAHAHVHVRGAETDWAFFAGTGAQRVDLPTYAFQRRQRYWM--
ORF10_pat02      SGRPEAETAVTALAQAHVHRGVDVDWAFFSGTGVQRVDLPTYAFQRRQRFWP--
ORF10_pat03      KARPEAESVTTALASAHVHGIPVDWQAYFFAGTGAQRVDLPTYAFQRRQRYWP--
ORF10_pat04      SGRSEAETAVTALAQAHVHRGVNVDWAFFAGTGAERVLDLPTYAFQRRQRYWL--
ORF10_pat05      SGRPEAESVTTALAQVHVHVGIAVDWQAYFFAGTGAQRVDLPTYAFQRRRYWL--
ORF11_pat01      KARPEAESVTTALATAHVHGGIPVDWQAFYAGTGAQRVDLPTYAFQHERYWL--
ORF11_pat02      AARPEAESVTTALATAHVHGGIPVDWRAYFFAGTGARRADLPTYFPQGRRYWP--
ORF12_pat01      KARPEAETVATALASHVHGTIPVDWRAYFAGTGAQRVDLPTYFPQGRRYWI--
ORF12_pat02      SGRSEAETVVTALAQAHVHRGVEVDWAFFAGTGAERIDLPTYAFQRRQRYWP--
ORF12_pat03      KGRPEAETVMATLGQAHVHRGVAVDWHSVYG-TGAQRVDLPTYSFQRRQRYWP--
ORF12_pat04      KGRPEAETITAAALAHATHGIAVDWQAYFFAGTGAQRVDLPTYAFQRRQRYWV--
ORF13_pat01      RGEGLLERFWLSLGEAWVRGVGDWHAFFAGTGAQRVDLPTYAFQSQRFWPEA
ORF14_pat01      TGRPEASSLTAAVAGAHVRGLSPDWTVRFAGTGAQRVELPTYAFQRELYWP--
ORF14_pat02      KARPEPESVTTALTTAHVHGGIPVDWQAFFAGTGARRVDLPTYAFQRRQRYWP--
ORF14_pat03      PGRPEAETVTTALARVHVQGVPDWQAYFSGTGAQRVDLPTYAFQRRRYWL--
ORF15_pat01      KGRSETGSLTDALARLHVHGGVAVDWDAYYSCTDVRVDLPTYAFQRAHYWL--
ORF15_pat02      SGRPEAESVTTALAQAHVHRGIAVDWQAYFAGTSAQRVDLPTYRFQREHYWP--
ORF15_pat03      ADDRSEETLTSAVARAHLRGITVDWDAYYSCTGARRVDLPTYAFQRRQRYWL--
ORF16_pat01      RGEGLLERFWLSLGEAWVRGVADWHAFFAGTGARRVDLPTYAFQQEHYWLSE
ORF16_pat02      RGEGLLERFWLSLGEAWVRGVGDWDSAVFAGTGARRVDLPTYAFQSQRFWPEA
ORF17_pat01      GDRPEAAAFATAVAQAHVHGVAVDWSAVFAGRGATRIDLPTYAFQRELYWP--
ORF17_pat02      RDRGEAEALTAAIAAAHTRGVPLDWSAYFFAGTGARRVELPTYAFQRRERFWL--
ORF17_pat03      AGRDEAETVLSALAAAHVHRGVFPVDWQAFYAPAGAQRVPLPTYAFQRRSVWL--
ORF17_pat04      KGRPETETITTTALALAHAGTSDWETYFAGTGAQGVELPTYAFQRDWWYL--
ORF18_pat01      SGRSEAESVTTALAQAHVHRGIAVDWQAYFAGTGAERVLDLPTYAFQRDHYWL--
ORF18_pat02      KGRPEAETITTTALAHNHGTSVDWETYFSGTGAQRVDLPTYAFQRRERYWI--

```

## Figure 4

```

ORF10_pDH03      IGLGDAGHPLLGAVALADSEGVLFRTGRLSLDTHPWLADHTILGSVLLPGTAFVDLAIIRA
ORF11_pDH01      AGLDPAGHPLLGAAVTLAGSDSVLFTGRLSLRTQPLWADHTVSGTTVLLPGAAFVELAVRA
ORF12_pDH01      AGLLEEAGHPLLGAAVPLADSEGVLFRTGRLSLRTSHPWLADHAVMDTVLLPGTAFVDLAVRA
ORF12_pDH04      AGIGSAGHPLLGAAVELPDSGFLFTGRLSLRTHPWLADHVVDTVVVPGAAFVELAVRA
ORF14_pDH02      IGLDDTAHPLLGAVALPESDGMVFAGRLALSTHAWLADHAILGSVLLPGTAFVELATRA
ORF14_pDH03      AGLDAADHPLLGAATVSLPGSDGLVLTGRLALSTHWPWLSDEHTVMDTVLLPGTAFVELALRA
ORF15_pDH01      AGLGAAGHPLLGAVALADLDGFLYTGRLSLDTHPWLADHAVMGSVLLPGTAFVELAIIRA
ORF15_pDH02      IGLAAAGHPLLGAAVTLADADGCVLTGRLSLRTHPWLADHAVMGSVLLPGTAFVELALHA
ORF15_pDH03      AGLGSAGHPLLGAAVELPDSGFLFTGRLSLRTHPWLADHVRVACTVLLPGTAFVELALRA
ORF17_pDH01      AGIGAADHPLLGAATLADGDGHLFTGRLSLATHPWLADHTVMDTVLLPGTAFVELALQA
ORF17_pDH02      AGMGAAHHPLLGAVALADGEGFLFTGRLSLDTHPWLADHAVMGNVLLPGTAFVELAIIRA
ORF17_pDH03      AGLGATDHPLLGAAVELPDSGFLFTGRLSLATHPWLADHAVLGSVLLPGTAFVELALRA
ORF17_pDH04      FGLGATDHPLLDAITIELPDSGFLFTSRLSLDTPWLADHAVLGSVLLPGTAFVEIAVRA
ORF18_pDH01      AGLRSADHPLLGAVALADAEGLLLTGRLSLDTHPWLADHAVACTVLLPGTAFVELALRA
ORF18_pDH02      AGLGAAEHPLLGAAVELPDSGGLLLTGRLSLLSHPWLADHAVACTVLLPGTAFVELALHA
* : : * * * * * : * . : : : * * . : : * * * * * : : : : * * : * : * : * : *

```

```

#
ORF10_pDH03      GDQVGCDDVVEELTLEAPLVVPQRGGVQLQLVVEAP--SGPGQRPFVSVHS
ORF11_pDH01      GDQAGCERVEALVLDAPLALPAEGAVRVQVLVEAP--DEQGRRPFTVSS
ORF12_pDH01      GDQVGCDDVVEELTLEAPLVLPERGAVQIQMHVVGAPDADGTGRRTFTLSS
ORF12_pDH04      GDEVGCEEVEELVLEAPLVLPKGAVALRLSVGGA--DDQGRRSVHVHS
ORF14_pDH02      GDQVGCDDYLEELTLEAPLVLPKHGGVQLRVWVGAA--DESGRRPFFALHS
ORF14_pDH03      GELVGCAGVEELALEAPLTLADQGAVALQFQLAVDAP--DGAGRRTLTLSHS
ORF15_pDH01      GDQVGCDDLLEELTLHAPLVLPAGGVQVQLWVGAP--DATGRRTLGVHS
ORF15_pDH02      GERVGTALDELTLQAPLILPNEGAVQLQVVGAP--DAAGHRTVAVYS
ORF15_pDH03      GDHAGCDLLEDLTLEAPLVLPKAGGVQLRLVVAEP--DASRRRVFHIYS
ORF17_pDH01      GDHTGCDLLEDLTLEAPLVLPKHGGVQIQLAVGAP--DAEGRRSLTLSHS
ORF17_pDH02      GDQAGCDLLEELTLEAPLILAPQAAARLQIVVGAP--DGSGRRTL DVYS
ORF17_pDH03      GDQVGCDDLIDELTLEAPLVLPKHGGVQLRLAVAAA--DATGRRTLAFHS
ORF17_pDH04      GDQVGCDDVLEELTLEAPLVVPERGAVQLRLTVAAA--DESGRRGLSLYS
ORF18_pDH01      GDQVGCDDLIDELTLAAPLVLPKGGVELQITVAAP--DESGRRSVAFHS
ORF18_pDH02      GQRVGSGLLEELTLEAPLVLPERGALQLRVSVAAAP--DEAGRRALHVHS
* : . * : : * . * * * : . . . : : * . . : * . . *

```

### Figure 5

ORF17\_per02  
AAF71776\_mod05 | NYST  
AAF71767\_mod15 | NYST

QLAVRRTVHAPRLARVPAAATPLTPPPGSAWRMDIEDKGTLDHLTLVSPSPAAPLEPFG  
QLALRDGGVLAARLARFDTAAALTTPPAD-RAWRLDSTAKGSLNGLALTPYPAALAPLTGH  
QAVVREGTVRVGRLLARLDSGRGLVPPP-G-TPWRLGSRAKSLDLGLALLPHPEARLPHTGH  
\* . : \* \* \* . \* \* \* . : . \* . \* . . \* \* : . \* \* : \* : \* \* \* : \*

ORF17\_per02  
AAF71776\_mod05 | NYST  
AAF71767\_mod15 | NYST

QVRVAARAAGLNFRDVLNALGMYPG-DPGLMGSEGAIVVETGPGVTGLAPGDRVGMGLP  
EVRVEVRAAGLNFRDVLNALGMYPGDVGSGSEAAGVVVEVGPEVTGLAPGDQVMGMT  
EVRVGIRAAGLNFRDVLNALGMYPG-DAGLFGSEAAGVVVEVGPEVTGLAPGDRVGMGLP  
: \* \* : \* \* \* \* \* \* \* \* \* \* \* \* \* \* : \* \* : \* \* : \* \* : \* \* \* \* \* :

ORF17\_per02  
AAF71776\_mod05 | NYST  
AAF71767\_mod15 | NYST

GSFGPLAVDDRMIAPMEGWTFEAASVPIVFMTAYYALHDLAQLQGGSLLVHAAGG  
GSFGSLAVDDARRLARLPEDWSWETGASVPLVFLTAYYALKELGGLRAGEKVLVHAGAGG  
GGFGPLGIADARLLTPVPADWSWETGASVPLVFLTAYYALKELGGLRAGEKVLVHAGAGG  
\* . \* . \* . : \* \* : : \* \* : . \* \* \* : \* : \* \* \* : \* : \* \* : \* \* \* \* \*

ORF17\_per02  
AAF71776\_mod05 | NYST  
AAF71767\_mod15 | NYST

VGMAAVQLARHWGADVATASPDKWTLRGLGLGDDRIASSRTLDFEETFRTATGGRGV  
VGMAAIQIARHVGAEVFATASEGKWDLVRLSLGVADDHIASSRTLDFEAAFAEVAGDRGLD  
VGMAAIQIARHVGAEVFATASEGKWDLVRLSLGVADDHIASSRTLDFEAAFAEVAGDRGLD  
\*\*\*\*\* : \* : \* \* \* : \* : \* \* \* \* \* \* \* \* : \* : \* \* \* \* \* : \* : \* : \* \* :

ORF17\_per02  
AAF71776\_mod05 | NYST  
AAF71767\_mod15 | NYST

VVLDSLAREFVDASLRLPRGGRFVEMGKTIDVRSQPQDVADAHPGVSQAFLDEAGLDRI  
VVLNSLAGDFVDASMRLLGDGGRFLEMGKTDIRADSVPD---GLSYQSFDLAWVPETI  
VVLNLSGEFVDASMRLLGDGGRFLEMGKTDIRADSVPD---GLSYHSFDLMGMDPEHI  
\* \* \* : \* : : \* \* \* \* \* \* \* \* \* \* \* \* \* \* : \* \* : \* \* : \* \* : \* \* : \*

ORF17\_per02  
AAF71776\_mod05 | NYST  
AAF71767\_mod15 | NYST

QEMLTELLTLFRSGLRPVPSAWDLRQAPEAFRYLSQARHVGVKIVLTLP  
GTMLAEMLDLFRTGALRPLPVRTWDVRHAKDAFRFMSMAKHIGKIVLTLP  
QRMLDLVELFDRGALAALPVRSDVRRAGEAFRFMSLAQHIGKIVLTLP  
\* \* . \* . \* \* \* \* \* . \* \* . \* \* . \* \* : \* \* : \* \* \* \* \* :



### Figure 6a

ORF10\_pKR01 PTGTVLVTGCTGVLGGRVARWLAGA-GAERLVLTSRRGLDAPGAVELVEELTTGFGVEVS  
ORF10\_pKR02 PTGTVLVTGCTGVLGGRVARWLAGA-GAERLVLTSRRGLDAPGTAEVLVEELTS-SGVEVS  
ORF10\_pKR03 PSGTVLVTGATGTLGLGFARHLVTAYGVRLLLLTSRRGPEAEGAELVAELEQ-LGAHVE  
ORF10\_pKR04 PTGTVLVTGCTGVLGGRVARWLAGA-GAERLVLTSRRGPDAPGAAELVEELTTGFGVEVS  
ORF10\_pKR05 PRGTVLVTGCTGALGHHVARWLAH-GAEHLVLLSRRGFPQAPGADALVAEIAA-LGAGAT  
ORF11\_pKR01 PAGTVLITGCGSCTLAGTIVARHLATAHGVRLLLLSRRGADAPGAGELTAELAG-LGAQVS  
ORF11\_pKR02 PRGTVLVTGCTGALGRHVARHLAER-GAERLVLVSRRGADAPGAETEAELSA-FGAAVT  
ORF12\_pKR01 PGSTVLITGAGCMLGGLIARRLVAAEHGVRHLLLVRRGAAAPGAEQLSAELAE-AGASVT  
ORF12\_pKR02 PTGTVLVTGCTGVLGGRVARWLAGA-GAERLVLTSRRGPDAPGAAELVEELTTGFGVEVS  
ORF12\_pKR03 PTGTVLVTGCTGVLGGRVARWLAGA-GAERLVLTSRRGPDAPGAAELVEELAG-SGVEVS  
ORF12\_pKR04 PRGTVLITGASCTGLGFLARHLVAEHGVRHLLLSRRGAAAEQAQLADELVA-LGAQVT  
ORF13\_pKR01 PQGTTLVTGCTGALGAHVARWLAGN-GAEHLLLSRRGPDAPGAAALRDELTA-LGTQVT  
ORF14\_pKR01 TTGTALITGCTGALGRHVARWLART-GAQHLLLVSRRGPEAEGADALAAELRA-LGAEVT  
ORF14\_pKR02 PGGTVLITGATGALGLGFARHLAAEHGVERLLLVGRRGADAPGAAELVAELAE-SGTLAT  
ORF14\_pKR03 ADGTVLVTGASCTTLGGLFARHLATHGARRHLLLSRRGDRAPGAGELTRELTE-AGVDVT  
ORF15\_pKR01 PDGTVLVTGASCTTLGLFARHLVTRGVRRLLLLSRRGADAPGAEELAAELTG-LGAEVS  
ORF15\_pKR02 VDGTVLVTGASCTTLGGLFARHLVVERGVRRLLLLVSRRGAAEGAELGAELTE-LGADVR  
ORF15\_pKR03 PEGTVLITGASCTTLGGLLARHLVTEHGVRRLLLLTSRRGAAAEAGATQLADELVT-LGAQVT  
ORF16\_pKR01 PQGTTLVTGCTGALGAHVARWLAEN-GAEHLLLSRRGPDAPGAAALRDELTA-LGAQVT  
ORF16\_pKR02 PQGTTLVTGCTGALGAHVARWLAEN-GAEHLLLSRRGPDAPGAAELRDELTA-LGAQVT  
ORF17\_pKR01 PDGTALVTGATGTLGLVARHLVAAHGVRHLLLSRRGEAAAGAELAAGLRE-LGAEVT  
ORF17\_pKR02 SQGTVLITGCTGTLGAVVARHAVTTRGARRLLLLTSRRGEAAAGAELAAELRE-LGAEVT  
ORF17\_pKR03 VDGTVLVTGASCTTLGLFARHLVVERGVRRLLLLVSRRGAAEGAELGAELTE-LGADVR  
ORF17\_pKR04 SDGTVLVTGASCTTLGGLFARHLVVERGVRRLLLLVSRRGAAEGAELGAELTE-LGADVR  
ORF18\_pKR01 SDGTVLVTGASCTTLGGLFARHLVVERGVRRLLLLVSRRGAAEGAELGAELTG-LGADVR  
ORF18\_pKR02 PDGTVLITGCTGSLGSLLARHLVVEHGVRRHLLLSRRGAAAEAPELVAALAE-LGAEAT

```

ORF10_pKR01      VVACDAADRDALRALLSAEAG-----SLTAVVHTAGVLDDGVLDALTPDRIDSVVRAKAV
ORF10_pKR02      VVACDAADRDALRALLSSEAG-----SLTAVIHTAGVLDDGVLDALTPDRIDGVVRAKAV
ORF10_pKR03      LVACDAADRSLAALLGAVPSE---HPLTAVVHTAGVLDDGILSSLTPERVAAVLRPKVD
ORF10_pKR04      VVACDAADRDALRTLSSAEAG-----TLTAVIHTAGVLDDGVLDALTPDRIDSVLRKAV
ORF10_pKR05      AVACDVTDRTAVSELLAGLADGTYGPGLTAVFHHTAGAGQFAPLDGTGPGEVAEVVAKV
ORF11_pKR01      WAACDAGDRDALAAVLAAPPA---HPLTAVVHTAGVLDDGVIGSLTPERLDTVLRPKAD
ORF11_pKR02      LVACDVADRDALGTLVARLAAD---GTPVRAVVHAAGVSQ---PGPGTGDLPGFARVAAKTA
ORF12_pKR01      WAACDVADRDALSAVLHAI PAE---HPLGAVVHTAGVLDDGVIASLTPERLSAVLRPKVD
ORF12_pKR02      IVACDAADRDALRALLSAEAG-----TLTAVIHTAGVLDDGVLDALTPDRIDSVLRKAV
ORF12_pKR03      VVACDAADRDALRALLSAEAG-----TLTAVIHTAGVLDDGVLDALTPDRIDSVLRKAV
ORF12_pKR04      WAACDVADRDALAALLASVP AE---QPLTAVVHTAAVLDGVDVLLTPERVDVLRPKAE
ORF13_pKR01      IASCDMADRDAVTALTAAPAD---QPLTAVIHAAAVDDGVIEITLPEQVEAVLRVKVD
ORF14_pKR01      IAACDVADRDAVAALLATLPAE---HPLTNVVAAGVLDDGVLDQAQTPQRLAGVLRPKAH
ORF14_pKR02      WAACDVADRDALAALLADIPAE---HPLTAVVHTAGVLDDGVISLTPERLSAVLRPKVD
ORF14_pKR03      WAACDAADRDALAAVLAAIPAE---RPLTAVVHTAGVLDDGVIDSLTPERLDTVLRPKVD
ORF15_pKR01      WAACDAGDRDALAAVLAAPPA---HPLTAVVHTAGVLDDGVIGSLTPERLDTVLRPKAD
ORF15_pKR02      WAACDVADREALESVLAGIPAE---YPLSGVVHTAGVLDDGVVSSLTAERVS AVLRPKVD
ORF15_pKR03      WAACDAADRDALAALLSVPA---HPLTAVVHTAGVLDDGTVESLTAGRMATVLRPKVD
ORF16_pKR01      IAACDVSDRDVAVALIAVPAD---QPLTAVVHTAAVLDGVI EALTPEQIERVLRVKVD
ORF16_pKR02      IATCDMADRDAVAALIAVPAD---QPLTAVMHHTAGVLDDGVIDALTPFERFGTVLAPKAD
ORF17_pKR01      IAACDAADRDALAALIGSVP AE---HPLTAVVHTAGVLDDGVLEALTPERIDAVLPAKVD
ORF17_pKR02      IAACDAADRDAALAI ESIPSE---HPLTAVIHTAGVLDDGVVDSLTPERLSTVLRPKVD
ORF17_pKR03      WAACDVADRDALEAVLAGIPAE---YPLSGVVHTAGVLDDGVVSSLTPERLSAVLRPKVD
ORF17_pKR04      WAACDVADRDALESVLAGIPAE---YPLSGVVHTAGVLDDGVVSSLTPERLSAVLRPKVD
ORF18_pKR01      WAACDVADREALESVLAGIPAE---YPLSGVVHTAGVLDDGVVSSLTAERVS AVLRPKVD
ORF18_pKR02      VAACDAADREALAALLAGIPAA---HPLTAVVHTAGRVDDGLLASLSPERIDTVLRPKAD

```

## Figure 6b

```

ORF10_pKR01  SALNLHELTAELGIELSDFVLFS SVTGTVGAAGQAN YAAANAFLDALAEQRRADGLAATS
ORF10_pKR02  SALNLHELTAELGIELSAFVLFS SMSGTVGTAGQAN YAAANAYLDALAEQRRADGLAATS
ORF10_pKR03  AAWNHLHELTRGL--GLSAFVLFS GAAAFGAAGQGN YAAANSFLEALAEQRRADGLPAT
ORF10_pKR04  SAFNLHELTAELGIELSAFVLFS SMSGTVGAAGQAN YAAANAYLDALAEQRRADGLAATS
ORF10_pKR05  GAAHLDELGLD--TELDADFVLFS SIAGVWGS GGQSA YAAANAHLDALAQRRRARGLTATS
ORF11_pKR01  AALHLHELTRDL--PLTAFVLFS AIAGTLGSAGQAN YAAANVFLDALAQHRRDQDLPAT
ORF11_pKR02  GAVHLDALFDAP--DSLDAFVLFS SIAGVWGS GGQSA YAAANTFLDTLAEERRRARGLAATA
ORF12_pKR01  AACNLHELTRHL--DLTAFVLFS SIGGVFGGPGQGN YAAANVFLDALAQHRRSQGLAATS
ORF12_pKR02  SALNLHELTAELDIELSAFVLFS SMSGTVGAAGQAN YAAANAFLDALAEQRRADGLAATS
ORF12_pKR03  SAINLHELTAELGIELSAFVLFS SVTGTWGTAGQAN YAAANAYLDALAEQRRADGLAATS
ORF12_pKR04  AALHLHELTKDL--DLSAFVLFS SAAAGTLGGAGQAN YAAANVFLDALARHRTARGLTALS
ORF13_pKR01  ATLILHELTRGL--DLSAFVLFS SFAATFGAPGQGN QAPGNAYLDAFAEYRRSGSLPAT
ORF14_pKR01  AAQVLHELTRDL--DLSAFVLFS SVAAVFGAAGQAN YAAANASLEALAEQRRADGLPATV
ORF14_pKR02  AAWNHLHELTRGL--DLAAFVLFS STSGLFGGPGQGN YAAANSFLDALAQHRRARGLPATS
ORF14_pKR03  AAWNHLHELTEGH--ELSAFVLFS SVAGCFGAGQGN YAAANTFLDALAQHRRARGLTASS
ORF15_pKR01  AALHLHELTRDL--PLTAFVLFS SAAGVFGAPGQGN YAAANSFLDALAQYRRARGLPGRS
ORF15_pKR02  AAWNHLHELTRGL--DLSLFLVLFS SAAGVFGGAGQAN YAAANVFLDALAQHRRAQGLAATS
ORF15_pKR03  AAWNHLHELTHGL--DLAAFVLFS SAAGVFGNAGQAN YAAANTFLDALAQHRRAQGLTAVS
ORF16_pKR01  ATLHLHELTRGL--DLSAFVLFS SFAATFGAPGQGN YAPGNAYLDAFAEYRRSGSLPAT
ORF16_pKR02  AALTLHELTRGL--GLSAFVLFS GVAGTLGDAGQGN YAAANSYLDALAEQRHADGLAATS
ORF17_pKR01  AAVHLHELTRGL--DLAAFVLFS SAAAGTLGGPGQAN YAAANTFLDALAHRRRAEGLPATA
ORF17_pKR02  AAWNHLHELTRHL--DLADFVLFS SAAGTFGGAGQAN YAAANVFLDALARHRRHAGLAATS
ORF17_pKR03  AAWNHLHELTRGL--DLSLFLVLFS SAAGVFGGAGQAN YAAANVFLDALAQHRRAQGLAATS
ORF17_pKR04  AAWNHLHELTRGL--DLSLFLVLFS SAAGVFGGAGQAN YAAANVFLDALAQHRRAQGLAATS
ORF18_pKR01  AAWNHLHELTRGL--DLSLFLVLFS SAAGVFGGAGQAN YAAANVFLDALAQHRRAQGLAATS
ORF18_pKR02  AALHLHELTRGL--DLAAFVLFS SAAAGTLGNPGQAN YAAANAFLDALAQHRRAAAGLPAVS
.: * . * * * : : : * * . . . * * : : * . * . .

```

```

ORF10_pKR01  IAWGPWA--EGGMAAD--EAMDARMRREGMPMPAPTSAMSALEQ
ORF10_pKR02  IAWGPWA--EGGMAAD--AALEARMRRDGVPPMPADPAIRALRQ
ORF10_pKR03  LAWGLWAPQTGGMAQQLDEVDLRRIARDGVGGLSGDEGLGLFDT
ORF10_pKR04  IAWGPWA--EGGMAGD--DAMDARMRREGLPMPAPDAALTLRQ
ORF10_pKR05  VAWGPWG--EGGLVAD--DEAAEQRLRRRGLPVMAPELSIAALQQ
ORF11_pKR01  LAWGLWA--DASGMTGGLDEAQLRRMEQHGMGTLSATDGMALFDA
ORF11_pKR02  IAWGPWA--DGGMATE--GDAEEQLSRRGLPMDRATNLLALER
ORF12_pKR01  LAWGLWA--DSTGMAGSLDEADISRMRGGGLPPLTTAEGLELFDL
ORF12_pKR02  IAWGPWA--EGGMAAD--AALEARMRRGGVPPMDAELALSALRQ
ORF12_pKR03  IAWGPWA--EGGMAAD--AALEARMRRGGVPPMKGEAAVNALQR
ORF12_pKR04  LVWGMWA--EERGMAGRLTEAELGRAGRGVAPLSATEGLALFDA
ORF13_pKR01  IAWGPWG--SADGDDS---AAGDRMRHGIIVMSPERTLVSLQH
ORF14_pKR01  LAWGAWA--EGGMATD--ELVAERLRLAGLPALAPELALSALHR
ORF14_pKR02  TAWGLWS--VADGMAGALDAADVNRMRAGLPPLTAADGLGLFDT
ORF14_pKR03  LAWGLWE--TTDGMAGALDEADLTRMARSQVAALAPDEGLALFDT
ORF15_pKR01  LAWGLWE--DAEGMAGALDRADLDRMKRGVHGLTASEGLALLDL
ORF15_pKR02  LAWGLWA--EPGGMAGALDADDVSRLGRGGVSGLSAGEGVALFDA
ORF15_pKR03  LAWGLWD--DEAGMAATLDEQDRRLSRGSMNPLSVAEGLALFDA
ORF16_pKR01  IAWGPWG--DGGMAEG---AVGDRMRHGVIEMSPERAVAAALQH
ORF16_pKR02  VAWGRWG--DSGLAAGG--AIGERLDRGGVPAMAPRSATRALQL
ORF17_pKR01  LAWGLWA--ERSGMTGDLADADLERISRAGVAALSSAEGVALLD
ORF17_pKR02  LAWGLWA--EASGMTGELDTADKDRMTRSGVLGLSSEEGVALLD
ORF17_pKR03  LAWGLWA--GVGGMGELTESDRERINRGGITALEPETGLALFDA
ORF17_pKR04  LAWGLWA--EPGGMAGALDADDVSRLGRGGVSGLSAGEGVALFDA
ORF18_pKR01  LAWGLWD--EPGGMAGALDADDVSRLGRGGVSGLSAGEGVALFDA
ORF18_pKR02  LAWGLWE--QRSAMTGALSDADVQRMARAGLAPLSAEGVALFDT
. * . * : : : :

```

## Figure 7

ORF10_pac00	SAALRDAAPDTLDPHRPFLDLGFD	SLAAVDLHARLVAGTGLRLPVTLAFDHPTPAHLARHLH
ORF10_pac01	AAVLGHGSDAVGAERAFKELGFD	SLTSVELRNRLGAATDLRLPTTLVYDYPTSAALAEYLR
ORF10_pac02	AAVLGHAGVENVGAGRAFKELGFD	SLMAVELRNRLGSAATELRLPATLIYDHPTSAALAEFLR
ORF10_pac03	AEVLGHTDARAVDADRAFKELGFD	SLTAVELRNRLKAATGLRLSPTLVFDYPTPVALARHLL
ORF10_pac04	AAVLGHGGSEAVGAERAFKELGFD	SLTAVELRNRLGAATGVRLPATLIFDYPTATALAAYLR
ORF10_pac05	AVVLGHGGATAVEAARAFKELGFD	SLTAVELRNRLSTATGLRLPASLVFDYPTPAALAAHIR
ORF11_pac01	ASVLGHASAEQVDPARAFKDLGFD	SLTAVELRNRLGAATGLRLPTTLVFDHPTPTALVRHLR
ORF11_pac02	ATALGHTSADAVAAERAFKDLGFD	SLTAVELRNRLGAACGLRLPSSLVFDYPTNPQALTRHLL
ORF12_pac01	AAALGYPGPSAVEPGRSFKELGFD	SLTAVELRNRLG DATGRRLPATLVFDYPTATALAGYLR
ORF12_pac02	AEVLGHSGAEDIEAGRAFREIGFD	SLTAVELRNRLGAAAEELRLPATLVFDYPTPAALAVHLR
ORF12_pac03	AAVLGHAGVESIGARAFKELGFD	SLTAVELRNRLGAVTGLRLPATLIYDYPTSGALAEYLR
ORF12_pac04	AAVLGYGSAEHIGGEQAFKELGFD	SLTAVELRNRLGAAGGLRLPATLIYDYPNPAALAQHLL
ORF13_pac01	AAVLGHADLAAVEAGRAFKELGFD	SLTSVELRNRLGAVSGLKLPASLVFDHPTPAAVAFLR
ORF14_pac01	AAVLGYAGPESVDPGSAFRDLGFD	SLTAVEIRNLLTSRTGLRLPATLIFDYPTNSLSLAFLQ
ORF14_pac02	AAVLGHAGPAAVESGRAFKELGFD	SLTAVELRNRLNAATALRLPATLIFDYDPTVLARYLR
ORF14_pac03	AAVLGYAGPDDVDAARGFLDLGFD	SLTAVDLRNRLTASAGRLPVTLIFDYPTPTALAYLA
ORF15_pac01	ADVLGHGSPDAIDPEQAFSELGFD	SLTAVELRNRLGAAIGRRLPATLIFDHPASLTARHLS
ORF15_pac02	AAVLGYASPEAVEKDSSFRELGFD	SLTAVELRNRLGAATGLRLPATLVFDYPTSAVLADHLR
ORF15_pac03	AQVLGHSGAAAIEPGSAFKELGFD	SLTAVELRNRLGAVTGLRLPATLIFDYPTPEALSGHLR
ORF16_pac01	AAVLGYAGPDAVEAGRAFKELGFD	SLTSVELRNRLNAASGLKLPPTLVFDHPTPTVLARHLR
ORF16_pac02	ATALGHPTTDEVGAGRAFKELGFD	SLIALELRNRLNAATGLRLPATLVFDHPTPTILAEFLR
ORF17_pac01	AAVLGYPGPEAVDPGRAFKELGFD	SLTAVELRNRLGSATGVRLPATLVFDYPTPNALSAFLR
ORF17_pac02	AAVLGHATPDAVEPTRAFKDLGFD	SLTAVEFRNRLGATAGIRLPATLVFDYPTPTVLAGYLK
ORF17_pac03	AAVLGHASTDEV PADRAFKELGFD	SLTSVELRNRLGATTGERLSATLVFDYPTPHALAEFLR
ORF17_pac04	AAVLGFAGPEAVDPARSFSEVGFD	SLTAVELRNRLGAATGVRLPATLVFDYPTPDALVEYLR
ORF18_pac01	AAVLGLAGPEAVDPARSFSEVGFD	SLTAVELRNRLGAATGVRLPATLVFDYPTSLALADFLG
ORF18_pac02	AAVLAYPSPDVAVGESQEFLELGLD	SLTAVELRNQLNAATGLRLPATLLFDHPTPALVAERLR

: . \* : \* : \* : \* : : : : : \* : \* : \* : : :

ORF18\_pTE02  
AAF71777|NYST

---RGDTRPGLVCFSSILSISG-----PHQ-----YARFASAFGRRDVHALGAPG---F  
MTTSTEEESLWARCFHPAPAAPVRLFCFPHAGGSASFYFPVSAQLSSVAEVFAIQYPRQD  
                  \*\*                  \*\*                  \*                  :                  :                  \*                  \*                  \*\*

ORF18\_pTE02  
AAF71777|NYST

LRGEQLPSATDAVIEAQAEAVLRHADGAPFVLL**GHSSG**GMLAHAVAGRLESEG-----  
RRKEAGVSDLATLADQVYDALRPLPKERPSTFF**GHSM**CATLAFEVARRFEADDGDLVRLF  
\* \* \* : : : \* : : : \* : : \* : : \* : : \* : : \* : : \* : : \*

ORF18\_pTE02  
AAF71777 | NYST

```

-----VFPQALVMDIYSHDDDAIIGIQPLSEGMDERQDTYVPVDDNRLLAMGAYFRLFG
ASGRRAPSRVREEAVHRRSDDGIVEELK-LLAGTNTALLGDEEILRMILPAIRSDYQAIE
      *   :       : :   ** * :       * *   :       :       * *   : : : :

```

ORF18\_pTE02  
AAF71777 | NYST

GWK--PEVVKTP<sup>1</sup>LLVRAGERFFD<sup>2</sup>WTRST<sup>3</sup>DGDWRSY<sup>4</sup>WDL<sup>5</sup>DHTALD<sup>6</sup>VE<sup>7</sup>GN<sup>8</sup>HFT<sup>9</sup>MEEHAPT  
TYRCP<sup>10</sup>PDV<sup>11</sup>TRAP<sup>12</sup>LTV<sup>13</sup>LTGD<sup>14</sup>RDPK<sup>15</sup>TS<sup>16</sup>LDEAE<sup>17</sup>AWRG<sup>18</sup>HT<sup>19</sup>TGDF<sup>20</sup>LK<sup>21</sup>VLE<sup>22</sup>CG<sup>23</sup>HF<sup>24</sup>-FVSSEAPA  
:: \*:\* . . \* \* :\*: \* . : . \*\* : . \* : \*\*: \*\* : : : \*\* :

ORF18\_pTE02  
AAF71777|NYST

TAQAVEGWLDTTG  
IIDLLRAHLGNG  
: : : \* : \*

Figure 9






Figure 10

a



b



c




Figure 11




Figure 12a




Figure 12b






Figure 12c




Figure 12d




Figure 12e






Figure 12f




023X04QB1\_R1

023QBA0704c01\_R1 1194 (31.880) Cm (1185:1207)

2: Scan ES-  
8.34e

023QBA0704c01\_R1 1196 (31.920) Cm (1184:1207)

1: Scan ES-  
3.3e7

023X04QB1\_R1

023QBA0704c01\_R1 1922 (32.135)


3: Diode Array  
2.10e6

Figure 14

Figure 15a





Figure 15b






Figure 15c

## STANDARD PROTON PARAMETERS

Pulse Sequence: gDQCOSY

Solvent: CD300

Ambient temperature

File: ECG\_02301\_gDQCOSY\_CD300\_high\_res

INOVA-500 "resonance"

Relax. delay 1.000 sec

Acq. time 0.128 sec

Width 3988.0 Hz

2D Width 3988.0 Hz

32 repetitions

2 x 500 increments

OBSERVE H1 499.7495714 MHz

DATA PROCESSING

Sg sine bell 0.096 sec

Shifted by 0.064 sec

F1 DATA PROCESSING

Sg sine bell 0.037 sec


Shifted by -0.025 sec

FT size 8192 x 8192

Total time 10 hr, 48 min, 6 sec

Filename: \_

Figure 15d



## STANDARD PROTON PARAMETERS

Pulse Sequence: ghsqc

Solvent: CD300

Ambient temperature

File: ECO-02301\_CD300\_ghsQC\_12\_02

INOVA-500 "resonance"

Relax. delay 1.000 sec

Acq. time 0.128 sec

Width 4001.6 Hz

2D Width 21361.8 Hz

64 repetitions

2 x 128 increments

OBSERVE H1, 499.7495714 MHz

DECOUPLE C13, 125.6727810 MHz

Power 40 dB

on during acquisition

off during delay

W40\_1d4719 modulated

DATA PROCESSING

Gauss apodization 0.059 sec

F1 DATA PROCESSING

Gauss apodization 0.022 sec

FT size 2048 x 2048

Total time 5 hr, 28 min, 9 sec




Filename: -

Figure 15e

## STANDARD PROTON PARAMETERS


Pulse Sequence: gHMBC  
Solvent: CD3OD  
Ambient temperature  
File: EC002301\_CD3OD\_gHMBC\_12\_02  
INOVA-500 "resonance"

Relax. delay 1.000 sec  
Acq. time 0.128 sec  
Width 4001.6 Hz  
2D Width 28901.7 Hz  
128 repetitions  
400 increments  
OBSERVE H1, 499.7495714 MHz  
DATA PROCESSING  
Sine bell 0.064 sec  
F1 DATA PROCESSING  
Sine bell 0.007 sec  
FT size 2048 x 4096  
Total time 17 hr, 18 min, 49 sec



Filename: \_

Figure 15f



## STANDARD PROTON PARAMETERS

Pulse Sequence: TOCSY

Solvent: CD3OD

Ambient temperature

File: 02301\_CD3OD\_TOCSY\_mix\_08

INOVA-500 "resonance"

Relax. delay 1.000 sec

Mixing 0.080 sec

Acq. time 0.128 sec

Width 4001.6 Hz

2D Width 4001.6 Hz

32 repetitions

2 x 200 increments

OBSERVE H1, 499.7495714 MHz

DATA PROCESSING

Gauss apodization 0.059 sec


F1 DATA PROCESSING

Gauss apodization 0.046 sec

F1 size 2048 x 2048

Total time 4 hr, 29 min, 30 sec

Figure 16





## SEQUENCE LISTING

<110> Ecopia BioSciences Inc  
 Bachmann, Brian O.  
 McAlpine, James B.  
 Zazopoulos, Emmanuel  
 Farnet, Chris M.

<120> POLYENE POLYKETIDES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS A PHARMACEUTICAL

<130> 3004-8PCT

<150> USSN 60/441,123

<151> 2003-01-21

<150> USSN 60/469,810

<151> 2003-05-13

<150> USSN 60/491,516

<151> 2003-08-01

<150> USSN 60/494,568

<151> 2003-08-13

<160> 78

<170> PatentIn version 3.0

<210> 1

<211> 11740

<212> DNA

<213> Streptomyces aizunensis

<400> 1

gatcatggcc ggcgaggtgg tcgcgggscgg ggcgaatccg aaggtcacgg tcctcccttc	60
gggttacgcg cgccgctgac gggcacggct gggttgcggg cgcgccgcag cgcggccctc	120
aagagtgccg acgagccgag cgggaacact ccaattctcg cgcggcccg cgcggccctc	180
caacgagcaa ttggcgccgc ggaccgtaat tggccggtat gccgttcata tccttgcccc	240
gttacgccgt cgatgacgca tccggtgccg cccggaccgc cggtagcagc ggaaacacct	300
cccgcgcggc ggcccgctgg agccgcggag atccaccgga caccctctgg gcctggcgga	360
gtccgtgcgt gccgcgtgga ttcgccgatt gtcggtggga tcgggttgca tgggggcatg	420
gacaacctgg agctccgtcg tgaagccgat gccatcctcg ctgagctggc cggtgcccct	480
gggggttcgg cgcggctgcg ggaggaccag tggcaggcgg tcgcggccct ggtggaggag	540
cgcggcggg ccctggtggt gcagcgcacg ggcgggggca agtccgcggc ctacttcgtc	600
gccaccgctc tgctgcgcgg gcgcggctcc gggccgacgg tgatcatttc tccgctgctg	660
gcgctgatgc gcaaccaggt cgaggcggcc gcgcgggccc ggatccaggc gcgcacgatc	720
aactcggcca acccgaggga gtgggaaacc atctacgggg aggtcgagcg cggcgagacc	780
gatgtgctcc tcgtcagccc cgagcgcctc aactccgtgg atttccgcga ccaggtactg	840

cccaagctgg	cggccacgac	gggtctgctg	gtggtcgacg	aggcgactg	catctccgac	900
tggggccacg	acttccgccc	cgactaccga	cggctgcgca	cgatgctggc	ggagctgccg	960
gagggcgctg	cggtcctggc	cacgacggcg	accgcgaacg	cgcggtgac	cgcgacgtg	1020
gcggagcagc	tgggcacgca	cggcgagcac	gccctgggtcc	tgcgcgacc	gctcgaccgg	1080
gagagcctgc	ggctgggagt	gctgcagctg	ccggacgcgg	cgacccggct	ggcctggctg	1140
ggggaccggc	tggcgcacct	gccgggttcg	gggatcatct	acacgctgac	cgtggcgggc	1200
gcggaggagg	tcgcggcggt	cctgcggcaa	cgcggtatc	cggtaggttc	ctacaccggg	1260
aagacggaga	acgccgaccg	gttgcaggcg	gaggaggatc	tgctggcgaa	ccgggtgaag	1320
gcactggtgg	cgacctcggc	gctgggcatg	gggttcgaca	agccggacct	ggggttcgtg	1380
gtgcacatgg	ggtcgccctc	gtccccgatc	gcctactacc	agcagggtgg	gcgcgcgggg	1440
cgtggggtgg	atcacgcgga	cgtgctgctg	ctgccggggc	gggaggacga	ggcgatctgg	1500
gcgtacttcg	cctcgggtgg	cttcccggcc	gaggagcagg	tccggcgcac	cctggacgta	1560
ctggcgcagg	cgggccgccc	gctgtcgctg	cccgcgctgg	agccgctggt	ggacctccgg	1620
cgctcgcgcc	tggagacgat	gctgaaggtc	ctggacgtgg	acggcgcggt	caagcgctg	1680
aagggcggtc	ggaccgccac	cgggcagccg	tggacgtacg	acgcggagcg	gtacgcctgg	1740
gtcgcgaagc	agcgggcggc	ggagcagcag	gccatgcggg	actacgtggc	gaccacgggc	1800
tgccggatgg	agttcctgca	gcggcagctg	gacgacgaga	aggcggtccc	gtgcggccgc	1860
tgcgacaact	gcgccggatc	ctggctggag	gcggtcgtgt	cggccgcggc	cctcgcggcc	1920
gcggcgggcg	agctggaccg	cgcgggggtc	gaggtcgagt	cccgaagat	gtggccgacc	1980
gggctcgccg	cggtcggcat	ggacctgaag	ggccggatcc	ccgcgggcca	gcaggccgtc	2040
accgggcgcg	cgctcggcag	gctgtcggac	atcggctggg	gcaaccggct	gcgccccctg	2100
ctgtcggcgc	aggccgcgga	cgggccgggt	ccggacgatg	tgctggccgc	cgtcgtgacg	2160
gtgctcgccg	actgggcccc	ctcgccgggc	ggctgggcga	gcggcgggcc	ggacgcgatg	2220
gcgcggcccg	tggggatcgt	cgccatgccc	tcccgtaccc	gcccgcggct	ggtcgcctcg	2280
ctggccgagg	gcgtggcccc	ggtcggcagg	ctcccgtctg	tgggcagcct	cgctacacc	2340
ccgcaggccg	acgtgtacgg	ggcgcaccgc	agcaactcag	cccagcggtc	gcgcgccctg	2400
gccgactcgt	tcaccgtgcc	cgaggaactc	gccgcggccc	tggccgcgcg	tcccggcccc	2460
gtcctgctcg	tcgacgacta	caccgactcc	ggctggaccc	tggccgtggg	cgcacgcctg	2520
ctgcgccagt	ccggcgcggg	cggcgtgctc	ccgctcgtcc	tcgcgctggc	cgggtaggcg	2580
gactccaccg	gcctcggcct	atcgccaacc	gacggggggc	ggcaagatca	aaacaaccgc	2640
ccgtaaagca	aacgtaaaga	tgtggcttct	ttgggaagtc	gcgtatgggc	ctgttttgag	2700
ccacgcggcg	gaagtcaccc	ctggcgggat	ccgtggtggc	gcattcgggt	cggacggccg	2760

aacggggccgt	cgtcgctccc	gttcggggccg	ggggggccctg	tcgtcgcacg	gggagagcga	2820
atgccggcccg	gggctgcgga	ccgggaggtt	ccagccaggg	taggggtaga	aagtaggggt	2880
actccccgcc	ttgatcgtcc	tggtagacat	gacacatccg	aaacgcgcgt	gcggaagtgg	2940
cgggaaggggt	cgaccctcgc	aacggggcgcg	ctgcatctgg	ggcttgaaca	gggagtttca	3000
gtccgtttgaa	taagcaagaa	actagcctct	gggttcgccg	ctaccacgct	tcggacgaaa	3060
gccggatcca	attggtctgt	ctgccgcacg	ccggtggctc	ggcctccttc	tacttcccca	3120
tgtcccagtc	gctggctccg	gcgatggacg	tcctctcggt	ccagtacccc	ggcaggcagg	3180
accgcaggga	cgagcccggg	atcgtggaca	tcggcgcccta	cgcggaacgc	ctgaccgagc	3240
aactcgtacc	gtggctcgac	cggcccctgg	ccttcttcgg	ccacagcatg	ggtgcgatcc	3300
tcgccttcga	ggtgacgcgc	aggctggagc	gtgaccacgg	cgtcactccg	gagcacatct	3360
tcgcttcocg	ccggcgctcg	cccgccagtt	tcgggcacga	gaccgtgcac	ctgcgggacg	3420
acgacggaat	cgtggcgga	atgcgggaac	tcagcggaac	cgacgcgaag	atactcggca	3480
acgaggaaat	cctccgcgat	gtgctccccg	cgattcgaag	cgactacacc	gccatcgaga	3540
actaccgtgc	cgcgccggaa	gacgtcgtgc	gtactcccat	cacggtgctg	accggtgacg	3600
cggaccccgag	gaccagcccg	gaagaggcgg	acgcctggaa	ggcgcacacg	accggcggat	3660
tcgatctgca	ttccttcccc	ggtggacatt	tccttcctggc	gaatcaccag	gagaagatca	3720
tgggaattat	ttcggaggaa	ctctccgcgc	cggtctgcat	ggcgtgagca	gagagctgtg	3780
gaccaggccg	gggaaacccg	gctcgcccct	tgccgacctc	caccgcgatg	gcggagccga	3840
gaagccgaat	gaccaacggc	cgcggtggcg	atcgaaaggg	gcaggccgcg	gtgacggccc	3900
gccggtgcac	accgtgcacc	ggcacaccaa	gcggtgcggc	ggcggtctcg	ccgggcgccc	3960
accgggcccc	ttgcgaagtc	ttcgcaagtc	gtgcagttcg	ggggaaagga	agcccgtggc	4020
ggttaggctc	gtcgagcgcg	agaagcagct	ggaaacgctg	aaggaactac	tcggcagcgc	4080
agtccgtggc	cgaggggcgg	tcgccgtcat	cagcggggca	gtcgccggcg	ggaaaacgag	4140
tctgctggaa	atcttcaccg	aagaggcgat	ctccgcgggc	gcgctggtgc	tggaagccac	4200
gggctccccg	gcggagcgct	atctgccctt	cggaaattctg	cgcagaatcc	tcgacagcgc	4260
ggcgccccctg	tcgcccgaga	tccacgccta	cgccaccgag	ctgctggacc	gcgtcagcgc	4320
cgggacgacg	gacgccgaag	gcgccgtcga	ggccggtatg	cgcgtcctgc	cccatgtcgc	4380
caccgcactg	ttaaggatcg	cccggaaaccg	gaccgtcgtc	atagccatcg	acgacgtcca	4440
ccacggggac	gaactctccc	tcgccttcct	gctgtgcctc	gcccgcggag	tgcgccaggc	4500
ggcgctcctg	atcgtgctca	ccgaagccgt	ccggctgcgg	tcgcgcgaac	tcgccttcca	4560
cgcggaactg	cagcgccagc	ccaactgcac	cagcctccgg	ctgcccctgc	tcaccacgcg	4620

cggcaccacc cgcgtcctcg ccgagcactt ctccccctcg acggcgcaac ggctgtccgc 4680  
 cgagtgccag gagaccaccg gcggcaatcc actgctggtc agggcgctga tcgacgacgg 4740  
 cctcacggcg ctcgagagaca gcgagccctt ccagcggctc gcccccgccg aaaccttcga 4800  
 acgcgccgtg ctcgactgcc tgcaccgcgg cgaccccgag ctgctgaccg tcgccccggg 4860  
 cgtcgccgta ctcggtagcg cctgctcctt ggccctgctc aacgggatcg tcgacctgca 4920  
 cgccaaggcc accgaacagg cccttcagga cctcagccgg tgcgccgtcc tgcaccacgg 4980  
 ctcttccgc gaccggcg cgccgtaccgc cgtcctggaa gccactccgc ccgcggcgct 5040  
 gtccgccctg cacctgcgca ccgcgcgact cctgcaccag gaaggcgca cggcgctcga 5100  
 tgtcgcccg cactcctcg ccgcccga gaacgtcgag gactgggca tccccgtcct 5160  
 ccaggaggcg gtcgagtacg ccctcgtcga ggacgagcac gaactcgccc tgcggtgcgg 5220  
 ggaactggcg gtcgcctcct gcgcggaggg ccccgacac gccgccctga agtcccgct 5280  
 ggcgagcatc gtctggcgca gcagcccggc cgccgctgaa ggcacatctgc ggcagctgtc 5340  
 ccgcgaactc gccgccggcc ggctcgccga ccgcgatctc gtccaggccg tgtcgctcct 5400  
 ggcgtggatg ggggagtcgg gggggggccg cgaggcggtg ctgcgactgc agcggaccga 5460  
 cagcgaggcc gagggcgccg gacggggcgc cgccctacgac ccgggcacgc tcaccgccgc 5520  
 acagagctgg ctctcgatgg tcagcccgcc ggcccgcgac ctcttcgacg ccgtggaacc 5580  
 gcgccggaca acgctgtcag gcgcgccggg ggcgctgccc ggcgcggggc ccgacaccgt 5640  
 cccctacgac atgcccgaca acgcctacgt ccaggccgcc gacgccgtcc gcaccgccct 5700  
 gcgcggcgga acccaggccg acgccgcgt cagcaaggcc acccgggtgc tccagcgcta 5760  
 ccacctgagc gaccgcaccc tccagccgt cgtcttcgcc ctcttcgccg tcactacgc 5820  
 gggtcgcctc gacctcgct ccgcctggtg cgaacgactg ctccggcagt gctccgccg 5880  
 caacgccccg acctggcagg ccgccctcgg tgtggtccgg gccgagatcc tgctgcgcca 5940  
 gggcgatctg cccggtgcgg ccgccaggc ccgccacgcc atgtcccgga tctccctgca 6000  
 gagctggggc gtgggcatcg cgtgcgcgt ggccgtcctc gtcgaggccg aggtccagat 6060  
 gggcgaccac gaggaggcga tgagcctgct cgaacagccg gtgccccagg ccatgttcga 6120  
 caccctggcc ggcctgcact acctcagggc ccgcggccgc tgccacctgg ccaccggccg 6180  
 ctaccacgcc gccgtgcggg acttcctgaa ctgcggcgag ctgatgcagg cctggggcgt 6240  
 ggacggggcg gagctggtgc cgtggcggt ggacgcgcc gaggcgtggc tggccctcgg 6300  
 caacgtcgcg cgcgccaagg agtacaccga gcagcagaag cagcgcgaga cggggcccg 6360  
 gggcagccgg acgcgtggct ccctgctgct cacgctcgcc cacaccggcg gtgacctcac 6420  
 ggtccggctc aagcggctcg tcgaggcgt cgagaccctg gaggagggcg gggaccggct 6480  
 ccagctggcg gtggcgctgg gggagctggg ccgcggctac cgtgcgctgg gcgacttcaa 6540



ccgggcccgg atgctggtgc gcaaggcctg gcacgtcgcc aagtcctgcg gcgccgaacc 6600  
 gctgtgccag cagttcatgc cggggcaggt cgacggcgag gccggtgcgc agagcggccg 6660  
 ggaggcggag cttcccagcg aggtcgaggt cctgtccgag gccgaggcgc gggtcgcgct 6720  
 gctggcggcg cgcgggccaca ccaaccgtga gatagcgacc aagctctacg tcacggtgtc 6780  
 cacggtcgag cagcatctga cgcgcatcta ccgcaagctg aaggtgaagc ggcgccgcga 6840  
 tctgcccgcc cggctgtcgg acctgagcct gccgagcatc gcctgaccgc gcccgtcgcc 6900  
 gggagcgcgt tgcgggagcg cgttgcccgg agcgcggcgc cacgcgcggc gcccgccgcc 6960  
 cgcgggccgc acccgtcagg acagcaggcc gagcttcagt gccgtgatca ccgcggccgt 7020  
 ccggtccgag accgacagct tcttgaacga gcgcagcaga tgcgtcttca ccgtcgcctc 7080  
 gctgatgaac agctggcggc cgatgtccgc gttggtcagc ccgaggctga ccaactggag 7140  
 cacctcgcgc tcacggtccg acagcgcggg cggctccacc acccgggccc ggaacagctt 7200  
 gggggcgagc gacggcgta ggaccgtctc accgcgggcc gccgccttta ccgcctgcac 7260  
 cagttcgtcg cgcgagctgc ccttgagcag gtagcccgcc gcgcccgcct ccacggcccc 7320  
 caggatgtcc gtgtcgtctc cgtacgtcgt cacgatcacc accttggtgg ccggcgcgac 7380  
 gcgcagcagg tggccggtgg tctccacccc gtccatcccg cccatctgaa ggtcgagcag 7440  
 gacgatgtcg ggagcaagtc tggtgaccat cgcgatcgcc tcctcgcccg agtcggcctg 7500  
 cccgacgacg ctcacgccgt cggcggattg cagcatcgag ctgagaccct cccgtacgac 7560  
 cgggtggtcg tcgaccagca tcacaccgat cgtcttgtca gcgctcatcg gcttcctctc 7620  
 ccttcgcggg cacgggcacc gtcacttcga tgggtggtgcc ctgtccgggg ctgctgacca 7680  
 cggtcgcccgc cccgctgatc tcgtgtgcgc gactctgcat gccgcgcagc ccgcttcccc 7740  
 gctggtcccc ggtgacggtg aaccggggtc cgtcgtcccg tacgagcagc cgtacggtgt 7800  
 cctgttcgta cacgagccgg atctcggccg cgcgtgcctt ccccgcgctg ttgcggatgt 7860  
 tcgcgatggc ctccctggagg gaacgcagca ggaccacgct gatcgccatc ggcagttccc 7920  
 gctcgtctcc ttcgacggtg acgtgcgccc gcattgccgt ctgcgccgtc aggccctcgg 7980  
 cctgccgccg cgtcgcctgc acgagcgagg actcctgcag cgcgggcggg gtcagctcgg 8040  
 tgacgaactc gcgggcttct cccaggcttt cgcgggccac gcggcccgcc agtgccagat 8100  
 gcgccctcgc ccggtccggg tcggccgtga agtcggtctc ggcgccctgt acgaggctga 8160  
 tgatgctggt gaggccctgg gcgagggtgt cgtggatctc ccgggcgagc cgctcgcgct 8220  
 cggcggagac ccccgcttg cgcgacagcc gggcgacttg cgcacggttg cggtgcaact 8280  
 cctcgatgag ctcggcccgg tcacggctct gccgggtcac ccgggtgatc cacagcccga 8340  
 gcatgaccga cagggcgatg ccgaggagcg aggtcggcag gacggccagg atgtcgcggc 8400

tcaggggtgcc	gccgcgcagc	cacaccacga	tgaccggaac	cagattggcc	agcgtgacca	8460
cggcgatggc	cggcgaggtc	gccaggctca	tcatcagcat	cgggaccacg	gcgaacagcg	8520
cgaacgaggc	cgcgaggtcg	aagaccacgg	ccaccgcgaa	cagcacgaac	aggccgacgg	8580
agaagacgac	gctgcgccgg	acggggccct	ggccctcgtg	gaccatgggtg	ctgcgccccca	8640
gggccgcgta	ccaggggcacg	gccgcgggtca	gcgcgggccat	ggccacggcc	cgggtggacct	8700
gttcaccgtc	ggaggtgaac	agcagcatgg	tggtgacggc	gtacgagacc	gcgaagagcg	8760
cgtcccacag	gccgaaccac	cgggctcccc	cctcggggcg	gtcgtcctgg	ccgtctgtcg	8820
cctgcgcgcg	gggggattca	gtgctcacc	gacaagtcct	atcacttcgg	tcgggcacgg	8880
tacgagggcg	gcccggcgcc	gtccaccgtg	tccaccggtc	ggtggacagc	cgaaccact	8940
ggtcggttgt	cctcgcgtcc	cttgcccgcc	gcctaacgtt	gcaggtgaga	ggcacgaagc	9000
gaccgcactg	ccggagagaa	ggcagtgccg	aggaagagga	agaggtcatc	ccctgagccc	9060
gttcttgaac	acactgatcg	ccagcgggac	gatcttggcc	gtcattctgt	cgaccgacct	9120
cggcaccgcg	aaagtcacca	cgacgcggat	gcttccttcg	ctcctcgcgg	tcgtcgtgat	9180
cctcgcgcgc	ctcgtgcaca	cactgccgct	cgacggcaac	gacccctcgc	tccaactggc	9240
gggcatcggc	gccggatatca	tctgcggact	ggccgccacg	gcgctcctcc	ccgcccaccg	9300
gaacgcctcc	ggtgaggtct	ccaccaaggg	cggtatcggg	tacgcgctgg	tgtggaccgc	9360
gctgtccgcc	tcgcgtgtgc	tcttcgccta	cggttcacag	cactgggtca	gcgagggcat	9420
cgtccggttc	agcaccgact	acaagctcag	cggacaggcc	gtctactcca	acgctttcgc	9480
cttcatggcc	ctggccatgg	tgctgacgcg	gaccgccgtc	ctgttgaaca	cgcgccgccg	9540
gctgcgcggc	gggcagcttc	ccgcggccga	caacacggcc	ccacatcagg	cgagttccgc	9600
caatacgcac	tgacatgacg	gagcgtcaga	tccggcttgg	gtgcaagatc	gtctcagaac	9660
taggggtgaag	cagtgaacaa	catgcatgat	gtcaggctcc	ggcccccgcg	caatcgtgtc	9720
gactcccggg	cagtgggctg	gtggacggtc	cagtccgcga	tgtacgccct	gcccctgccg	9780
atcaccttcg	gcgtgctgta	cctgtgcac	ccgcccgcca	ggccgttctt	cggctggggc	9840
ttcctgatct	cgctcgtacc	gggcctcgcc	tacatggccg	tcatgcccg	ctggcgctac	9900
cgggtgcacc	gttgggagac	caccgacgaa	gccgtctacg	cggcgtccgg	ctggctctgg	9960
cagcagtggc	gggtcgtgcc	gatgtccgc	atccagacgg	tggacaccct	gcgcggaccc	10020
ctccagcagc	tcttcggcct	ctccggcatc	accgtcacca	ccgcctccta	ctccggcgcc	10080
gtgaagatca	agggaatcga	ccaccggacc	gcgcgggacg	tggtcgagca	cctcaccagg	10140
gtgaccacag	ccacccccgg	agacgcgaca	tgagccacga	caccggacag	tgggaggcca	10200
ccgcgacctc	ccacggcgcc	gccgaagacc	ccgagtggag	caggctcagc	ccccgactgc	10260
tgctgggtcaa	cctgagcatg	ctcgccggcc	cgctcgccct	gttcgcgcgc	acggtcgccc	10320

tgaccggcgc caacctccag gccctcatct ccctcggctc cctgctgac gtcttcctgg 10380  
 tcatcaccgg gatcagcacg atgcggctgc tgaccacccg cttccgcgtc accgccgaac 10440  
 gcgtcgaact gcgctcgggc ctgctcttcc gcagccgccg ctcggtcccc atcgaccggg 10500  
 tccgcagcgt cgacgtcgaa gccaagccgg tgcaccgcct cttcggcctc gcctcgtctc 10560  
 gcatcggcac cgggtgaacag ggcgctcca gccgcaggct ctccctcgac ggcatcacca 10620  
 ggcgtcaggc gcggcgactg cgcaggctcc tcatcgaccg ccgtggcagc ggcatgcca 10680  
 ccggccagga ccaggacgtc accatcgccg agatggactg ggctggctg cggtagcgc 10740  
 cgctcaccat ctggggcgtc ggcagcgtct tcgcccgtc cggcaccgcc taccgcatcc 10800  
 tgcacgagat gaaggtcgac ccgctcgaac tgggcgtcgt caaggacatc gaggaccgct 10860  
 tcggttccgt acccctgtgg ttccggcatcc tcgtcgccgt cgtgatcacc gccgtcgtgg 10920  
 gcgccgcggt ctccaccgcc accttcgtgg acgcctggac caactaccgc ctggagcgtg 10980  
 aggggggtcgg catcttcggg atccgccgcg gactgctcat ttcccgctcc gtcaccatcg 11040  
 aggagcgcgg gctgcgcggc gtcgagctcg ccgagccgat gctgctgcgc tgggcggggc 11100  
 gcgccaccct gagcgccatc gccagcggcc tcagcaacag ccaggagaac cgcagccgct 11160  
 gtccctcac cccgcccgtg ccccgggacg aggcgctgcg ggtcgccgcc gacgtcctcg 11220  
 ccgaggaagg gtccccgacg gagctgacca agctcgtccg gcactcccggt gccgccctgc 11280  
 gccgtcgcac caaccgcggc ctgctgggtc tcgcggccgt cgtcgcggtg ccgctggggc 11340  
 tggggctgtg gtcaccccc gtccctgggtc acaccgcctg gatcacggcg ctgctcggcc 11400  
 tgccggtcgt catcgtcctc gccaacgacg cctaccgctc cctcggccac ggaatccgcg 11460  
 accgctacct cgtcgtccgc gccggcacct tcgcccgcg tacggtcgcc gtccagcggg 11520  
 acggcgtcat cggctggaac atctcccgt cctacttcca gcggcgacg ggactgctca 11580  
 ccatcggcgc caccaccgcg ggcgtcggct gccacaaggc gcgcgacgta tccgtcggcg 11640  
 ccggcctcgc cttcgccgaa gaggcgttac ccaggctgct cgcgccgttc atcgaacgcg 11700  
 tcccgcgcgg ctgaaccccc tcagaccaac tggcgaaccc 11740

&lt;210&gt; 2

&lt;211&gt; 719

&lt;212&gt; PRT

<213> *Streptomyces aizunensis*

&lt;400&gt; 2

Met Asp Asn Leu Glu Leu Arg Arg Glu Ala Asp Ala Ile Leu Ala Glu  
 1 5 10 15

Leu Val Gly Ala Pro Gly Gly Ser Ala Arg Leu Arg Glu Asp Gln Trp  
 20 25 30

Gln Ala Val Ala Ala Leu Val Glu Glu Arg Arg Arg Ala Leu Val Val  
 35 40 45  
 Gln Arg Thr Gly Trp Gly Lys Ser Ala Val Tyr Phe Val Ala Thr Ala  
 50 55 60  
 Leu Leu Arg Arg Arg Gly Ser Gly Pro Thr Val Ile Ile Ser Pro Leu  
 65 70 75 80  
 Leu Ala Leu Met Arg Asn Gln Val Glu Ala Ala Ala Arg Ala Gly Ile  
 85 90 95  
 Gln Ala Arg Thr Ile Asn Ser Ala Asn Pro Glu Glu Trp Glu Thr Ile  
 100 105 110  
 Tyr Gly Glu Val Glu Arg Gly Glu Thr Asp Val Leu Leu Val Ser Pro  
 115 120 125  
 Glu Arg Leu Asn Ser Val Asp Phe Arg Asp Gln Val Leu Pro Lys Leu  
 130 135 140  
 Ala Ala Thr Thr Gly Leu Leu Val Val Asp Glu Ala His Cys Ile Ser  
 145 150 155 160  
 Asp Trp Gly His Asp Phe Arg Pro Asp Tyr Arg Arg Leu Arg Thr Met  
 165 170 175  
 Leu Ala Glu Leu Pro Glu Gly Val Pro Val Leu Ala Thr Thr Ala Thr  
 180 185 190  
 Ala Asn Ala Arg Val Thr Ala Asp Val Ala Glu Gln Leu Gly Thr His  
 195 200 205  
 Gly Glu His Ala Leu Val Leu Arg Gly Pro Leu Asp Arg Glu Ser Leu  
 210 215 220  
 Arg Leu Gly Val Leu Gln Leu Pro Asp Ala Ala His Arg Leu Ala Trp  
 225 230 235 240  
 Leu Gly Asp Arg Leu Ala His Leu Pro Gly Ser Gly Ile Ile Tyr Thr  
 245 250 255  
 Leu Thr Val Ala Ala Ala Glu Glu Val Ala Ala Phe Leu Arg Gln Arg  
 260 265 270  
 Gly Tyr Pro Val Ala Ser Tyr Thr Gly Lys Thr Glu Asn Ala Asp Arg  
 275 280 285  
 Leu Gln Ala Glu Glu Asp Leu Leu Ala Asn Arg Val Lys Ala Leu Val  
 290 295 300  
 Ala Thr Ser Ala Leu Gly Met Gly Phe Asp Lys Pro Asp Leu Gly Phe  
 305 310 315 320  
 Val Val His Met Gly Ser Pro Ser Ser Pro Ile Ala Tyr Tyr Gln Gln  
 325 330 335  
 Val Gly Arg Ala Gly Arg Gly Val Asp His Ala Asp Val Leu Leu Leu  
 340 345 350  
 Pro Gly Arg Glu Asp Glu Ala Ile Trp Ala Tyr Phe Ala Ser Val Gly  
 355 360 365

Phe Pro Pro Glu Glu Gln Val Arg Arg Thr Leu Asp Val Leu Ala Gln  
 370 375 380  
 Ala Gly Arg Pro Leu Ser Leu Pro Ala Leu Glu Pro Leu Val Asp Leu  
 385 390 395 400  
 Arg Arg Ser Arg Leu Glu Thr Met Leu Lys Val Leu Asp Val Asp Gly  
 405 410 415  
 Ala Val Lys Arg Val Lys Gly Gly Trp Thr Ala Thr Gly Gln Pro Trp  
 420 425 430  
 Thr Tyr Asp Ala Glu Arg Tyr Ala Trp Val Ala Lys Gln Arg Ala Ala  
 435 440 445  
 Glu Gln Gln Ala Met Arg Asp Tyr Val Ala Thr Thr Gly Cys Arg Met  
 450 455 460  
 Glu Phe Leu Gln Arg Gln Leu Asp Asp Glu Lys Ala Val Pro Cys Gly  
 465 470 475 480  
 Arg Cys Asp Asn Cys Ala Gly Ser Trp Leu Glu Ala Val Val Ser Pro  
 485 490 495  
 Ala Ala Leu Ala Ala Ala Ala Gly Glu Leu Asp Arg Ala Gly Val Glu  
 500 505 510  
 Val Glu Ser Arg Lys Met Trp Pro Thr Gly Leu Ala Ala Val Gly Met  
 515 520 525  
 Asp Leu Lys Gly Arg Ile Pro Ala Gly Gln Gln Ala Val Thr Gly Arg  
 530 535 540  
 Ala Leu Gly Arg Leu Ser Asp Ile Gly Trp Gly Asn Arg Leu Arg Pro  
 545 550 555 560  
 Leu Leu Ser Ala Gln Ala Ala Asp Gly Pro Val Pro Asp Asp Val Leu  
 565 570 575  
 Ala Ala Val Val Thr Val Leu Ala Asp Trp Ala Arg Ser Pro Gly Gly  
 580 585 590  
 Trp Ala Ser Gly Gly Pro Asp Ala Met Ala Arg Pro Val Gly Ile Val  
 595 600 605  
 Ala Met Pro Ser Arg Thr Arg Pro Arg Leu Val Ala Ser Leu Ala Glu  
 610 615 620  
 Gly Val Ala Arg Val Gly Arg Leu Pro Leu Leu Gly Ser Leu Ala Tyr  
 625 630 635 640  
 Thr Pro Gln Ala Asp Val Tyr Gly Ala His Arg Ser Asn Ser Ala Gln  
 645 650 655  
 Arg Leu Arg Ala Leu Ala Asp Ser Phe Thr Val Pro Glu Glu Leu Ala  
 660 665 670  
 Ala Ala Leu Ala Ala Ala Pro Gly Pro Val Leu Leu Val Asp Asp Tyr  
 675 680 685  
 Thr Asp Ser Gly Trp Thr Leu Ala Val Gly Ala Arg Leu Leu Arg Gln  
 690 695 700

Ser Gly Ala Gly Gly Val Leu Pro Leu Val Leu Ala Leu Ala Gly  
 705 710 715

<210> 3

<211> 2160

<212> DNA

<213> *Streptomyces aizunensis*

<400> 3

atggacaacc tggagctccg tcgtgaagcc gatgccatcc tcgctgagct ggtcgggtgcc	60
cctggggggtt cggcgcggtt gcgggaggac cagtggcagg cggtcgcggc cctgggtggag	120
gagcgccggc gggccctggt ggtgcagcgc acgggctggg gcaagtccgc ggtctacttc	180
gtcgccaccg ctctgctgcg ccggcgcggc tccgggccga cggatgatcat ttctccgctg	240
ctggcgctga tgcgcaacca ggtcgaggcg gccgcgcggg ccgggatcca ggcgcgcacg	300
atcaactcgg ccaaccggga ggagtgggaa accatctacg gggaggtcga gcgcggcgag	360
accgatgtgc tcctcgtcag ccccgagcgc ctcaactcgg tggatttcgg cgaccaggta	420
ctgcccgaagc tggcgccac gacgggtctg ctggtggtcg acgaggcgca ctgcatctcc	480
gactggggcc acgacttcgg ccccgactac cgacgggtgc gcacgatgct ggcggagctg	540
ccggagggcg tgccggctct ggccacgacg gcgaccgcga acgcgcgggt gaccgcggac	600
gtggcgaggc agctgggcac gcacggcgag cagccctggg tcctgcgcgg accgctcgac	660
cgggagagcc tgcggctggg agtgctgcag ctgccggacg cggcgccaccg gctggcctgg	720
ctgggggacc ggctggcgca cctgccgggt tcggggatca tctacacgct gaccgtggcg	780
gcggcgaggc aggtcgcggc gttcctgcgg caacgcgggt atccggtggc ttctacacc	840
gggaagacgg agaacgccga ccggttgacg gcggaggagg atctgctggc gaaccgggtg	900
aaggcactgg tggcgacctc ggcgctgggc atggggttcg acaagccgga cctggggttc	960
gtggtgcaca tggggtcgcc ctctgccccg atcgccctact accagcaggc ggggcgcgcg	1020
gggcgtgggg tggatcacgc ggacgtgctg ctgctgccgg gccgggagga cgaggcgatc	1080
tgggcgtact tcgcctcggg gggcttcccg cccgaggagc aggtccggcg caccctggac	1140
gtactggcgc aggcggggccg cccgctgtcg ctgcccgcg tggagccgct ggtggacctc	1200
cggcgctcgc gcctggagac gatgctgaag gtcctggacg tggacggcg cgtcaagcgc	1260
gtgaagggcg gctggaccgc caccgggcag ccgtggacgt acgacgcgga gcggtacgcc	1320
tgggtcgcga agcagcgggc ggcggagcag caggccatgc gggactacgt ggcgaccacg	1380
ggctgccgga tggagtctct gcagcggcag ctggacgacg agaaggcggc cccgtgcggc	1440
cgctgcgaca actgcgcggg atcctggctg gaggcggctg tgcgcccgc ggccctcgcg	1500
gccgcggcgg gcgagctgga ccgcgcgggg gtcgaggtcg agtcccgcaa gatgtggccg	1560
accgggctcg ccgcggtcgg catggacctg aagggccgga tccccgcggg ccagcaggcc	1620

gtcaccgggc ggcgcgtcgg caggctgtcg gacatcggct ggggcaaccg gctgcgcccc 1680  
 ctgctgtcgg cgcaggccgc ggacgggccg gttccggacg atgtgctggc cgccgtcgtg 1740  
 acggtgctcg ccgactgggc ccgctcgccg ggcggctggg cgagcggcgg gccggacgcg 1800  
 atggcgcggc cggtagggat cgtcgccatg ccctcccgtg cccgcccgcg gctggtcgcc 1860  
 tcgctggccg agggcggtggc ccgggtcggc aggtcccgcg tgctgggcag cctcgccctac 1920  
 accccgcagg ccgacgtgta cggggcgcac cgcagcaact cagcccagcg gctgcgcgcc 1980  
 ctggccgact cgttcaccgt gcccaggaa ctcgcgcggc ccctggccgc cgctcccggc 2040  
 ccggtcctgc tcgtcgacga ctacaccgac tccggctgga ccctggccgt gggcgcacgc 2100  
 ctgctgcgcc agtccggcgc gggcggcgtg ctcccgtcg tcctcgcgct ggccgggtag 2160

<210> 4  
 <211> 253  
 <212> PRT  
 <213> Streptomyces aizunensis

<400> 4

Leu Asn Lys Gln Glu Thr Ser Leu Trp Val Arg Arg Tyr His Ala Ser  
 1 5 10 15  
 Asp Glu Ser Arg Ile Gln Leu Val Cys Leu Pro His Ala Gly Gly Ser  
 20 25 30  
 Ala Ser Phe Tyr Phe Pro Met Ser Gln Ser Leu Ala Pro Ala Met Asp  
 35 40 45  
 Val Leu Ser Val Gln Tyr Pro Gly Arg Gln Asp Arg Arg Asp Glu Pro  
 50 55 60  
 Gly Ile Val Asp Ile Gly Ala Tyr Ala Asp Ala Leu Thr Glu Gln Leu  
 65 70 75 80  
 Val Pro Trp Leu Asp Arg Pro Leu Ala Phe Phe Gly His Ser Met Gly  
 85 90 95  
 Ala Ile Leu Ala Phe Glu Val Thr Arg Arg Leu Glu Arg Asp His Gly  
 100 105 110  
 Val Thr Pro Glu His Ile Phe Ala Ser Gly Arg Arg Ser Pro Ala Ser  
 115 120 125  
 Phe Arg His Glu Thr Val His Leu Arg Asp Asp Asp Gly Ile Val Ala  
 130 135 140  
 Glu Met Arg Glu Leu Ser Gly Thr Asp Ala Lys Ile Leu Gly Asn Glu  
 145 150 155 160  
 Glu Ile Leu Arg Met Val Leu Pro Ala Ile Arg Ser Asp Tyr Thr Ala  
 165 170 175  
 Ile Glu Asn Tyr Arg Ala Ala Pro Glu Asp Val Val Arg Thr Pro Ile  
 180 185 190  
 Thr Val Leu Thr Gly Asp Ala Asp Pro Arg Thr Ser Arg Glu Glu Ala

195

200

205

Asp Ala Trp Lys Ala His Thr Thr Gly Gly Phe Asp Leu His Ser Phe  
 210 215 220

Pro Gly Gly His Phe Phe Leu Ala Asn His Gln Glu Lys Ile Met Gly  
 225 230 235 240

Ile Ile Ser Glu Glu Leu Ser Ala Pro Ala Arg Met Ala  
 245 250

&lt;210&gt; 5

&lt;211&gt; 762

&lt;212&gt; DNA

&lt;213&gt; Streptomyces aizunensis

&lt;400&gt; 5

ttgaataagc aagaaactag cctctgggtt cgccgctacc acgcttcgga cgaaagccgg 60  
 atccaattgg tctgtctgcc gcacgccggt ggctcggcct ccttctactt ccccatgtcc 120  
 cagtcgctgg ctccggcgat ggacgtcttc tcggtccagt accccggcag gcaggaccgc 180  
 agggacgagc ccgggatcgt ggacatcggc gcctacgcgg acgccctgac cgagcaactc 240  
 gtaccgtggc tcgaccggcc cctggccttc ttcgccaca gcatgggtgc gatcctcgcc 300  
 ttcgaggtga cgcgccaggct ggagcgtgac caccggcgtca ctccggagca catcttcgct 360  
 tccggccggc gctcgccgc cagtttcgg caccgagaccg tgcacctgcg ggacgacgac 420  
 ggaatcgtgg cggaaatgcg ggaactcagc ggaaccgacg cgaagatact cggcaacgag 480  
 gaaatcctcc gcatgggtgct ccccgcgatt cgaagcgact acaccgccat cgagaactac 540  
 cgtgccgcgc cggaagacgt cgtgcgtact cccatcacgg tgctgaccgg tgacgcggac 600  
 ccgaggacca gccgggaaga ggccggacgcc tggaaggcgc acacgaccgg cggattcgat 660  
 ctgcattcct tccccggtgg acatttcttc ctggcgaatc accaggagaa gatcatggga 720  
 attatttcgg aggaactctc cgcccggtt cgcattggcg ga 762

&lt;210&gt; 6

&lt;211&gt; 956

&lt;212&gt; PRT

&lt;213&gt; Streptomyces aizunensis

&lt;400&gt; 6

Val Ala Val Arg Leu Val Glu Arg Glu Lys Gln Leu Glu Thr Leu Lys  
 1 5 10 15

Glu Leu Leu Gly Ser Ala Val Arg Gly Arg Gly Arg Val Ala Val Ile  
 20 25 30

Ser Gly Ala Val Ala Gly Gly Lys Thr Ser Leu Leu Glu Ile Phe Thr  
 35 40 45

Glu Glu Ala Ile Ser Ala Gly Ala Leu Val Leu Glu Ala Thr Gly Ser  
 50 55 60



Arg Ala Glu Arg Tyr Leu Pro Phe Gly Ile Leu Arg Arg Ile Leu Asp  
 65 70 75 80  
 Ser Ala Ala Pro Leu Ser Pro Glu Ile His Ala Tyr Ala Thr Glu Leu  
 85 90 95  
 Leu Asp Arg Val Ser Ala Gly Thr Thr Asp Ala Glu Gly Ala Val Glu  
 100 105 110  
 Ala Gly Met Arg Val Leu Pro His Val Ala Thr Ala Leu Leu Arg Ile  
 115 120 125  
 Ala Arg Asn Arg Thr Val Val Ile Ala Ile Asp Asp Val His His Gly  
 130 135 140  
 Asp Glu Leu Ser Leu Ala Phe Leu Leu Cys Leu Ala Arg Arg Val Arg  
 145 150 155 160  
 Gln Ala Gly Val Leu Ile Val Leu Thr Glu Ala Val Arg Leu Arg Ser  
 165 170 175  
 Ala Gln Leu Ala Phe His Ala Glu Leu Gln Arg Gln Pro Asn Cys Thr  
 180 185 190  
 Ser Leu Arg Leu Pro Leu Leu Thr Thr Arg Gly Thr Thr Arg Val Leu  
 195 200 205  
 Ala Glu His Phe Ser Pro Ser Thr Ala Gln Arg Leu Ser Ala Glu Cys  
 210 215 220  
 Gln Glu Thr Thr Gly Gly Asn Pro Leu Leu Val Arg Ala Leu Ile Asp  
 225 230 235 240  
 Asp Gly Leu Thr Ala Leu Gly Asp Ser Glu Pro Phe Gln Arg Leu Ala  
 245 250 255  
 Pro Ala Glu Thr Phe Glu Arg Ala Val Leu Asp Cys Leu His Arg Gly  
 260 265 270  
 Asp Pro Glu Leu Leu Thr Val Ala Arg Gly Val Ala Val Leu Gly Ser  
 275 280 285  
 Ala Cys Ser Leu Ala Leu Leu Asn Gly Ile Val Asp Leu His Ala Lys  
 290 295 300  
 Ala Thr Glu Gln Ala Leu Gln Asp Leu Ser Arg Cys Ala Val Leu His  
 305 310 315 320  
 His Gly Ser Phe Arg Asp Pro Ala Ala Arg Thr Ala Val Leu Glu Ala  
 325 330 335  
 Thr Pro Pro Ala Ala Leu Ser Ala Leu His Leu Arg Thr Ala Arg Leu  
 340 345 350  
 Leu His Gln Glu Gly Ala Thr Ala Leu Asp Val Ala Arg His Leu Leu  
 355 360 365  
 Ala Ala Arg Lys Asn Val Glu Asp Trp Ala Ile Pro Val Leu Gln Glu  
 370 375 380  
 Ala Val Glu Tyr Ala Leu Val Glu Asp Glu His Glu Leu Ala Leu Arg  
 385 390 395 400

Cys Gly Glu Leu Ala Val Ala Ser Cys Ala Glu Gly Pro Arg His Ala  
 405 410 415  
 Ala Leu Lys Ser Arg Leu Ala Ser Ile Val Trp Arg Ser Ser Pro Ala  
 420 425 430  
 Ala Ala Glu Gly His Leu Arg Gln Leu Ser Arg Glu Leu Ala Ala Gly  
 435 440 445  
 Arg Leu Ala Asp Arg Asp Leu Val Gln Ala Val Ser Leu Leu Ala Trp  
 450 455 460  
 Met Gly Glu Ser Arg Gly Ala Gly Glu Ala Val Leu Arg Leu Gln Arg  
 465 470 475 480  
 Thr Asp Ser Glu Ala Glu Ala Ala Gly Arg Ala Pro Ala Tyr Asp Pro  
 485 490 495  
 Gly Thr Leu Thr Ala Ala Gln Ser Trp Leu Ser Met Val Ser Pro Pro  
 500 505 510  
 Ala Arg Asp Leu Phe Asp Ala Val Glu Pro Arg Arg Thr Thr Leu Ser  
 515 520 525  
 Gly Ala Pro Gly Ala Leu Pro Gly Ala Gly Pro Asp Thr Val Pro Tyr  
 530 535 540  
 Asp Met Pro Asp Asn Ala Tyr Val Gln Ala Ala Asp Ala Val Arg Thr  
 545 550 555 560  
 Ala Leu Arg Gly Gly Thr Gln Ala Asp Ala Ala Val Ser Lys Ala Thr  
 565 570 575  
 Arg Val Leu Gln Arg Tyr His Leu Ser Asp Arg Thr Leu Gln Pro Leu  
 580 585 590  
 Val Phe Ala Leu Leu Ala Val Ile Tyr Ala Gly Arg Leu Asp Leu Ala  
 595 600 605  
 Ser Ala Trp Cys Glu Arg Leu Leu Gly Glu Cys Ser Ala Arg Asn Ala  
 610 615 620  
 Pro Thr Trp Gln Ala Ala Leu Gly Val Val Arg Ala Glu Ile Leu Leu  
 625 630 635 640  
 Arg Gln Gly Asp Leu Pro Gly Ala Ala Ala Gln Ala Arg His Ala Met  
 645 650 655  
 Ser Arg Ile Ser Leu Gln Ser Trp Gly Val Gly Ile Ala Leu Pro Leu  
 660 665 670  
 Ala Val Leu Val Glu Ala Glu Val Gln Met Gly Asp His Glu Glu Ala  
 675 680 685  
 Met Ser Leu Leu Glu Gln Pro Val Pro Gln Ala Met Phe Asp Thr Leu  
 690 695 700  
 Ala Gly Leu His Tyr Leu Arg Ala Arg Gly Arg Cys His Leu Ala Thr  
 705 710 715 720  
 Gly Arg Tyr His Ala Ala Val Arg Asp Phe Leu Asn Cys Gly Glu Leu  
 725 730 735

Met Gln Ala Trp Gly Val Asp Gly Ala Glu Leu Val Pro Trp Arg Leu  
740 745 750

Asp Ala Ala Glu Ala Trp Leu Ala Leu Gly Asn Val Ala Arg Ala Lys  
755 760 765

Glu Tyr Thr Glu Gln Gln Lys Gln Arg Glu Thr Gly Pro Val Gly Ser  
770 775 780

Arg Thr Arg Gly Ser Leu Leu Leu Thr Leu Ala His Thr Gly Gly Asp  
785 790 795 800

Leu Thr Val Arg Leu Lys Arg Leu Val Glu Ala Val Glu Thr Leu Glu  
805 810 815

Glu Gly Gly Asp Arg Leu Gln Leu Ala Val Ala Leu Gly Glu Leu Gly  
820 825 830

Arg Gly Tyr Arg Ala Leu Gly Asp Phe Asn Arg Ala Arg Met Leu Val  
835 840 845

Arg Lys Ala Trp His Val Ala Lys Ser Cys Gly Ala Glu Pro Leu Cys  
850 855 860

Gln Gln Phe Met Pro Gly Gln Val Asp Gly Glu Ala Gly Ala Gln Ser  
865 870 875 880

Gly Arg Glu Ala Glu Leu Pro Ser Glu Val Glu Val Leu Ser Glu Ala  
885 890 895

Glu Ala Arg Val Ala Leu Leu Ala Ala Arg Gly His Thr Asn Arg Glu  
900 905 910

Ile Ala Thr Lys Leu Tyr Val Thr Val Ser Thr Val Glu Gln His Leu  
915 920 925

Thr Arg Ile Tyr Arg Lys Leu Lys Val Lys Arg Arg Arg Asp Leu Pro  
930 935 940

Ala Arg Leu Ser Asp Leu Ser Leu Pro Ser Ile Ala  
945 950 955

<210> 7

<211> 2871

<212> DNA

<213> Streptomyces aizunensis

<400> 7

gtggcggtta ggctcgtcga ggcgcgagaag cagctggaaa cgctgaagga actactcggc 60

agcgcagtcg gtggccgagg gcggtcgcc gtcacgcagc gggcagtcgc cggcgggaaa 120

acgagtctgc tggaaatctt caccgaagag gcgatctccg cgggcgcgct ggtgctggaa 180

gccacgggct cccgggcgga ggcctatctg cccttcggaa ttctgcgcag aatcctcgac 240

agcgcggcgc ccctgtcgcc cgagatccac gcctacgcca ccgagctgct ggaccgcgtc 300

agcgcgggga cgacggacgc cgaaggcgcc gtcgaggccg gtatgcgcgt cctgccccat 360

gtcgccaccg cactgttaag gatcgcccgg aaccggaccg tcgtcatagc catcgacgac 420

gtccaccacg gggacgaact ctccctcgcc ttctgctgt gcctcgccc cagagtgcgc 480

caggcgggcg tcttgatcgt gctcaccgaa gccgtccggc tgcggtccgc gcaactcgcc	540
ttccacgccg aactgcagcg ccagcccaac tgcaccagcc tccggctgcc cctgctcacc	600
acgcgcggca ccacccgcgt cctcgccgag cactttctccc cctcgacggc gcaacggctg	660
tccgccgagt gccaggagac caccggcggc aatccactgc tggtcagggc gctgatcgac	720
gacggcctca cggcgctcgg agacagcgag cccttccagc ggctcgcccc cgccgaaacc	780
ttcgaacgcg ccgtgctcga ctgcctgcac cggggcgacc ccgagctgct gaccgtcgcc	840
cggggcgctg ccgtactcgg tagcgctgc tccttggccc tgctcaacgg gatcgctgac	900
ctgcacgcca aggccaccga acaggccctt caggacctca gccggtgcgc cgtcctgcac	960
cacggctcct tccgcgaccc ggcgggccgt accgcgctcc tggaagccac tccgcccgcg	1020
gcgctgtccg ccctgcacct gcgcaccgcg cgactcctgc accaggaagg cgcgacggcg	1080
ctcgatgtcg cccgccacct cctcgccgcc cgcaagaacg tcgaggactg ggcgatcccc	1140
gtcctccagg aggcggtcga gtacgcctc gtcgaggacg agcacgaact cgccctgcgg	1200
tgcggggaac tggcggtcgc ctctgcgcg gagggccccc gacacgccgc cctgaagtcc	1260
cgctggcgga gcatcgtctg gcgcagcagc ccggccggcg ctgaagggca tctgcggcag	1320
ctgtcccgcg aactcgccgc cggccggctc gccgaccgcg atctcgtcca ggccgtgtcg	1380
ctcctggcgt ggatggggga gtcccggggg gccggcgagg cggctactgcg actgcagcg	1440
accgacagcg aggcggaggc ggccggacgg gcgcccgcct acgaccggg cacgctcacc	1500
gccgcacaga gctggctctc gatggtcagc ccgccggccc gcgacctctt cgacgccgtg	1560
gaaccgcgcc ggacaacgct gtcaggcgcg ccggggggcg tgcccggcg ggggcccgc	1620
accgtcccct acgacatgcc cgacaacgcc tacgtccagg ccgccgacgc cgtccgcacc	1680
gcctgcgcg gcggaacca ggccgacgcc gccgtcagca aggccaccgc ggtgctccag	1740
cgctaccacc tgagcgaccg caccctccag ccgctcgtct tcgccctcct cgccgtcatc	1800
tacgcgggtc gcctcgacct cgcgtccgcc tggcggaac gactgctcg cgagtgtcc	1860
gcccgaacg ccccgacctg gcaggccgcc ctcgggtgtg tccgggcccga gatcctgctg	1920
cgccagggcg atctgcccgg tgcgggccgc caggcccgc acgccatgtc ccggatctcc	1980
ctgcagagct ggggcgtggg catcgcgctg ccgctggccg tcctcgtcga ggccgaggtc	2040
cagatgggcg accacgagga ggcgatgagc ctgctcgaac agccggtgcc ccaggccatg	2100
ttcgacaccc tggccggcct gcactacctc agggcccgcg gccgctgcca cctggccacc	2160
ggccgctacc acgccgccgt gcgggacttc ctgaactgcg gcgagctgat gcaggcctgg	2220
ggcgtggacg gggcgagct ggtgccgtgg cggctggacg ccgccgaggc gtggctggcc	2280
ctcggcaacg tcgcgcgcgc caaggagtac accgagcagc agaagcagcg cgagacgggg	2340

```

cccgtgggca gccggacgcg tggctccctg ctgctcacgc tcgcccacac cggcggtgac 2400
ctcacgggcc gggtcaagcg gctcgtcgag gccgtcgaga ccctggagga gggcggggac 2460
cggctccagc tggcggtggc gctgggggag ctggggccgc gctaccgtgc gctgggcgac 2520
ttcaaccggg cccggatgct ggtgcgcaag gcctggcacg tcgccaagtc ctgcggcgcc 2580
gaaccgctgt gccagcagtt catgccgggg caggtcgacy gcgaggccgg tgcgcagagc 2640
ggccgggagg cggagcttcc cagcgaggtc gaggtcctgt ccgaggccga ggcgcgggtc 2700
gcgctgctgg cggcgcgcg cccacaccaac cgtgagatag cgaccaagct ctacgtcacg 2760
gtgtccacgg tcgagcagca tctgacgcgc atctaccgca agctgaaggt gaagcggcgc 2820
cgcgatctgc ccgcccggct gtcggacctg agcctgccga gcatcgctg a 2871

```

```

<210> 8
<211> 201
<212> PRT
<213> Streptomyces aizunensis
<400> 8

```

```

Met Leu Val Asp Asp His Pro Val Val Arg Glu Gly Leu Ser Ser Met
1           5           10           15

Leu Gln Ser Ala Asp Gly Val Ser Val Val Gly Gln Ala Asp Ser Gly
20           25           30

Glu Glu Ala Ile Ala Met Val Thr Arg Leu Ala Pro Asp Ile Val Leu
35           40           45

Leu Asp Leu Gln Met Gly Gly Met Asp Gly Val Glu Thr Thr Gly His
50           55           60

Leu Leu Arg Val Ala Pro Ala Thr Lys Val Val Ile Val Thr Thr Tyr
65           70           75           80

Glu Ser Asp Thr Asp Ile Leu Arg Ala Val Glu Ala Gly Ala Ala Gly
85           90           95

Tyr Leu Leu Lys Gly Ser Ser Arg Asp Glu Leu Val Gln Ala Val Lys
100          105          110

Ala Ala Ala Arg Gly Glu Thr Val Leu Thr Pro Ser Leu Ala Pro Lys
115          120          125

Leu Phe Arg Ala Arg Val Val Glu Pro Pro Ala Leu Ser Asp Arg Glu
130          135          140

Arg Glu Val Leu Gln Leu Val Ser Leu Gly Leu Thr Asn Ala Asp Ile
145          150          155          160

Gly Arg Gln Leu Phe Ile Ser Glu Ala Thr Val Lys Thr His Leu Leu
165          170          175

Arg Ser Phe Lys Lys Leu Ser Val Ser Asp Arg Thr Ala Ala Val Ile
180          185          190

Thr Ala Leu Lys Leu Gly Leu Leu Ser

```

195

200

<210> 9  
 <211> 606  
 <212> DNA  
 <213> Streptomyces aizunensis

<400> 9  
 atgctgggtcg acgaccaccc ggtcgtacgg gaggggtctca gctcgatgct gcaatccgcc 60  
 gacggcgtga gcgtcgtcgg gcaggccgac tcgggcgagg aggcgatcgc gatggtcacc 120  
 agacttgctc ccgacatcgt cctgctcgac cttcagatgg gcgggatgga cggggtggag 180  
 accaccggcc acctgctgcg cgtcgcgcgg gccaccaagg tggatgatcgt gacgacgtac 240  
 gagagcgaca cggacatcct gcggggcgtg gaggcgggcg cggcgggcta cctgctcaag 300  
 ggcagctcgc gcgacgaact ggtgcaggcg gtaaaggcgg cggcccgcgg tgagacggtc 360  
 ctgacgccgt cgctcgcccc caagctgttc cggggccggg tggaggagcc gcccgcgctg 420  
 tcggaccgtg agcgcgaggt gctccagttg gtcagcctcg ggctgaccaa cgcggacatc 480  
 ggccgccagc tgttcacacg cgaggcgacg gtgaagacgc atctgctgcg ctcgttcaag 540  
 aagctgtcgg tctcggaccg gacggccgcg gtgatcacgg cactgaagct cggcctgctg 600  
 tcctga 606

<210> 10  
 <211> 416  
 <212> PRT  
 <213> Streptomyces aizunensis

<400> 10

Val Ser Thr Glu Ser Pro Ala Ala Gln Ala Thr Asp Gly Gln Asp Asp  
 1 5 10 15  
 Ala Pro Glu Ala Gly Ala Arg Trp Phe Gly Leu Trp Asp Ala Leu Phe  
 20 25 30  
 Ala Val Ser Tyr Ala Val Thr Thr Met Leu Leu Phe Thr Ser Asp Gly  
 35 40 45  
 Glu Gln Val His Arg Ala Val Ala Met Ala Ala Leu Thr Ala Ala Val  
 50 55 60  
 Pro Trp Tyr Ala Ala Leu Gly Arg Ser Thr Met Val His Glu Gly Gln  
 65 70 75 80  
 Gly Pro Val Arg Arg Ser Val Val Phe Ser Val Gly Leu Phe Val Leu  
 85 90 95  
 Phe Ala Val Ala Val Val Phe Asp Leu Ala Ala Ser Phe Ala Leu Phe  
 100 105 110  
 Ala Val Val Pro Met Leu Met Met Ser Leu Ala Thr Ser Pro Ala Ile  
 115 120 125  
 Ala Val Val Thr Leu Ala Asn Leu Val Pro Val Ile Val Val Trp Leu

130 135 140  
 Arg Gly Gly Thr Leu Ser Arg Asp Ile Leu Ala Val Leu Pro Thr Ser  
 145 150 155 160  
 Leu Leu Gly Ile Ala Leu Ser Val Met Leu Gly Leu Trp Ile Thr Arg  
 165 170 175  
 Val Thr Arg Gln Ser Arg Asp Arg Ala Glu Leu Ile Glu Glu Leu His  
 180 185 190  
 Arg Asn Arg Ala Gln Val Ala Arg Leu Ser Arg Lys Ala Gly Val Ser  
 195 200 205  
 Ala Glu Arg Glu Arg Leu Ala Arg Glu Ile His Asp Thr Leu Ala Gln  
 210 215 220  
 Gly Leu Thr Ser Ile Ile Ser Leu Val Gln Ala Ala Glu Thr Asp Phe  
 225 230 235 240  
 Thr Ala Asp Pro Asp Arg Ala Arg Ala His Leu Ala Leu Ala Gly Arg  
 245 250 255  
 Val Ala Arg Glu Ser Leu Gly Glu Ala Arg Glu Phe Val Thr Glu Leu  
 260 265 270  
 Thr Pro Pro Ala Leu Gln Glu Ser Ser Leu Val Gln Ala Thr Arg Arg  
 275 280 285  
 Gln Ala Glu Gly Leu Thr Ala Gln Thr Gly Met Arg Ala His Val Thr  
 290 295 300  
 Val Glu Gly Asp Glu Arg Glu Leu Pro Met Ala Ile Ser Val Val Leu  
 305 310 315 320  
 Leu Arg Ser Leu Gln Glu Ala Ile Ala Asn Ile Arg Lys His Ala Gly  
 325 330 335  
 Lys Ala Arg Ala Ala Glu Ile Arg Leu Val Tyr Glu Gln Asp Thr Val  
 340 345 350  
 Arg Leu Leu Val Arg Asp Asp Gly Pro Gly Phe Thr Val Thr Gly Asp  
 355 360 365  
 Gln Arg Gly Ser Gly Leu Arg Gly Met Gln Thr Arg Ala His Glu Ile  
 370 375 380  
 Ser Gly Ala Ala Thr Val Val Ser Ser Pro Gly Gln Gly Thr Thr Ile  
 385 390 395 400  
 Glu Val Thr Val Pro Val Pro Ala Lys Gly Glu Glu Ala Asp Glu Arg  
 405 410 415

<210> 11  
 <211> 1251  
 <212> DNA  
 <213> Streptomyces aizunensis

<400> 11  
 gtgagcactg aatccccgcg ggcgcaggcg acagacggcc aggacgacgc gcccgaggcg 60  
 ggagccccgt ggttcggcct gtgggacgcg ctcttcgctg tctcgtacgc cgtcaccacc 120

atgctgctgt tcacctccga cggatgaacag gtccaccggg ccgtggccat ggccgcgctg 180  
 accgcggccg tgccttggtg cgcggccctg gggcgcagca ccatgggtcca cgagggccag 240  
 gggcccgtcc ggcgagcgt cgtcttctcc gtcggcctgt tcgtgctgtt cgcggtggcc 300  
 gtggtcttcg acctcgccgc ctcgttcgcg ctgttcgccg tgggtccgat gctgatgatg 360  
 agcctggcga cctcgccggc catcgccgtg gtcacgctgg ccaatctggt tccggtcatc 420  
 gtggtgtggc tgcgcggcgg caccctgagc cgcgacatcc tggccgtcct gccgacctcg 480  
 ctctcgga tcgccctgtc ggtcatgtc gggctgtgga tcaccgggt gaccggcag 540  
 agccgtgacc gggccgagct catcgaggag ttgcaccgca accgtgcgca agtcgcccgg 600  
 ctgtcgcgca aggcgggggt ctccgccgag cgcgagcggc tcgcccggga gatccacgac 660  
 accctcgccc agggcctcac cagcatcatc agcctcgta aggccgccga gaccgacttc 720  
 acggccgacc cggaccgggc gagggcgcat ctggcactgg cgggcccgt ggcccgcgaa 780  
 agcctgggag aagcccgcga gtctgtcacc gagctgacct cggccgcgt gcaggagtcc 840  
 tcgtctgtgc aggcgacgcg gcggcaggcc gagggcctga cggcgagac cggcatgcgg 900  
 gcgcacgtca ccgtcgaagg agacgagcgg gaactgccga tggcgatcag cgtggtcctg 960  
 ctgcgttccc tccaggaggc catcgcaac atccgcaagc acgcggggaa ggcacgcgcg 1020  
 gccgagatcc ggctcgtgta cgaacaggac accgtacggc tgctcgtacg ggacgacgga 1080  
 cccgggttca ccgtcaccgg ggaccagcgg ggaagcgggc tgcgcggcat gcagactcgc 1140  
 gcacacgaga tcagcggggc ggcgaccgtg gtcagcagcc ccggacaggg caccaccatc 1200  
 gaagtgcgg tgcctgtgcc cgcgaaggga gaggaagccg atgagcgtg a 1251

<210> 12

<211> 186

<212> PRT

<213> Streptomyces aizunensis

<400> 12

Leu Ser Pro Phe Leu Asn Thr Leu Ile Ala Ser Gly Thr Ile Leu Ala  
 1 5 10 15

Val Ile Leu Ser Thr Asp Leu Gly Thr Arg Lys Val Thr Thr Thr Arg  
 20 25 30

Met Leu Pro Ser Leu Leu Ala Val Val Val Ile Leu Ala Leu Leu Val  
 35 40 45

His Thr Leu Pro Leu Asp Gly Asn Asp Pro Ser Leu Gln Leu Ala Gly  
 50 55 60

Ile Gly Ala Gly Ile Ile Cys Gly Leu Ala Ala Thr Ala Leu Leu Pro  
 65 70 75 80

Ala His Arg Asn Ala Ser Gly Glu Val Ser Thr Lys Gly Gly Ile Gly  
 85 90 95



Tyr Ala Leu Val Trp Thr Ala Leu Ser Ala Ser Arg Val Leu Phe Ala  
 100 105 110

Tyr Gly Ser Gln His Trp Phe Ser Glu Gly Ile Val Arg Phe Ser Thr  
 115 120 125

Asp Tyr Lys Leu Ser Gly Gln Ala Val Tyr Ser Asn Ala Phe Ala Phe  
 130 135 140

Met Ala Leu Ala Met Val Leu Thr Arg Thr Ala Val Leu Leu Asn Thr  
 145 150 155 160

Arg Arg Arg Leu Arg Gly Gly Gln Leu Pro Ala Ala Asp Asn Thr Ala  
 165 170 175

Pro His Gln Ala Ser Ser Ala Asn Thr His  
 180 185

<210> 13

<211> 561

<212> DNA

<213> Streptomyces aizunensis

<400> 13

ctgagcccggt tcttgaacac actgatcgcc agcgggacga tcttggccgt cattctgtcg 60  
 accgacctcg gcacccgcaa agtcaccacg acgcggatgc ttccttcgct cctcgcggtc 120  
 gtcgtgatcc tcgcgctcct cgtgcacaca ctgccgctcg acggcaacga cccctcgctc 180  
 caactggcgg gcacgcggcg cggtatcatc tgcggactgg ccgccacggc gtcctctccc 240  
 gccacccgga acgcttccgg tgaggtctcc accaagggcg gtatcggtta cgcgctgggtg 300  
 tggaccgcgc tgtccgcctc gcgtgtgctc ttcgcctacg gttcacagca ctggttcagc 360  
 gagggcatcg tccggttcag caccgactac aagctcagcg gacaggccgt ctactccaac 420  
 gctttcgcct tcatggccct ggccatgggtg ctgacgcgga ccgccgtcct gttgaacacg 480  
 cgccgcccggc tgcgcggcgg gcagcttccc gcggccgaca acacggcccc acatcaggcg 540  
 agttccgcca atacgcactg a 561

<210> 14

<211> 163

<212> PRT

<213> Streptomyces aizunensis

<400> 14

Met His Asp Val Arg Leu Arg Pro Pro Arg Asn Arg Val Asp Ser Arg  
 1 5 10 15

Ala Val Gly Trp Trp Thr Val Gln Ser Ala Met Tyr Ala Leu Pro Leu  
 20 25 30

Pro Ile Thr Phe Gly Val Leu Tyr Leu Cys Ile Pro Pro Ala Arg Pro  
 35 40 45

Phe Phe Gly Trp Ala Phe Leu Ile Ser Leu Val Pro Gly Leu Ala Tyr

50

55

60

Met Ala Val Met Pro Ala Trp Arg Tyr Arg Val His Arg Trp Glu Thr  
65 70 75 80

Thr Asp Glu Ala Val Tyr Ala Ala Ser Gly Trp Leu Trp Gln Gln Trp  
85 90 95

Arg Val Val Pro Met Ser Arg Ile Gln Thr Val Asp Thr Leu Arg Gly  
100 105 110

Pro Leu Gln Gln Leu Phe Gly Leu Ser Gly Ile Thr Val Thr Thr Ala  
115 120 125

Ser Tyr Ser Gly Ala Val Lys Ile Lys Gly Ile Asp His Arg Thr Ala  
130 135 140

Arg Asp Val Val Glu His Leu Thr Arg Val Thr Gln Ala Thr Pro Gly  
145 150 155 160

Asp Ala Thr

<210> 15

<211> 492

<212> DNA

<213> Streptomyces aizunensis

<400> 15

atgcatgatg tcaggctccg gcccccgccg aatcgtgtcg actcccgggc agtgggctgg 60  
tggacgggtcc agtccgcgat gtacgccctg cccctgccga tcaccttcgg cgtgctgtac 120  
ctgtgcatcc cgccccccag gccgttcttc ggctgggcct tcctgatctc gctcgtaccg 180  
ggcctcgctt acatggccgt catgcccggc tggcgctacc ggggtgcaccg ttgggagacc 240  
accgacgaag ccgtctacgc ggcgtccggc tggctctggc agcagtggcg ggtcgtgccg 300  
atgtcccgca tccagacggt ggacaccctg cgcggaaccc tccagcagct cttcggcctc 360  
tccggcatca ccgtcaccac cgcctcctac tccggcgccg tgaagatcaa gggaatcgac 420  
caccggaccg cgcgggacgt ggtcgagcac ctcaccaggg tgaccagggc ccccccgga 480  
gacgcgacat ga 492

<210> 16

<211> 514

<212> PRT

<213> Streptomyces aizunensis

<400> 16

Met Ser His Asp Thr Gly Gln Trp Glu Ala Thr Ala Thr Ser His Gly  
1 5 10 15

Ala Ala Glu Asp Pro Glu Trp Ser Arg Leu Ser Pro Arg Leu Leu Leu  
20 25 30

Val Asn Leu Ser Met Leu Ala Gly Pro Leu Ala Leu Phe Ala Val Thr  
35 40 45

Val Ala Leu Thr Gly Ala Asn Leu Gln Ala Leu Ile Ser Leu Gly Ser  
 50 55 60  
 Leu Leu Ile Val Phe Leu Val Ile Thr Gly Ile Ser Thr Met Arg Leu  
 65 70 75 80  
 Leu Thr Thr Arg Phe Arg Val Thr Ala Glu Arg Val Glu Leu Arg Ser  
 85 90 95  
 Gly Leu Leu Phe Arg Ser Arg Arg Ser Val Pro Ile Asp Arg Val Arg  
 100 105 110  
 Ser Val Asp Val Glu Ala Lys Pro Val His Arg Leu Phe Gly Leu Ala  
 115 120 125  
 Ser Leu Arg Ile Gly Thr Gly Glu Gln Gly Ala Ser Ser Arg Arg Leu  
 130 135 140  
 Ser Leu Asp Gly Ile Thr Arg Arg Gln Ala Arg Arg Leu Arg Arg Leu  
 145 150 155 160  
 Leu Ile Asp Arg Arg Gly Ser Gly His Ala Thr Gly Gln Asp Gln Asp  
 165 170 175  
 Val Thr Ile Ala Glu Met Asp Trp Ala Trp Leu Arg Tyr Ala Pro Leu  
 180 185 190  
 Thr Ile Trp Gly Val Gly Ser Val Phe Ala Ala Val Gly Thr Ala Tyr  
 195 200 205  
 Arg Ile Leu His Glu Met Lys Val Asp Pro Leu Glu Leu Gly Val Val  
 210 215 220  
 Lys Asp Ile Glu Asp Arg Phe Gly Ser Val Pro Leu Trp Phe Gly Ile  
 225 230 235 240  
 Leu Val Ala Val Val Ile Thr Ala Val Val Gly Ala Ala Val Ser Thr  
 245 250 255  
 Ala Thr Phe Val Asp Ala Trp Thr Asn Tyr Arg Leu Glu Arg Glu Gly  
 260 265 270  
 Val Gly Ile Phe Arg Ile Arg Arg Gly Leu Leu Ile Ser Arg Ser Val  
 275 280 285  
 Thr Ile Glu Glu Arg Arg Leu Arg Gly Val Glu Leu Ala Glu Pro Met  
 290 295 300  
 Leu Leu Arg Trp Ala Gly Gly Ala Thr Leu Ser Ala Ile Ala Ser Gly  
 305 310 315 320  
 Leu Ser Asn Ser Gln Glu Asn Arg Ser Arg Cys Ser Leu Thr Pro Pro  
 325 330 335  
 Val Pro Arg Asp Glu Ala Leu Arg Val Ala Ala Asp Val Leu Ala Glu  
 340 345 350  
 Glu Gly Ser Pro Thr Glu Leu Thr Lys Leu Val Arg His Ser Arg Ala  
 355 360 365  
 Ala Leu Arg Arg Arg Ile Asn Arg Gly Leu Leu Val Leu Ala Ala Val  
 370 375 380

Val Ala Val Pro Leu Gly Leu Gly Leu Trp Leu Thr Pro Val Leu Val  
 385 390 395 400

His Thr Ala Trp Ile Thr Ala Leu Val Gly Leu Pro Val Val Ile Val  
 405 410 415

Leu Ala Asn Asp Ala Tyr Arg Ser Leu Gly His Gly Ile Arg Asp Arg  
 420 425 430

Tyr Leu Val Val Arg Ala Gly Thr Phe Ala Arg Arg Thr Val Ala Val  
 435 440 445

Gln Arg Asp Gly Val Ile Gly Trp Asn Ile Ser Arg Ser Tyr Phe Gln  
 450 455 460

Arg Arg Ser Gly Leu Leu Thr Ile Gly Ala Thr Thr Ala Gly Val Gly  
 465 470 475 480

Cys His Lys Val Arg Asp Val Ser Val Gly Ala Gly Leu Ala Phe Ala  
 485 490 495

Glu Glu Ala Val Pro Arg Leu Leu Ala Pro Phe Ile Glu Arg Val Pro  
 500 505 510

Arg Gly

<210> 17  
 <211> 1545  
 <212> DNA  
 <213> Streptomyces aizunensis

<400> 17  
 atgagccacg acaccggaca gtgggaggcc accgcgacct cccacggcgc cgccgaagac 60  
 cccgagtgga gcaggctcag ccccgactg ctgctggtca acctgagcat gctcgccggc 120  
 ccgctcgccc tgttcgccgt cacggctcgcc ctgaccggcg ccaacctcca ggccctcatc 180  
 tccctcggct ccctgctgat cgtcttctg gtcacaccg ggatcagcac gatgcggctg 240  
 ctgaccaccc gcttcgcgt caccgccgaa cgcgtcgaac tgcgctcggg cctgctcttc 300  
 cgcagccgcc gtcgggtccc catcgaccgg gtccgcagcg tcgacgtcga agccaagccg 360  
 gtgcaccgcc tcttcggcct cgctcgtg cgcacggca ccggtgaaca gggcgctcc 420  
 agccgcaggc tctccctcga cggcatcacc aggcgtcagg cgcggcgact gcgcaggctc 480  
 ctcacgacc gccgtggcag cggccatgcc accggccagg accaggacgt caccatcgcc 540  
 gagatggact gggcctggct gcggtacgcg ccgctcacca tctggggcgt cggcagcgtc 600  
 ttcgccgccg tcggcaccgc ctaccgcac ctgcacgaga tgaaggctga cccgctcgaa 660  
 ctgggctcgc tcaaggacat cgaggaccgc ttcggttccg taccctgtg gttcggcatc 720  
 ctgctcgccg tcgtgatcac cgccgtcgtg ggcgccgagg tctccaccgc caccttcgtg 780  
 gacgcctgga ccaactaccg cctggagcgt gagggggctg gcatcttccg gatccgccgc 840  
 ggactgctca tttcccgtc cgtcaccatc gaggagcgcc ggctgcgcgg cgtcgagctc 900

gccgagccga tgctgctgcg ctgggcgggc ggcgccaccc tgagcgccat cgccagcggc 960  
 ctcagcaaca gccaggagaa ccgcagccgc tgttccctca ccccgcccgt gcccggggac 1020  
 gaggcgctgc gggtcgcccgc cgacgtcctc gccgaggaag ggtccccgac ggagctgacc 1080  
 aagctcgtcc ggcactccccg tgccgccctg cgccgtcgca tcaaccgcgg cctgctggtc 1140  
 ctgcggggccg tcgtcgcggt gccgctgggc ctggggctgt ggctcacccc cgtcctgggtg 1200  
 cacaccgcct ggatcacggc gctcgtcggc ctgccggtcg tcatcgtcct cgccaacgac 1260  
 gcctaccgct ccctcggcca cggaatccgc gaccgctacc tcgtcgtccg cgccggcacc 1320  
 ttgcggccgc gtacggtcgc cgtccagcgg gacggcgta tgggtggaa catctccgc 1380  
 tcctacttcc agcggcgag cggaactgct accatcgggc ccaccaccgc gggcgtcggc 1440  
 tgccacaagg tgcgcgacgt atccgtcggc gccggcctcg ccttcgccga agaggccgta 1500  
 cccaggctgc tcgccccgtt catcgaacgc gtcccgcgcg gctga 1545

<210> 18

<211> 164051

<212> DNA

<213> *Streptomyces aizunensis*

<400> 18

ctggctcagc ccgccagctc ctccagcctc ggcaccagcg acaccggaga gggcatcgtc 60  
 cggatctccg cgcgcacctc gcgcggggcc gccgtcatct tctcgtccga aagcagctgt 120  
 acgaggacct ccgcggagag gtcgtcggcg gtgccgagca gaccggcacc ccggtcccgt 180  
 acggcctccg cattgatgtg adggtccgct ccgtccggca ggacgagctg cggcacaccg 240  
 gcgttcagcg ccgccagcgt cgtccccgca ccaccgtggg gcacggccgc gtcgcaggtc 300  
 tgcagcagcg ccgtcagcgg caccacccc acggcccggga cgttgggagg cagtccaccg 360  
 agcgcggtgg tgtccacatc gcccagcgc agcacgaact cggcgtccac cccggcagcc 420  
 gccgccgcga gccgctgcac cggggccagg ccgttgatgt ggaccgaggc cgtgccgagc 480  
 gtcaccccgga cccggcggcg ccccggttc tccagcagcc agtcgggcag caccgcaccg 540  
 ctgttgtaag ggaccggccg catcgaccag ccgtcccgtt cgggctccgc catgctcggc 600  
 ggcgcgatgt cgatcacccg gaccggttcg gacacccggt ccacgcccgt ccgcgccatc 660  
 gtctcgggtga gcatcgacac cgtcagctcg cgcagctgcg taccgccgcg gaaaccgaag 720  
 ttgtgctgca cggccggcac acccagccgc gccgccgcga tcagaccgga cacgaagatc 780  
 tgctcgaaga cgatcagatc gggccggaaa tcgtcggcgg tccgcacgat gccgtccgcc 840  
 aggtggttgt tgaggtgggc gaagagggtc agcccgtcca tcgggtcgac gccgcccgga 900  
 ccgcgcaggc gggccatcag ctacccggcc gtcgactgga ggaagtcctc cagggtggaag 960  
 ccgggggcga catccgccac gtgcagaccg gcgttgggcg cctccagcgc gtcacccgcg 1020

ctggcgacca gcacctcgtg gccggccgag cgcaacgccc aggccagcgg aacaatggga	1080
aaaacgtggc cgatggccgg atacgtcacg aacagtatgc gcaaggaaac gcgccccctt	1140
gggtagcttt gtattctccg gaccggtatg gtccagatgg aatacggtag atattcttta	1200
aatccccgac ggtgcctggg catcctgatg cagtcgcaca tgccgagtca aggcggcgtc	1260
cgaaggcccg tgttaggggt ccgtaggggc ctgttagggg tttctccac ttccctcgca	1320
tgcaagagtg tcccctggtc ttggattctt tattcggggg taatggagcg cgcgatgttg	1380
aatgagtccg aggaattcac gcccgaaatc aatgtcgcct ccgaagtcgg tggaacgcag	1440
ggcgaaagtc ctgaaagcac gccgtcgtgg cagcagcgcc tgaccggcct caccgaggcc	1500
gagcagcaca ccgcactgct ggagtgggtg tcctcgctgg catccgccgc actgcgcgac	1560
gcggcccccg acacgctcga cccccaccgc ccttctctgg atctgggctt cgactcgctc	1620
gccgcgctcg acctgcacgc caggctcgtc gcgggaaccg ggctgcggct gccggtcacc	1680
ctggccttcg accaccccac ccccgcgac ctcgccgctc atctgcacgc ggcgatcctc	1740
ggactgaccg gccccgccga gacgcccgtc accgcggcgg tcggcagcga cgaaccatc	1800
gccatcgctg gcatcggtct ccatttcccg ggcgcgctac agtccccga ggcgctgtgg	1860
aacctcgctg agaccggcac cgacgccatt tccgcattcc ccaccgggcg cggctgggat	1920
ctcgacgcgc tgtatgacct ggatcccgac cgggcgggca ccagttatgc ccgcgagggc	1980
ggattcctgc acgacgccga cgcattcgac gcggcattct tcgggatatc cccgcgcgaa	2040
gccctcgcca tggatccgca gcagcgactc cttctcgaag cgtcctggga ggcattcgac	2100
cgcgcgggg tagacccgc cgcattgcgc ggcggtcagg tcggcgattt cgtcggcgcc	2160
gagaccagg aatacggccc ccggctccag gacgccaccg acggattcga gggctacctc	2220
gtcaccggaa acgcggccag cgtcgcctcc ggccgtatcg cctacacctt cggcttcgag	2280
ggcccgacgg tcaccgtcga cacggcctgc tcctcctcac tcgccgccct ccacctcgcc	2340
gtccaggcgc tgcgcaccgg cgaatgctcc ctgcgcctcg ccggtggcgt cgcggtcagt	2400
gcgagccccg gtcgttcgt ctcgttcagc gccagcgcg gcctggcccc cgacggccgc	2460
tgcaagccgt tcgcggccgc cgccgacggc acggcgtggg gcgagggcgt cggcatgctg	2520
ctggtcgaac ggctctccga cgcgcgcgcc aagggccacc ggatcctcgc ggtcgtccgc	2580
ggctccgcca tcaaccagga cggcgccagc aacggcctca ccgccccag cggctccgtcc	2640
cagcagcgcg tcatccgcca ggccctcgcc aacgcgggcc tgtccgccgc cgaggtcgac	2700
gtcgtcgagg cgcacggcac cggcaccggc ctcggcgacc cgatcgaggc ccaggcgtc	2760
ctcgccacgt acggccagga gcacaccgat gaccggccgc tgtggctcgg ctccctgaag	2820
tcgaacatcg gccacacgca ggccgccgcc ggagtcgccg gcatcatcaa gatgatcatg	2880

gcgatgcggc acgggggtact gccccggacc ctgcacgtcg acgcgccgac cccgcacgtc 2940  
 gactgggagg ccggagcggc caccttgctg accgaagccg tggagtggcc ggagtccgac 3000  
 cgcccgcgcc gtgcgggctg gtcttccttc ggcatgagcg gcaccaacgc ccacgtcatc 3060  
 gtcgaagagc cggccgcccc ggaccgcgag ggcgccccca cctccggcgc ccaagcccc 3120  
 gactccagcc agggccaggc acagggcacc tccaccgcgc cggttctcct cccgtgggcg 3180  
 ctctccgcca agacccccga ggccctccgc gccaggcac gccgactcgg caccctgatc 3240  
 gcggcgcagc cgcacgtcac cccctcgac atcgccact ccctcgcgac caccggggc 3300  
 cgcttcgagc agcgcgccat cgtgctcggc gacgaccgcg aggcgttcct cgacgccctg 3360  
 cacgccctcg ccgagggcaa cgacacgccc tccgtggtcc agggcgccgc cgcaccgggc 3420  
 aagctcgcct tcctcttcac cggccagggc agccagcgcc tcggcatggg ccgcgaactg 3480  
 tacgagacc acccggtgtt cgccgacgcc ctcgacgacg cctgctggta cctggacgac 3540  
 caactcgaac tcccgtcct cgacgtgctg ttcgccgacg agggcagccc cgaggccgca 3600  
 ctctcgcacc agaccgccta cacgcagccc gcgctgttcg cggtcgaggt ggcgctgttc 3660  
 cgcttggtcg acagctgggg cctgaagccc gacttcgtcg cgggcccactc catcggcgag 3720  
 atcgggccg cacacgtggc cggagtgttc tccctggagg acgcctgcat gctcgtcgcc 3780  
 gcacgcggcc gcctcatgca ggcgctgccg gccggtggcg tgatgatcgc gctgcaagcg 3840  
 tccgaggacg aggtgctgcc gctgctcacc gaccgggtga gcacgcgccg gatcaacggc 3900  
 ccgcaggccg tggtcacgc cggtgacgaa gacgcggcgg ccgcgatcgc cgagaccttc 3960  
 caggccgcgg gccgcaagac caagcggtg acggtcagcc acgcgttcca ctgccccac 4020  
 atggacgcca tgctggagga attcctccgc gtcgcccagg tgctggacta cgccaagccc 4080  
 accctccccg tcgtctccct cctcaccggc accaccgcga ccccgccga actggccacc 4140  
 cccgcatact ggggtgcgcca cgtccgggac gccgtccgtt acctcgacgg cgtacgcacc 4200  
 ctccaccagc ggggcgtacg caccttcctg gaactcgggc cggacgcggc gctcaccgcc 4260  
 atggcacagg actgcgtcga cccgcagggc gccgccttcg ccccgcgct gcgctccggc 4320  
 cgcccgagg cggccactgt gctcaacgcc gtcgcgcacg cccacgtccg ggggtgcggag 4380  
 acggactggg ccgcgttctt cgccggtacg ggcgctcagc gggtcgatct gccgacgtac 4440  
 gccttcacgc ggcagcgcta ctggatggac tcccgacccc cggccccgga ctccgccgcg 4500  
 cagcggggcg acggcggcg cgatccggtc gaccgtgtgt tctgggacgc cgtcgagcac 4560  
 gaggacgtgg ccacgctcgc cgccgccctc gaactcgacc tcgacggcga acagccgctc 4620  
 agcgaggctg ttccggcact gtccgcctgg cgtcgccgcc gccgcacca gtcggagggtg 4680  
 gacggctggc gttaccgggt gacgtggaag ccgctgactg aggtctcgac gtctgggttg 4740  
 tccggttcct gggtggtgat ctgccagct gggggtgccg atgactcgcc tgtggtgagt 4800

gcgctgggttg ggcgtgggtgt tgacgtccgt cgggttggttg tcgaggcggg tgtggaccgt 4860  
 tcggcgctgg ctgggttgct ggctgaggtt ggttcgcctt cgggtgtggt gtcgcttctc 4920  
 gggctggatg agtccggggg gttgttgggg actgttggtt tgggtgcaggc gttgggtgat 4980  
 gccgggggtg gggcgccgtt gtgggtgcctg actcgtgggt cgggtgtctgt ggggcgttcg 5040  
 gatcggcttg tgtcgccggg tcaggcgag gtgtgggggt tggggcgggt tgctgctctg 5100  
 gaggttccgg agtgggtggg cgggctcatc gatctgcctg aggtgctgga cgagcgggct 5160  
 gtgtcccgt tggtcgggtg acttgccggg tccggtgagg atcaggtcgc gggtcgttcg 5220  
 tctggtgtgt tcggtcgtcg tctggtgcgt gcaccgagg cggagggtgc ttcggcgtgg 5280  
 tctccgaccg gcacggttct cgtcaccgtt ggtacgggtg tgctgggtgg ccgggtggcg 5340  
 cgttggtggt cgggggcggg tgctgagcgt ctggtgctga ccagccgtcg tgggctggat 5400  
 gcgccgggtg cggttgagct ggtggaagag ctgaccaccg gctttggggg ggaggtttcg 5460  
 gtcgtcgcgt gtgatgcggc cgaccgtgac gccctgcgtg ccctgctgtc cgctgaggcc 5520  
 ggggtctctga ccgctgtggt gcacacggcc ggtgttcttg acgacggcgt cctggatgct 5580  
 ctgaccccg accgtatcga cagcgtcgtg cgtgcgaaag ccgtctcggc tctcaacctg 5640  
 catgagctga cggccgagct gggatatcag ctgtccgact tcgtcctctt ctccctccgtc 5700  
 acaggtagcg tcggcgcggc cggacaggcc aactacgccc ctgcgaatgc cttcttggtat 5760  
 gctctggccg agcagcggcg cgccgatggt ctgcggcgga cgtccatcgc gtgggggtccg 5820  
 tgggcccagg gaggcattgc cgccgacgag gcgatggacg cacggatgcg ccgcgagggc 5880  
 atgccccga tggcgccac atccgcgatg agcgcactgg agcaggccgt tgggtgcgggc 5940  
 gagacggcgc tgaccgttgc cgacatcgac tgggagcgtt tctcctccgt catcgccgca 6000  
 gtccgcccc aaccgctgat cggtgacttc gtgctcggag cggaaggcac ggccgcccgc 6060  
 agcggccacg gatccgtggt caccggcgcc gatgtgcgg ccaccgtctc gggccgggtg 6120  
 gcgggcctga ccagggcga gcaggagcgg gaactgctca gcctgggtccg tctgcacgtg 6180  
 gccgcggtac tcgggcacga cggatcggac gcggtcggtg ccgaacgggc cttcaaggaa 6240  
 ctcggttcg actccctgac ctccgtcgag ctgcgcaacc gcctcggagc cgccaccgat 6300  
 ctccggctcc ccaccacgt cgtctacgac taccacacgt ccgcgctct cgccgagtac 6360  
 ctgcggggcg aactggccgg cagcgcgcag gacgcggggc cggccctgcc cgccgtggtc 6420  
 ggctccgccc ccgacgacga tccgatcgtg atcgtctcga tgagctgccc cttccccggt 6480  
 ggcgtacgga ctccggaaga cctgtggcag ctccctgcgg acggcacgga cacggtcgcc 6540  
 gccttcccgg ccgaccgagg ctgggacctg gacggcctct acagcgccga cccggagcgt 6600  
 tcggggacct cgtacacgcg tgaaggcggg ttcctctacg acgcccga cttcgacgcg 6660



gacttcttcg ggatctcgcc gcgcgaggcc ctccgcatgg acccgagca gcgcctgctg 6720  
ctcgaaaccg cctgggagac ctccgagcgc gccgggatcg acccggcgtc gctgcggggc 6780  
agccaggccg gtgtcttcgt cggcaccaac ggccaggact acctctcgct ggtcacgcgc 6840  
gaaggcgacg gactcgacgg actcgaagga catgtcggca ccggcaatgc ggccagtgtc 6900  
gtctccggcc ggctctctta cgtcttcggg ctccaaggcc cggcgatcac ggtcgacacg 6960  
gcctgctcgt cgtcgttggt cggcctgcac ctggccgtgc aggcgtcgcg ccaggggcag 7020  
tgcaccttgg cgctcgccgg tgggtgtgac gtgatgtcca ctccggacgc ctccgtcgac 7080  
ttcagccgtc agcgtgggct cgcggaggac ggccgtatca aggcgttcgc gtcggccgcg 7140  
gacggtaagg gctgggggtga gggcgctggc atgctcctgg tggagcggct gtccgacgcc 7200  
cgtaggaacg gtcacccggt cctggcggtc gtgcggggct cggcgatcaa ccaggacggc 7260  
gcgagcaacg gcctgaccgc gccgaacggt ccgtcccagc agcgcgatcat ccgccaggcg 7320  
ctggccgggt cggggctgtc ggccgccgac gtggacgcgg tggaggcgca cggtaagggc 7380  
accgggctcg gtgaccgat cgaggcgag gcgctgctcg ccacgtacgg ccaaggccgc 7440  
ccggcggaac ggccgttggt gctgggctcc gtgaagtcca acatcgggtc cagcgaggcc 7500  
gccgcggggc tggcgggcgt gatgaagatg gtcatggcga tgcggcacgg tgtgctcccg 7560  
cgcacgctgc acgtggacgg gccgacccg cagctcgact ggtcggcggg cgacgtcgcc 7620  
ctgctgaccg agcagcggga gtggccggcg accggccacc cgcgcgggg aggtgtgtcc 7680  
tcgttcggcc tgagcggtag gaacgcccac accatcatcg aagaagccc ggccgacgac 7740  
gacgccgagc ccacgaccgg cgcggggacg gcccgtccg ttctgccgt gtcacatctc 7800  
gccaagagcg acgccggcct gcgcgcacag tcggagcagc tggcgacca tctggtcgga 7860  
aaccggacg tccccatcg ggacatgcc tactccctca cgaccggacg ctccgggctg 7920  
gagacgcgag cgatcctggt cggcgacgcc gacaaccga cagggtcgc ggccgcgctg 7980  
cgaagcctcg ctgccggcga gcaggctccg ggcctggtcc agggcacggt gaccgagggc 8040  
gggctggcgt tcctgttcac ggggcagggg agccagcggc tggggatggg ccgtgagctg 8100  
tacgagacgt atccggtgtt cgcggatgcg ctcgacgcgg tgtgcgcgcg gatggatctc 8160  
gaagtccgc tgaggacgt gctgttcggg gcgtatgcgg gtctgctgga tgagaccgcg 8220  
tatacgagc ctgcgttgtt cgcggttgag gtggcgttgt tccggctggt ggagagctgg 8280  
ggtctgaggc cggacttcgt ggcgggtcat tcgattggtg agatcgctgc tgcgcatgtg 8340  
gcgggggttc tgtccctgga tgacgcctgt gctctggtgg aggcgcgtgg gcggttgatg 8400  
ggtgcgctgc ctggtggtgg cgtgatgatc gcggtccagg cgctgaggc tgaagtcctg 8460  
ccgctgctga ccgagcgcgt gagcattgcc gcgatcaatg gtccgcagtc ggtcgtgatc 8520  
gcgggtgacg aggcgcacgc ggtggcgatc gtggagtcgt tcacggggcg taagtccaag 8580

cggtcacg	tcagccacgc	gttccattcg	ccgcacatgg	acggcatgtt	ggaggacttc	8640
cgggccgtgg	cggaagggct	gtcgtacgag	gccccgcgca	tccctgtggt	ttccaacctc	8700
accggggccc	tggtctcggg	tgagatgggg	tcggctgagt	tctgggtgcg	tcattgtccgc	8760
gaggcggttc	gcttcctgga	cgggatgcgt	gttctggagg	ccgccgggggt	tacgacgtac	8820
gtcgagcttg	gccccggggg	tgtgctgtcg	gcgctggcgc	aggagtgtgt	cagtggggac	8880
ggtgctgctt	tcgtgccggt	gctgcgttct	ggccgtcccg	aggccgagac	cgcggtcacc	8940
gcgttgggcc	aggcacatgt	gcggggtgtg	gacgtcgact	gggccgcgtt	cttctccggg	9000
accggcgctc	agcgggtcga	cctgcccacc	tacgccttcc	agaggcagcg	gttctggccc	9060
gcgatgacgg	cggagagtgc	gccggtcggc	gggacggctg	acgcggtgga	cgccacttc	9120
tgggatgtca	tcgagcagga	ggacgtcgag	tcccttgctg	agttgctcgg	tctcgacgac	9180
gcgagcgcgt	gggggagtg	ggtccccgcg	ctctcggcct	ggcgtcggca	gggccaacag	9240
caggcccagg	tcgacggatg	gcgctaccgg	gcgagctgga	agccggtgac	ggctgcgggtg	9300
tcgtccggcg	tggtgagcgg	gacatgggtt	gtcgccgtac	ctgccggatc	tgcgggggac	9360
gacgcgcggg	tcgaggccgt	gaccaacggg	ctggctgggc	gtggcggtga	cgtccgtcgg	9420
gttgtggtcg	aggcgggtgt	ggaccggggc	gcgctggctg	ggttgctggc	tggtgaggga	9480
tctctcgtcg	gtgtggtgtc	gcttctcggg	ctggatgagt	ccggggggct	ggcggtact	9540
gctggtttgg	tcagggcggt	gggtgatgcc	ggggtgtcgg	cgccgttgtg	gtgcctgacc	9600
cgcggggctg	tttccgtcgg	tcgttcggat	cggcttgtgt	cgccggttca	ggcgcagggtg	9660
tggggtctgg	ggcgggttgc	tgctctggag	gttcccagac	gttggggcgg	gctgggtgac	9720
cttccggaag	tgctggatga	gcgggctgtg	tcccgttga	tcggtgtact	tgcggttcc	9780
ggtgaggatc	aggttgcggt	tcgttcgtct	ggtgtcttcg	gtcgtcgtct	ggtgcgtgca	9840
ccgcgggccc	aggggtgctg	gtcgtggact	ccgaccggca	cggttctcgt	caccggtggc	9900
acgggtgtgc	tgggtggccg	ggtggcgcgt	tggctggcgg	gggcgggtgc	tgagcgtctg	9960
gtgctgacca	gccgtcgtgg	gctggatgcg	ccgggtacgg	ctgaactggt	cgaggagctg	10020
accagctccg	gggtggaggt	gtcggtcgtc	gcgtgtgacg	cgcccgaccg	tgacgccttg	10080
cgcgccctgc	tctcctctga	ggccgggtct	ctgaccgctg	tgatccacac	ggccggtgtc	10140
ctggacgacg	gtgtcctgga	tgctctgacg	ccggaccgta	tcgatgggtg	cgtgcgtgcg	10200
aaggccgtct	cggctctcaa	cctgcacgaa	ctgacggccg	agctgggcat	cgagctgtcc	10260
gccttcgtcc	tgttctcgtc	catgagcggc	acggtgggca	cgccgggtca	ggccaactac	10320
gcggctgcca	atgcctacct	ggatgctctg	gccgagcagc	gccgggcgga	cggctctcgcg	10380
gcgacgtcca	tcgcttgggg	tccgtgggcg	gagggtggca	tggccgccga	tgcggcgtc	10440

gaagcccgtat tgcgccgaga cggggtgcct ccgatgcccg cggatccggc gatccgcgct 10500  
 ctccggcagg ccgttgcagg cgacgacgcc gtgcttaccg ttgccgatgt cgaatgggac 10560  
 cggttcctcc cgggcttcgt cgccgcacgg cacagcgagc tggtcagcga gctgcgtgac 10620  
 gtccgtgatg cccgcgcggc acaggatcgg gcgcaggccg ccgttgccgc cgaccgtccg 10680  
 gactcccttt ccggggcggt gtccgcccag gcgcggccg agcaggagcg agagctgctg 10740  
 gacctggtcc gtacgcaggc cgccgccgtg ctccggcacg ccggagtggg aaacgtgggc 10800  
 gcggggcggg cggtcaagga gcttggcttc gactcgctca tggccgtcga gctgcgcaac 10860  
 cgcacgggtc cggccaccga gcttcggctc ccggccacct tgatctacga ccacccacg 10920  
 tccgccgcc tgcggaggt cctgcggggt gagctggtcg gcaccgtgcg ggtcgccgac 10980  
 aagtgctgc ccgccgtggc ctccgccgac gaggatccga tcgcgatcgt ctcgatgagc 11040  
 tgccgcttcc ccggtggcgt acggactccg gaagacctgt ggcggctcct cgtggacggc 11100  
 acggacgccg tcggcgcggt cccggccgac cgcggtggg acctggacag gctctacagc 11160  
 cccgaccgg accagccggg cacctcgta acccgcaag gcgggttctt cgacggggcc 11220  
 gcggacttcg atcccggtt ctccgggac tcgccgcgc aggcgctcgc catggaccgc 11280  
 cagcagcgac tgctgctcga aacctcctgg gaggcgatcg agcgggcggg catcgaccgc 11340  
 tcgtcgctgc gcggcagcca ggccggtgct ttcgtcggca ccaacggcca ggactacctc 11400  
 tccctcatca cccgtgaatc ggagggcctg gaaggtcact tgggcacggg taacgcgggc 11460  
 agcgtcatgt ccggccgcgt ctccctacgt ctccggcctg aggggtccggc ggtcacggtc 11520  
 gacacggcgt gctcgctcctc gctggtcgcc ctgcactggg cgatccaggc cctgcgtcag 11580  
 ggcgagtgca gcatggctct ggccggcggc gtgaccgtca tgtcgacgcc cgagaacttc 11640  
 gtcgacttca gccgtcagcg cgggctcgcg gaggacgggc gcatcaaggc gttcgcgctg 11700  
 gccgcggacg gtacgggctg gggtgagggc gtcggcatgc tcctgggtgga gcggctgctg 11760  
 gatgcccggc gcaacgggca tccggttctg gcggtagtac gtgggttcggc tgtcaatcag 11820  
 gacgggtgca gcaatggtct gacggctccg aatggtcctt cgcagcagcg ggtgatccgt 11880  
 gcggcgctgg cgagtgcagg tctgtcggcc gctgatgtgg atgtgggtgga ggcgcacggc 11940  
 acggggacga agctgggtga cccgatcgag gcgcaggcgc tgctggcgac gtacggggcag 12000  
 gaccggccc cgggccgtcc gctgtggctg ggttccatca agtcgaacat cggtcatacg 12060  
 caggccgccg ccggtgtcgc gggcatcatc aagatggtcc tcgcatgca gcacggcgtg 12120  
 ctgccgcaga cgctgcacgt cgacgagccg accccgcacg tcgactgggtc ggccggcgag 12180  
 gtcaccctgc tgaccgagca gacggcctgg ccgacggtgg accggccgag gcgagcggga 12240  
 gtgtcgctct tcggcatcag cggcaccaac gccacacca tcatcgaaca ggccccggcg 12300  
 gtcgagcagt tggcggacgg tgacgcgact cccgccactc cggccctcgc gctcccgtg 12360

ccgtacgtcc tctccgcgaa gagccccgag gccctgcgcg cccaggcgtc cgtactgcgc 12420  
acgcacctgg aggccacgga ccacaacggg cccggttccg acgacctggc cttctcgcctc 12480  
gccacggcac gtgcgcacct cgaacaccgc gcagtcctga ccgccgacga cccacaggaa 12540  
ttccgggagg cactcgcacg cctcgcgcgac ggtgatccct caccgaggat caccaccggg 12600  
gcggtgagcg acggtcgtac ggcgttctcg ttacacgggcc aggggagtcg gcggctcggg 12660  
atgggccgtg agctgtacga ggcgtatccg gtgttcgcgcg acgcgcttga cgcggtctgc 12720  
gcgcatgtgg acgcgcacct cgaagtgcgc ctgaaggacg tcctgttcgg ggcggatgcg 12780  
ggtctgctgg accagacggc ttacacgcag cccgcgttgt tcgcggtcga ggtggcgctg 12840  
ttccggctgg tggagagctg ggggtgtgaag ccggacttcg tggccgggtca ttcgatcggt 12900  
gagatcgcgg ccgcgcacgt ggcgggcgctc ttctcgcctc aggacgccag tgaactggtc 12960  
ttcgcctcgtg ggcggttgat gcaggcgcgt cgcaccgggt gcgtgatgat cgcggtccag 13020  
gcgtcggagg acgaggctct gccgctcgtg accgaccggg tgagcattgc cgcgatcaac 13080  
ggccccagc cggtcgtcat cgcgggcgac gaggccgacg cgggtggccat cgcgcagtc 13140  
ttcacggacc gcaagtccaa gcgcctcacg gtgagccacg cgttccactc gccgcacatg 13200  
gacggcatgc tcgacgcctt ccgtgagatc gccgagggcc tctcctacga accttcgcgc 13260  
atccccggtc tctcgaacct caccggcgct ctcgtctccg atgagatggg ctcgcccgag 13320  
ttctgggtgc ggcacgtccg cgaggccgct cgtttcctcg atggcatccg cacgctggaa 13380  
gccgcgggcg tcaccaagta cgtcgaactc ggccccgacg gcgtgctgtc ggcgatggcc 13440  
caggactgcg tgagtggcga gggctccgctc ttcatccccg tgctccgcaa ggccgcgccc 13500  
gaggccgaga gcgtcacgac cgcctcgcctc tcggcccacg tccacggcat ccccgctcgc 13560  
tggcaggcgt acttcgcggg gaccggcgcc cagcgcgtcg acctccccac ctacgccttc 13620  
cagcgcacgc gctactggcc cagcgtgcc gcgttcgtca ccggcgatcc gacggcgatc 13680  
gggctcgggg atgccgggca cccgttgctg ggtgcggcgg tggcgctcgc cgactccgag 13740  
ggcgtgctct tcaccggccg cctgtcgcctc gacaccacc' cctggctcgc cgaccacacc 13800  
atcctcggca gcgtcctgct gccgggcacg gccttcgtcg acctggcgat ccggggccggc 13860  
gatcaggctg gatcgatgt ggtcgaggag ctgaccctcg aagcggccct cgtcgtcccc 13920  
cagcggggcg gtgtgcagct ccagctcgtc gtcgaggcgc cgagcgggccc cgggcagcgg 13980  
ccgttcagcg tgcaactccc gcggcaggac gcctacgcgg aggagccgtg gatgcggcac 14040  
gcctccggag tgctgacttc cggcgtttcc cgcgcggaac tgtccgtgga aggcgggggag 14100  
ttcgaggcgc tggccgtctg gccgccgacc ggagccgtac ccgtggacgt acgaggtctg 14160  
tacgaggagc tcgccgaggc cgggtgtggcc tacgggcccgc tggtccaggg gctcaaggcg 14220

gcgtggcggc gggacggtga actgttcacc gaggtggcgc tcccgggtga agcccggcgt 14280  
 gaggcggcac ggttcggtct gcacccggct ctgctggacg ccggtctgca cgccatcggc 14340  
 cacggcgagg gaccggaacc ggcaatgacc ggcgcgctgt tgcccttctc ctgggcagga 14400  
 gtctcgctgt acgcggcggg cgcctcctca ctcaggatgc ggctgacccc gcacacaccc 14460  
 gacgacgccc acaccatggc gttgctcgtg gcggatgaga ccggacgtcc ggtggcggcc 14520  
 gtggagtctg tgatcctgcg taccgcgtcg gccgaccagg tgcgcgcggc cgacggaggt 14580  
 cacctcgact ccctcttcaa ggtggagtgg ctgcccgtgg cgggcggagc cacgccgcac 14640  
 ggcgactcca ccggacggcg atgggccgtc ctgggccgcg acggactcgg cctgccggcc 14700  
 accggcgtgc aggggcaggt ggccgagtac gacgatgcct ccgcgctcgg tcgggcgctc 14760  
 gcggccggcg aaccggtgcc ggacgccgtg ttcgtccacc ctggggctct tccggggcag 14820  
 gacacggaca ccacggcggc ctccgtacac gccgcctga cggacgcgt gtccttcgta 14880  
 caggaatggc tggcggacga gcggttcgcc gccacgcgcc tgggtgtggc gacatccggc 14940  
 gcggtggcgg acgagcccgg cgcgggcgtc cgggacctgg cgggcagcgc cgtacgcggc 15000  
 ctgctgcgtc cggcgcagtc cgagaacccc ggccagctgc tgatgctcga cctcgaccag 15060  
 gacccggcct cgctcgcgcc gctgcccgcc gcgctggccg cgggtgagcc ggaactggcg 15120  
 atacgacgcg gagaactccg taccgcgcgc ctgacgcgcg tcccctcggc ggacgccgcg 15180  
 gcagagccgc tcggcacact cggcgacccg tccggcacgg tactcgtgac cggagccacc 15240  
 ggaaccctgg gcggactctt cgcgcccat ctggtgacgg cgtacggggc gcggcgactg 15300  
 ctgctcacca gccgtcgcg ccccgaggcc gaagggtgcg ccgaactggt cgccgaactg 15360  
 gagcagttgg gggcgcacgt cgaactcgtc gcctgcgacg ccgccgaccg ctccgcgctc 15420  
 gccgcgctcc tcggagccgt accgtccgag caccgcgtga cggccgtggt gcacacggca 15480  
 ggcgtactgg acgacggcat cctctcctcg ctcacccccg agcgcgtggc cgccgtactg 15540  
 cgtccgaagg tggacgccgc ctggaacctg cacgagctga cgcgggaact cggcctctcg 15600  
 gcgttcgtgc tcttctcggg cgcgcgcgcc gcgttcggcg cggccgggca ggggaactac 15660  
 gccgcgcga acagcttctt ggaagccctg gcggagcagc gccgcgcga aggcctgccc 15720  
 gccacctcac tcgctggggg cctgtgggct ccgcagacgg gcggcatggc ccagcagctg 15780  
 gacgaggtcg acctgcggcg catcgccagg gacggcgtcg gcgggctctc cggtgacgag 15840  
 ggccctcggc tcttcgacac cgcgatgacg gtgcagcggc cggctctgct gcccatgcgg 15900  
 ctcgacctcg cgggtggcgc ggcgcaggcc gtctccacgg gcgagacacc ggcgctgctg 15960  
 cgcgccctca tacgggtgcc cgcgcggcgc gcggtcgagc agcgtacggc ggcggacggg 16020  
 gcctcgcccc tggcggccag gctgtccgcc ctgccggacg cggaacgcga ggacatgctg 16080  
 ctggacctgg tgtgcgggcg ggtggccgag gtctcggcc acaccgacgc ccgcgcggtc 16140

gacgcggacc gcgcgttcaa ggaactcggga ttcgactccc tcacggccgt cgagctgcgc 16200  
aacgtcctga aggccgcgac cggcctcagg ctctcaccga ccctcgtctt cgactatccg 16260  
accccggtgg cgctggcccg gcacctgctc gccgagctgg cgggaaccgc cgatgaccag 16320  
gacgccgtac gcggccggaa ggcaccgcga cggcccgcca cggccgcggt cacctccgtg 16380  
accggcgaag acccgatcgt catcgtcggc atgggctgcc gcttccccgg cggcgtacgg 16440  
tcgccggagg acctgtggca gctcgtcggc accggcggcg acggcatcac cggcttcccc 16500  
tccgaccgcg gctggaacgt cgaggccctc taccaccccc acccggaacca cgcaggcacc 16560  
tcgtacaccc gcgaaggcgg ctctctgcac gacgccgcgc acttcgatcc cgggttcttc 16620  
gggatctcgc cgcgcgaggc cctcgccatg gacccgcagc agcgctgct gctggaaacc 16680  
tcgtgggagg cgttcgagcg ggccggaatc gaccggcgga cgctgcgcgg aagccgtacg 16740  
ggcgtcttcg ccggtgtcat gtaccacgac tacgtgaccg gcatcggcga cggcggcagc 16800  
gccgtcgaac tgcccagggg ggtcgagggc tacctcgga cgggcaacgc cggcagcatc 16860  
gcctccggcc ggatcgcta caccttcggc ctggaaggcc cggcggtcac cgtcgacacg 16920  
gcctgctcct cgtcgctcgt cgcctgcac tgggcgatcc aggcgctgcg cagcggcgag 16980  
tgcacgatgg cactggccgg cgggtgcgc gtcattggcca ccccgagac ctctcgtcgc 17040  
ttcagccgcc agcgcgccct ctggccgcac ggtcgctgca agtccttcgc cgcggcggcg 17100  
gacggtacgg gctgggcccga aggcgcgggc atgctcctgg tggagcgct ctccgacgcc 17160  
gaacgcaacg ggcacccggt cctggccgtg gtccgcggct cggcgatcaa ccaggacggc 17220  
gcgagcaacg gcctgaccgc accgaacggt ccgtcccagc agcgcgctcat ccgcgaggcg 17280  
ctggccagtg ccgacctgtc ggccgcgcac atcgacgcgg tcgaggccca cggcacgggc 17340  
acccggctcg gcgaccgat cgaggcgcag gcactcctgg ccacgtacgg ccgtgagcgc 17400  
gaggcggggc gcccgctgtg gctcggctcg atcaagtga acatcggtca cagcaggcg 17460  
gcggccggtg tcgcgggcat catcaagatg gtcattggca tcgggcacgg cgtactgccg 17520  
cagaccttgc acgtcgacga gccgtcaccg caggctcgact gggaggcccg tgaggctctc 17580  
ctgctgaccg gggcgatgcc ctggccgcag acgggcccgc cgcgccgtgc gggcgtgtcg 17640  
tcattcgga tcagcggcac caacggccac acgatcatcg agcagccgcc gaccctgag 17700  
gtgacgccga cggttccggt ggctccggtg gttccgacgg ttccgacggt tccggtggtg 17760  
ccgtgggtgc tctcgggcaa gggcgaggag gcgctgcgag cgcaggcacg tcagctccag 17820  
tcgtacgtgc tccgcgcacc ggaactgcgt ccggctcgaca tcgccggctc gctggcggtg 17880  
ggccgggctg ccttcgagga ccgcgcggcg gtggctcgcc cgcaccgcga gggccttctg 17940  
gccgcccttg cggcgctggc ggacggcggc tcggcgacgg gggctgtgga gggttccgcg 18000

gtgggaggga agctggcggt cctgttcacg gggcagggga gccagcggct ggggatgggg 18060  
 cgcgagctgt acgaggcgta tccggtgttc gcggaggcgt tggatgcggt gtgtgctcgt 18120  
 cttgaactgc ctttgaagga tgtgtgttc ggggcggatg cgggtctgct ggatgagacc 18180  
 gcgtatacgc agcctgcgtt gttcgccgtt gaggtggcgt tgttccggct ggtggagagc 18240  
 tgggggtctga ggccggactt cgtggcgggt cattcgattg gtgagattgc tgccgccccat 18300  
 gtggcggggg tgttctcgct ggatgacgcc tgtgctctgg tggaggcgcg tgggcgggtg 18360  
 atgggtgcgc tgcctgcggg tggcgtgatg atcgcggtgc aggcgtcga ggacgaggtc 18420  
 ctgccgttgt tgaccgaccg ggtgagcatt gccgcgatca acggtcctcg gtcggtggtg 18480  
 atcgcggtg acgaggccga cgcggtggcg atcgtggagt cgttcacggg gcgtaagtcg 18540  
 aagcggctta cggtagtca cgcgttccat tcgccgcaca tggacggcat gttggaggac 18600  
 ttccggggcg tggcggaggg cctgtcgtac gaggccccgc gcatccccgt cgtctccaac 18660  
 ctaccggca ctctcgtcac cgacgagatg ggctcggctg agttctgggt gcgtcatgtc 18720  
 cgtgaggcgg ttcgcttctt ggacgggtatt cgggctttgg aggtgctgg ggttacgacg 18780  
 tatgtcgagc ttggccctgg ggggtgtgctg tcggcgctgg cgcaggagtg tgtcagtggg 18840  
 gacggtgctg ctttctgtgcc ggtgctgcgt tctggacgtt ccgaggccga gactgcggtg 18900  
 accgcgttgg ccagggcgca tgtgcggggg gtgaacgtcg actggggcgc attcttctgcc 18960  
 gggaccggcg ctgagcgggt cgacctgccg acgtacgcct tccagcggca gcgctactgg 19020  
 ctgcacatcc cccgcgtcgc gcagagcggg gtcgccgacg aggtggacgc ccggttctgg 19080  
 gatgccgtgg agcgtgagga tctggagtgc ctcgcctcca ccctggagggt cgacgacgag 19140  
 agcgcgtgga gcagcgtctt gcctgcgtg tcggcggtgg gtcgggagcg gcgtgcccag 19200  
 tccgaggtgg acggttggcg ttaccgggtg tcgtggaagc cgctggctga ggtctcggcg 19260  
 tcggggttgt ccggttcttg ggtggtgatc tcgcctgctg ggagtgtgga cgactcggct 19320  
 gtggtgagtg cgctggttgg gcgtggtgct gaggtccgtc gggttgtggt cgaggcgggt 19380  
 gtggaccgtt cggcgctggc tgggttctg gccgatgcgg gttctgccgc ggggtgtggtg 19440  
 tcgcttctcg ggctggatga gtctgagggg ttgttgggga ctgttggttt ggtgcaggcg 19500  
 ttgggtgatg ccggggtgga ggcgccgtt tgggtgcctga ctctggtgc ggtctccgtc 19560  
 ggtcgttcgg atcggctggg gtcgccggtt caggctcagg tgtggggtct ggggcgggtt 19620  
 gccgccctgg aggttccgga gcgttggggc gggctggtt acctgccgga agtgctggat 19680  
 gagcgggctg tggcccgtt ggtcgtgtga cttgcgggtt ccggcgaaga tcaggtcgcg 19740  
 gttcgttcgt ctggtgtgtt cggtcgtcgt ctggtgcgtg caccgcgggc cgagggtgct 19800  
 tcggcgtgga caccgaccg cactgttctt gtcaccggtg gtacgggtgt gctgggtggc 19860  
 cgggtggcgc gttggctggc gggggcgggc gctgagcgtc tgggtgctgac cagtcgtcgt 19920

ggtcgagatg ctccgggtgc ggctgagctg gtggaggagc tgaccaccgg cttcgggggtg 19980  
gaggtttcgg tcgtcgcgtg tgacgcggcc gaccgtgacg ccctgcgcac cctgctctcc 20040  
gccgaggccg ggactctgac cgctgtgatc cacacggccg gtgttctgga cgacggcgtc 20100  
ctcgacgcgc tcaccccgga ccgtatcgac agcgttctgc gtgccaaggc tgtctcggcg 20160  
ttcaacctgc acgagctgac ggccgagctg gggatcgagc tgtccgcctt cgtgctgttc 20220  
tcgtcgatga gtggcacggt ggggtcggcc ggtcaggcca actacgccgc tgccaacgcc 20280  
tacctggatg ctctggccga gcagcggcg gccgatggtc tcgaggcgac ctcgctcgct 20340  
tgggggtccgt gggccgaggg cggcatggcc ggcgacgacg cgatggacgc acggatgcgc 20400  
cgcgaggggc tgcgcccgat ggcgccggac gcggcactga ccctgctgcg tcagagcgtg 20460  
gggtccgccg atgcggcgct gatggtggtc gacgtggagt ggcagcgggt cgcacctgcc 20520  
ctgaccgtcg tgcgccccag caacctctc gccgagttgc ccgaggctcg ccccgccgga 20580  
acggattccc gtacgggtgg cgcaacgtcc tccgaggggg ccggctcggt cgcgagcgg 20640  
ttggccgcc tgggtggggc cgagcaggac aaggagctgc tgaacctggt ccgtacgcat 20700  
atcgccgccg tactcggaca tggcggtcg gaggccgtgg gtgccgaacg ggccttcaag 20760  
gaactcggct tcgactccct gaccgccgtc gagctgcgca acaggctcgg tgccgcgacc 20820  
ggtgtacgtc tcccggccac gctgatcttc gactaccgga ccgccacggc tctcgccgcc 20880  
tacctgcggg gcgagttgct cggtagcag gtcgtggtgt ccggctcgggt gtccaacggc 20940  
gtcgctgtgg acgacgatcc gatcgcgatc gtcgcgatga gctgccgctt ccccggtggc 21000  
gtacggacgc cggaagacct gtggcggtcg ctgtcgaccg gcggtgacgc catcggtgag 21060  
ttccccgccg atcgcggtcg ggatctgagt cggctctaca gccccgacc cgacaagcag 21120  
ggcaccttct atgcccgcgc gggcggtttc ctctacgacg ccgccgactt cgacgcggac 21180  
ttcttcggga tctcgccgcg cgaggccctc gccatggacc ccagcagcg actgctcctg 21240  
gagacgtcct gggaggcctt cgagcggggc ggcacgacc cgtcgctcgt gcgcggcagc 21300  
caggccggtg tcttcgtcgg caccaacggc caggactacg gagcgatgct ccagaccatc 21360  
ccggacggca tcgagggtt cctcggtacg ggcaacgcgg cgagcgtcgt ctccggccgg 21420  
ctgtcctacg ccttcgggct cgaaggctcg gccgtcacgg tggacaccgc ctgctctgcc 21480  
tcgtggtcg cccttactg ggcggtccag gcgctgcgca gcggcgagtg ctcgctcgca 21540  
ctggccggtg gcgtgaccgt catgtcctcg ccggtgcct acatcgactt cagccgtcag 21600  
cgtgggctcg cggaggacgg tcgtatcaag gcattcgcgg cagccgcgga cggtagggc 21660  
tggggcgagg gcgtcggcat gtcctcgtg gagcggctct ccgacgccc caggaacggt 21720  
caccgggtcc tggccctggt ccggggctcg gccatcaacc aggacggcg gagcaacggc 21780



ctgaccgcgc cgaacggccc ctgcgagcag cgtgtgatcc gccaggccct ggccaacgcg 21840  
 ggcttgtccg ccgcggaggt ggacgcggtc gaggcgcacg gcaccggcac gaggctcggc 21900  
 gacccgatcg aggtgcaggc actcctggcc acgtacggcc gtgagcgcga ggccgaccag 21960  
 cccctgtggc tcggctcgat caagtcgaac atcggccaca cgcaggcggc cgccggtgtc 22020  
 gcgggagtca tcaagatggt cctcgccatg gagcacgggg tgctgccgca gaccctgcac 22080  
 gtggacgagc cgactccgca cgtggactgg tcggcaggcg atgtcgccct gctgaccgac 22140  
 gccgtggagt ggcccagac cggtcgcccc cgtcgagcgg gtgtgtcgtc gttcggcttc 22200  
 agcgggacga acgctcacac ggttctggaa caggcaccga agcccagga gcctgaggag 22260  
 tctcagcagc ctgaggagac gaacgcgccc gcccgaccgc atcagtccgg agtcatgccg 22320  
 tggacgctct cggcgaagag cgaggcggcg ctgcgggtcc aggccgagcg gctgcggacg 22380  
 cgcacgcctt ccgaccgcct gctccagccc gtcgacgtgg cctactcact cgcgacatcg 22440  
 agggccgccc ttgagcggcg cgccgtggtc gtcgcgacgg aacgtgacga gttcctggcc 22500  
 ggactcaagg cgctggcctc cgggcagcct gctccgggcc tgggtcaggg cagggtgacc 22560  
 gagggcgggc tggcgttcct gttcacgggg caggggagcc agcgactggg gatgggcccg 22620  
 gagctgtacg agacgtatcc cgtcttcgcg gatgcgctcg acgcggtgtg tgtgcgtctt 22680  
 gaactgccct tgatggatgt gctgttcgga accgagcgcg acgcgctgga cgagaccggg 22740  
 tacaccacg cggtctctct cgcggtcgag gtggcggtgt tccggctggt ggagtcgtgg 22800  
 ggtgtgaggc cggacttcct ggccgggcac tcgatcggtg agatcgcggc cgcgcatgtg 22860  
 gcgggagtgt tctcgctgga tgacgcctgc gctctggtgg aggcgcgtgg gcggttgatg 22920  
 caggcgcctg cgaccggcgg cgtgatgac gccgtccagg cgtctgaggc cgaggtcctg 22980  
 ccgctgctga ccgagcgcgt gagtatcgcc gcgatcaatg gtccgcagtc ggtcgtgatc 23040  
 gcgggtgacg aagccgatgc ggtggccctc gtggagtcct tcacgggccg caagtccaag 23100  
 cggctcacgg tcagtcacgc cttccactcg ccgcacatgg acggcatgct cgccgacttc 23160  
 cgcaagggtg cgagggggtt gtcgtacgag gccccgcgta tcccggtcgt ttcgaacctc 23220  
 acggggggccc tggtcaccga cgagatgggc tcggccgact tctgggtgcg gcacgtccgc 23280  
 gaggccgtcc gcttcctgga cggcaccgc acgctggaag ccctgggcgt cacgacgtac 23340  
 gtcgaactcg gccccgacgg ggtcctgtcg gcgatggccc aggagtgtgt gaccggcgag 23400  
 gactccgtct tcgtgccggt cctgcgctcg ggtcgtcccc aggccgagag cgtcaccacg 23460  
 gccctcgccc aggtacacgt ccgcgggac gccgtcgact ggcaggcgta cttcgccggg 23520  
 accggcgccc agcgcgtcga cctcccagac tacgccttcc agcggcgcg ctactggttg 23580  
 gaagaggctc ccgccacggc ggccgtcgag cccctgaccg gtcgctcgg ggccgtggac 23640  
 gcgcagttct gggcgggcgt cgacaacgcg gatctctccg cgctcaccgc caccctggac 23700

atcgacgtcg acgccgacca gccactgagc gccctgctgc ccgcactgtc cgcctggcgg 23760  
cggcagcgtc aggagcagtc ggtcgtcgac ggctggcgct acacggtcac atggaagccg 23820  
atggccgatac cggccgtcgc acggccgacc gggacctggc tcgtcgtgac ccccgccacc 23880  
agccttgtcg acctgcccgc ggtctccgcc gcgttggcag cgcagggagt ggacgtacgg 23940  
gaagtcgccc tggaggcggc cgagttggat cgcgacggcg tggcggggccg gatgcgtgag 24000  
gcgctcgcgg gcgaccgggc cgacgggggt ctgtccctgc tggcgctcgc cgaacacccg 24060  
caccggccc atccggcggc gccaccggg ctgtcctga ccgggacgct cgtacaggca 24120  
ctcggtgacg ccggagtcga cgcctcgctg tggcgcctca ccaccggcg cgtggcgacc 24180  
gcacctccg acctgatcgg gagcgcggcg caggcgcagg tctggggcct cggccgggtc 24240  
gtcgccctgg aacaccccga gcgctggggc gggctcgtgg acctgcccgt accggcggac 24300  
gagcgggcac tcgaccggct gctcgccgtc ctgcggggcg ccggggacga ggaccagatc 24360  
gccgtacggt ccgcgggcct cctcgcccgc cgcacggggc acgccgcgc tcccgcgcgc 24420  
gggcagcacg ccgacagcgg gacatcgggc gccggcgctg cggccggctc cgcctggcgg 24480  
ccgcgcggca ccgtcctggt caccggaggc acgggcgcgc tcggcgggca cgtcgcccgc 24540  
tggctcgcgg cacacggcg ggaacacctg gtgctgctca gcaggagggg cccgcaggcg 24600  
cccggcgccg atgccctggt cgccgagatc gccgcgtgg gtgccggggc caccggcgtc 24660  
gcctgtgacg tgaccgaccg gaccgcccgt tcggagctgc tcgccgggct cgccgacggc 24720  
acgtacggtc ccggcctcac cgccgtcttc cacacggcg gcgccgggca gttcgcgccg 24780  
ctcgacggga ccggccccgg cgaggctgcc gaggtcgtcg ccgccaaggc cgcgggcgcc 24840  
gccacctcg acgagctgct cggggacacg gaactggacg ccttcgtcct cttctcctcc 24900  
atcgccggcg tctggggcag cggcggccag agcgcctacg cggcgggcaa tgccacctg 24960  
gacgccctgg ccagcagcg ccggggccgc ggactgacgg ccacgtccgt ggcctggggc 25020  
ccgtggggcg agggcggcct ggtcgccgac gacgaagcgg ccgaacaact gcgccgccgc 25080  
ggcctgcccg tcatggcgcc ggagctgtcg atcgccgcc tccagcaggc gctggacggg 25140  
gacgagacgg cggtagcggg ggccgatgtc gactgggacc tgttcgtgcc ggccctcacc 25200  
gccgcccggc cgcgtccgct gatcaccgac ctccccgagg tcgcccgcgc tctggcgga 25260  
gagcaggacg gagccgccac cgcggccggg gaagcggccg gcctcgaagc cgagctgcgg 25320  
gggatgagcg gaaccgaggc ggaggcgctc gtccgaacc tggtcggtac gcaggtcgcc 25380  
gtcgttctcg gacacggggg agcgacggcg gtcgaggcg cccgcgcctt caaggaactg 25440  
ggcttcgact cgtcaccgc ggtcgagctg cgcaaccgcc tcagcaccgc caccggactg 25500  
cggctgcccg cgagcctggt cttcgactac ccgacccgg ccgcactggc cgcgcacatc 25560

cgggcggaac tcctcggcga ggacaccacg cccgaactgc ccgccctcgc ggagatcgac 25620  
aagctggaat tcctcctctc gtcggttccc gaggacacca ccgaacgcgc ccgcgtcacc 25680  
gcacggctcg aatcgctcct gtcgaactgg aacagggcag aacgagcggc catcggagag 25740  
gacgaagaaa tatccatcga atcggcatcc gccgacgacc tcttcgacat catcaacaac 25800  
gaattcggaa aatcctgacc tgatgaccga tccgatgacc gatccgaatt ccgatccaat 25860  
gtccgtatgc attccgcaat tccccaggag gtgacgttcc agtggccagc gcgaacgaag 25920  
aaaagcttct cgaaaacctg aagtggatga ccaatgagct gcggcggggc cgccgtcgcc 25980  
tccatgaggt cgaggcggac gcccaggaa cgcacgcgat cgtcgcgatg agctgccggt 26040  
tccccaacgg ggtgggatcc ccggaggatt tgtggcgccct ggtcgacgag ggccggcgacg 26100  
ccatcaccgg attccccgcc gaccgcggct gggacatcga gtcgctcgcc gatccggacc 26160  
ccgaccgcaa gggcaccttc tacaacaccg gcggcggatt cctcgacggg gccaccgcat 26220  
tcgatcccg attttttcggc atatcgcccc gcgaagcgct cgccatggac ccgcagcagc 26280  
gccagctcct ggagacctcg tgggaggat tgcagcgcgc gggcatcgac ccgcgggccg 26340  
tacgcggcag ccgcaccggc gtctacgtcg gcgcggggcg gatgggggtac ggagccgacc 26400  
tcaaggaagc gccggaaggg ctggaggagac tgctgctgac gcggcgccgc accagcgtcc 26460  
tgtcgggacg ggtcagctac gtgttcggac tggagggccc cgccgccacc gtcgacacgg 26520  
cctgctcctc ctcgctcgtc gccctgcacc tcgccacca ggcctgcgt cagcgcgagt 26580  
gctcgtcgc gctggctcgc ggcgtgtgc tgatgccag cccgatgtg ttcgtcgagt 26640  
tcagccgcca gcgcggcctg tcgcccagc gccgctgcaa gtccttcgcc gcgtccgccc 26700  
acggcaccgg ctggtccgaa ggcgtcgggt tcctcctggt ggagcgctc tccgacgccc 26760  
gtaggaatgg tcatccggtc ctcgcggtgg tgcgtggctc ggccgtcaat caggacggcg 26820  
ccagcaacgg cctgaccgcc cccaacgggc ccgccagca gcgcgtcata cgccaggccc 26880  
tgagaaacgc ccggctgtcg gcggccgagg tcgacgtcgt cgaggccac gccacgggga 26940  
ccacgctcgg cgaccccatc gaggcccagg cactcctcgc gacctacggg caggaccgcc 27000  
ccgagggccg cccctgcgc ctgggggtccc tcaagtcaa catcggtcac acgcaggccg 27060  
ccgcgggtgt cgcgggcatc atcaagatgg tcatggcgat gcggcacggc gtactgccgc 27120  
agaccctcca cgtcgacgag ccgacccga acgtcgactg gaccgcgggc gccgtttccc 27180  
tgctcaccga gccgatgccc tggcccgaga ccggcgcgcc ccgccgcgc gccgtctccg 27240  
cgttcggcgt gagcggcacc aacgcgcaca ccatcatcga acaggcccc gagccggacg 27300  
ccgagtccgt gtccgtgtcc ggctccgcgc ccgcggcggc tcccgccgtc ccgaccctg 27360  
tcccgaccct cgtcccggcg gtccctgcct ggacactctc cggcaggagc accgcggcgc 27420  
tgcgcgccca ggccgcccga cttctcacca cccagggcca ggacggtgcg accgaaccg 27480

ggcgtccctt cgacatcggc tactcactgg ccaccacccg cgcagccctt gagcaccgcg 27540  
cgggtgctcct cgggctgacg gaggacgact ttgccgccgc cctctcggcg ctcgccgagg 27600  
gtgcggagtc cgcaggcctg gtacagggca gggtgaccga gggcgggctg gcgttcctgt 27660  
tcacggggca ggggagtcag cggctgggga tgggccgtga gctgtatgag gcgtatccgg 27720  
tggtcgcgga tgcgctggat gcggtgtgtg cccgtcttga actgcctttg aaggatgttc 27780  
tggtcggggc ggatgcgggt ctgctggacg agaccgcgta cacgcagccg gcgttggttcg 27840  
ccgttgagggt ggcgctgttc cggttggtgg agagctgggg tgtgaagccg gacttcgtgg 27900  
ccgggcattc gatcgggtgag atcgcgcccg cccatgtggc gggggtgttc tcgctggagg 27960  
atgcgtgcgc gctgggtgctg gctcgtgggc gggtgatggg cgcgctgcct gcgggtggcg 28020  
tgatgatcgc ggtccaggcg tcggaggccg aggtcctgcc gctgctgacc gaccgggtga 28080  
gcattgccgc gatcaatggt cccagtcggt tcgtgatcgc gggtgacgag gccgacgcgg 28140  
tggcgatcgc agggctcctt gccgaccgca agtccaagcg gcttacggtc agtcacgcct 28200  
tccactcgcc gcacatggac ggcatgttgg aggacttccg gctcgtggcg gagggcctgt 28260  
cgtacgaggc cccgcgcac cgggtcgtct cgaatctcac cgggtgctctc gtctccgatg 28320  
agatgggctc ggctgagttc tgggtgcggc acgtccgcga ggccgtccgt ttccttgacg 28380  
gcacccggac gctggaagcc gctggcgtga ccaagtacgt cgaactcggc cccgacggcg 28440  
tgctgtcggc gatggcccag gactgcgtga gtggcgaggg ctccgtcttc atccccgtgc 28500  
tccgcaaggc acgccccgag gccgagagcg tcaccaccgc cctcgccacg gccacgtcc 28560  
acggcatccc cgtcgactgg caggcgttct acgccggaac cggcgcccag cgcgtcgacc 28620  
tccccaccta cgccttcag cagagcggt actggctgga gcccgccacc ggcgagccg 28680  
gtgatgtgag cggagccggg ctcgaccggc ccgggcatcc cctgctcggc gcggccgtca 28740  
ccctggccgg ctcgacaggt gtgctgttca ccggtcggct ctcgctccgc acgcagccct 28800  
ggctcgccga ccacaccgtg tccggtacca ccgtgctgcc gggcgccgca ttcgtcgaac 28860  
tcgccgtgcg tgccggtgac caggcaggct gcgagcgggt cgaggcgttg gtgctcgatg 28920  
cgccgctcgc cctgcccgcg gaggcgccg tacgcgtcca ggtgctcgtc gaggcgcccc 28980  
acgagcaggg ccgccgtccc ttcaccgttt cctcccagcc ggagaccgcg ccggccgaca 29040  
ccccctgggg gcggcacgcc cggggcgtgc tcgcgcccac ggcccccgca ccgtcgttcg 29100  
atctggcgca gtggccgccc gccggggccg aggcctgga catcacggac ctctacgcgt 29160  
cccacgacac ccctggcgcg cacgggcccc agcgcggtgg cctgttcctg gccgtggagg 29220  
ccgtctggcg ctgtgacggt gacctcttcg ccgaggtgcg tctgcccag ggcgccccgg 29280  
acgcacaggc cttcggcctg caccggcgcg tgctcgacgc cgccgcgcac gcggcctcgg 29340

tactggacga	gcagcacgga	acgggggacg	ggctggggcac	gtggtccgat	gtgactctgc	29400
acgccgtggg	cgccggcgcc	ctgcgcgtac	ggatacggtc	ggccctcgac	ggcactgtgg	29460
gcctggacct	cgcggacgac	ctgggtgaac	cggtggcgac	cgtgggcggg	ttgactccgc	29520
gacccttcgc	gcaagcgggt	tcaggtggac	aggttgtcca	gcatgacgcg	ctgttccagc	29580
tcgactgggt	gcggtctgcc	ctcgccgacc	gctcgtccgc	tcccaccggg	gagtggggccg	29640
tactcggctc	tgccgacggg	ttcgccgacc	tggaggcgct	gggcgcagcg	gtcgacgcgg	29700
gtgctccccg	accgccgtac	gtcgtcgtcc	ccttggagcg	gcaggccacc	ggcaacgggt	29760
cggacgccct	gcacgaggcc	gtgcaccggg	cgctcgccct	ggtgcggtcc	tggctggacg	29820
accagcgctt	cgagacctcg	cgcctcgtgg	tcctgaccgc	aggcgcggtc	gccggggccc	29880
gcgaaggcgt	cgaggacctg	ccgcatgccg	cggtgtgggg	cctggtgcgt	tcggcggaga	29940
cggagaaccc	cggccgtttc	gttctcgccg	acgtagacgt	agacctcgac	gcggacttgg	30000
gctcaggcgt	gggcctcgcc	gccgtactcg	cctccggtga	gccggagttg	ctgctgcggg	30060
acggagtcgt	acacgcccc	cggctgaacc	gggcccgtac	cgccacctcg	tccgacgccc	30120
ccggcatcga	tccggccgga	accgtcctga	tcaccggtgg	gtccggcacg	ctcgccggta	30180
tcgtcgcccc	gcacctggcc	accgcccacg	gtgtgcggcg	tctgctgctg	ctgagccgca	30240
ggggcgccga	tgcccccggt	gccggtgaac	tgaccgctga	gctggccggg	ttgggcgcgc	30300
aggctctcgt	ggcggcggtg	gacgcgggtg	accgcgacgc	gctcgcgggc	gtactggccg	30360
ccgttccccg	agcgcacccg	ctcaccgcgg	tcgtccacac	ggccggtgtc	ctcgacgacg	30420
gcgtgatcgg	ttcgctcacc	ccggaacgtc	tcgacacggt	ccttcgcccc	aaggccgatg	30480
ccgtctcca	cctgcacgaa	ctgaccgcgg	acctgcccct	gaccgccttc	gtcctcttct	30540
ccgcgatcgc	cggaaccctc	ggcagtgcgg	gtcaggccaa	ctacgcggcc	gccaacgtct	30600
tcctggacgc	tctggcccag	caccgccatg	accaggacct	gccggccacc	tcgctcgccct	30660
ggggcctgtg	ggccgatgcc	agcgggatga	ccggcggcct	cgacgaggcc	cagctgcggc	30720
gcatggagca	gcacggcatg	ggcacgctct	ccgccaccga	cggcattggc	ctgttcgacg	30780
ccgccctcgc	cgccggcccg	ccggtcctcg	tcccggcccc	tctgcacctc	cccggcctgc	30840
gcaatgccgc	cgggcccggc	ccggtggctc	cggtgttccg	gtcgtccttg	ggtgcctcgg	30900
gccgccgggc	cgcgcggacc	cgtaccgacg	gcggcacccc	gctcgccgag	cggctgacct	30960
gcctcgccgg	tcccgaacag	gaccgggcgc	tgctcgatct	cgtacgggca	caggtcgcat	31020
ccgtactcgg	ccacgcctcg	gccgaacagg	tggaccccg	acgcgcgttc	aaggatctgg	31080
gcttcgactc	cctgaccgcc	gtcgagctgc	gcaaccggct	gggcgccgcc	accggactcc	31140
ggctgccgac	cacgctcgtc	ttcgatcatc	cgacgcccac	cgcgctcgtc	cggcacttgc	31200
gtacggacct	tctcggcgcc	gcgccggacc	ccggagccga	cgccccgggc	ctgcccgcgc	31260

gcgtcggcct cgccgacgac ccgatcgcca tcgtggccat gagctgccgc taccgccggc 31320  
 gtgtccgcac ccccgaggag ctgtggcggc tcgtcgagac cggcggcgac gcgatcgccg 31380  
 gactcccggg caaccggggg tgggacaccg acgcgttgca cgccgacgag gacggccgga 31440  
 ccttcgcggg cggtctctctg tacgacgccg actcgttcga cgcggaactt ttcggcatct 31500  
 cgccgcgcga ggcgctcgcc atggaccgcg agcagcgact gctgctcgaa acctcctggg 31560  
 aggcgatcga gcgcgccggg atcgaccctg cgtcgtcgcg cggcagccgg gccggtgtct 31620  
 tcgtcggcgc cgcctacagc ggctacgacg cgcaattgga gcagtccgga gtggacggtg 31680  
 tcctcggcca tgtgatgacc ggcaatgcgg gcagtgtcat gtccggccgt gtgtcctacg 31740  
 cgctgggcct ggaggggtccg gcggtcacgg tcgacacggc gtgctcgtcc tcgctggctg 31800  
 ccctgcactg ggcgatccag gccctgcgca acggcgaatg ctcgctggcg ctcgccggtg 31860  
 gtgtgacggg gatgtcgacc ccgggcacct tcagcgagtt cagccagcag ggcggcctgt 31920  
 caccggacgg ccggtgcaag gcgttcgcgt cggccgcgga cggtacgggc tgggggtgagg 31980  
 gtgtcgggat gctgctgggt gagcggctgt ccgatgcccg taggaatggg catccggttc 32040  
 tggcgggtgt gcgtgggttcg gctgtcaatc aggacgggtc gagcaatggg ctgacggctc 32100  
 cgaatgggtc ttcgcagcag cgggtgatcc gtgcggcggt ggcgagtgcg ggtctgtcgg 32160  
 ccgctgatgt ggatgtgggt gaggcgcacg gtacggggac gaagctgggt gaccgatcg 32220  
 aggcgcaggc gctgctggcg acgtacgggc aggaccggcc cgatggccgt ccgctgtggt 32280  
 tgggttccat caagtccaac atcggtcaca cgcaggccgc cgccggtgtc gcgggcatca 32340  
 tcaagatggg catggcgatg cggcacgggg tgctgccccg gaccctgcac gtcgacgagc 32400  
 cgacctcgca tgtggactgg tcggcggggc aggtgtccct gctgtcggag tcggccgaat 32460  
 ggccgctcac cgagcggccc cggcgagccg gagtgtcgtc cttcggcatc agcggcacca 32520  
 acgcccacac catcatcgag caggcgccgg agaccgggac cgaggcggag ccgtcggcgg 32580  
 agaccctcac gcacgggacc gtgccctacg tcctctccgc caagagctcc gacgctctcc 32640  
 gcgcccgaag gcggcagctg cttgccgtgg tggaagccgc cgagagcccc cgagtccggc 32700  
 atctggccta ctcgttggtc accagtcggg ccggtctcga tcaccgcgcg gcgctcgtcg 32760  
 ccgacgaccg ggagaacctg acgcgggcgc tcgcggccct ggcgggcgac gagcaggtgc 32820  
 ccggcctggt gcggggcacg gccaccgggt gcggcctcgc cttcctgttc acggggcagg 32880  
 ggagtcagcg gctggggatg ggccgggagc tgtacgagac gtatcccgtc ttcgcgcggg 32940  
 ctctcgacgc ggtggacgca cgcctggaac tgcccatgaa ggaggtgctg ttcggcgcgg 33000  
 acgcggatct gctgaacgag accgcccaca cgcagccggc tctcttcgcc gtcgaggtgg 33060  
 cgctgttccg tctgctggag tcgtggggcg tgccggccga cgtcctggcc gggcactcga 33120

tcggtgagat cgccgcggcc catgtggccg ggggtgttctc cctggacgat gcgtgcacgc 33180  
 tggtcgagggc tcgcggtcgg ctcatgcagg cgctgccgac cggcggcgtg atgatcgccg 33240  
 tccaggcgtc ggaggacgaa gtccctgccgc tgctgaccgg ccagggtgagc attgccgcga 33300  
 tcaacggccc ccagtcggtc gtcacgcggc gcgacgaggc cgacgcggtc gcgatcgccg 33360  
 agtccttcac cgaccgcaag tccaagcggc tcaccgtcag ccacgccttc cactcgcccc 33420  
 acatggacgg catgctcgcc gacttccgca aggtcgccga gggcctcgtc tacgagaacc 33480  
 cgcgcatccc catcgtctcg aacctcaccg gcactctcgt caccgacgag atggcttcgg 33540  
 ccgacttctg ggtccgccac gtccgcgagg ccgtccgttt cctcgacggc atccgcgcgc 33600  
 tggagagccg cggggtcacc acctacatcg aactcggccc cgacggggtc ctctccgccc 33660  
 tcgcccagga ctgcctcacc gccgggaccg ggaccgggac cgcgatcttc gctcccgtac 33720  
 tccgggcggc ccgtcccag gccgagagcg tcaccaccgc cctcgccacg gcacacgtcc 33780  
 acggcacccc cgtcgactgg cgggcgtact tcgccgggac cggtgcccgg cgcgccgacc 33840  
 tccccaccta ccccttcag ggcaggcgct actggcccga agccgccgcc ccgagcggtg 33900  
 cggcggccgg actcggggac caggcggtcg acgcgcgctt ctgggacgcg gtcgagcggg 33960  
 cggacctggg ctccctgata ggtgggcccg agatcgacgg ggaccagccg ctcaactccg 34020  
 tactgcccgc cctctccgac tggcggcgca accagcaggc gcagtcgcag gcggacgccc 34080  
 ggctctaccg catcgcgtgg cagccgtggg ccggggcccg ccggggcaca cccgcgggta 34140  
 cctggctggg ggccgtgccg gcgccgtacg cggacgatcc gtgggtccgt gcgctgaccg 34200  
 accgcatggc cgagggtggc gcggaggtcg taccgctcac gctcgatgtc gccgacagcg 34260  
 acccggcgtc gctgcgcgcc cggtggacg agcggctgcg cgaggcggtg ggcgacggcc 34320  
 cggtgggccg tgctcctgtc ctgctcgcgc tggacgagcg gcccacccc gaccacccga 34380  
 gcgtgcccgt aggactggcc ctcaccagcg ccctcacctc cgtgctcacc ccggtgctca 34440  
 cggaaaccgga cccggaaggc ggggcgagcg gaggcacga agcaccgctg tgggtgtgtca 34500  
 cgcgtagcgc cgtcgcggca gccgggtggg acgaactcgg cggcgccgcc caggcgcagg 34560  
 tctggggcct cggccgcgtc gtgcacctgg agcaccgccga ccgctggggc ggtctcgtcg 34620  
 acctcccggc ggtatgcgac gaccgggtcc tgtcccggct gatggcggtg ctgcaggat 34680  
 ccggtgacga ggaccaggtg gcggtcctga cctccggcac cctcgtagca cggctcctgc 34740  
 gggccgcccc gacgagcgtg ccgtccgcac cctggacccc gcgcggcacg gtgctcgtca 34800  
 ccggcgggcac gggcgccctc ggccgccatg tggcgcgcca cctcgccgag cggggcgccc 34860  
 aacggctcgt gctcgtcagc cgccggggcg ccgacgcgcc cggtgccggc gagaccgagg 34920  
 cggaaactctc cgcgttcggc ggggcgtga ccctcgtggc ctgcgacgtc gccgaccgcg 34980  
 atgcgctcgg aacgctcgtc gcgcggctcg ccgccgacgg cactccggtc cgtgccgtgg 35040

tgcacgccgc cgggtgtctcg cagccgccag gtacgggaac ggacctcccc gggttcgccc 35100  
 gtgtcgtggc cgcaagacg gcgggagccg tccacctcga cgcgctgttc gacgcgccgg 35160  
 actccctcga cgcgttcgtc ctcttctcct ccatcgccgg tgtctggggc agtggcgggc 35220  
 aaggggccta ctccgccgc aacaccttcc tcgacacgct cgccgaacgg cgccggggccc 35280  
 gcggtctcgc cgccacggcg atcgccctggg gaccgtggggc cgacggcggc atggccaccg 35340  
 agggcgacgc ggaggagcag ctgagccgac gcggcctgcc gcccatggac cgggcgacga 35400  
 acctgctggc gctggagcgt gccgtcgcg gccgggaggc ggcgctgacc gtcgccgacg 35460  
 tcgactgggc gcgcttcgca cccgtgttcg ccgcggcccg ccccgcccg ctcacggtcg 35520  
 acctgcccga ggtacgggac gactgcgcg gggacacccc ggccggggaa ggaccggccg 35580  
 agaccgcttc ctccgccgta ctccggaggc tgacggaaact caccggggcg gaccgggaaa 35640  
 cgccctcct cgacctcgtg cgcgagcacg cggcaacggc cctggggccac acgtccgccc 35700  
 acgcggtcgc ggccgaacgg gccttcaagg acctcggtt cgactcgctc accgcagtcg 35760  
 aactgcgcaa ccgcctcggc gccgcgtgcg gcctgcggct gccctccagc ctgctcttcg 35820  
 actaccccaa ccgcgaggcg ctcacccggc acctgctgca caccctcttc cccgaagggg 35880  
 cgggcgggcc ggacgtaccg gctctggaca ccgaccccca ggaagcggaa ctgcgccgga 35940  
 cgctcgccgc catcccgctg ggccggatcc gcgaggcagg gctcctggac acgctgctcc 36000  
 ggctcgccgg acccgacacc cccgctccc ccacgagtac cgccgacgag agcgagtcca 36060  
 tcgacacgat ggatctccag gacctcctcg acctggcgct cgacggcggc ggcgatcccc 36120  
 acggcctcaa cggcctcgac agcctcgacg gcccagtggt caacgacaac gacagcaacc 36180  
 gattctgacg tgcccgaagt gcggagtaag tgatgacaac cccaacgaa aaagtctgtg 36240  
 aagcgctgcg ggcctccctc aaggaaaccg agcggctgcg ccgccggaac caggagctca 36300  
 ccgacgccgc gcgcgagccc atcgcgatcg tcggcatgag ctgccgcttc ccggcgggag 36360  
 tcagctcgcc cgaggacctg tggagactcg tcgagagcgg tggcgacgcc atctcgggct 36420  
 tccccgtcaa ccgcggctgg gacatcgagt cgctgtacga ccccgatccg gaccacgagg 36480  
 gcaccaccta cgcccgcgac ggcggtcttc tccacgaggc ggccgacttc gaccccgct 36540  
 tcttcgggat ctccccgcgc gaggccctcg ccatggaccc gcagcagcgg ctgctcctgg 36600  
 agaccacctg ggaggtcttc gaacgagccg gaatcgatcc cgcgtcgctg cgcggcagcc 36660  
 gggccggcgt ctctgctggc gcgtccgcca acgcctacgg agccggctcc cacgaccttc 36720  
 ccgacggcgt ggaggacac ctctcaccg gcaccgcgtc cagtgtcctg tccggccggc 36780  
 tcgcctacgt cttcggcctg gaggggcccc ccgccaccat cgacacggcg tgctcgtcct 36840  
 cctccgtcgc cctgcacatg gccgtccagg cgctgcgcca gggcgagtgc tcgctcgcg 36900



tggccgcggg cgtcaccgtc ctgcggggcc cggacgtctt cgtcgagttc agccgccagc 36960  
gcggcctgtc gcccagcggc cgctgccggt ccttcgccga gtcggccgac ggcaccggct 37020  
ggtcggaggg cgccggcgtc ctcttggtgg agcgcctctc cgacgcccgc cgcaacggcc 37080  
accacatcct cgccgtggtc cgcggtctcg ccgtcaacca ggacggcgcc agcaacggcc 37140  
tgaccgcccc caacggggccc gccagcaga aggtcatccg ccaggccctg gagagcgccc 37200  
ggctgacccc cgcgggacatc gacgcggtcg agggccacgg caccggcacg accctcggcg 37260  
accccatcga ggcgcaggcg ctcttcgcca cctacgggca agggcgcacg gacggccggc 37320  
cgctgtgggt cggctccttg aagtccaacc tcggccacac ccagaacgcc gccggtgtcg 37380  
ccggcatcat caagatgggt atggcgatgc ggcacgggggt gctgccccgg accctgcacg 37440  
tcgacgagcc cacctcgac gtcgactggt cgacggggcg ggtggcgctg ctgaccgagc 37500  
cgggtggagt gccggagacc gggcgcccgc gccgggtcgg cgtctccgcc ttcggcgta 37560  
gcggcacgaa tgtgcacacg atcatcgagc agggccccgc cctgccccg gccccgctg 37620  
cggacgacac atcggaaccg gcgcccgcgc cccggccgaa ggcgctgccc tggctcctct 37680  
ccgcgaaggg ccgggacgcc ctgcgcgacc gggccgcaca gctgctcgcg tacgccgagg 37740  
aacaccccga cctgcggccg gtcgacatcg ccgggtcgtt ggcgggtgggc aggcctcct 37800  
tcgaggaccg cgccgcggtg gtcgcccgc accgcgaggg gctgctggcc ggcctcgcgg 37860  
cactggcgga cgccggctcg gcgacgggtc tcgtcaaggg gtcgtcgag ctctgtggga 37920  
agctggcggt cctgttcacc gggcagggga gccagcggct ggggatgggc cgtgagctgt 37980  
acgagacgta tcccgctctt gcgcaggcct tggacgcggt gtgtgagcgg ctggaactac 38040  
ccctgaagaa cgtgctgttc gggacggaca gcgctgcgt ggacgagacc tcgtacacgc 38100  
agcctgctct cttcgccgtt gaggtggcgt tgttcgggt cgtggagagc tggggcctga 38160  
agccggactt cctggccggg cattcgatcg gtgagatcg gcccgcgcat gtggccgggg 38220  
tgttctcgct ggacgacgcg tgccgcgtgg tgcggctcg cgcccggtt atgggggcgc 38280  
tgccgggcgg tggcgtgatg atcgcggtcc aggcgtcgga ggacgaggtc ctgccgctgc 38340  
tgaccgatcg cgtgagcatt gcccgatca acggtccgca gtcggtcgtg atcgcggtg 38400  
acgaagccga tgcggtagcc atcgccgagt ccttcgcgga ccgcaagtcc aagcggctca 38460  
cggtcagtca cgcgttccat tcgccgcaca tggacggcat gttggaggac ttccgggtcg 38520  
tggcggaggg tctgtcgta gaggtccgc gcatcccgtt cgtctcgaa ctcaccggcg 38580  
ctctcgtctc cgacgagatg ggctcggccg acttctgggt ccgccacgtc cgcgagaccg 38640  
tccgcttcc tggacggtatc cgcaccctgg aagccgctgg cgtcaccaag tacgtcgaa 38700  
tcggccccga cggcgtgctg tccgccctgg ccaggactg cgtgagcggc gaggactccg 38760  
tcttcatccc tgtactccgc aaggcacgcc ccaggccga gacggtcgcc accgccctcg 38820

cctcggccca cgtccacggc atccccgtcg actggcgggc gtacttcgcc gggaccggcg 38880  
cccagcgcgt agacctcccc acctaccct tccagcgcca gcgctactgg atcgagccgg 38940  
gcggccgtgc cggagacgtg ggcgcggccg ggctggagga ggcggggcat ccgctgctgg 39000  
gtgcggccgt accgctcgcc gactccgagg gcttctctt caccggggcg ctcggtcgca 39060  
cctcgcaccc ctggctggcc gatcacgcgg tcatggacac cgttctgctc cccggcacgg 39120  
ccttcgtcga cctcgcgggt gcgcgcgggt accaggctcg atgcgatgtc gtcgaggagc 39180  
tgacgctgga agcgcgcgtg gtgctgccc agcgcgggtc cgtccagata cagatgcacg 39240  
tcggcgcgcc cgacgcggac ggtacgggac ggcggaagtt caccctgtcc tcgctacgc 39300  
aggacggcgc ggccgacgaa ccgtggacgc ggcacgcggc cggcgctctc gcgcacggcg 39360  
cggcgcaacc ggccttcgcg ccgggtccagt ggcggcgccg gggcgccgag ccgatcccga 39420  
cggagagcct gtacgcggac ctggccgagg tcggcatggg atacggacct gcgttcgcg 39480  
gcctcacggc cgcctggcg cagggcgaga gcgtctacgt cgaggtcgcg ctccccgagg 39540  
aaaccgcctc cacggcacgg gacttcggcc tgcacccgc cctcctggac gcggcgctgc 39600  
acgcgctggg tctcggcgta ctgggtggcg tcgaggggtga agggcggtc ccttcgctg 39660  
ggagcgggtg gaccctgcac gcggccggag cggacgcgct gcgcgtgcac ctcgctccgg 39720  
cgggcgcca cggcgctacgc ctggagatcg cggacgcgcg gggcgcacct gtcgcgaccg 39780  
tcgactcgct cgtcctgcgg accgtatcgg aggagcagg acgcgcgcg cgacccgct 39840  
accacgagtc ggtgttcgcg gcggagtga cggccctgcc gaccgccgcc gaatccgcg 39900  
ccacgcatgg ccgttgggccc gtgctgggag cggcggaagc gggcgattcg ccgcgcgacg 39960  
cgctggtgaa cgggctgctc ggcacactgc ccggcgaggt cgcgcgctac gccgacctgg 40020  
ccgagctggc ggcggccgct gagggcggag cggccacgcc ggacgccgtg ttcgccgct 40080  
acgcgcggtc cgatgacgac ggaccggccg caccggacgt gtccgcaccg gacgtgtccg 40140  
cgcaggcggg gcacgcggcc accacgacg ccctcgact cgtccagacg tggttcgggtg 40200  
aggagccctt cgcgggggac cggttcgccg ccaccgcct ggtcgtgctc acccgggggc 40260  
cggtcgcgcc gggcgacggc gacacggtca ccgacccgc acacgcggcc gtctggggtc 40320  
tgctgcgctc cgcgcagtc gagtaccocg accggctgct gctgatcgac accgacgggg 40380  
tcgaggactc cgtacacgcc ctgcccgcg tgctcgccgt cggagagccg caactcgccc 40440  
tgcggtgcagg ctccgtacac gcgctccggc tcgcccgcgt ggcgcgcg acgcccggagg 40500  
acgcgcgcgc tccgacgcag tacgcgcgc gatcgacggg gctgatcacc ggcgcggggc 40560  
gcatgctcgg cggctctgat gcccgccgct tcgtcgccga acacggcgta cggcacctgc 40620  
tgctgggtgg cgcgcgcggc gccgcgcctc ccggagcgga acagctgagc gccgaactgg 40680

ccgaggcgagg cgcctcgggtg acctggggccg cgtgcgacgt cgccgaccgg gacgccctct 40740  
cgcccggtact gcacgcgata cccgcccagc acccgctcgg cgcggtcgtc cacaccgctg 40800  
gtgtgctgga cgacgggtgtg atcgccctcac tgacccccga gcggctctcg gccgtgctgc 40860  
gccccaaaggc cgacgcccgc tgcaacctcc acgagctgac ccggcacctc gacctcacgg 40920  
cgttcgtgct cttctcctcc atcgggcgggc tcttcggcgg cccgggacag ggcaactacg 40980  
cgggcgcgaa cgtgttcctc gacgcactcg cccagcaccg ccgctcccag ggactcgccg 41040  
ccacctccct ggcttggggc ctgtggggcc acagcacggg catggccggc agcctcgacg 41100  
aggccgacat cagccggatg cgggcgggcg gcctgcccc gctgaccacg gccgagggcc 41160  
tggaactgtt cgacctcgcc caccgcatcg acgaggccgc accggctcctg atgcgcgccc 41220  
acctgaccgc cctgcgcacg caggcccagg ccggcacgat gtcgccgctg ctgcgcggtc 41280  
tcgtacgggt ccccgcgcg cgcagcgcca gtggcgcggc cggtagggg ggtgagtccg 41340  
gactgcgcga gcgcctcgcc ggactctcgg ccgccgaacg ggaccgtacg ctgctcgacc 41400  
tcgtccgcaa gcaggtcgcc gcggccctcg gctacccccg accctccgcc gtcgagcccg 41460  
gccgctcctt caaggaactc ggcttcgact cgctcaccgc cgtcgaactg cgcaacctgc 41520  
tcggcgacgc caccggccgc cgctccccg ccacctcgt cttcgactac ccgacggcga 41580  
ccgccctcgc cgggtacctc cgcgaggaga tcatcgga cctggcgga gccgtcaccg 41640  
ccccggccct cgtgccgtcc gcggccgtgg cgggcgcggg cgcgggcgcg gacgacgacg 41700  
atccgatcgc gatcgtcgcc atgagctgcc ggttccccg agggatcgca tccccgagg 41760  
acctgtggca gctgctcgtc accggccgcg acggcatcac gggcttcccg gcggaccgtg 41820  
gctgggacct cgacagcctc tacagcgacg accccgaccg cgagggcacg agctacgcc 41880  
gcgagggcgg attcctgcac gaggccgcgg agttcgacgc ctcttcttc gggatctcgc 41940  
cgcgcgaggc cctcgccatg gacccgcagc agcggtgct cctggagacc acctgggaga 42000  
cgttcgagcg cgcgggcatc gacccgacca gcctgcgcgg cagccggacc ggctgttctg 42060  
tcggctccaa cgcccaggac tacctccagc tctgggtgaa cgacgaggac ggcttcgaag 42120  
gacacctggg caccggcaac gcggccagcg tcgtctccgg ccgcctctcc tacacctcg 42180  
gcctggaggg ccggcccgtc acggtcgaca cggcctgctc gtcctccctc gtcacctgc 42240  
acctggccgc ccaggccctg cgccgcggcg agtgctccat ggcgctcgcc ggcgcggta 42300  
ccatcatgtc cagcccggc gcgttcaccg agttcagccg ccagcgcgga ctcgccgcgg 42360  
acggccgcat caaggcgttc gccgcgcgg ccgacggcac gagctgggtc gaaggcgtcg 42420  
gcctgctgct cgtcgagcgg ctctcgagc caccggcga cggtcacccg gttctggcgg 42480  
tggtgcgggg caccgcccgc aaccaggacg gcgcgagcaa cggcctgacc gcgccgaacg 42540  
gcccgtccca gcagcgcgtc atccgcgagg cgctggccga cgcgggcctg tcggccgcgg 42600

agggtggatgc ggtcagaggcc cacggcaccg gcacgaccct cggcgacccc atcgaggcgc 42660  
aggcgctcct cgccacgtac ggccagggcc gcccgacga ccagccgctg tggctcggct 42720  
ccgtgaagtc caacatcggc cacaccagc ccgtggccgg agccgccggc atcatcaaga 42780  
tggtcatggc gatgcgccac ggcgtactgc cgcagaccct gcacatcgac gagccgacgc 42840  
cgtacgtgga ctggtcggcg ggcgacatcg ccctgctgac cgagcagcgg gcgtggccgg 42900  
agaccggccg cccgcgcagg gcgggcgtct cctcgttcgg ctacagcggg accaacgcgc 42960  
acgccgtcat cgagcaggca ccgcagaac cgatggagcg gaccccgag ggcgacaacc 43020  
tgccggcccc cacccccgcg acgcggaccc tcccggtgct gccgctgctc gtctccggcc 43080  
gcacggcgcc ggccctgcga gccagggcg aacgcctgcg accggccgcg accgccctcg 43140  
cgacgggcac ggtaacgaac tccggagctt tggaagcact cgacctgggc tactccctgg 43200  
ccacgagccg cgccgcactg gaacaccggg cggtcctgat cggcaccgag tcggacggcc 43260  
aggcactggc ctgcgcactc gacgccctgg cggcgggcca gcaggtgccc ggccctggcg 43320  
agggcacggc ttccggtgcc gggctcgcct tcctgttcac gggacagggg agccagcggc 43380  
tggggatggg gcgcgagctg tacgagacgt acccgggtgt cgcggaggcg ttggatgcgg 43440  
tgtgcgcccc gctcgaactg cctttgaagg aggtgctgtt cggggcggat ggcgctgcgc 43500  
tggtatcgac ggcggtgaca cagccggccc tcttcgccat tgaggtggcg ttgttcgggc 43560  
tggtcagtc gtggggtctg aggcgggact ttgtggcggg tcattcgatt ggtgagatcg 43620  
ccgctgcgca tgtggcgggg gtgttctcgc tggaggacgc ctgcaggttg gtcgaggcgc 43680  
gtgggcgtct tatgcaggcg ctgcctgggt gtggcgatgat gatcgcggtc caggcgctcg 43740  
aggatgaagt cctgccgttg ctgaccgatc gcgtgagcat tgccgcgatc aatggtccgc 43800  
agtcgggtgg gatcgcggtg gacgaggccg acgcggtggt catcgcgag tccttcacgg 43860  
gccgcaagtc gaagcatctg gcggtcagcc acgcgttcca ttccgcgcac atggacggca 43920  
tggttgagga cttccggggc gtggcggagg gcctgtcgta cgaggctccg cgtattgcgg 43980  
tggtgtcgaa tctgacgggt gcgttggtct ccgacgagat gtcgtcggct gagttctggg 44040  
tgcgatcatgt ccgtgaggcg gttcgccttc tggacgggat tcgggctttg gaggctgctg 44100  
gggttacgac gtatgtcgag cttggccctg ggggtgtgct gtcggcgctg gcgcaggagt 44160  
gtgtcagtgg ggacgggtgt gctttcgtgc cgggtgctgc ttctggacgt tccgaggccg 44220  
agaccgtggg gaccgcgctg gctcaggcgc atgtgcgggg tgtggaggte gactgggcgg 44280  
cgttcttcgc cgggaccggg gctgagcggg tcgatctgcc gacgtacgcc ttccagcgcc 44340  
agcgctactg gccggagacc gtgctgtcga ccgtggggcc ggtcgttgcc gaggccgtcg 44400  
atgcgggtgga cggccgggtc tgggatgcgg tggagcggga ggatctcgcg tcgcttgctg 44460

cagagctgga cgtggacgag acgcctctcg gcgaggtcgt tcccgcgctg tcggcgtggc 44520  
gtcgggagcg gcgtgcccag tcggaggtgg acggttggcg ctaccgggtg tcgtggaagc 44580  
cgctggctga tgcttcgacg gcgcggttgt ccggtcttgg ggtggtggtg tcgcccata 44640  
aggggtgtgga tgactcggct gtggtcgccg gtctggctgg gcgtggtgct gaggtccgtc 44700  
gggttgtggt cgaggcgggt gtggaccgtt cggcgctggc tgggttgctg gccgatgcgg 44760  
gttctgctgc ggggtgtggt tcgcttctcg ggctggatga gtctgagggg ctgctgggga 44820  
ctgttggttt ggtgcaggcg ttgggtgatg ccgggggtgga ggcgccgttg tggcgctga 44880  
cccgtggctg tgtctccgtc ggtcgttcgg atcggttgt gtcccggtg caggcgcagg 44940  
tgtggggtct gggccgggtt gccgccctgg aggttccgga gcattggggc gggctggttg 45000  
acctgccgga agtgctggat gagcgggtg tggcccgctt ggtcgggtg cttgcgggtt 45060  
ccggcgaaga tcaggtcgcg gtctgttcgt ctggtgtgtt cggtcgtcgt ttggtgcgtg 45120  
caccgcgggc cgagggtgct gcggcgtgga caccgaccgg cactgttctt gtcaccggtg 45180  
gtacgggtgt gctgggtggc cgggtggcgc gttggctggc gggggcgggc gctgagcgtc 45240  
tgggtgctgac cagtcgtcgt ggtccggatg ctccgggtgc ggctgagctg gtggaagagc 45300  
tgaccaccgg cttcgggggtg gaggtttcga tcgtcgctg tgacggggt gaccgtgacg 45360  
ccctgcgcgc cctgctctcc gctgaggccg ggactctgac cgctgtgatc cacacggccg 45420  
gtgtcctgga cgacggcgct ctcgacgcac tcaccccgga ccgcatcgac agcgttctgc 45480  
gcgccaaggc cgtctcggca ctcaacctgc acgaactgac ggccgagctt gatatcgagc 45540  
tgtccgcctt cgtcctcttc tcgtcgatga gtggcacggt ggggtgcggc ggtcaggcca 45600  
actacgcggc cgccaacgcc ttcttggtatg ccctggccga gcagcggcgc gccgatggtc 45660  
tcgcggcgac ctcgctcgct tgggggtcgt gggcggaagg cggcatggcc gccgatgcgg 45720  
cgctcgaagc ccgtatgcgc cgcggcggag taccgcccatt ggacgcggag cttgcccttt 45780  
cggctcttcg gcaggccatc ggttccgcgc atgcgcctct gaccatcgtg gacttogact 45840  
gggcacggtt cgcgcgggc ttacccgcgc tgcgagccgg caacctgctc gccgaactgc 45900  
ccgaggcggc ggccgtcatg cgcggcccg agaacgcgga cagccgcccg gaacacgcgc 45960  
actcgtcgct cgccttgagg cttcagggca tggcccaggc cgaccaggag ctttctcttc 46020  
tgagctcgt gcgtgcacag gtcgcccagg tgcgggaca ctccggcgcc gaggacatcg 46080  
aggcgggacg cgcgttcagg gagatcggct tcgactcgct gaccgccgtc gagctgcgca 46140  
accgcctcgg ggcggctgcc gagctgcggc tcccgccac gctcgtctac gactaccgga 46200  
caccggcggc cctcgccgtc cacctccgta ccgaactgct cggcaagcag gtcgtcgtgt 46260  
ccggtccggt ctccaaggtc gttgacgacg atccgatcgc gatcgtctcg atgagctgcc 46320  
gcttcccgg tggcgtgcgg accccggaag acctgtggga actgctgtcc accggcggcg 46380

acgccatctc ggatcttccc ctggaccgtg gctgggacat cgacgcgctg tacgacgccg 46440  
 atcccagcac acagggcact tcgtacgccc gcgcgggtgg cttcctctac gacgccgccg 46500  
 acttcgacgc ggacttcttc gggatctcgc cgcgcgaggc cctcgccatg gacccccagc 46560  
 agcgactgct cctggagacg tcctgggaag ccttcgagcg ggcgggcatc gacccccaga 46620  
 cgctccgggg cagccaggcc ggtgtcttcg tcggcaccaa cggccaggac tacctctccg 46680  
 tactgctgga ggagcccga ggctcgaag gccacttggg caccggcaac gcggcgagcg 46740  
 tcgtctccgg tcggctctcg tacgtgttcg gcctggaggg tccggcggtc acggtcgaca 46800  
 cggcgtgctc gtcctcgttg gtcgccctgc actgggcgat ccaggccctg cgcaacggcg 46860  
 aatgctcgct ggcgctcgcc ggtggtgtga cggatgatgc gacccccggc accttcatcg 46920  
 agttcagccg tcagcgtggg ctgcgcgagg acggccgtat caaggcggtc gcggcgcccg 46980  
 cggacggtac gggctggggc gagggcgctc gcatgctcct ggtggagcgg ctgtccgacg 47040  
 ccgagcggaa cgggcacccg gtccctggca tcgtgcgggg ctccggcgatc aaccaggacg 47100  
 gtgcgagcaa cggcctcacc gcccctaag gccctcgcga gcagcgcgctg atccgtgcgg 47160  
 cgctggcgag cgcgggtctg tccgcgcgcg acgtggacgc ggtcgaggcg cacggcaccg 47220  
 gtacgacgct gggcgacccg atcgaggcgc aggccttgcg gccacgtac gggcaggacc 47280  
 gcccggccga ccggcctctg cagctcggtt ccatcaagtc caacatcggg cacacgcagg 47340  
 ccgcggccgg tgtcgccgga gtgatcaaga tgggtgctggc catggagcac ggcgtgctcc 47400  
 cgcagagcct ccacatcgac gcaccgtcac cgcaggtcga ctgggaagcc ggtgacatcg 47460  
 cgctgctcac cgagcagcgg cagtggccgg agaccggacg tccccgccgg gcagggtgtgt 47520  
 cgtcgttcgg cttcagtggc accaacgctc acaccatcat cgagcaggca ccggcgctga 47580  
 cggagaccga ccgggcccga tccggctcgg tgaaccgga cttcgttccc ctgatgctct 47640  
 cggcgaagag cgacgtcgca ctccggggcc aggcgcgaag cctgcgcgca cggctgatcg 47700  
 ccgccccga catgcgcctg tccgacgtcg gctccacgct gacgaccggc cgctcggcgt 47760  
 tcgagcgccg ggcggcgctg gtggcagggg gccgcgaggg gctgctcgcg gggcttgagg 47820  
 cactggcgga cggcggttcg gcggcagggc tgggtgaagg ttccgccgtg agtggaagc 47880  
 tggcgcttct gttcacgggg caggggagtc agcgtctggg catgggccgt gagctgtacg 47940  
 aggcgtatcc ggtgttcgcg gatgcgctgg atgcggtgtg tgtccgtctt gaactgccct 48000  
 tgatggatgt gctgttcggg gcggatgcgg gtctgctgaa cgagaccgcg tacaccagc 48060  
 cggcgctctt cgccgttgag gtggcgttgt tccggctggg ggagagctgg ggtctgaggc 48120  
 cggacttcct ggcgggtcat tcgatcggtg agatcgcggc cgcgcatgtg gccggggtgc 48180  
 tgtccctgga cgatgcctgt gctctggtgg aggctcgggg gcggttgatg ggtgcgctgc 48240

ctgcgggtgg cgtgatgatc gcggtgcagg cgtcggagga cgaggtcctg ccgctgctga 48300  
cggaccgcgt gagcattgcc gcgatcaatg gtcctcagtc ggtggtgatc gcgggcgacg 48360  
aagccgacgc ggtcgcgatc gtggagtcgt tcacggggcg taagtcgaag cggctatcgg 48420  
tgagtcacgc gttccattcg ccgcacatgg acggcatgtt ggaggacttc cgggtcgtgg 48480  
cggagggcct gtcgtacgac gccccgcgca tccccgtcgt ctgaaacctc accggcgctc 48540  
tggtcaccga cgagatgggt tcggcggact tctgggtccg gcacgtccgc gaggccgttc 48600  
gcttcctgga cggcatccgg gccctggagg ccgcgggcgt gacgacgtac gtcgaactcg 48660  
gccccgacgg tgttctgtcg gcgatggccc aggagtgtgt gaccgaaggt ggagcggcgt 48720  
tcgttcccgt cctgcggaag gggcggcccc aggccgagac ggtgatggcc acccttggcc 48780  
aggcacacgt caggggcgtc gcggtcgact ggcattcggc ctacgggacc ggtgcccagc 48840  
gggtcgatct gccgacctac tccttcacgc gacagcggta ctggccggcg gcgtcttcga 48900  
cggcaggtgg ttcggtcgac aggagcgtcg atgcggtgga cggccgggtc tgggatgcgg 48960  
tggagcggga ggatctcgcg tcgctggccg cggagctgga cctggacgac gacgtccct 49020  
tcagtgaact ggcccccgcg ctgtcggcgt ggccggcgga gcggcggtgc ctgtcggagg 49080  
tggatggctg gcgctatcgg gtgtcgtgga agccgctggc ggatgtctcg gcgtcgggg 49140  
tgtccggctc ttgggtgggt atctcgctg ctgggggtgt ggacgactcg gctgtgggtg 49200  
gtgcgctggt tgggcgtggt gctgaggtcc gtcgggttgt ggtcgaggcg ggtgtggatc 49260  
gttcggcgct ggctgggttg ctggccgatg cgggttctgc tgcgggtgtg gtgtcgcttc 49320  
tcgggctgga tgagtctgag gggctgctgg ggaactgttg tttgggtgcag gcgttgggtg 49380  
atgccggggg ggaggcgccg ttgtggtgcc tgaccgctgg tgcgtctctc gtcggctggt 49440  
cggatcggct tgtgtcgccg gttcaggcgc aggtgtgggg tttggggcgg gttgccgccc 49500  
tggaggctcc cgagcgtgg ggccggctca tcgatctgcc tgagggtgct gatgagcggg 49560  
ctgtgtcccg tctggtcggt gtgcttctcg gtggtggttc tggtaggat caggttgcgg 49620  
ttcgttcgtc ggggtgtgtc ggtcgtcgtc tgggtcgtgc accgcgggct gagggggctt 49680  
cggcgtggtc tccgaccggc acggttcttg tcaccggtgg tacgggtgtg ctgggtggcc 49740  
gggtggcgcg ttggctggcc ggggcgggtg ctgagcgtct ggtgctgacc agtcgtcgtg 49800  
gtccggatgc tccgggtgcg gctgagctgg tcgaggaact ggccgggtcg ggggtcgagg 49860  
tttcggctgt cgcgtgtgat gcggccgacc gtgacgtctc gcgcgccctg ctctccgccc 49920  
aggccgggac tctgaccgct gtgatccaca cggccggagt tctggacgac ggcgtcctcg 49980  
acgcgtcac cccggaccgc atcgacagcg ttctgcgcgc caaggcagtc tcggccatca 50040  
acctgcacga actgacggcc gagctcggca tcgaactctc cgccttcgtc ctcttctctc 50100  
ccgtcacagg cacctggggt acggcggggc aagccaacta cgcggctgcc aacgcctacc 50160

tggatgctct ggccgagcag cggcgcgccg acggcctcgc ggcgacgtcc atcgcggtggg 50220  
gtccgtgggc cgagggcggc atggccgccc atgcggcact cgaagcccgt atgcgccgtg 50280  
gcggagtacc gcccatgaag ggtgaggcag ccgtcaacgc ccttcagcgg gcgttgaacg 50340  
cgaacgacac ggttgtcacc gtcgtggatg tggaatggga gcggttcgca cccggtttca 50400  
ccgccgcacg ggcaagcacg ctctcgcgcg aactgccaga ggcccagcgg gcacttgctc 50460  
cgcaggaggg cgacgagggc caggacgacg gcgctgtcca cggtcgcggg ggtcactcgc 50520  
ttgcggaacg gctcgcggag ctgtcggccc ccgagcgcga ccggctgctg ctcggcctcg 50580  
tgcgcaagga agtcgcccg gttactcggtc acgccggcgt ggaaagcatc ggtgcggcgc 50640  
gcgcgttcaa ggaactcggc ttcgactcgc tcacggccgt cgaactgcgc aaccggctcg 50700  
gcgcggtcac cgggcttcgg ctcccggcca cgctgatcta cgactacccc acgtccgggg 50760  
ccttggcggg atacctgcgg ggcgagttgc tcggtacgca ggccgtggtg tccggtccgg 50820  
tgtccaatgc cgtcgccgtc gacgacgacc cgatcgcgat cgtcgcgatg agctgccgct 50880  
tccccggcgg cgtacggacc ccggaagacc tgtggcaact gctggcgacg ggacgcgacg 50940  
ccatcggcga gttcccggaa gaccgtggct gggacgcgga ggccctgttc gggccccagt 51000  
tcgagcagga cgccccgtat gcgcgtgagg gcgggttcct ctacgacgtc gccgacttcg 51060  
atcccgcctt cttcgggatc tcgccgcgcg aggccctcgc catggacccg cagcagcgcc 51120  
tgctgctcga aacctcctgg gaagccttcg agcgggcccg gatcgatccg ctctcgggtgc 51180  
ggggcagcca ggccgggtgc ttcgtcggca ccaacggcca ggactacctc tcgctcgtgc 51240  
tgaactccgc ggacggcggc gacggcttca tgagcaccgg aaactcggcg agtgtcgtct 51300  
ccggccgact ttcctatgtg ttcggcctgg aaggccccgc ggtcacgctc gacaccgct 51360  
gctcggcgtc cctggtcgcg ctgcatctcg cgggtgcaggc gctgcgcaac ggcgaatgct 51420  
ccctggcgct cgccggcggt gtgacggtga tgtccacgcc cggcgccctc gccgagttca 51480  
gccgtcagcg ggggctcgcg gaggacggcc gtatcaaggc gttcgcggcg gccgcggacg 51540  
gtacgggctg gggcgagggc gtgggcatgc tcctgggtgga gcggctctcc gacgcccgca 51600  
ggaacggtca cccgctcctg gccctggtcc ggggctcggc cgtcaaccag gacggcgcgca 51660  
gcaacgggct cacggctccg aacggccctc cgcagcagcg cgtcatccgt gccgctctcg 51720  
cgagcgccgg cctggcaccg ggcgacatcg acgcggtcga ggcacacggc accggtacca 51780  
agctcggcga cccgatcgag gcgcaggccc tgctcgccac gtacgggcag gaccgcccgg 51840  
ccgaccggcc cctgcagctc ggttccatca agtccaacat cgggcacacg caggcccgcg 51900  
ccggtgtcgc cggtttgatg aagatggtcc tcgccatgca gcacgggggtg ctgccgcaga 51960  
ccctgcacgt ggacgagccg acccccacg tcgactggtc ggccgggtgac atcgcgctgc 52020



tgaccgagcg gcgggagtg cgggagacgg gccgtccgcg ccgggcgggc atctcctcgt 52080  
 tcggtgtgag cggtagaac gcgcacacca tcctggagca ggcaccgccg ctacacggaga 52140  
 aggacgagcg tgaggccgcg agggccggaga ccggctccgc cgtctcggcg tggcccctcg 52200  
 cgggcaagac cgaagccggc ctgcgtgagc aggcggaacg gctgctggca cacatcgatg 52260  
 cccactccga gctgcggccg gtggacgtcg gtcactcgtc cgcgaccggc cgggcgggcg 52320  
 tcgaccaccg tgccgtgctc gtggcgggag acgaccggtc ggagttccga cgggcactgg 52380  
 ccgcgctggc gtcgggagaa tccgtcgcgc aggtggtaca gggcatcgcg cgaccggatc 52440  
 agcaagtggc gttcctgttc acggggcagg ggagccagcg gctggggatg gggcgtgagc 52500  
 tgtacgagac gtatcccgtc ttcgcggatg cgctggacgc ggtgtgtgct cgccttgaac 52560  
 tgccgctgaa ggatgtgctg ttcggagggg acgcggatcg gctgaacgag accgcgtaca 52620  
 cccagccggc tctcttcgcg gtcgaggtgg cgttgttccg gctgggtggag tcgtgggggtg 52680  
 tgaggccgga cttcctggcc gggcattcga tcggtgagat cgcggccgcg catgtggcgg 52740  
 ggggtgttctc gctggatgac gcctgtgctc tgggtggaggc gcgtgggcgg ttgatgcagg 52800  
 cgctgccgac cgggtggcgtg atgatcgcg tccaggcgtc ggaggccgag gttctgccgc 52860  
 tgctgaccga gcgctgagc atcgccgcga tcaacgggtc gcagtcggtc gtgatcgcg 52920  
 gtgacgagcg cgacgcggtc gcgatcggtg acgcattcaa cgaccgcaag tccaagcggc 52980  
 tcgcggtcag tcacgcgttc cactcgccgc acatggacgg catgctcgcc gacttccgca 53040  
 aggtggcgga ggagctgtcg tacgaggctc cgcgcattccc catcgtctcg aacctcacgg 53100  
 gggccctggt caccgacgag atggggtcgg ccgacttctg ggtgcggcac gtccgcgagg 53160  
 ccgtccgctt cctggacggc atccggggcc ttgaggccgc gggggtcacg gtgtacgtcg 53220  
 aactggggcc ggacggagtc ctgtcggcta tggcccagga gtgcgtcacc ggcgaggggtg 53280  
 cggccttcgt gcccgctctc cgcaagggtc gtcccagggc cgagacgatc acagcggccc 53340  
 tcgcccacgc gcacaccac ggcacgcggc tcgactggca ggcctacttc gccgggaccg 53400  
 gcgcccagcg cgtcgacctc ccgacctacg ccttccagcg ccagcgctac tgggtggatt 53460  
 ccttcgccga gttcgacgat gtcgcctcgg ccgggatcgg atcggccgggt catccactgc 53520  
 tgggtgcggc ggtcgagctg ccggactcgg acgggttcct gttcaccggg cggctctccc 53580  
 tccgtacgca cccctggctc gccgatcacg tgggtggcgga caccgttggt gtgccggggc 53640  
 cggcgttcgt cgagctggcg gtgcgcgccg gggacgaggt cggatgcgag gaagtggagg 53700  
 agctggttct tgaggcgccg ctcgtactgc ccgagaaggg ggccgtgcag ctgcggctca 53760  
 gcgtgggcgg ggcggacgac cagggacgcc ggtccgtaca cgtgcacagc cgcgttgagg 53820  
 cggccgatgg gggcggggtc cccggcgggg cgtgggtccc caatgcaacg ggtctcctct 53880  
 ccaccggcgg tagcggaagc gacgtcgact ccggcacgggt catcgggtgag tggccgccgg 53940

ccggagccga gcaggtggat gtgaccgcgg tacgcgaacg actggcggcc gcggggctcc 54000  
accacggggc gggcttccgg acgctgaccg aggtgtgggt gcggggcgag gaggtgttcg 54060  
cggaggctag gctctccgac gaactgagcg cgtccgcagg gcggttcgcc ctgcaccgca 54120  
cgctgctcga cgccgcctcg caggcgctgg cggccggtac gaccgccgcc gcatccggca 54180  
tcggtggtgc gggacggctg cctcaggcat ggcgcggggg acggctgcac gcggggggag 54240  
cggacgctct gcgtctccgg atcaccgcgg gcggtcagga caccgtttcc gtcgtcctga 54300  
ccgacacgca ggggtgcgcc gtcgcgacgg tcggctcgct ggtcacggag gcggtcgacg 54360  
ccgagcggta cgcggcggtt ccggacggat cccacgattc gctgttcgcc ctcgactggg 54420  
tgcgagacgac ggctccgggg cggccgacct ccgcggactt cgcggtgctc ggtacccccg 54480  
gcactggcat cggcgccccg atcggcgggt acgagggctt cctcgtcggc gcgttggagc 54540  
gggcgggtct gaccgccgag acgtacgacg gtctcgcggc gtcgactcg gccgtcgcgg 54600  
ccgggatggc gatgccgga acgggtggtg tgtcattcgc cgcagctttg gacccgccct 54660  
cggactcggc cgcggacacg gtggcctccg tcgactcggc ggaggaggtc gcgcggctcg 54720  
cccaggcggg gcgcgaggcg acgcaccggg cgctcgcgac cgtgcagggc tggctggaca 54780  
acggccgggt cgcgggagcg cgtctggtcg tcgtcaccgg aggagcgggt gccacgggca 54840  
gggacaccga ggtggaggac ctgcgccacg caccgggtgt gggctctgct cgtgccgcac 54900  
agaccgagca cccggaccgg ttctctctcg tcgacctga cggggcggac gcctccgtcc 54960  
gggccctgcc gggcgccatc gcctcgcagg agtccgaact ggccgtacgt gacggtgtgt 55020  
tgtacgcgcc gcgcctggtc agggtcgggg cggaggcggg cacgggtgac accggcggtc 55080  
gccgcatcga tccgcggggc acggctctga tcaccggggc gagcggcgga ctgcggggc 55140  
tcttcgcccc ccatctggtg gcggagcacg gcgtacggca tctgctgctc accagccgca 55200  
ggggcgccgc cgccgaaggt gccgcccaac tcgccgatga actcgtcgcg ttgggtgcgc 55260  
aggtgacctg ggcggcggtc gacgtggccg accgggacgc gctggccgca ctgctggcgt 55320  
ccgtaccggc cgaacagccg ctgacggccg tcgtgcacac cgcggccgtc ctggacgacg 55380  
gcgtcgtgga cctgctcacc cccgagcggg tggaccgggt gctgcggccc aaggcgggaag 55440  
cggcgctcca cctccacgag ctgaccaagg acctcgatct gtcggcggtc gtcctcttct 55500  
ccgccgccgc cggcacgctc ggcggcgcgg ggcaggccaa ctacgccgcg gcgaacgtct 55560  
tcctcgacgc cctcggccgg caccgcacgg cccgtggtct caccgcgctg tccctcgtct 55620  
ggggcatgtg ggccgaggag cggggcatgg cgggcaggct gacggaggcg gagctgggca 55680  
gggcggggcg cggcgggtgt gcaccgctgt cggcgacgga ggggctcgcc ctcttcgacg 55740  
cgccctcgc cgcgagcag gccgtgctcg taccggtcag gatcgatgtc ccgaccctgc 55800

gggcccgggc ggcggacggc gggatccacc cgatgttccg cggactggta cggactccgg 55860  
 tgccgaggtc ggcgcagagc gcgggcccgc cggcgggcac cgtgcccacg gacggcgcg 55920  
 gggagcggac gctggccccg caactggccg agctgtccgt cgccgagcgg gagcggaccg 55980  
 tactggacct ggtacgcggc cagggtggccg ccgtactcgg gtacgggtcc gccgaacaca 56040  
 tcggcggtga gcaggcggtc aaggaactcg gcttcgactc gctgaccgcg gtcgagctgc 56100  
 gcaaccgact cggcgcgggc ggcggtctga ggctgcccgc cacgctgacg tacgactacc 56160  
 cgaaccggc cgccctcgcc cagcacctgc tgagcgaggt ggccccggac acggcggagc 56220  
 gcaagctctc cgtactggag gaactcgacc ggctggagag caccttctcc tcgctggctc 56280  
 ccgcggaact gtccgcggcc gccggtgacg aggcggccca cgcgcggtc gcggtacgcc 56340  
 tccagaccct gctggcccag tggaacgacg cccgtctggc agagggcggg agcggggccc 56400  
 acgcgatcga agaggcgagc gacgacgagc tgttcgccct catcgacaag aagttcggac 56460  
 agggctgaac ctgcgccacc gggcgcgccg ccgggtcagt ccccgcggc gccgccacc 56520  
 cctgaaacga gacccgagac attccgagta cgtgcgaata ccgccacgat ctcggccacg 56580  
 cgaataggtg gaagcgccag tggcgaacga agcaaagctc cgcgagtacc tcaagaaagt 56640  
 cagcaccgat ctggacgagg cgtacggacg cctgcgggag atcgagagcc agggccacga 56700  
 gccattgcc atcacggcga tgagctgccg gttcccgga ggcgtaggt ctcccgaaga 56760  
 gctgtgggaa ctgctccga ccggcgggga cgcactcacc gcgtttccc cggaccgcgg 56820  
 ctgggacctc gacaacctgt tctcgacga ccccgacgac cacaacacgt cggtcacccg 56880  
 tgagggcggg ttcctcggcg aggcgtcctc gttcgacgcc gcgttcttcg ggatctcgcc 56940  
 gcgcgaggcc atggcgatgg accgcagca gcggctgctg ctggagacct cgtgggaggc 57000  
 gttcgaacgg gccgggatcg acccccaggc gctgcgcggc agccagtccg gtgtgttcgt 57060  
 cgggatcaac gggtcggact acctgacccc gctgctggaa gcggccgagg actacgcggg 57120  
 gcacctgggg accggcaacg cctccagcgt gatgtcgggc aggtctctgt acacgttcgg 57180  
 cctggagggc ccggcggtca cggtcgacac ggctgtctcc gcgtcgctgg tcgccctgca 57240  
 cctggccgtg caggcgctgc gggccggaga gtgctcgctg gccgtcgccg gcggggtgca 57300  
 cgtcatgtcc acgcccggac tcttcgtcga attcagcaag cagcgcgac tgtccacgga 57360  
 cggccgctgc aaggccttcg cggcgggcgc cgacggattc ggcccgcgcg aaggcgtggg 57420  
 cgtcctgctg ctggagcggc tctccgacgc ccgcaagaac gggcgtccgg tccttgcggt 57480  
 ggtccgcggc tcggcggtca accaggacgg tgcgagcaac ggtctgacgg ctccgaacgg 57540  
 tccgtcgag cagcgctca tccggcaggc cctcgccaac gcacggctct ccaccgacca 57600  
 ggtcgatgtc gtggaggcac acggcaccgg caccagcctc ggcgaccga tcgaggcca 57660  
 ggcgctcatc gccacgtacg gccaggaccg cccggccgat caaccgctgc tgctcggtc 57720

ggtcaagtcc aacatcggtc acaccagggc ggccgccggt gtggccggcg tgatcaagat 57780  
ggtgctggcg atgcagcacg gcgtgcttcc gcagagcctg cacatcgacg agccgtcgcc 57840  
ccacgtggac tgggagtcg gcgcgggtctc gctgctcacg gaacagacgg cctggcccga 57900  
gacgacgcat ccgcgtcgtg cgggtgtgtc gtcgttcggg ttcagcggga cgaacgcgca 57960  
tgtgatcgtc gagcaggctc cgggtggtga ggaggtggcg ggggatccgg ccggtgtggt 58020  
cgagggttcg ggtcccgggg tggtgccggt ggtgcccttg gtgttgctcg gcaagagtgc 58080  
gggggctgtg cgggcgaggc cggagcgggt gtccggatc ctgcgggtg cttcggctgt 58140  
ggatgtgccg tcggttgatg tggggtggtc gttggcgctg tcgcgtgctg ggctggaaca 58200  
ccgggctgtg gtgctgggag atcacgcggc cgggtgtggc gcggtggcgt cgggtgtgat 58260  
ggccgcgggt gtggtgacgg ggtcgggtgt cggcgggaag accgcgttcg tgttcccggg 58320  
gcagggtcgt cagtgggttg gtatggcggg ggggttgctg gattcctcgc cgggtgttcgc 58380  
tgccgggtg gaggagtgtg cgaaggcgtt ggagccgtt accgactggt cgttggtgga 58440  
tgtgctgcgg ggtgtggagg gtgcgccgtc gttggagcgg gtggatgtgg tccagcccgc 58500  
tctgttcggt gtgatggtgt cgttggcgga ggtgtggcga gccgctgggt tgcgtcctgg 58560  
cgcggtgatc ggtcattcgc aggggtagat cgctgccggt tgtgtggcgg ggatcttgtc 58620  
gcttgaggat gcggcgcggt tgggtgctgt gcgtagtcag gcgatcgcc gggtcctggc 58680  
gggtctgggc gggatggtgt cggtgccgtt gccggcgaag gctgtgcggg agctgatcgc 58740  
tccgtggggg gagggccgga tctcgggtggc cgcggtgaac gggccgtcgt cgggtggtgt 58800  
ttcgggtgag gccgcggccc tggatgagct gctggtctcg tgcgagtcgg aggggtgtgcg 58860  
ggcgaagcgg atcgcggttg attacgcgtc gcattcggct cagggtggagt tgctgcggga 58920  
agagcttgct gagctgctgg ctccgattgt tccgcgcgct gctgaggtgc cgttcttgtc 58980  
gacggtcacc ggtgagtggg tgcgaggccc ggagctggat ggccgggtact ggttccagaa 59040  
cctgcgtcgg acggtggagt tggaagaggc gacgcggacg ttgctggagc agggcttcgg 59100  
tgtgttcgtc gagtgcagcc cgcacccggt gttgagcgtg ggcatgcagg agacggtcga 59160  
ggacgcgggc cgggaggcgg ctgttctggg ctggttgctg cgtggtgagg ggggtctgga 59220  
gcgtttctgg ctgtcgtcgg gtgaggcctg ggtccgtggc gtgggtgtcg actggcatgc 59280  
cgtgttcggt ggcacgggtg cccagcgggt tgacctgcc acctacgcct tccagtcgca 59340  
gcggttctgg ccggaggccg cgcctatcga ggctgtggcg gtgtcggcgg agagtgcgat 59400  
cgatgcccgg ttctgggagg ccgtcgagcg cgaggacctg gaggcgctga ccgcggaact 59460  
cgacatcgag ggcgaccagc cgctgaccgc actgctgcc gcgctgtcgt cgtggcgtcg 59520  
gcagagccgt gagcattcga cagtggacgg ctggcgctac cgcgtcacct ggaagcggat 59580

cgctgagcct tccccggccc gcctgtcggg tacgtggctg gtcgtcgttc ccgaggtcgg 59640  
 cccggccgac gagtggacgg gagccgtcct gcgcatgctc gccgagcgcg gcgctgaggt 59700  
 ccgtaccgtg accgtccccg ctgacggggc ggaccgtgac cggctcgccg tcacgctgaa 59760  
 ggccgagacg agcgaggtcg ctccgagcgg cgttctctcc ctccctcgccc tcgcccggcg 59820  
 tgcgggagcc ttgcccggcg aactcgccct gtgccaggcg ctcggtgacg ccgacgtggc 59880  
 cgcacctctg tgggtcgta cgcgtggcgc tgtcgccacc ggccgttccg agcaggtggc 59940  
 cgacccccgc caggcgctcg tctgggggtc cgggcgggtc gcctccatgg agcagggggg 60000  
 caggtgggga ggctgtctcg accttccgc cgatctcgac ggccgtacgc tcgaacgtct 60060  
 cgcgggtgtc ctggccggtg atggttcgga ggaccaggtg gcgctgcgcg cctcgggtct 60120  
 cttcggtcgg cgtctggtgc acgcacctt cgccgacacc gccgccgtgc aggagtggcg 60180  
 tccgcagggc acgacctgg tcacgggcgg tacgggcgcg ctgggcgcgc acgtggcccc 60240  
 ctggctcgcc gggaacggcg ccgagcacct gctgctcacc agccgacggg gccccgacgc 60300  
 gcccggagcc gccgcactcc gcgacgaact caccgccctc ggcacccagg tcaccatcgc 60360  
 gtcctgcgac atggccgacc gggacgccgt caccgccctc atcgccgcca tccccgcca 60420  
 ccagccccctc accgcggtga tccatgccgc ggcggtcgtg gacgacgggg tcatcgagac 60480  
 gctggccccg gagcaggtgg aggcgttct gcgggtcaag gtcgacgga cctcatcct 60540  
 ccacgagctg acccgtggcc tggacctgtc ggcgttcgtc ctcttctcct ccttcgccgc 60600  
 caccctcggc gccccggcc agggcaacca ggcacccgga aacgcgtacc tggacgcctt 60660  
 cgccgagtac cgccgggggt cgggactgcc cgccacctcc atcgccctggg ggccgtgggg 60720  
 cagcgcggaac ggcgacgaca gcgcggcggg cgaccggatg cgccgccacg gcatcatcgt 60780  
 gatgtcgccc gaacggaccc tcgtctccct ccagcacgcg ctggaccgtg acgagacgac 60840  
 cctgaccgtc gccgacatgg actggaagcg gttcaccctc gccttcaccg cggaccggga 60900  
 ccggccgctg ctcttgagc ttcccaggc ccggcgcatc atcgagagcg cggagcggga 60960  
 gtccgccgac gacctggccg ggggagtgcc gtcacgcag cagctcgccg ggctgcccga 61020  
 ggtcgaacag gagcggctgc tcctcgacct ggtccgtacg gccgtcgccg ccgtcctcgg 61080  
 ccatgccgac ctggccggcg tcgaggcggg ccgggcgttc aaggagctcg gcttcgactc 61140  
 gctcacctcg gtcgaactgc gcaaccggct cggcgcggtc agcgggtctga agctgcccgc 61200  
 cagcctggtc ttcgaccacc cgacccccgc cgccgtcgcg gccttcctac gcgccgggat 61260  
 cgtgcccgac gcggccgcgg gcggcgcgcc gctgctggag gagctcgaca agctcgaagc 61320  
 cgtactggag cggggcaccg ccgacaacgt cgtacgggcc cgggtgacca tgcggctcca 61380  
 gaagctcctg gggaagtga acgagagcga ggaccagtcg ggcgccgagg tgtggcgggc 61440  
 cgcgccaac ggctccgggt cgggcacgcg cgcggggtcg gcggacggcg tgctggacga 61500

ggtcgagcag ctccaggagg cgagcgacga agagctgttc gccttcatca acaagggact 61560  
cggccgcgcc tgaccgcaat ggatgtggat attgacggcg tgccgttaat tggccaggat 61620  
agtcagcccc cttgttaatt tccacaaggc tctactgcccc ctgtcacacc ctcccaccca 61680  
ggggtgtgta gggggcagtt aggggttgtc gggaagattg ggcggcgaat aacctgccgc 61740  
tgagcagtcg attcaggcaa gaagtgaacc ggctgcatac ccgattcaat tctcggcttt 61800  
atctgcacag ttattccgat gccgtctgtc gcaaatgggt gggtgcgtta aatggcgaat 61860  
gaagagacgc tgcgggacta cctgaagctg gtgacggcgg atctgcacca gacgcgacag 61920  
cgtctgcgcg acgtcgaggc gaagaatcag gaccccatcg cgatcgtcgg catgggctgc 61980  
cgctatcccc gcggtgtgac ctgcgccgag gagctgtggc agctcgtcgt ggacgggtgg 62040  
gacgccatth ccggcttccc cgccgaccgc ggctgggaca tggagacggc ctaccacccg 62100  
gatccccgagc accccggcac gagctacgcc aaccaggggt gcttcgtccg ggacttcgcc 62160  
cggttcgacc cgtcgtctct cggcattctc ccgcgcgagg ccctcgccat ggacccgcag 62220  
cagcgggtgc tcctggagac ctcgtgggag gcgttcgagc gggccgggat cgacccgacg 62280  
tcgatgcggg gcaagcaggc cgggtgtctc gtcggcacca gcaaccacga ctacctgtcg 62340  
gcgtgctga gttcctcggg gaacgtggag ggctacctcg gcaccggcaa cgcggcgagc 62400  
gtcgctcgg gccggctctc gtacacctc ggctcgaag gcccgggcgt caccgtcgac 62460  
acggcctgct cgtcgtctc ggtagccctg cacctggccg tgcaggcgt gcgcaacggc 62520  
gagtgtcgc tcgccctcgc gggcgggtgc acgtgatgt cggtccccg cacgttcac 62580  
gactacagca agcagcgcgg actggccacc gacggacgct gcaaggcgtt ctgcgccgac 62640  
gccgacggct tcagcctcgc cgagggcgtg ggcattcctg tggtcgagcg gctctccgac 62700  
gcccgcgcga agggacatcc cgtcctggcc gtgggtccgtg gcaccgccgt caaccaggac 62760  
ggcgccagca acggcctgac cgcgcccaac ggcccgctcc agcagcgcgt catccttcag 62820  
gcgtgtcca acgccaggct cacccccgc caggctcgacg cggtcgagc ccacggcacg 62880  
ggcaccggcc tcggtgacct gatcgaggcg caggcgtca tcgccacctt cggccaggac 62940  
cgccccgacg ggcggccgct gtggctgggt tcgctcaaga ccaacatcgg acacgcacag 63000  
gccgcggccg gtgtcgcggg cgtcatcaag agcgtcatgg cgatgcgcca cggcgtgctg 63060  
ccgcgcaccc tgcacgtgga cgagccgacc cccgaggtcg actggtcggc gggtgacgtc 63120  
tccctgctca ccgaagcgcg gccctggccc ctgggcgacc agccgcgcgg gatcggcgtc 63180  
tcgtcgttcg gcatgagcgg caccaacgcc cacatcatcc tggagagcgc gcaggagtac 63240  
gccgacggcc ggcaggccga cgccggtacc gcggggaacg aaccggccac cggccgtacg 63300  
aaccgcccc gcgccctccc cgtcgtcctg tccggccgga ccgagcccg cctgcgcgcc 63360

caggccgccc cgctgcacgc ccacctcgcg gccacccccg gcctcggcat cgccgacctc 63420  
gcctttctccc aggcctcac ccgcgcagcg ctggaccggc gtgcggccgt cgtcgccgac 63480  
gaccgcgacg ccttgctggc cgggctcgcg gactggcgg aaggacgccc cagcgcggac 63540  
gtggtcgaag gcagcgccac ggacggaaaag ctggcggttcc tcttcaccgg gcaggggagc 63600  
cagcggcccc gcattggggccg tgagctgtac gcgacgtatc ccgtcttcgc gcaggctctg 63660  
gacgcgggtgt gcgagcggct cgaactgccg ctcaaggacg tgctgttcgg gaccgacggc 63720  
gccgcccggc ccgcgctcga cgagaccgcg tacaccacgc ccgcgctgtt cgcggtcgag 63780  
gtggccctct tccggctcgt ggagagctgg gccctgaagc ccgactacct ggccggggcac 63840  
tcgatcgggtg agatcgccggc cgcgcacgtg gccggagtgt tctcgctgga ggacgcctgc 63900  
acctgggtcg aggcgcgtgg ccgtctgatg caggcgctgc cgaccggcgg cgtgatgatc 63960  
gcggtcgagg cgtcggagga cgaggtcctg ccgtctcga ccgactgggt gagcatcgcc 64020  
gccgtcaacg gcccccggtc ggtcgtcgtc gccgggtgatg aggacgctgc ggtcgcgatc 64080  
gcggaggcct tcgcagccca gggccgcaag accaagaagc tgacggtcag ccacgccttc 64140  
cactcgccgc acatggacgg catgctcgac gccttcgcga cggtcgcca gggactctcg 64200  
tacgggactc ctgcacccc ggtcgtctcg aacctcaccg gcgccctcgt caccgacgag 64260  
atgggctcgg ccgacttctg ggtccggcac gtccgcgaag ccgtccgctt cctcgacggg 64320  
atccgctggc tggagagccg cggggtcacc acctacatcg aactcggccc cggcggcgtc 64380  
ctgtccgccc tcggccagga ctgccagacc gcgaccggcc ccgcgcggc cgccttcctc 64440  
cccgcgctgc gcaccggccg ccccgaggcg tcgtcgctga ccgcggccgt ggccggcgcc 64500  
catgtccgcg ggtctctccc ggactggacc gtccgcttcg ccggcaccgg cgcacagcgc 64560  
gtcgagctgc ccacctacgc cttccagcgc gagctgtact ggccccgcga ccccttcacc 64620  
gacccgccg aatccgcca cggggcgaa ctggcgcca ccgacgcca gttctgggag 64680  
gtcgtcgaca gcgaggacct cgcgcgctc gccgacacc tcggggtcgg cggcgacgaa 64740  
cccctcagca gcgtgctgcc cgcgctctcc gcctggcacc gccgccaccg cgaccgcgac 64800  
accgtggacg gctggcgcta ccgcgtcacc tggaagccgc tgacggacac cagccccgcg 64860  
tccccctccg ggcactggct cctggctcgtc cccaccgagc acgcccagc ccttggggc 64920  
gtcgccgccc agcgggcaact gaccgcacgc ggtgtcaccg tgagcaccgt cgtgctcgac 64980  
gcgacctcg acgaccgggc cgccaccgcc cggcggtatg gcgaagccct cgctgcctcc 65040  
gccgccaccg actccgcccc ggcggggcgcc gaaacgctcg cggcggtgtt ctgctgctc 65100  
gccctggagg agcggccgca ccccgcgga cgggactgt ccgccgggct cgcgcgacg 65160  
gtcgccctca tccaggcaact cggcgacgcg ggagtggag ccccgctgtg ggccgccacc 65220  
tgcggcgcg tctccaccgg ccgcaccgac cggctctcca gcaccgcca ggcgcaggtg 65280

tggggcctcg gccgcaccgc cgccctcgaa ctgcccgtgc gctggggcgg tctcgtcgac 65340  
ctgcccggga cccccgacga gcgggcccgc ggccggctcg ccgacgtcct cggcggactc 65400  
ggcggacccg gcgccgagga tcacctcgcc gtacgtccca ccggcgtctt cgtccgcagg 65460  
ctggcccgcg ccacccgcga cgagcgcccc accaccgagt gggccaccac cggcacggct 65520  
ctcatcaccg gcggcacggg cgcaactcggc cgccacgtcg cccgctggct cgcccggacc 65580  
ggggcgcagc acctgctcct ggtcagcagg cgcgggcccg aagccgaggg agccgacgcg 65640  
ctcgccgcgc aactgcgcgc actgggcgcc gaggtcacca tcgcgcctg cgacgtcgcc 65700  
gaccgcgacg ccgtcgcggc cctgctcgcc accctcccgg ccgagcaccg gctgaccaac 65760  
gtcgtgcacg ccgccggggt gctcgacgac ggcgtcctgg acgccagac cccgcagcgc 65820  
ctcgcggggg tcctgcgccc caaggccac gcggcgcagg tcctgcacga gctgaccgcg 65880  
gacctggacc tctccgcctt cgtcctcttc tcgtccgtcg ccgcctctt cggcgcgcgc 65940  
ggtcaggcca actacgtgc cgcgaaacgcc tccttgagg ccctcgccga gcagcgcgcg 66000  
gccgacggcc tgcccgccac cgtgctggcc tggggcgctt gggccgaagg cggcatggcc 66060  
accgacgaac tcgtcgccga gcgcctgcgg ctggccggac tgcccgcctt cgcacccgaa 66120  
ctcgccctgt ccgcaactga cagggcgtc accctggacg agaccgcctc gctcgtcgcc 66180  
gacatcgact gggagcgcct ggcccccggc ctcaccgcgc tacgcccctg cccgctgac 66240  
gccgacctcc ccgaggccgt gcacgcctc gccggagccg aggcgtccac cgggcccggc 66300  
gccgcgcgcg acacgttcgc gcggcagctg gccgacgccc ccgcccgtga acgcgaccag 66360  
ctcgccctgg agttcgtacg caccaggtc gcggccgtac tcggttacgc cgggtcccag 66420  
tcctcgacc cgggcagcgc cttccgggac ctgggcttcg actcgtcac cgcggtggag 66480  
atccgcaacc tcctcacctc ccggaccggc ctgcgcctcc cggcgacgct gatcttcgac 66540  
taccccaact ccctctccct ggccgccttc ctgcagggag aactgctcgg cgcgcaggcg 66600  
accgaccccg ccgcccacac ccccgcgggc ccgggcaccg ccaccgatga cgaccccatc 66660  
gcgatcgtcg cgatgagctg ccgcttcccc ggcggcgtac agagcccgga agacctctgg 66720  
cagctgctct ccaccggccg tgacgcgac tcgggcttcc ccggcgaccg cggctgggac 66780  
ctcgacgggc tgtacgacc cgagtcgcgc ggggagaaca ccagttacgt ccgcgagggc 66840  
ggcttcctcg ccggtgccac cgagttcgac cccgcgttct tcgggatctc cccgcgcgag 66900  
gccctcgcca tggacccgca gcagcgcctg ctgctcgaaa cctcgtggga ggccttcgag 66960  
cgcgccggaa tcgacccgc caccgtgcgc ggcgaaacaga tcggcgtctt caccggcacc 67020  
aacggccagg actacctcaa cgtcatcctg gccgcaccg acggtgtcga ggggttcctg 67080  
ggcacgggca acgcggcgag cgtggtctcc ggccgcgtct cctacgtcct cggcctggag 67140



ggccccggccg tcacggtcga cacggcctgc tcgtcctcgc tggtcgccct gcactgggcg 67200  
atccaggccc tgcgccaggg cgagtgcacc atggccctgg ccggcggcgt gaccgtcatg 67260  
tccacgcccc cctccttcat cgacttcagc cgtcagcgcg gcctcgcgga agacggccgt 67320  
atcaaggcgt tcgccgcggc cgcggacggt acgggctggg gcgagggcgt cggcatcctc 67380  
ctcgtcgaga ggctctccga cgcacagcgc aacggccatc cggtcctggc gatcgtgcgc 67440  
ggctcggcca tcaaccagga cggcgccagc aacggcctca cggcgcccaa cggcccgtcc 67500  
cagcagcgcg tcatccgcca ggccctcgcc agcggcggac tgacgacgat ggacgtcgac 67560  
gccgtcgagg cccacggcac gggtagaag ctcggcgacc cgatcgaggc gcaggcactc 67620  
ctcgccacct acgggcagga ccggccgga ggccgtccgc tgctcctcgg ctcgatcaag 67680  
tcgaacctcg ggcacacgca ggccgcccgc ggtgtcgccg gtgtcatgaa gatggctcctc 67740  
gccatgcagc acggtgtgct gccgcagacc ctgcacgtcg acgagccgac cccgcacgtg 67800  
gactggtcgg cgggcgacgt cgccttgctg gccgatgccg tggcgtggcc cgagaccggg 67860  
cgtccgcgcc gggcggggt ctcgtcgttc ggcatcagcg gcaccaacgc ccacaccatc 67920  
atcgaacagg ccccggcagc cgtggcgccc gtcccgcccg tcgccaccac gcccgcacgg 67980  
gccgacggac cgcagccgtg gtcctctcgc gcgaagacc gcgacgcact ccacgaccag 68040  
gcgcgccgac tgcacgcca cgcggagctg aacccggaac tgagccccgc cgacctcgga 68100  
ctctccctgg cggccggccg ttccggcttc gagcggcgcg cggccgtgat cgccgcagac 68160  
cgtgacgggc tgctggcccg cctcgcggcc ctggcgagc gcggcgcggc ggcaggactg 68220  
gtggagggct caccggtcgc cggaaagctg gcgttcctgt tcaccgggca ggggagtcag 68280  
cggctcggga tgggcccgtga gctgtacgac acgtaccccg tcttcgcgga cgcgctcgac 68340  
gcggctctgc cgcattgtga cgcgcacctc gaagtcccgc tgaaggacgt cctgttcggg 68400  
gcggatacgg gtctgtgga ccagacggct tacacgcagc ccgcgttgtt cgcggttgag 68460  
gtggcgttgt tccggctggt ggagagctgg ggtctgaggc ccgacttcct ggccggtcac 68520  
tcgatcgggt agatcgcgcc cgcgcattgt gcgggctct tctcgcttca ggacgccagc 68580  
gaactggtcg tcgcccgtgg gcggttgatg caggcgctgc cgaccggtgg cgtgatgatc 68640  
gccgtccagg cgtcggagga cgaagtcctg ccgctgctga ccgaccgggt gagcattgcc 68700  
gcgatcaacg gccctcagtc ggtcgtcatc gcgggtgacg aggccgacgc ggtcgcgatc 68760  
gcggagtcgt tcacggggcg caagtccaag cgcctcacgg tcagccacgc gttccattcg 68820  
ccgcacatgg acggcatgct ggaagacttc cgggcccgtg cggagggcct ctcgtacgag 68880  
gctccgcgca tccccgtcgt ctggaacctc accggcgctc tgatctcgga cgagatgggc 68940  
tcggccgagt tctgggtccg gcacgtccgt gaggccgtcc gcttcctcga cggcatccgc 69000  
acgctggaag ccgcaggcgt caccaagtac gtcgaactcg gccccgacgg cgtcctgtca 69060

gccatggccc aggaactgcgt gagcggcgag ggctccgtct tcatccccgt actccgcaag 69120  
gcgcgccccg agcccgagag cgtcaccacc gccctacca cggcccacgt ccacggcatc 69180  
cccgtcgact ggcaggcggt cttcgccggg accggcgccc ggcgcgtcga cctccccacc 69240  
tacgccttcc agcgccagcg ctactggccc gccgtctcct ccctctacct cggcgacgtc 69300  
gaggcgatcg ggctcgacga caccgcgcac ccgctgctca gtgcgggtgt cgccctgccc 69360  
gagtccgacg gcatgggtgt cgccggggcg ctcgcgtctt ccaccacgc ctggctcgcc 69420  
gaccacgcca tcctcggcag cgtcctgctg cccggtacgg ccttcgtcga gctggccacc 69480  
cgcgccggcg accaggctcg ctgcgattac ctggaagagc tgaccctcga agcgccccctc 69540  
gtcctgcccc agcacggcg cgtccagctg cgcgtgtggg tcggcgccgc cgacgagtcc 69600  
ggccgacggc cgttcgccct gcaactccgg gccgaaggcc tgccggtcga ggagccgtgg 69660  
acgcggcacg ccggcggtgt actcgccgaa ggcggggcgc ccccggccga cttcgacctg 69720  
acggcctggc ccccgccggg cgccgtcga gtggacctg acgggcgcta cgaccagctc 69780  
gacggcatcg gcttcgccta tggccccacc ttccgtggcc tgcgtacggc ctggcagctc 69840  
gacggcgaga tctacgccga ggtcaggctg cccgagggag ccgagggcga ggcgggcccg 69900  
ttcggcctgc acccggccct gctcgacgc gcaactgcacg ccacgcggct gggcgccctc 69960  
ggcgccgacg acggccaggg gaggtcccc ttgcctgga gcggagtatc gctgcacgcg 70020  
ggcggggctg ccgcactgc cgtccacctc gctccggcg gcgccgagg cgtccgcctg 70080  
gagatcgcg acgcctcgg cgcacggtc gcggccgtcg agtcgctcg gctgcgccc 70140  
gtgacggccg agcagctccg tgccgctcgt gccacctacc acgagtccgt gttccgtcag 70200  
cagtggaccg agctgccggg tctcggcgt cccgccgcga ccccgccgt ccggtacgcg 70260  
ttcctcggcg gcgacagcg cgacagcggc gacagcggtg acaccgcagc cgccgaccgt 70320  
caccaggacc tggcggcgt cgccgccgcg atcgacgccg gaaggcccgt accggacgag 70380  
gtggtcgtcg aactcgccgc cgcgccctgg gccgtgtcgg cgtcgccgt gcacagtgc 70440  
gcgcacgatg cgctggcact catccagacc tggctcgcgg acgaccggtt cgccgccgca 70500  
cgctgggtgt tcctcaccgc cggcgcggtg gcccgggacg cgggcgacga cgtgaccgat 70560  
ctcgccgccg ccaccgtgtg gggcctgctg cggctccgcg agacggagaa ccccggcagg 70620  
atcgccctcg tcgacaccga cggccacgac cggagcgagc aggccttcg ggcggcgctc 70680  
acctccgacg aggagcggtt cgcgctgcgc gccggagcgg tcctcgtgcc ccggctcgcc 70740  
cgggtcgaga tccagcagga cgactccgcc cggacaccgg ccctcacgcc cggcggcacg 70800  
gtactgatca ccggagccac cggagcgctg ggcggtctct tcgcccggca cctcgccgcc 70860  
gaacacggcg tggagcggct gtcctcgtc ggcaggcgcg gggccgacgc ccccggcgcg 70920

gccgaactcg tcgccgaact cgccgagtcg ggcaccctcg ccacctgggc ggcgtgcgac 70980  
gtggccgacc gggacgcgct cgcggcactg ctgcgggaca ttcccggcca gcacccgctg 71040  
accgccgtcg tccacacggc cggagtcctc gacgacggcg tcattctctc gctgacgccc 71100  
gagcggctct ccgccgtgct gcggcccaag gtggacgcgg cctggaacct gcacgagctg 71160  
accggggggc tcgacctcgc cgccttcgtg ctctttctct ccacctccgg cctcttcggc 71220  
ggccccggac agggcaacta cgccgccgcc aactccttcc tggacgccct cgcccagcac 71280  
cgccgcgctc acgggctccc cgcgacctcg acggcctggg gcctgtggtc cgtggccgac 71340  
ggcatggcgg gcgccctgga cgcggccgac gtcaaccgca tgcggcgggc cggactgccg 71400  
ccgtgaccg ccgccgacgg cctcggcctg ttcgacacgg cggctctccct cgacgaggcc 71460  
tccctggccc tgatgcgggt ggacaccgaa gtcttgcgca ccaggccgg ggccgggtacc 71520  
atcgcccgcc tgctgcggcg tctcgtacgg ggcgtggccc gccggtcggc cgacgtgtcg 71580  
gccggtgccg ggggcgcca atcggagctg cgcggcaggc tggcggcgct caccgccgcc 71640  
gagcaggacc gggcgctgct ggacctggtg cgtacgcagg tcgcggcggc cctcggacac 71700  
gccggacccg cggccgtgga gtcgggacgg gccttcaagg aactcggttt cgactcgctc 71760  
accgcggtag agctgcgcaa ccggctgaac gccgccaccg cgctgcgcct gccgcgcagc 71820  
ctgatcttcg actatccgga cccgaccgtt ctgcgccggc acctgcgcgg cgagctgac 71880  
ggtgacgaca ccacggacgc cgtggccgag ccgctcacgg ccgtggccga cgacgagccc 71940  
atgcccatcg tcgccatgag ctgccgtac ccgggtgacg tacgcacccc cgaggacctg 72000  
tggcagctgc tgacggcggg cgcgcacggc atcaccggc tccccagaaa ccggggctgg 72060  
gacaccgagg gcctgtacga cccggacccg gagagccagg gcacctcgta cgccgcgac 72120  
ggcggattcc tgcacgacgc ggccgagttc gacgcctcct tcttcgggat ctgcgcgcgc 72180  
gaggccctcg ccatggacct gcagcagcgc ctctctctgg agacgacctg ggaggtcttc 72240  
gaacggggcg gcatcgcgcc gtccgcgggt cgcggcagcc ggacgggtgt cttcgcgggt 72300  
gtcatgtacc acgactacgg cgcgcgcctg cacgccgtgc ccgacggcgt cgagggtac 72360  
ctcggcaccg gcagctccag cagcatcgtg tcggggccggg tcgcctacac cttcggcctg 72420  
gagggcccg cggtcaccgt cgacacggcc tgctcctcgt cgctggtcgc cctgcacctc 72480  
gcggcccagg cgctgcgcaa cggcgagtgc tcgctcgctc tcgcgggcgg tgtcaccgtg 72540  
atgttcacgc ccggaacctt catcgagttc agccgtcagc gcggcctggc cgccgacgga 72600  
cgctgcaagt cttcgcggc cgccgccgac ggcacgggct ggggcgaggg cgcgggcatg 72660  
ctcctgctgg agcggctctc cgacgcgcga cgcaacggcc accaggtcct cgcggtcgtc 72720  
cgcggtcgg ccgtcaacca ggacggcgcc agcaacggcc tcaccgcccc gaacggcccc 72780  
tcgcagcagc gcgtcatccg gcaggccctc gccaacggc gtgtcgccgc cggacacgtc 72840

gacgccgtcg aggcacacgg caccggcacc accctcgggtg accccatcga ggcgaggcc 72900  
ctgctcgcga cctacggcca ggagcacacc gacgaccggc cgctgctcct cggctcgggtg 72960  
aagtccaacc tcggtcacac acaggccgct tcgggctcg cggtgtcat caagatggtc 73020  
atgtcgatgc ggcacgggtg gctgccgaag accctgcacg tcgacgagcc gaccccgac 73080  
gtggactggc cggcggggcg ggtctcgtc ctcaccgagc agaccccggtg gcccagacc 73140  
ggcgtccgc gccgcgcggg cgtctcctcc ttcggcatca gcggcaccaa cgcgacgcc 73200  
atcatcgagc agggcccgga gccggaccgg gccggggcga aggcgacggc gcggcccgcg 73260  
ccggacgcc cggcgccgtc gtccgtgccc ctgatcgtgt ccggcccgcg cgaggacgcg 73320  
ctgcgcgcc aggcccgag gctccacgcc cactccacg ccgaccccg cctgcgcgcc 73380  
gtcgacctcg gcctctccct ggcgaccacc cgctcggccc tggagcagcg cgcggcgctg 73440  
gtggccggcg accgcgcgga actgctgcgc ggcctggacg ccctggccc cggcgaggac 73500  
accgcggggc tgggtgcgcg caccgcccgc gagggccagg tggcgctcct gttaccgggt 73560  
cagggcagcc agcggccggg gatgggacgc gagctgtacg acgcgcatcc cgtcttcgcg 73620  
gacgcgctcg acgagatctg cggcgaactg gaccggcacc tcgaagtacc gctcaagggc 73680  
gtgctgttcg cgaccgaggg cgatctgac caccagaccg cgtacacgca gcccgcgctg 73740  
ttcgccgtgg aggtggccct gttccggctc ctggagagcc ggggctgca gcccgacttc 73800  
ctggccggtc actcgatcgg tgagatcgcc gcagcccatg tggcgggctt cttctcgtc 73860  
caggacgcca gtgaactggc cgccgcccgt gggcggttga tgcaggcgct gccgaccgg 73920  
ggcgtgatga tcgccgtcca ggcacggag gacgaggtcc tgccgctgct gacggaccgg 73980  
gtgagcatcg ccgcgatcaa cggcccccag tcggtcgtga tcgcgggcga cgaggccgac 74040  
gcgggtggcca tcgccgagtc cttcacggac cgcaagtcca agcggctcac ggtcagtcac 74100  
gccttcact cgccgcacat ggacggcatg ctgcgcgact tccgcaaggc cgccgagggc 74160  
ctcgtctacg agaaccgcg catcccggtc gtctcgaacc tcacgggggc cctggtcacc 74220  
gacgagatgg gttcggccga cttctgggtc cggcacgtcc gcgaggccgt ccgcttctc 74280  
gacggcatcc gcgccctgga agccgcgggc gtcaccacac acatcgagct gggcccgac 74340  
ggcgtgctct gcgccatggc ccaggaatgc gtgagcggcg aggacaccgt cttcgtcccc 74400  
gtactgcgcc ccggccgccc cgaggccgag accgtcacca ccgccctcgc ccgcgtccac 74460  
gtccaggggc taccctgga ctggcaggcg tacttctccg gcaccggcg ccagcgcgtc 74520  
gacctgcca cctacgcctt ccagcgcaag cgctactggc tcgacgtcgg cgtctccgtc 74580  
gaggacgtgc tggcggccgg tctcgatgcg gccgaccacc ccctgctggg cgccaccgtc 74640  
tcctgcccg gatccgacgg gctggtcctc accggacgcc tcgcgctgtc cacgcacccc 74700

tggctgagcg	accacaccgt	catggacacc	gtcctgctgc	ccggcacggc	cttcgtcgaa	74760
ctcgccctgc	gggccggtga	actggtcggc	tgccggcgccg	tcgaagagct	ggcgctcgaa	74820
gccccgctca	ccctcgccga	ccagggcgcc	gtccagttcc	agctggccgt	ggacgcgccc	74880
gacggcgccg	ggcgccggac	cctgaccctg	cactcccgcc	gcgcgggtgc	cccggccgaa	74940
gagccgtgga	cacggcacgc	caccggcggt	ctcacgccc	aagcgtccgc	cgtgcccgcg	75000
caccccttcg	acctgaccgc	atggccggcc	gccgacgcgg	agcccgtgcc	caccgacgcc	75060
ttctaccccc	gcgcggccgc	ggccggcctc	ggctacggac	cggtcttcca	ggggctgcgg	75120
gccgcctggc	ggcgcgccga	cgaactgttc	gccgaggtcg	cactcgacga	ggagcacgag	75180
gccgacgccg	ccgcctacgg	gctgcacccc	gccctgctcg	acgcggccct	gcacgccatc	75240
ggcctcggag	cgcccgggcg	gcccggcgac	gccccggccg	aaggagccc	gctgcccttc	75300
gcctggaccg	gcgtacgcct	gtacgcggcc	ggcgcgccgg	gcacccgcgt	ccggctgacc	75360
gcccgcgcac	ccggcgccat	cgccctggac	gtggccgact	ccaccggagc	gccggtggcc	75420
tccgtcgagt	ccctgatcct	gcgccccgtc	tccgcggagc	agctcgccgg	ggaccgcacg	75480
gcccaccacg	agtcgtcttc	cggcgctcag	tggaccaggc	tgtccctccc	caccggtgcg	75540
atccctcccg	gcgaacgctg	ggccgtactc	ggcgaggacg	agccggacct	ccgggtcggc	75600
ggcgaacgcc	tcgacgtgta	cagcggcttc	acggcgctgc	gcgaggaaat	cgccgcgggc	75660
acctcggcgc	cggacgtcgt	cgctgtacc	ctgtcctccg	ccgcgtccgg	tggcggacgt	75720
gcggggaccg	cccggggccg	cgcgccacc	gcgctggccc	tgggtcaagg	gtggctggcc	75780
gacgaacggc	tcgacggcgc	acggctcgtg	ctgctgaccc	ggggcgccgt	ggccgccgta	75840
cccgcagagc	acgtgaccga	tctgaccac	gccccgggtg	ggggcctcgt	acggtccgcg	75900
cagtcggaga	accccgcccg	gttcgtgctc	gccgacaccg	acggcgccga	cgcctccttc	75960
ggggcgctgg	ccgccgcgct	cgccaccgac	gagccgcagc	tcgccctgcg	gtccggcgag	76020
gcacacgcct	tccggctgcg	ccgcatcgcc	cgtaccgcga	gcgatccggc	cggtgaaacc	76080
ggcacggggc	acggccccac	ccgtgccgac	gacgccggga	ggatcgccgc	cgacggcacg	76140
gtcctggtca	ccggcgcgag	cgccaccctc	ggcgggctct	tcgcccgcca	cctggccacc	76200
acgcacggcg	cacggcacct	gctgctgctg	agccgtcgcg	gggaccgggc	ccccggggcc	76260
ggggaaactga	cccgtgagct	gaccgaagcg	ggcgtggacg	tgacctgggc	ggcgtgcgac	76320
gcggccgacc	gggacgcgct	cgccgcgcta	ctcgccgcga	tcccggccga	ccggccgctg	76380
acggcggtcg	tccacaccgc	cgggtgtgctc	gacgacggca	tcacgactc	cctcacaccc	76440
gaacgcctcg	acaccgtgct	gcggcccaag	gtcgacgcgg	cctggaacct	gcacgagctg	76500
accgagggcc	acgaactctc	cgccttcgtg	ctcttctcct	cggtcgccgg	ctgcttcggc	76560
gccgcggggc	agggcaacta	cgccggcgcc	aacaccttcc	tggacgccct	cgcccgacac	76620

cgcaaggccc ggggcctcac cgccagttcc ctgcctggg gcctgtggga gacgacggac 76680  
ggcatggccg gcgcgctcga cgaagccgac ctgacccgca tggcccgcctc cgggtgtggcc 76740  
gcgctcgccc ccgacgaggg cctggccctc ttcgacacct cccgcaccct ggacgacgcg 76800  
gtcctcgtcc ccatgcggat cgaactgggc gcgctgcgcg ccagggccgc ggacggcacc 76860  
ctgccgcgcg tgctgcgcgg actggtgcgc actcccgcgc gccgggcccgc cggctccacg 76920  
gcacgcgcgc gaacgcgcgc cggcaccgac ccggcggggca ccctcgaaga gcgcctcgcc 76980  
ggactgtcgg ccgccgaacg cgaccgggccc ctcatggagc tggtcgcgac acaggtggcc 77040  
gcggtcctgg gctacgcggg ccccgacgac gtcgacgcgc cagggggctt cctcgacctg 77100  
ggcttcgact cgctcacggc cgtcgacctg cgcaaccgcc tcacggcgag cgccggactc 77160  
cggctgcccc tcacgctcat cttcgactac ccgtctccga ccgcgctcgc cgcgtacctc 77220  
gccgaacgcc tcggccaggg cgaccgtcc cgccggcccgc tccacgcgga actcgacaag 77280  
ctcgaatcga tcctctcgac ggtcggcccc gacgacgtcg aacgcgcggg catcaccgcc 77340  
cggctgcgag accttctggc gaagtggaat gaaacgcaca gtgcacagga cagcgccgca 77400  
gacgagcggg aaatccagtc cgcgacggcc gacgagatct tcgatctcct cgacgacgaa 77460  
ctcgggctgt cctgaccggc tcctgcccgg cggcgggccg gccggtgcgg agcaccggct 77520  
cccggccgcc cgcccgctcg gacccacct tccgatccac cggctccgcg cgagctttcc 77580  
gactctgacc acgggggatg cgtaaatggt gaacgaggag aagtacctcg attacctcaa 77640  
gcgggcgact accgacctcc gcgaggcacg acgacggctg cgcgaggtgg aggaacggga 77700  
gcaggagccg atcgccgtcg tggcgatgag ctgccgctac cccgggggga tcgacacccc 77760  
cgagaagctg tgggacctcg tcgcccacgg ccgggacgcc gtctccgcct accccacgga 77820  
ccgcggctgg gacgccgaag tcctcttcga ccccgacccc gagaccggga tcgaggcgta 77880  
cgaacaggtc ggcggcttcc tgcacgacgc ggccgacttc gaccccgcg tcttcgggat 77940  
ctcgccgcgc gaagccctcg ccatggacct ccagcagcgg ctgctgctgg aaacctctg 78000  
ggaggcgctc gagcggggcc gaatcgacct ggccgacctg cgcggcagcc gtacgggctg 78060  
cttcgccggc ctgatgtacc acgactacgc cgcccggtcg ttcagcgtgc ccgaggagat 78120  
cgagggcttc ctcggaacg gcagctccgg cagcatcgcc tcgggcccga tcgcctacac 78180  
cctcggcctc gaaggccccg ccgtcaccgt cgacacggcc tgctcctcct cactggctgc 78240  
cgtgcacctc gggggccagg cactgcgcaa cggcgagtgc acgctcgccc tcgccgggtg 78300  
tgtcaccgtc atgtcgacct ccggcacctt caccgagttc agccgccagc ggggcctggc 78360  
ggccgacggc cgctgcaagt ccttcgcggc cgcgggcgac ggtacgggct ggggcgaagg 78420  
cgccggcatg ctgctcctgg aacggctctc cgaagcccgc aggaacggcc accccgtcct 78480

ggcactcgtg cgcggttcgg ccgtcaacca ggacggcgcc agcagcggtc tgacggcccc 78540  
caacggggccg tcccagcagc gcgtcatccg ccaggcactc gccggtgcgc ggctgtcggc 78600  
caccaggtc gacgcggtcg agggccacgg caccggcacc accctcggcg acccgatcga 78660  
agcgcaggcc ctgctcgcca cctacggcca ggaccgtccc gacggccgccc cgctgtggct 78720  
gggctccatc aaatcgaaca tgggtcacac ccaggccgccc gccggtatcg cgggcattat 78780  
caagatgggtc atggcgatgc gccacggcat cctccccaag accctgcacg tcgacgagcc 78840  
gaccccgaaac gtcgactggc ccgagggcgc ggtctccctg ctcaccgagt ccgtgccgtg 78900  
gcccagagacc ggcgcgcccc gccgcgcggg agtctcgtcg ttccggcatca gcggcaccaa 78960  
cgcccacacc atcctcgaac agggcccgga cgcgctcgag gccgcacccg ggaccgagcc 79020  
ccccgcggcg gccgcaccgc ccgtgcccc gctctggacc ctctccgcca agagcccggc 79080  
cgcgctgcgc gcccaggccg ggaaactgca cgcccacctg accgcacacc ccggcctgcg 79140  
ccccggggac atcgcccact cgtcgcgct cggacgcacc gacttcgagc accgcgccgt 79200  
cctcacctcc gccgacgggc ccgtgggcct cgtccgtgcg ctggaagccc tcgcggaactc 79260  
ggctcccgag gacacggcac ccgccgacag ggcaccgggg gtcaccgggg gccgcccggc 79320  
cgccgggaag ctggcgcttc tgttcaccgg gcaggggagc cagcggctgg ggatggggcg 79380  
cgagctgtac gagacgtatc ccgtcttcgc gcaggctttg gacgcggtgt gtgagcggct 79440  
gaatctcgaa gtgccgctga gggatgtcct gttcggggcg gatgcgggtc tgctggacca 79500  
gacggtctac acgcagaccg cgttggttcgc ggtcgagggt gcgttggttc ggctgggtgga 79560  
gagctggggc ctgaagcccg acttcctggc gggtcattcg atcggtgaga tcgcgggccg 79620  
gcatgtggcg ggggtgttct cgctggagga tgcgtgcgcg ctggtgtcgg cgcgtggccg 79680  
cttgatgggt gcgctgccgg gtggcggcgt gatgatcgcc gtccaggcgt cggaggacga 79740  
ggtcctgccg ctgctcaccg accgcgtgag cattgccgcg atcaacggtc cgcagtcggt 79800  
cgtgatcgcg ggcgacgagg ccgacgcggt ggcgatcgcc gagtccctcg cggaccgcaa 79860  
gtccaagcgg ctcacgggtc gtcacgcctt ccattcgccg cacatggacg ccatgctgga 79920  
ggacttcggg gccgtggcgg agggcctgtc gtacgaggcc ccgcgcatcc ccgtcgtctc 79980  
caacctcacc ggcgccctcg tctccgacga gatgggctcg gccgacttct gggctccgcca 80040  
cgtccgcgag accgtccgct tcctcgacgg catccgcgcc ctcaccgagc gcaacgtcgt 80100  
ccacttcgtc gaactcggcc cggacgccgt gctgtcggcc atggcccagg actgcccctc 80160  
cgccgacacc gcggccttcg tgcccgtact ccgcaagggc cgttcggaga ccggttcgct 80220  
gaccgacgcc ctcgcgcggc tccatgtggg cggggtggcc gtcgactggg acgcgtacta 80280  
ctccggtacg gacgtccagc gcgtcgacct gccacctac gccttcagc gcgcgcacta 80340  
ctggctcgac gcaggccggc ccctcggcga cgtctcctcg gccgggctcg gtgcggccgg 80400

ccacccgctg ctcgggggccg cctggtggccct cgccgacctc gacgggtttcc tctacaccgg 80460  
ccgtctctcg ctcgacaccc acccctgggt cgccgaccac gccgtcatgg gttcgggcgt 80520  
actgccgggc accgccttcg tcgaactggc catccgcgcc ggtgaccagg tcggctgcga 80580  
cctgctcga gaactcacc tgcacgcacc gctcgtactg ccccgggccg gaggtgtgca 80640  
ggtccagttg tgggtcggcg caccggacgc caccggccgc cgcaccctgg gtgtgcactc 80700  
ccgccccgag ccgcacccg acgccgtcgg cccggacgcc gacgcggcgg agccgtggac 80760  
ccggcacgcc gacgggtgtg tcgccacggg tgccccgcag ccgtccttcg ccccgacgt 80820  
ctggccggcg gccgggtgca ggcccctgcc cgtcgacgag ctgtacgccg ggctcgccga 80880  
ggcgggcctc gaatacggc ccgccttcca gggcgtccgc gcggcctggg cgagcgacga 80940  
cgcgccctac gtcgagatcg cggccgccga cggacagtgg gccgatgcc cgctgttcgg 81000  
actgcatccc gcgtcctcg actcggcgct gcacgccatc ggtctggccg ggctcgtcga 81060  
ggacaccggc cgcggccggc tgcccttctc ctggtccggg gtgtccctgt acgccgtggg 81120  
cgctcgggtg ctgcgcgtac ggctggccaa ggccggaccg gacgcggtgt ccctggccct 81180  
cgccgacggc gccggacagc cctggggcga catcgccctg ctcaccctgc gccctgtctc 81240  
ggccgagcag ctggacaccg ggccggggcg tcaccatgac gcgtgttcc aggtggactg 81300  
gaccccgctg aacctgcccc gtgctgtcga cagccgctgg gccgtgctcg gcgagcccgt 81360  
ccccaccgac gagccggggc acggcggtggc gcgccacgcg gacgcggagg cgctgagcgc 81420  
ggccctcgac gcgggtgtct cggtgccgga tgccgtactc gtacgccacc ccgccctgcc 81480  
cgaaccacc cccgaggcgg tccaccaggc cgcgcaccgg accctcggcc tgctgcggca 81540  
ctggctcggc gacgaccggc tcgccgacag ccgcctcgtc ctgctcacgc acggcgcggt 81600  
cgccgcggga gacgcggacc aggtaccga cccggtgcac gccgtggtct gggggctggt 81660  
ccgtccgca cagtccgagc acccggggcc gttcctgctg atcgacagcg attccggtat 81720  
cgacacactc tcctggccga cgttcgggtg cgttctcgcc tccgaggagc cgcaggtcgc 81780  
cctgcgcggc ggctgggccc acgcaccag gctggccaag gttcccgcca ccgtaccgc 81840  
cgctgccgtc gtcgagacgt cgtcgtacga cctgacggc accgtcctcg tcaccggggc 81900  
cagcggcacg ctcgggcgac tcgtcgcccc tcacctcgtg accggggcgc gcgtacggcg 81960  
tctgctgctg ctgagccgtc ggggcgccga tgcccccggt gccggtgaac tggccgctga 82020  
gctgaccggg ttgggtgccg aggtgtcgtg ggccggcgtgt gacgcgggtg accgcgacgc 82080  
gctcgcggcc gtactggccg ccgttccgc agcgcacccg ctcaccgcgg tcgtccacac 82140  
ggccgggtgtc ctcgacgacg gcgtgatcgg ttcgctcacc ccggagcgcc tcgacacggt 82200  
ccttcgcccg aaggccgacg ccgtcttcca cctgcacgaa ctgaccgcgc acctgcccct 82260



gaccgccttc gtctctcttct cctccgcggc cgggggtcttc ggcgccaccgg gtcagggcaa 82320  
ctacgcccgc gccaaactcct tcctggacgc cctcgcccag taccggcgtg cccacgggct 82380  
ccccggccgg tcgctggcct ggggcctctg ggaggacgcc gaaggcatgg cgggcgcctt 82440  
cgaccgcgcc gacctcgacc ggatgaagcg cggcggagtc cacggactca ccgcctccga 82500  
gggcctcgcg ctctctgacc tcgcccagcg cctcggcgcg gaccgtgacg accagggcca 82560  
ggatcaggag acggccggac gggcgctgct cgtgccgatg cggctgacct ttcccgcctg 82620  
cgcccccggc gccgaagtgc ccccgctgtt cgggggatgt gtccgcacct ccgcgagacg 82680  
cgtcgcgggc ggagccacca cgggagccac caccggaacc gggcccgacc tctccgctct 82740  
cgaacggcgg ctctctggcc tcgacgcgc ggagcgggag cggctgctcc tcgacctcgt 82800  
ccgcggccat gtcgccgacg tgctcggcca cggctccccg gacgccatcg accccgaaca 82860  
ggccttcagc gagctgggct tcgactccct gacggcgggtg gaactgcgca accgcctggg 82920  
cgcgggccatc ggccggcggc tgcccgcac gctgatcttc gaccaccgg cctcgtctac 82980  
cctcgcccgt cacctctccg gtgaactcgc cgggtcccag gccgcgttgg cgccagccgg 83040  
gcccgcgccc accgtgaccg acgacgacct gatcgccatc gtggcgatga gctgccgcta 83100  
ccccggcggc gtgaccacct ccgaggagct gtggcagctc ctgcggggcg gcggggacgc 83160  
gatatccggc ttccccgccc accgcggctg ggacgtcgag tcgctgtacg accccgatcc 83220  
cgaccaccgc ggcacctcgt acaccgcga cggcggcttc ctgcgcgacg ccgccgcgtt 83280  
cgatccgacg ttcttcggga tcagcccgcg cgaggccgtc gggacggacc cgcagcagcg 83340  
gctcctctg gagaccacct gggaggcgtt cgaacgggccc gggatcgacc cggccaccgt 83400  
gcgcggcagc cggaccggtg tgttcgcggg cgtcatgtac cacgactacg cggccctgct 83460  
ggagcgtcgc aaggacggag cggacggctc cctcggctcg ggcagcaccg gcagcatcgc 83520  
ctcgggcccgc gtctcgtaca cttcgggtct cgaaggcccc gccgtcacga tcgacaccgc 83580  
ctgctcgtcg tcgctcgtgg ccctgcacat ggccatccag gcgctgcgca ccggcgagt 83640  
cgacatggcg ctggccggcg gtgtcaccgt catggcgacc cccggcacgt tcatcggtt 83700  
cagccgtcag cgcggcctgt ccgcccagcg ccgctgcgc gccttctcgg ccgacgccga 83760  
cgggtacgggc tggggcgagg gcgtcggcat gctcctcgtg gaacgcctgt ccgacggccg 83820  
ccgcaacggg catccgggtc tggccgtggc ccgtggctcg gcgatcaacc aggacggcgc 83880  
gagcaacggc ctacccgccc ccaacggccc ctgcgacgag cgcgtgatcc gcgcggccct 83940  
cgcgagcgcg ggctgtcgg ccgcccaggc cgacgcggtc gaggcgacg gcaccgggtac 84000  
gacgctcggc gatccgatcg aggcgcaggc gctcctggcc acctacggcc gggagcacac 84060  
cgaggacagc ccgctgtggc tcggctcgat caagtccaac atgggtcaca cgcaggcggc 84120  
cgccggtgtc gcgggcgtca tcaagatggc cctcgccatc cagcacggcg tgctgccgcg 84180

caccctgcac gcggaccggc cctcgcccca cgtggactgg tcgcagggcg ccgtctcgct 84240  
gctcaccgag tccgtcccgt ggccggagac gggccgtccg cgccgcgcgg gcgtgtcgtc 84300  
gttcggcatc agcggcacca acgcgcacac gatcatcgag caggcgccgg aggaggccac 84360  
ggtggccccg gccgacgcgg tggccgcgcc gagcgcgctg cccctgcagc tcgcggggccg 84420  
cagcgcggag gcgctctccg cccaggcccc tgctgtgagc gcacacctga ccgcacaccc 84480  
cgacgtcccc ctgcagacc tcgcctactc cctggccacg agccgtgcca ccttcgacca 84540  
ccgggcggtc ctggtcgca cggaggcac aacggccgcc acggccgtca cggcgctcga 84600  
cgccctcgcc gaccggcgca cggcaccggg cctggtgcgg ggcacggcca gcaagggcg 84660  
tcgcacggcg ttcctgttca cggggcaggg gagccagcgg ctggggatgg ggcgtgagct 84720  
gtacgaggcg catcccgtct tcgcgcgggc tctcgacgcg gtgtgtgatc gcctggaact 84780  
gccgctgaag gatgtgctgt tcggtactga cgcgggtctg ctgaacgaga ccgtgtacac 84840  
gcagccgggt ctcttcgccg tcgaggtggc gctgttccgt ctgctggaga gctggggtgt 84900  
gaagcccgac ttcttgccg ggcactcgat cggtgagatc gccgcagccc atgtggccgg 84960  
ggtgctctcc ctcgatgacg tgtgcgctct ggtggaggcg cgtgggcggg tgatgggtgc 85020  
gctgccgggc ggtggcgtga tgatcgccgt ccaggcgtct gaggctgagg tcttgccgt 85080  
gctgaccgac cgggtgagca ttgccgcgat caacggcccc cggtcggtcg tcatcgccgg 85140  
cgacgaggcc gacgcggtcg cgatcggtga gtccctcacg gaccgcaagt cgaagcggct 85200  
cacggtcagt cacgccttcc actcgccgca catggacggc atgctcgacg ccttccgtga 85260  
aatcgccgag ggtctgtcgt acgaggctcc gcgcacccc gtcgtctcca acctcaccgg 85320  
ggccctggtc tcggatgaga tgggttcggc ggacttctgg gtgcggcacg tccgtgaggc 85380  
cgttcgtttc ctggatggca tccacgcctt ggaggccgcg ggcgtgacga cgtacgtcga 85440  
actcgccccc gacggagtcc tgtcggcgat ggctcaggag tcgctgaccg gcgaggactc 85500  
cgtcttcgtg ccggctcctgc gctcgggtcg tcccgaggcc gagagcgtca ccacggccct 85560  
cgccaggcg catgtccgcg ggatcgccgt cgactggcag gcgtacttcg ccgggaccag 85620  
tgcccagcgc gtgcacctgc ccacctaccg cttccagcgc gagcactact ggcccagac 85680  
gggcatcccc ctgcccggcg acaccgctgg gctcgggctc gccgcgcggg gtcacccgt 85740  
gctgggtgcg gccgtgacac tcgcggacgc cgacggatgc gtccctaccc gtccgctctc 85800  
cctgcggacg catccctggc tcgcggacca cgccgtcatg gggtccttac tgcctccggg 85860  
aacggctctc gtcgaaactgg ccctgcatgc gggcgagcgc gtcggaaccc gtgccctgga 85920  
cgagctgacg cttcaggccc cgctgatcct gccgaacgag ggcgcgggtc agctgcaagt 85980  
cgtggtcggg gcgcccgatg ccgcgggcca ccgcacggtg gccgtgtact cccgcccgga 86040

cgccgacggc gaagcgtggg tccggcacgc cgacggactg ctggtggacg aggtccgggg 86100  
cgccgccgcc gacctcggcg tctggcccc ggccggtgcg accgccgttc cgggtggacga 86160  
cgcctacgcg atcttggaga cctcggggct cgcgtacggc cccctgttcc aggggctgcg 86220  
ggcggccttg cggcgagcag gagagctgtt cgcggaactg gccctgcccc cggaggcgca 86280  
ggcggacgcc gccgcgttcg ggctgcaccc tgcgctgctg gactcggcgc tgcacaccct 86340  
ggcgtgggt gatctgctgt ccggcgcgga cgcggaggaa acgcccggcg ccgcacggct 86400  
gccgttcgcc tggcgtggtg tccgcctcca cgcggccggg gccccggcg tacgggtccg 86460  
gctggccgag gccggtcagg gcgcggtgtc gctggaactg gccgactccg cgggtgcccc 86520  
cgtcgcctcg gtggattccc tggtagtgcg ggcgatgtcg cccgagcagc tcggcgcggc 86580  
gagcgccggc cgccaggagt cgttgttcca gatcgactgg gtggagccgg cggccgaccg 86640  
gacggcggct gcgaccgatg tcgaacgggc cctggtgggc cggagctgc ggggtctgga 86700  
cgccacgccg tacgccgacc tggccgcgct ggcggccgcg gactccgacg tgcccgaact 86760  
cgtgttcac accacgcgag cggagtcgga gccggagggc ctgccgggga cgggtgcacgt 86820  
ccgggccgct gacgcgtca cccacgtacg ggcatggctg gccgaggaac gcttcgcgctc 86880  
cgccccgctg gtgttcgtca cccgcggtgc catgaccgtg gggtcggacg aggccgtccg 86940  
cgatctcgcg ggtgcccgcg tgtggggtct ggtccgctcc gccggtaccg agcaccgccg 87000  
ccggttcgct ctcgtcgatc tcgacgacga cgacgtgctg cccgagcaga ccgtcctgac 87060  
ggccctggcc gcaggggaat cggaactggt cgtacgcgag ggatccctcc ttgtgccgcg 87120  
cctcgcgct gctgctgtcg ttgagggttc cggtcgtgaa ctggacgtcg acggcacggg 87180  
gttggtgacg ggtgcgagt gcaccttggg tggtttgttc gcccgtcatt tgggtggtga 87240  
gcgtggtgtg cggcgctgc tgttggtgag tcgtcgtggt ggggctgcgg aggggtgctgc 87300  
tgaactgggc gccgaactca cggagctggg tgctgatgtg cgggtggcgcg cgtgtgatgt 87360  
ggccgaccgt gaggcgcttg agtcggtcct ggccgggatt cccgccgagt atccgttgtc 87420  
gggtgtggtg cataccgctg gtgtgctgga cgacggtgtg gtgtcgtccc tgaccgctga 87480  
gcgcgtgtcg gcggtgctgc gtccgaaggt ggacgcggca tggaacctgc atgagctgac 87540  
ccgtggcctg gatctttctc tcttcgtgtt gttctcgtcg gctgccggtg tggtcgggtg 87600  
tgccggtcag gcgaactatg cggcggcgaa tgtgttcctg gacgctctgg ccagcaccg 87660  
cagggcccag ggtctggccg cgacctccct tgcgtggggg ctgtgggctg agccgggtgg 87720  
tatggcgggc gcgctggacg ctgatgatgt gtcgcgtctg ggccgtggtg gtgtcagcgg 87780  
gctgtccgcg ggggaggggt tggcgttggt cgacgcggca tccgcgtccg aacaggcctt 87840  
gttcgttccc gtgaagctgg acctggccgc cctgcgcgcc caggcgggta gcgggatgct 87900  
gccgcgctg ctcagcggtc ttgtccgtac cccaccgcgc cgcgccgcgg gcaccgcaa 87960

cgctgcggta tccgccccgg gggaccgcct cgccggattg tccgccgctg aacagggtggc 88020  
 gcacgtactg gagttgggtcc gtactcaggt tgccgcgggtg ctgggggtacg cctccccgga 88080  
 ggcgggtcgag aaggacagct cgttccgcga gctgggcttc gactcgctga ccgccgtcga 88140  
 gctgcgcaac ctgctcggcg cggcgacggg gctgcgcctg cccgccacgc tcgtcttcga 88200  
 ctacccgacc tcagcgggtcc tggccgacca cctgcgggtcg gagctgggtcg gaacggcgcc 88260  
 cgtgacatcg gctccgggtcg ttctcgcggc ccgggacgat gacgagccca tcgcgatcgt 88320  
 gggcctcggc tgccgctacc ccggcggcgt ggagagcccg gacgacctct ggcggtcgt 88380  
 cctggaaggc cgggatgcca tcacggagtt cccggaggac cggggctggg acgtggacgc 88440  
 gctgttcgac gccgaccccg accagcaggg tacgagttat gccgcgagg gcggcttcgt 88500  
 ccgcgacgcg ggccacttcg acccggcgtt cttcgggatc tcgccgcgcg aggccgtggc 88560  
 catggacccg cagcagcgac tcctcctcga aacctcgtgg gaggcgttcg aacgggcggg 88620  
 catcgacccg gcggccctgc gcggcagccg gaccggcgtc ttgcgggtg tgatgtacca 88680  
 cgactacgct tcccggctca cggccctccc cgagggcgtc gagggcttcc tcggcacggg 88740  
 caacgcggcg agcgtcatct ccggacggct gtcgtacgcc ttcggcctgg aaggcccgcc 88800  
 catcacctgc gacacggcct gctcgtcctc gctggtcgcc ctgcacctgg cgggtgcaggc 88860  
 gctccgcaac ggcgagtgtt ccctcgtctc cgcgggcggg gtcacggtca tggcgacccc 88920  
 cgctgccttc gtggagtcca gtcgccagcg cgggctcgcg gccgacggcc ggtgcaaggc 88980  
 gttctcggcc ggcgccgacg gcacgggctg gtccgagggc gcgggcgtcc tgctggtgga 89040  
 gcggctctcc gacgcgcggc gcaacggtca cccggtgctc gcggtggtcc gtgggtcggc 89100  
 gatcaaccag gacggtgcga gcaacggtct gacggctccg aacggtccct cgcagcagcg 89160  
 ggtgatccgc caggcgttg ccagcgcggg cctgtcggcg gcggatgtgg acgtcgtgga 89220  
 ggcgcacggc accggcacca ccctcggcga cccgatcgag gcgcaggcgc tcctcgccac 89280  
 ctatggccag gagcacacgg acgagcagcc gctgctgctc ggctcgatca agtccaactt 89340  
 cggccacacg caggccgccc ccggtgtcgc gggcatcatc aagatcgtcc aggcgatgcg 89400  
 tcacggtgtc gtccccaaga cgtgcacgt ggacgagccc accccgcacg tcgactggtc 89460  
 ggcgggcgcg gtctcgtctc tcaccgagca ggtggcctgg cccgaaaccg gccgtccccg 89520  
 ccgcgcggcg atctcttcct tcggcttcag cggcaccaac gcgcacgcca tcatcgagca 89580  
 ggccccgac cccgtctccg aggacctgcc cgacgcagga cccgacgtac ggccccagcc 89640  
 cgcccgact ccgggcagcc tgccgtggct cctctcggcg aaggcgcgcg acgccctgcg 89700  
 cgaccaggcc gcccggtctc gggcgcatgc catcgggcac cccgagctgt ccctcgccga 89760  
 catcggctac gccctggcca cgagcaggac cgcgctcgac cggcgggccc ccgtggtcgc 89820

cggggaccgc gaggagtcc tcgcgggact cgcggcgctc gccgaggggtg ccacggcggc 89880  
 cggcctgacg gagggatcac cggccggtgg caagctcgcc ttcctgttca ccgggcaggg 89940  
 cagccagcgc ctggccatgg gcaggagct gtactccgcc catcccgtct tcgcccgggc 90000  
 cctggacgcc gtgtgcgacg ggctcgccct ggacgtaccg ctgaagcagg tgctgttcgg 90060  
 gtccgacgcg gacctgctcg accggaccgc gtacaccag ccgcccctct tcgccgtcga 90120  
 agtcgcgctg ttccgcctgg tcgagagctg gggcctgaag cccgacttcc tggccgggca 90180  
 ctccatcggc gagatcaccg cggcccattgt ggccgggggtg ctctccctcg acgacgcctg 90240  
 cacgctggtc gccgcccgcg gccggctcat gcaggcactg cccaccggcg gcgtgatgat 90300  
 cgccgttgag gcatcgagg acgaggtcct gccgctgctc accgaccggg tgagcatcgc 90360  
 cgcgatcaac ggccccagt cggtcgtgat cgcgggtgac gaggccgacg cgggtggcgat 90420  
 cgcggagtcc ttcaccggtc gcaagtccaa gcggtctacg gtcagccacg ccttccactc 90480  
 gccgcacatg gacggcatgc tcgacgcctt ccgcgaggtc gccgagggac tgtcgtacgg 90540  
 gaccccgctc atcccggtcg tctcccacct caccgggacc ctggtcaccg acgagatgcg 90600  
 gtcgccggac ttctgggtcc ggcacgtccg cgaggcggtc cgcttctctg acggcatccg 90660  
 cacgctggag gacgcgggcg tcaccacgta catcgaactc ggccccggcg gcgtcctctc 90720  
 cgcgatgggt cagtcgtgcg tcacgcgcga cgacgcggcc ttcttcccg ccttgcgcgc 90780  
 ggaccgctcc gaagaggaga cgctcacctc ggccgtcgcc cgggcacacc tgcgcgggat 90840  
 caccgtcgac tgggacgcgt actactccgg caccggcgcc cggcgcgctc acctgccgac 90900  
 gtacgccttc cagaggcagc gctactggct ggaggcccc gccacgccc ccggcgggga 90960  
 cgtgacgtcc gccgggctcg gctccgcggg gcaccgctc ctcggcgcgg ccgtcgaact 91020  
 gccggactcg gacgggttcc tgttcaccgg gcggctctcc ctgcgcaccc acccctggct 91080  
 cggcgaccac aggggtggcg gcaccgtcct gctgccgggc gccgcgctgc tggaactcgc 91140  
 cgtgcgcgcc ggggaccacg cgggctgcga tctgctggag gacctcacgc tggaggctcc 91200  
 gctcgtactg cccgaggcgg gcggggtaca gctgcggctc gtcgtggccg aaccgacgc 91260  
 gtcgcgcagg cgggtgttcc acatctactc ccgcccggag gacgcggcct tcgaggagcc 91320  
 gtggaccggc caccggcg gtgtcctggc cgtcgagggc gcgcaccgg ccgaggcgga 91380  
 gtccgagtgg ccgcccgcg gagccgtccc ctgcccggtg gaggacctct acccgtcgct 91440  
 cgacgccatc gggctcggat acggtcccgc gttccgcaat ctgctgctgg cctggaagcg 91500  
 cggcgacgag gtgttcgccg aggtcgtctt cggcgaggac cggcggaccg aaggcgccct 91560  
 ctacgggctc caccggcg tgctcgacgc cgccctgcac gcggtcggcc tcggggactt 91620  
 cttccccgac gggcccagg gcgcgcggct gccgttctcg tgggacggcg tcgggctgca 91680  
 cgccgtgggc gccgcggcgc tccgggtacg gatggcaccg gccgggcagg acgcggtcac 91740

gctggccgctc tccgacgaaa cgggcccggcc ggtcctcacc gtcgactcgc tcgtcctgcg 91800  
tccgctggcc ctcgatggtc cgggcccggct cggcggagcg ggccggggac cgggttcggt 91860  
gcgcgacgcg ctgttccagg tcgactggca cgcgctgccg ctgcccagg cgcagtcacc 91920  
ggccgaaggc cgtctggccc tgctcggcgg cgacccgctg aagctggccg ccgcgctgga 91980  
gcgcaccggg gtcttgagc cgggcgcgct gttcggcacg gcctccgagg acaccggcgg 92040  
gcaccctcgc gacctgtccg ccctggcgga cgcggctcag ctggccgagg cactcgggga 92100  
gcccgcgccc gagaccgtcc tcgtctccct ggcacccgac ctgcgccca cgggcggcct 92160  
cgcgtcggcc gccacccgcg ccgcgcgga cgcgctggag ctgatccagg cctggctggc 92220  
ggacgagcgg ctgcgcggtt cagggtggc cctcgtcacg cggggcgccg tcgccacgga 92280  
ccccgacgcg gacgtggacg acctcgcgca cgcgcgggtg tggggactgg tgcgctccgc 92340  
gcaggccgag caccgccg ccgtgggttct ggtcgacctc gacgacgagg acgactccta 92400  
ccgggcccctg cccgcgcgc tcgacaccga tgagaccag ctgcgcgtgc gcgacggggc 92460  
cgtcctggcc ccgcgtctgg cgcgagcgg catcgcccc gcaacggatg cggcgggccc 92520  
ggacgttgcc cgggaccgg agggcacct cctcatcacg ggcccgagcg gcaccctcgg 92580  
cggcctgctg gcccggcacc tggtagcgga gcacggtgtg cggcatctgc tgctcaccag 92640  
ccgcaggggc gccgctgccc aaggcgccac ccaactcgca gacgaactcg tcacgttggg 92700  
tgcgaggtc acctggggcg cgtgtgacgc ggccgaccgg gacgcgctgg ccgcgctgct 92760  
ggagtccgta cccgcggccc atccgctgac ggccgtcgtg cacaccgccg gtgtgctgga 92820  
cgacggcacg gtcgagtcgc tgaccgccgg acggatggcg acggtgctgc ggcccaaggt 92880  
cgacgcccgc tggaacctgc acgaactgac ccacggactc gacctggccg cattcgtcct 92940  
gttctcctcg gcggccggtg tgttcggcaa cgccgggcag gccaaactacg cggcgggcaa 93000  
caccttcctg gacgccctcg ccagcaccg ccgcgccag ggcctcacgg ccgtctcact 93060  
ggcctgggggt ctgtgggacg acgaggcggg catggcagcc acctcgacg agcaggaccg 93120  
gcggcgctg agccgggggca gcatgaacct gctgtcgggtg gccgaggggc tcgcgctctt 93180  
cgacgccgcg ctgcggggcg gggcatcctc cggcgccgtg cccgagggcg cgcggaccgc 93240  
gagcgtactc gtgcccgcgc ggctcgactt ggccgtgctc caggcccaag tgggggatct 93300  
cgtaccgccc ttgctgcgc gcctgctccg tactccggta cggcgcaggg cgagcggcgc 93360  
ggcggccgac gcgcccgact cgtggcgca gcggctcgcc caactgccgc ccgccgaacg 93420  
ggaccgggtg ctgctcgacc tcgtctgcac ccagggtggc cagggtgctg gccacagcgg 93480  
cgcggccgcc atcgaaccgg gaagcgctt caaggaactc ggcttcgact cgtgaccgc 93540  
ggtggagctg cgcaaccggc tcggtgcgt gacggggctg cgcctcccc ccacgctcat 93600

ctctcgactac ccgacccccg aagcgctgag cggacatctg cgctccgcgc tgcccctcga 93660  
 cgaggacgga ccgtccgtct tcagcgaact cgaccggctg gagagcgctt tgggcgcggc 93720  
 ggacgcggac agcgtcacgc gttcacggat cadgatgcgc ctccaggccc tgatgaccaa 93780  
 gtggaacgac gcacaggacg cgaacggcgg cgcccccgac gaggacgccg acgacggcgc 93840  
 cctcgaaaacg gcgaccgacg acgagctgtt cgacctgctc gacaacgagc tcgggcgcctc 93900  
 ctgagaaaacc gcgcggcgcg cctcccttcc gggccttccg ggccggggggc gcgccgcccc 93960  
 gcaccaccgc aacagccacg ggatcccgcg cgccggggacc ccggggccacc cagacgaccg 94020  
 accgtacaac cgcctctctg gcatggagcc cagcaatgg tgaacgagga caagcttcgc 94080  
 gactacctca agcgggcgac cgccgatctg cgccaggccc gcaggcggct gcgcgaggtc 94140  
 gaggacaaga accaggaacc catcgccatc gtcgcgatga gctgccgcta ccccggcggc 94200  
 gtccgcagcc ccgaggacct gtggcggctc gtggagaacg gcgacgacgc cgtctccggc 94260  
 ttccccgtcg accgcggctg ggacgtggag gcgctctacg acgccgaccc cgacagctcc 94320  
 ggatccagct acgtcagcga gggcggcttc ctctacgacg ccgcgagctt cgacccccgc 94380  
 cccttcggga tctcgccgcg cgaggccctc gccatggacc cgcagcagcg gctgctcctc 94440  
 gaagcgtcct gggaggcgtt cgagcgcgcg ggcatcgacc cgtcgtccgt gcgcggcagc 94500  
 cggacggccg tggttcgccg tgatgatgtac cacgactaca ccgcgcgcct cgattccgtg 94560  
 cccgagggcg tcgaaggatt cctcggcacc ggcagctcag gcagcatcgc ctccgggccc 94620  
 gtggcctaca cgttcggcct ggagggcccc gcggtcaccg tcgacacggc ctgctcgtcc 94680  
 tcgctcgtca ccctgcacct ggccgtccag gcgctgcggg ccggcgaatg ctcgatggcg 94740  
 ctgcggggcg gtgtcaccgt catggcgacc ccgcgcacct tcaccgagtt cagccgccag 94800  
 cgccggcctc cgccggacgg gcgctgcaag cccttcgcgg ccgccgcgga cggtagggc 94860  
 tggggcgaag gcgtcggcat gtcctcgtc gagcgctt cggacgctca gcgcaacgga 94920  
 catccgatcc tcgcggtggt ccgcgggtcg gcgatcaacc aggacggtgc gagcaacggc 94980  
 ctgacggctc cgaacggtcc gtcgcagcag cgcgatcatc accaggcgct caccaacgca 95040  
 cggctgtcgg ccgcggatgt ggacgtcgtc gaggcgcacg gtacggggac gaccctcggc 95100  
 gaccgatcg aggcgcaggc cctgctcggc acctacggcc aggaccgccc ggccggacgc 95160  
 ccgctgctgc tcggctccat caagtccaac atcgccaca cccaggccgc cgccgggtgc 95220  
 gcgagcatca tcaagatggt cgaggcgatg cgtcacggag tggccccaa gaccctccac 95280  
 ctcgacgagc cgactccgca cgtggactgg gaggcggggc ccgtctccct gatcggcgag 95340  
 aagatcgctt ggccggagac cggtgaaact cgtcgtgcgg gtgtgtcgtc gttcgggttc 95400  
 agcgggacga acgcgcgtgt gatcgtcgag caggctccgg tggtcgagga ggtggcggg 95460  
 gatccggccg gtgaggtcga gggttcggaa ctgcgggtgg tgccgtgggt gttgtcgggc 95520

aagagtgcgg gggcggttgcg ggcgcaggcg gagcggttgt cggggtggct cgccggtgct 95580  
tcggctgcgg gtgtggcgtc ggttgacgtg ggctggtcgt tggcgtcgtc gcgggcccgg 95640  
ctggaacacc gggctgtggt gctgggcat cacgcggccg gtgtggggc ggtggcgctcg 95700  
ggtgtgatgg ccgcgggtgt ggtgacgggg tcggttgcgt gcgggaagac cgcgttcgtg 95760  
ttccccggggc agggctcgca gtgggtgggt atggcgggtg ggttgctgga ttccctcgccg 95820  
gtgttcgctg cgcgggtgga tgagtgtgcg aaggcgttgg agccgttcac tgactggctg 95880  
ttggtggatg tgctgcgggg tgtggagggt gcgccgtcgt tggagcgggt ggatgtggtc 95940  
cagcctgctc tgttcgcggt gatggtgtcg ttggcggagg tgtggcgggc tgctggtgtg 96000  
cgtcctgggtg cggtgatcgg tcattcgcat ggtgagatcg ctgcggcgctg tgtggcgggg 96060  
atcttgctgc ttgaggacgc cgcgcgagtg gttgcgttgc gcagtcaggc gatcggccgg 96120  
gtcctggcag gtctcggcgg gatggtgtcg gtgccgtgc ccgcgaaggc agtacgagag 96180  
ctgatcgctc cgtgggggtga gggccggatc tcggtggccg cggtgaaagg gccgtcctcg 96240  
gtggtcgttt cgggtgaggc cgccgccctg gacgagatgc tggcctcgtg cgagtcggag 96300  
ggtgtgcggg cgaagcggat cgcggtggat tacgcgtcgc attcggctca ggtggagttg 96360  
ctgcgggaag agcttgctga gctgctggct ccgattgttc cgcgcgctgc tgaggtgccg 96420  
ttcttgctga cggtgacggg tgagtgggtg cgaggcccgg agctggatgc tggttactgg 96480  
ttccagaatc tgcgccggac ggtggagttg gaagaggcga cgcggacgtt gctggagcag 96540  
ggcttcgggtg tgttcgtcga gtcgagccc caccgggtgt tgagcgtggg catgcaggag 96600  
acggtcgagg acgcggggccg ggaggcggct gttctgggtt cgctgcgtcg tggtgagggg 96660  
ggtctggagc gtttctggct gtcgctgggt gaggcctggg tccgtggcgt ggctgtcgac 96720  
tggcatgccg tgttcgcggg tacgggtgcc cggcgggtgg acctgcccac ctacgccttc 96780  
cagcaggagc actactggct cgaaagcggc accgccgagg acgtcacggc caccgcccac 96840  
cccgtcgacg ccgtcgaagc ccgcttctgg gaggccgtcg agcgcagga cgtggcggcg 96900  
ctcaccgccg agctggacgt ggacgagaac gagaacctca ccgcgctgct gcccgcgctg 96960  
tcgtcgtggc gtcggcagag ccgtgagcgg tccgccgtgg acggctggcg ctaccgggtg 97020  
acctggaagc ccgcgccgga gccacgacg gccgcctct ccggcacctg gcttggtgcc 97080  
gtcgccgagg gcgcgccggg tgatgagtgg acgtccgtcg tcctgcgtac gctcgccgaa 97140  
cacggcgccg acgtacggca gatcacggtc gccgggaccg aggacaccg ggccggtctc 97200  
gccgagcggg tacgtgacgt actcgggac ggtcccgcgg tgtegggagt cttgtccctg 97260  
ctgaccccgg cggggggcga cgagccgttc caggtctccg cgcccggcgg tgtgatcacc 97320  
accctgtccc tcgtccaggc gctcggcgac gccgaggtgg ccgcaccct gtggtgcgtc 97380



acgcgcggcg ccgtcgccac cggccgttcc gagcaggtgg ccgaccccg cgcaggctccg 97440  
 gtctggggcc tgggcccgggt gaccgcgctg gagcacggcg agcgctgggg agggctgatc 97500  
 gacctgcccc gcacggacgc cgtggacgac cgggcactcg cccggctcgc gggcgtcctc 97560  
 gccggtgacg ccgccgagga ccagggtggcg gtgcgcgcct ccggcctctt cgtacgacgg 97620  
 ctctgacgcg tccgtctcgc cgagacgccc gtctgacggg agtggcgctc gcagggcacc 97680  
 accctgggtca cgggcgggtac gggcgcgctg ggcgcgcacg tggcccgtg gctcgctgag 97740  
 aacggcgccg agcacctgct gctcaccagc cggcggggcc ccgacgcgcc cggagccgcc 97800  
 gcaactccgc acgaactcac cgccctcggc gcccaggtca ccatcgcggc ctgcatgtg 97860  
 agcgaccggg acgccgtcgc ggccctcatc gcccgggttc ccgccacca gccctcacc 97920  
 gccgtcgtgc acacggcggc cgtcctcgat gacgggggtca tcgaggcgct cacgcccag 97980  
 cagatcgagc gcgtcctgcg ggtgaaggtc gacgcgacgc tgcacctgca cgaactgacc 98040  
 cgcgagctcg acctgtcggc gtctcgtgtt ttctcgtcct tcgccgccac cttcggcgcc 98100  
 cccggccagg gcaactacgc gccgggcaac gcgttcctgg acgccttcgc cgagtaccgc 98160  
 cgggcatccg gactgccccg cacctccatc gcctggggcc cttggggcga cgggggcatg 98220  
 gccgagggcg cggtcgggtga ccggatgcgc cgccacgggg tcacgcagat gtcgcccag 98280  
 cgtgccgtcg ccgcactcca gcacgccctg gaccgcgacg agacgaccct gaccgtcgcc 98340  
 gacatggagt ggaagcgctt cgtcctcgcc ttacactccg gccgcgccag gccgctgctg 98400  
 cacgacctgc ccgaggcgcg ggaggatcatg gacgccacgc gcacggaggc ggcggaggac 98460  
 accggcagcg ccgccgcgct ggcccagcag ctgaccggcc ggcccaggc cgaacaggag 98520  
 cgactgctcc tcgaactggt ccgcaccgcc gtcgccgccg tcctcggcta cgcgggcccc 98580  
 gacgcggctg aggcggggcg ggcccttaag gagctgggct tcgactccct cacctccgtc 98640  
 gaactgcgca accgcctgaa cgcggccagc ggccctcaag tgccgccac cctcgtcttc 98700  
 gaccacccga cggccaccgt cctcgcccgg cacctgcggg ccgagttctt cggccagggc 98760  
 gccgcggccg ccgtgcccgt gccgatggcc gcggtctccg acgacgagcc gatcgccatc 98820  
 gtcgcgatga gctgccgctt ccccgggcgg gtccgcaacc ccgaggagct gtggcagctg 98880  
 ctacactccg agggtgacgg gctgtcccag ttccccctgg accgcggctg ggacgtcgac 98940  
 gcgctgtacg accccaaccc cgacgcgcaa ggcacctcgt acacgcggga gggcggcttc 99000  
 ctgtccgacg ccgcggcctt cgactcctcg ttcttcggga tctcgccgcg cgaggccctc 99060  
 gccatggacc cgcagcagcg gctgctcctc gaaacctcgt gggaggcggt cgagcggggc 99120  
 ggcatcgacc cgcagaccct gcgcggcagc cagtccgggtg tgttcgtcgg caccaacggc 99180  
 tctgactact ccaacctcgt acgggcgggg gcggacggcc tggaggggca cctggccacc 99240  
 ggcaacgcgg gcagtgtcgt ctccggccgg ctctcctaca ccttcgggtc cgaaggcccg 99300

gccgtcaccg tcgacaccgc ctgctcggcc tccctcgtcg ccctccacct cgccgtgcag 99360  
gccctgcgca gcggtgaatg ctgctcggcc ctggccggtg gcgtgacggt gatgtccacg 99420  
ccgggcacct tcacgcagtt cagccgtcag cgcggactct ccaccgacgg ccgctgcaag 99480  
gcgttctcct cggacgccga cggattcagc cccgcggagg gcgtcggcgt gtcctcgtc 99540  
gagcgccttt cggacgctcg gcgcaacggg catccgatcc tcgcgggtggg ccgtgggtcg 99600  
gcgatcaacc aggacggtgc gagcaacggt ctgacggctc cgaacggtcc gtcgcagcag 99660  
cgcgtcatcc ggcaggccct cgccaacgca cggctgtcgg ccgcggatgt ggacgtcgtc 99720  
gaggcgcacg gtacgggtac gacgctgggt gaccgatcg aggcgcaggc cctgctcgcc 99780  
acctacggcc aggaccgcc ggccggccgg ccgctgctgc tcggctccat caagtccaac 99840  
atcggccacg cccaggcggc ggccggtgtc gcggggtca tgaagatggg gtcgccatg 99900  
cagcacggag tgctgccga gagcctgcac atcgccgagc ccacgccga cgtcgactgg 99960  
agcgcgggcg aggtcgccct gtcaccgag gagcgggcct ggcccagac cggccgccc 100020  
tggcgggcg gcgtctcgtc gttcggcttc agcggcacca acgcccacgc catcatcgag 100080  
caggctccgg ccgaagcggg atccgacgac gaccgggaga ccctgagcc gtcggcccaa 100140  
cccctactgg tcgcgccac ccgggacgac tccgcgtccg cccgggacga ctccgcgtcc 100200  
gccccggacg gtcctgtatc cggcccgac gactccgtgt ccgaccgtcc cggcgtgctg 100260  
ccctggacct tgacggccaa gaccgagaag gcgctgcaag gccaggccga acgcctgctg 100320  
accagctca ccaccgctc tgacctgcga cttgtcgatg tcggccactc cctggcgacg 100380  
accgtaccg cgctcgacca gcgcgccgtc ctcatcggac gggaccgcc cgactacctc 100440  
ggagccctga ccgcactcg gcggggggac acctcccc tgctggtgca gggggcggtc 100500  
gtcgggggga agacggcggt cgtgttcccc ggacaggggt cgcaatgggt aggcattggc 100560  
gtggcgctgt tggacgcttc acccgtgttc gtcgccgag tggatgagtg tgcgaaggcc 100620  
cttgagccct tcaccgactg gtcgctgcgc gatgtactgc gcggcgctac aggcgcgccg 100680  
tcgttggaac gcgtggatgt ggtccagcct gctctgtttg cggatgatggg gtcgttggcg 100740  
gaggtgtggc gggccgctgg tgtgcgtcct gatgcgggtga tcggctactc gcagggcgag 100800  
atcgctgccg cgtgtgtggc gggcatcttg tcgcttgagg acgcggcgcg agtggtcgcg 100860  
ttgcgcagtc aggcgatcgg ccgggtcctg gcgggcctgg gcgggatggg gtccgtggca 100920  
ctgccggcga aggetgtgcg ggagctgac gtcctgtggg gcgaggaccg gatctcgggtg 100980  
gccgcgggtga acgggccttc ctccgtggtc gtttccgggtg agaccgccgc cctggacgag 101040  
ctgctggcct cgtgcgagtc ggacggcgtc cgggcgaagc ggatcgcggt ggattacgcg 101100  
tcgcattcgg ctacggtgga gttgctgcgt gaggagcttg ctgagctgct ggctccgatt 101160

gttccgcggg ctgccgaggt gccgttcctg tgcacgggtga cgggtgagtg ggtgcgcggg 101220  
ccggagctgg atggcgggta ctggttccag aacctgcgtc ggacgggtga gttggaagag 101280  
gcgacgcgga cgttgctgga gcagggcttc ggtgtgttcg tcgagtcgag cccgcacccc 101340  
gttctgacga tgggtgtgca ggagaccgtc gaggacgcgg gccgtgacgc ggctgttctg 101400  
ggctcgctgc gtcgtgggtga ggggggtctg gagcgtttct ggctgtcgct ggggtgaggcc 101460  
tgggtccgtg gcgtgggtgt ggactggagt gccgtgttcg cgggcacggg tgcgcggcgg 101520  
gtggatctgc ccacttacgc cttccagtcg cagcggttct ggccggaggc cgcgcccac 101580  
gaggctgtgg cgggtgtcggc ggagagtgcg atcgatgcgc ggttctggga ggccgtcgag 101640  
cgcgaggatc tcgaagcgcg gaccgctgag ctgcacatcg agggcgacca gccgctgacc 101700  
gcgctgctgc ccgcgctgtc gtcgtggcgt cggcagagcc gtgagcactc gacgggtggac 101760  
ggctggcgtc accgggtcac ctggaagccg ctggccgagg ccaagacctc tcgcctctcc 101820  
ggtacttggc tggctgtcgt tcccagaaac ggcccgccg acgagtggac gggggccgtg 101880  
ctgcgcgtgc tcgccgaccg cggcgcggag gtccgtactg tgaccgtccc ggccgacggg 101940  
gccgatcgtg accggctcgc cgccacgctg aaggccgaga cggacggggc cgctccggcc 102000  
ggagtgtgtt ccctcctcgc ccttgccgtc gaaagcgcgt aactccgtac gcacaccggg 102060  
ctcctcgcca ccgccgcgtc cgtccaggcg cttggtgacg ccgatgtggc cgcacccctg 102120  
tgggtgcgtca cgcgtggcgc tgtctccgtc gcccgtagcg agcgggtcca ggaccggcg 102180  
caggcgctcg tgtcgggctt cggacgcacg gtcgccctgg agtaccgga ccgttggggc 102240  
ggtctcgtcg acctgccgga gcaggccgac ggccgtacgc tcgaacgtct tgcgggtgtg 102300  
ctggccgggtg acggttccga ggaccagggt gcgctgcgcg cctcgggtct cttcggccgg 102360  
cgtctggtcc acgcacccct cgccgacacc gccgcggtac gggagtggcg tccgcagggc 102420  
acgaccctgg tcaccggtgg tacgggtgcg ctgggcgcgc acgtggcccg ctggctcgct 102480  
gagaacggtg ccgagcactt gctgctcacc agccgccggg gcccgacgc gcccggtgcc 102540  
gccgaactcc gcgacgaact cacggccctc ggcgcccagg tcaccatcgc cacctgcgac 102600  
atggccgacc gggacgccgt cgcggccctc atcgccgcg ttcgccgga ccagcccctc 102660  
accgcggtga tgcacacggc cgggtgtcctc gacgacggcg tgatcgacgc gttgactccg 102720  
gagcggttcg ggacggtgct cgcgggcaag gcggacgcgg ccctcaccct ccatgagctg 102780  
acccgcgagc tgggcctctc ggcgttcgtc ctcttctccg gtgtcgcggg cacgctcggc 102840  
gacgcgggac agggcaacta cgccgcgcga aactcctact tggacgccct cgccgagcag 102900  
cgtcacgccg acggcctcgc cgccacctcg gtggcctggg gtcgctgggg cgacagcggg 102960  
ctcgccgcgg gcggtgcgat cgggtgagcg ctcgaccgcg gcgggggtgcc cgccatggca 103020  
ccccgctcgg cgatccgcgc gctgcagctg gccctcgacc acgcggaggc ggccgtcgcc 103080

gtcgcgcgaca tccagtggga gcggttcgcg cccggctaca cggcgggtgcg gccagcccc 103140  
ttcctcgggtg acctgccga ggtgcggcag ctgcgcgcgt ccgctccggc ggccggtgaa 103200  
gcgggcgggg actccccggc cgaggcgctg cgcgcacggc tcgccgtcat gccgcaggcc 103260  
gaacaggccc tggccgtcct cgaactggtc cgctcccacg cggccaccgc gctgggccac 103320  
cccacgaccg acgaggtggg cgcggggccg cggttcaagg agctcggatt cgactccctg 103380  
atcgcgctgg aactgcgcaa ccggctcaac gcagccaccg ggctgaggct cccggccacg 103440  
ctcgtattcg accacccgac cccgacgac ctggccgagt tcctccgggc cgagatcacc 103500  
caggacggca gtgccggggc cgccccgggc atcacggaac tcgaaaagct ggagtccgcg 103560  
ctgtccgttc tcgaccgga cagtgaacg cgtaccgata tcgcactgcg cctgcaggca 103620  
cttctcgcga aatgggggtga accgcacatc gaatcaagtg gcgaggccgt gaccgagaaa 103680  
ctccaggagg ccacgcccga cgaactcttc gaattcatcg agaaagagtt cggtathtag 103740  
cacagcggac agcaggcagt agcagcgcaa gggtttgtga cgagaagcat gggtgagggt 103800  
ccaatggcag atcaggacaa gatcctcggg tacctgaagc gggtgacggc cgatctgcac 103860  
cagacgcgcc agcgccttcg tgaggtcgag gccaggagc cggagccgat cgcgatcgtc 103920  
ggcatgagct gcaggttccc cggcggcacc gagtcgcccg agggcctgtg ggacctggtg 103980  
gccggtgggc gggacgcgat caccgatttc cccaccgacc gtggctggga catcgagtcg 104040  
ctgtacgacg ccgaccccga ccagcagggc acctcgtaca cccgtgaggg cggattcctc 104100  
gacggcgctg ggaagttcga cgcgtccttc ttccgggatca gccgcgcga aacctcggc 104160  
atggacccgc agcagcgctt gtcctcgaac acgtcctggg aagccttcga aagagccgga 104220  
atcgacgcgg ctacctgcg cggcagcaag gccggtgtct tcataggcac caacggccag 104280  
gactatccgg agctgctgcg cgaagtcccc aagggtgtcg agggatatct cctcaccgga 104340  
aacgcggcca gcgtcgtctc cggccgcatt tcctacacct tcggcctcga aggcccgcc 104400  
gtcaccgtcg acaccgctg ctgggcctcg ctgctgcgcc tgcacctgcg cgtccaggcg 104460  
ctgcgcaacg acgagtgtc gctggcgctg gcgggcgggtg tcaccgtgat gtcgagcccc 104520  
cgcgcgttcg tacagttcag ccgccagcgc gggctcgcgc ccgacggacg ctgcaagccg 104580  
ttcgcgcacg gggccgacgg caccggctgg ggcgagggcg tcggcatgct gctcgtcgag 104640  
cggctctccg acgcccgcag gaacgggtcat cccgtcctcg ccctcgtgcg cggctcggcg 104700  
atcaaccagg acggcgcgag caacggcctg accgcgcca acggcccgtc ccagcagcgg 104760  
gtgatccggc aggcgctcac gaacgcggg ctcacccccg cgcaggtcga cgtcgtcgag 104820  
gcgcacggca ccggtacgac cctcggcgac ccgatcgagg cgcaggccct gctcggccacg 104880  
tacggccaga accgccccga ggggcgcccg ctgtggctgg gttccgtcaa gtcgaacatc 104940

gggcacacgc aggccgccgc cgggtgtcgcg ggcacatcatca agatgggtcct cgccatgcag 105000  
cacggcgtgc tgcccagatc gctccacatc gaccagccgt ccggcaacgt cgactggggc 105060  
gccgggtgacg tcaagctgct caccgaggcc gtgccgtggc cgcagaccgg ccagccgcgc 105120  
cgcgccggcg tctcctcctt cggcgtcagc ggcaccaacg cgcacaccgt catcgagcag 105180  
gccccgcccc cgacgacgc gccggagacc ggcgcggaca ccgcacccac cgccgaggcg 105240  
ccggaggcg cctccgcgga cgcttccgag gccgggacgc cgaccgggtgc caccggcccc 105300  
gtgccgggtgc tcgtctcggg ccagagcgac gccgcactgc gcgcccaggc cgagcgccctc 105360  
gccgcccacc tgcgcgcccc ccccgactc ggggcccaca ccggaaccct gaccgacctc 105420  
ggttttctgc tcgccaccag ccgctcctcg ctgcaccgca gggccgtcct gttcggcgac 105480  
cgggacagcc tgctcgccga cctcagcgcc ctgcgcgagg gcgagcagcc cgccggcccc 105540  
gtcctcggcg cgggtggcgga gggcaagacc gccttctctt tcaccggcca gggcagccag 105600  
cgcttgggca tgggacgcga gctgtacgcc acgcattccg gcttcgcccc cgccctcgac 105660  
gagggtccgc cggaactgga ccagcacctc gaacgcccc tggtcgacgt cctgttcgcc 105720  
gccgaaggca ccccgaggc ggacctgctc gacgagaccg cctacacca gagcgccctg 105780  
ttcgccgtcg aggtcgccct gttccggcag ctgaacagt ggggcgtcgg cgccgacttc 105840  
ctcatcggcc actccatcg cgaactcgcc gccgcccacg tctccggcgt gttcacctc 105900  
gccgacgcgg ccaagctcgt cgccgcccc gcgcgcctca tgcaggcgct gcccgccgac 105960  
ggcgcgatga tcgccgtcga ggccaccgag gacgaggtcg caccgctgct caccggccgg 106020  
gtgagcatcg ccgccgtcaa cggccccgc tccgtggtcg tctcgggga cgaggacgcc 106080  
gccacggcgc tcgccgagac cctgcgcgca cggggccgca ggacgaagcg gctcacggtc 106140  
agccacgcct tccactcgcc gctgatggac ggcattgctc acgcgttcg tgaggtcgcc 106200  
gagagcgtcg cctacgcgcc gcccgtcac ccgatcgtct ccaacctgac cggcgcctcc 106260  
gtcacgcgg aggagatctg cgccgcccac tactgggtgc gccacgtccg cgaggccgtc 106320  
cgcttctcgc acggagtcc caagctctcc gcgcaggcg tcaccacctt cgtcgagggtg 106380  
ggaccggggc gggctctcac cgccctggcg caggagtgcg tcaccggcca ggacgcgcgc 106440  
ttcgtgccc tctgcgcgg tgaccgccc gagggggcg ccttcgcgac ggccgtcgcc 106500  
caggcccatg tccacggtgt ggccgtcgac tggtcgcgcg tcttcgcgg gcgcggagcc 106560  
accgcacatg acctgccgac gtacgccttc cagcgcgagc tgtactggcc cgagcagccc 106620  
accgcctggg cgggcgacgt caccgcccgc gggatcggcg ccgcccacca ccgctgctg 106680  
ggcgcggcca tcgccctggc cgacggcgac gggcacctgt tcaccgggcg gctctcgctg 106740  
gccaccacc cctggctcgc cgaccacag gtgatggaca ccgtgctgct gcccggcacc 106800  
gccttcgtcg aactcgccct ccaggcgggc gaccacacc gctgcgacct gctggacgaa 106860

ctcacccctgg aagcaccgct ggtgctgccc ccgcacggcg ggggtgcagat ccagctcgcc 106920  
gtgggcgcg cgcacgccga gggccgcccgc tcgctgacac tgcactcccg gcccgaggac 106980  
gccgcccacg acacctgggg agaggggcgcc tggacgcgcc acgccaccgg ctctcctcgcc 107040  
accgcccgcc agggcgcccg cgagcccctc gccgacctca ccagctggcc gccgaagaac 107100  
gccacgaagg tcgacgtaga aggcctgtac gcgtacctca ccgagtccgg ctctgcctac 107160  
gggtccggtct tccagggcct gaccggcgcc tggcagcgcg gcgacgaggt ctctgcgag 107220  
gtccgcctgc cggagcaggc gcacgccgag gccgccctgt tcggtctgca tcccgcgctg 107280  
ctggacgccc cgctgcacgc cgtcggcatc ggctccctcc tggaggacac cgaacacggc 107340  
aggctgccgt tctcctggag cggagtctcc ctgcggggcg tcggcgcccg tgccctgcgc 107400  
gtccggctcg ccccgccagg caacgacacc gtgtcgggtga cctcgcgga cgagaccgga 107460  
gcgcccgtcg ccgcgctcga cgcgctgctg ctgcggcccg tctccccgga ccaggtgcac 107520  
gccgcccga ccgcctcca cgactcgctg ttccgcgtgg agtggaccgg tacgcccctc 107580  
ccggccgcca ccaccgtgc cgcgggcccag tggcgctgc tggcgagcc ccgtacggag 107640  
ttcacgccg cgctgcccac cgcgccacc cagccgacc tcgccccct cggcgcgggc 107700  
ctggacgccc ggcggccgggt cccgcgggcc gtcatcgtcc cgttctccgc gtccggcgcc 107760  
cctcggcga ctcccgctga cgcgcgctg cccaccgccc tcgccgacgc cctgcaccgc 107820  
accctggagc tcgccaggc gtggctcgcc gacgaccgggt tcgccggctc ccggctcgtg 107880  
ttcgtcacc gcgacgccgt cgcaccacc gccggatccg atgtcgccga cctggcccac 107940  
gccccgctgt ggggtctgct gcgctccgc cagtccgagc acccgaccg gttcgtcctg 108000  
ctggacctgg acggacgca ggactccctg cgggccctgc ccgcccgcgt cgcacggcc 108060  
gagccgcagc tcgccctgc cgcgggcaag gccctcgtgc cccggctcgc ccgggtcgcc 108120  
gccgcccccg gccaggaggc gcccgcgctc gaccccgacg gcaccgccct ggtcaccggc 108180  
gccaccggca cctcggcgcg cctggctgcc cgcacctcg tcgccgcga cggcgtccgc 108240  
cacctgctgc tgaccagccg gcgcggcgag gccgccgccc gcgccgccga actcgccgcc 108300  
ggactgcggg aactgggccc cgaggtcacc atcgcgccct gtgacggcg cgaccgcgac 108360  
gcgctcgccc cgctcatcgg gtccgtaccg gccgaacacc cgctcaccgc cgtcgtccac 108420  
accgcccggag tctcgcagca cggcgtcctc gaagcgctca ccccgagcg catcgacgcc 108480  
gtcctgccc ccaaggctga cgcggccgtg cacctgcacg agctgaccgg cgagctggac 108540  
ctcgcgccct tcgtcctgtt ctccgcccgc gccggcacc tcggcgggcc cggacaggcc 108600  
aactacgcc ccgccaacac ctctcctgac gcgctcgccc accggcgccc cgcgaagga 108660  
ctgcccgcca ccgcctcgc ctggggcctg tgggcccgaac gcagcgccat gaccggcgac 108720

ctcgccgacg ccgacctgga gcggatctcc cgcgccggag tcgccgccct gtcgtccgcc 108780  
gagggcctgg cgctgctgga caccgcccgc gccgtgggcg accccaccgc cgtcccatg 108840  
cacctcgacc tggcgctccct gcgccacgcc gacgcgagca tgggtccccgc gctgctgcgc 108900  
ggcctgggtcc gcgcgcccgc ccgcagggtcc gtcgagtccc cgggcgccgc cccggccggc 108960  
ggcctcgccg agcgcctgct gccctgacc gccgccgagc gcgaccggct gtcctggac 109020  
accgtccggg tccaggctgc cgcctctc ggctaccccg gccccgaggc cgtcgaccgc 109080  
ggcgtgcct tcaaggaact cggcttcgac tcgctgaccg ccgtagagct gcgcaaccgc 109140  
ctcgggtccg ccaccggcgt acggctgccc gccaccctcg tcttcgacta cccaccccg 109200  
aacgcgtctt ccgcgttcct gcggaccgaa ctctcggcg acgccgcgga ctcggccccg 109260  
gtcgcggccg tcaccgcccg tgacgacgag cccatcgcca tcgtcggcat gagctgccgc 109320  
taccgccggc gggtcaccac ccccgaggag ctgtggcagc tcgtcgccgg ctccgtcgac 109380  
gcgatctcgc ccttccccac ggaccgccc gcggaacctc acgcgctgta cgacgccgac 109440  
cccgccggg ccgggacctc gtacaccggc gaggcggtt tctgcacga cgcgccgac 109500  
ttcgaccggc acgtcttcg catcaaccgc cgcgaagccc tcgccatgga cccgcaccag 109560  
cggctcctcc tggagacgtc ctgggaggcg ttcgagcagg ccgggatcgc cccctcgtcc 109620  
atgcgcggca gccgcaccgc cgtgttcgcc ggctcatgt accacgacta cctgaccggc 109680  
ctcccgccg tgcggaggc cctggagggc tacctcggca ccggcaccgc gggcagcgtc 109740  
gcctccggcc gcatctcgta caccttcggc ctccaaggcc ccgccgtcac cgtcgacacg 109800  
gcctgctcct cctcgtcgtt cgcctgcac ctccggccc aggcctcgc caacggcgaa 109860  
tgcgacatgg cctcgcggg cgggtgcacc gtcattcca cccggacac cttcatcgac 109920  
ttcagccgc agcgcggcct ctccggcaac ggccgtgca agtccttctc cgcgacgcc 109980  
gacggaaccg gctgggcca gggcgccggc atgatcctc tcgagcggct ctccgacgcc 110040  
cgccgcaacg gccaccagg cctggcggtc gtccgcggca ccgccgtcaa ccaggacggc 110100  
gccagcaacg gcctgaccgc cccgaacggc cctcccagc agcgcgtcat ccgccaggcc 110160  
ctcgccaacg cgggcctgac caccgccgag gtcgacgtc tcgaggcgca cggcaccggc 110220  
accaccctc gcgaccccat cgaggcgag gccctcctc ccacctacgg ccaggaccgc 110280  
ccggccgggc agcgcgtcgc gtcgggtcc atcaagtcca acatcggcca caccaggcc 110340  
gcggcgggcg cggcgggcat catcaagatg atcctcgcca tgcgccacgg cgtcatgccg 110400  
ccgtcgtgc acatcggcg gccgtcccc cacatcgact ggaccgccc cgcggtctc 110460  
ctgctcaccg aggcggcca gtggcccgac gcgggccc ccgcgcgc gggcatctc 110520  
tccttcggcg tcagcgccac caacggccac gtcattcatg agcagccgc cgtcgaggaa 110580  
cccgccaccg cgaccgagc cggctccggc accggcctgc ccgccggc gccctgcg 110640

ttcgccctct ccggccggac ccccgccgcg ctgcgcgccc aggccgcccg gctgatcggc 110700  
cacctcgcgc cgcggcccga ggccgcccc gccgatgtgg cgctctcgct ggccaccacc 110760  
cgtaccgccc tggaccgcag ggccgcccgc atcgcgcacg accgcaccga gtcctcgcgc 110820  
gggctcaccg ccctggccga gggccacgac agcgcccggc tgggccagca caccgcccgc 110880  
gacggccgca ccgcgatcct gttcaccgga cagggcagcc agcgccccgg catgggacgc 110940  
gagctgtacg agacgtaccc cgccttcgcc gaggcgctgg acgcggtctg cgccgagctg 111000  
gacccgcacc tcgaacagcc cctcaaggag gtcctgttca ccgcccagcg cgacctgctg 111060  
aaccggaccg gccgcacca gcccgccctg ttgcgcgtgg agaccgccct gtaccggctc 111120  
gtcgaatcgt ggggcgtgcg ccccgacttc gtcgccgggc actccatcgg cgagatcacc 111180  
gccgcgcacg tcgcggggct cctctccctg cccgacgcgg ccaccctggc cgccgcccgc 111240  
ggccgcctca tgcaggaact gcccgagggc ggcgcgatga tcgcgctcac cgccaccgag 111300  
gacgaggtcc tgccgctgct ggccggccac gaggaccgca tcggcatcgc cgccgtcaac 111360  
tcagcctcct ccgtggtcat ttccggcgag gagggcctcg cgctggagat cgccgcccag 111420  
ttcgagcggc gcggtcggcg caccaagcgg ctcaccgtca gccacgcctt ccactcgccg 111480  
ctgatggacg gcatgctcga cgccttcgcg gaggtcgccg agtccctgac ctaccggggc 111540  
cccgccatcc cggtcgtcac gtcctcacg ggaacggctc ccggggacga actgcgacc 111600  
gccgagcact gggctctcca cgtccgcgag gcggtcgct tcctcgacgg catccgcacc 111660  
ctggacgccg agcacgtcac cacctacctc gaactcggcc cgcagggcgt gctgtccggc 111720  
ctcggccgcg actgcctcac cgaccccgcc gaccggccg acaccgccgt cttcgtaccg 111780  
gcgctgcgcc gcgaccgcgg cgaggccgaa gccctgaccg ccgcgatcgc cgcgccccac 111840  
acccgcggtg tgccgctcga ctggtccgcg tacttcgcgg gcaccggcgc ccgcccgcgc 111900  
gaactgcca cctacgcctt ccagcgcgag cggttctggc tcgaagcccc ggccggctac 111960  
atcggcgacg tcgaatcggc gggcatgggc gcggcccacc acccgctgct cggcgccgc 112020  
gtcgccctcg ccgacggcga aggattcctg ttaccggcc ggctctcgct cgacaccac 112080  
ccctggctcg ccgaccacgc cgtcatgggc aacgtcctgc tgccgggcac cgccttcgctc 112140  
gaactcgcca tccgcgcggg cgaccaggcc ggctgcgacc tcctcgaaga actcacctc 112200  
gaagcaccgc tgatcctcgc cccgcaggcc gcggcacgcc tccagatcgt ggtcggagcc 112260  
cccgacgggt ccggccgccc caccctggac gtgtactcca gcgaccgga cggccccgc 112320  
gacgagccgt ggacccgcca cgccggcggc atcctcgcca ccggggcaca ggcaccgc 112380  
ttcgacctga ccgcgtggc cccgccgggc gccgaagccg tcggcgctga cggcctctac 112440  
gaacacctcg gccggggcgg cttcgcctac ggtcccgtc tccaggggct gcgcgccgc 112500



tggtcctcgc gcgacgacgt gtacgccgag gtcgccctgc ccgacgaccg gcaggccgag 112560  
gccgcccggc tcggcctgca cccggcgctc ctgcacgcgg ccctgcacgc caccttcgtc 112620  
cagccgtccc ccgacgggga ccagcagggc cggctgccgt tctcctggcg cgatgtgtcc 112680  
ctgcacgcgg tcgggtgcgtc cgcgctgcgc gtccgcctca ccccgacgg ccgggacacc 112740  
ctctccctcc agctcgtgta caccaccggc gctcccgctc ccgccgtcgg ccacctgacg 112800  
ctgcggcccg tctccgccga ccagctcggc agcgcacgct ccgcacacca cgagtccctg 112860  
ttccggatcg actgggccac cgtgccgctg ccgtccgacg ccccgccgc cacggacgag 112920  
tgggccgtca tagccgcgga cggaggcacg gacggcggtta cggacggagg cacggacggc 112980  
ggcatccccg ccgccctccc cgggcgcgtg cacaccggcc tggacgccct cggcgccgca 113040  
gtgcacgcgg gcgccccggc gcccgccac gtccctggtg accacacccc cgcggccacc 113100  
accgccgacg ccgtccacgc ggccaccac gaggcgtcc gcctcgtccg ggcttggtc 113160  
gccgacgacc ggttcgccgc gtcccgctg gtcttcgtca cccgcggcgc gatcgccacg 113220  
cagagcgact gggacctcac cgacctgacc caccgccccg tgtggggact ggtgcgcacc 113280  
gcccagtcgg agaacccga ccggttcgtc ctgcgcgacc tcgacgccga cccggcctcg 113340  
acggacgccc tcgcccagc cctcgccacc ggcgagccgc agctcgcggc ccgccgtggc 113400  
accgtccacg cccccgcct cgcgcgcgtc ccgcgcgcca ccccgctgac cccgcccccg 113460  
ggcgagtccg cctggcgcat ggacatcgag gacaagggaa cgctcgacca cctcaccctc 113520  
gtccccagcc cggagtccgc cgcgcccctg gagcccgcc aggtccgcgt cgcggtccgc 113580  
gccgcgggccc tcaacttcg cgatgtgtc aacgccctcg gcatgtaccc cggcgacccg 113640  
ggcctcatgg gcagcgaagg cgcggcatc gtcgtggaga cgggcccccg tgtcaccggc 113700  
ctcgaccccg gcgaccgct catgggcatg ctgcccggct cgttcggccc gctcgcggtc 113760  
gtcgaccgcc gcatgatgc ccccatgccc gagggctgga ccttcgccga ggccgcgtcc 113820  
gtaccatcg tcttcatgac ggcgactac gccctccacg acctcgccg actgcagggc 113880  
ggcgagtccc tctcgtgca cgcgcgcgc ggtggcgctg gcatggcgc cgtccagctc 113940  
gcccgccact ggggcgcga cgtctacgc agggccagcc ccgccaagtg ggacaccctg 114000  
cgcggactcg gcctcggcga cgaccggatc gcctcgtccc gcaccctcga cttcgaggag 114060  
accttcgcga cggccaccgg gggacgcggc gtgcagctcg tactcgactc gctggccccg 114120  
gagttcgtcg acgcctccct gcggctcctg ccgcgcggcg gacgcttcgt cgaaatgggc 114180  
aagaccgacg tccgctcccc gcaggacgtc gccgacgccc accggggcgt cagctaccag 114240  
gcgttcgacc tgaccgaggc cggcctcgac cgcattcagg agatgctcac cgagctgctc 114300  
acctcttcc gctcggcgc cctgcgccc gtaccggtct ccgcatggga cctgcggcag 114360  
gccccgagg cgttcgcta cctcagccag gcacgccacg tcggcaagat cgtgctcacc 114420

ctgccgggag agtggaactc gcagggcacc gtcctcatca ccggcggcac cggcaccctc 114480  
ggcgcggtgg tcgcccggca cgccgtcacc acccgcgggc cccgccgcct gctgctcacc 114540  
agtcggcgcg gcgaggccgc cgccggcgcc gccgaactcg ccgccgaact gcgggaactg 114600  
ggcgccgagg tcacgatcgc ggcttgcgac gccgccgacc gcgacgcgct cgccgcgctc 114660  
atcgaatcca taccgtcaga gcacccgctg acggccgtca tccacaccgc cggagtctctc 114720  
gacgacggcg tcgtcgactc gctgaccccc gagcgctgtt ccacggctct gcgcccgaag 114780  
gtggacggcg cctggaacct gcacgagctg acccgtcacc tcgacctggc cgacttcgtc 114840  
ctgtttctct ccgccggcgg caccttcggc ggcgccggac aggccaacta cgcgcccgcg 114900  
aacgtcttcc tggacgcctt cgcccgccac cggcacgccc acggcctcgc cgccacctcc 114960  
ctggcctggg gcctgtgggc cgaggccagc ggcatgaccg gcgaactcga caccgccgac 115020  
aaggaccgga tgacgcgctc cggcgctctc ggctctctct ccgaagaggg cgtggcgctg 115080  
ctcgacaccg cacggctcac cggcgacgcc ctctctgtcc ccatgcacct cgacctggcg 115140  
ccgctgcgcc ggaccgacgc cagcatggtc cccgccctgc tgcgcggcct ggtccgcgcc 115200  
cccgccgca gggccgctcg agccaccgcc gccggcgccg gaaccccgct ggtggagcgg 115260  
ctcgtacggc tccccgagaa cgagcgcgac ccgctctgct tcgacctcgt acgccagcag 115320  
gtggccggcg tactcgcca cgccaccccc gacgccgtcg aaccacccg cgcgttcaag 115380  
gacctcggct tcgactcgtt gaccgccgtg gagttccgca accggctcgg cgcgaccgcc 115440  
ggcatccggc tgcccgccac gctcgtcttc gactacccca cccccacggt cctggccggc 115500  
tacctcaagg acgaactcct cggctccgag gccgcggccg ccctcccga gctcgccgcc 115560  
accgccgtcg agggcgacga ccccatcgcc atcgtcgcca tgagctgccg cttccccggt 115620  
gacgtccgca ctcccagga cctgtgggag ctgctcgccg agggccgca cggcatctcc 115680  
gacctcccg acgaccgcgg ctgggacacc gaggcgctgt acgacccga ccccgacagc 115740  
cccggcacct cctatgccag ggaggggcga ttcttctacg acgcccacca cttcgacctg 115800  
gcgttcttcg ggatcaacct gcgcgaggcc ctcgccatgg acccgagca gcgcctgctg 115860  
ctggagacgt cctgggaggg gttcgagcgg gccgggatcg acccgacggg cctgcgcggc 115920  
aagcaggtcg gcgtcttcgt cggccagatg cacaacgact acgtgtcccg gctgaacacc 115980  
gtccccgaag gcgtcgaggg ctacctcggc accggcggct ccagcagcat cgcctccggc 116040  
cgcgtctctt acaccttcga cttcgaaggc cccgccgtca ccgtcgacac ggcttgcctc 116100  
tcgtcgctgg tcgccctgca cctcgcggcc caggccctgc gcaacggcga gtgcacgctg 116160  
gccctcgcg gcggcgctac catcatcacc acccccagc tcttcaccga gttcagccgc 116220  
cagcgcggcc tcgccagcga cggccgctgc aagccgttcg ccgaggccgc cgacggcacg 116280

gcgtggggag agggcgctcg catgctgctc gtcgagcggc tctcggacgc ccgccgcaac 116340  
ggccaccagg tcctggcggt cgtccgcggc accgccgtca accaggacgg cgccagcaac 116400  
ggcctgaccg ccccgaacgg cccttcccag cagcgcgtca tccgccaggc cctcgccaac 116460  
gcggggcctga ccgccgccga ggtggacgcg gtcgaggcac acggcacggg cacccggtc 116520  
ggcgacccga tcgaggcgca ggcgctgctc gcgacctacg gtcaggaccg ccccgagggc 116580  
agccccctgt ggctgggctc catcaagtcc aacttcggtc acacgcaggc cgccgccgg 116640  
gtcgccggga tcatcaagat ggtccaggcg atgcaccacg ggggtgctgcc gaagaccctg 116700  
cacgtcgacg cgccgtcccc gcacgtggac tggtcggcgg gcgcgggtctc gtcctcacc 116760  
gagcagatgg cctggcccga aaccggccgc ccgcgccgcg cgggtgtgtc gtcgttcggc 116820  
atgagcggta cgaacgcccga cgccatcatc gaactcgccc cggacgcgcg cccccgagt 116880  
gccgcccggc cggagccggc cccggccgcc ctcccgtgga acctctcggc ccgcaccccg 116940  
gacgccctgc gcgccaggg cgagcggctg ctgtcccacc tggagacca ctgtgagacc 117000  
caccgggaga cgggtgctgc cgacatcggc cactcgctga cgaccggccg tgccctcttc 117060  
gagcaccgcg cgacgggtgg ggcgggcgac cgcgacggct tccgcgccgg actggccgca 117120  
ctcgccgaag gccggacggc ggcgggcctg atccagggtc cgtcctcgac cggcggtcgc 117180  
acggcgttcc tggtcacggg gcaggggagc cagcggctgg ggatggggcg cgagctgtac 117240  
gaggcgatc ccgttttcgc gcgggctctg gacgagggtg gtgcccgtct ggaactgcct 117300  
ctgcctctga aggatgtgct gtccggtact gacacgggtc tgctgaacga gaccgcgtac 117360  
accagccgg cgctgttcgc cgtcgagggt gcgctgttcc ggctgggtgga gagctggggc 117420  
ctgaagccgg acttcctggc gggtcattcg attggtgaga tcgtgctgc gcatgtggcg 117480  
ggggtgctct cgctggagga tgctgtgct ctggtgtcgg ctcgcgggcg gttgatgggt 117540  
gcgctgcctg gtgggtggcgt gatgatcgcg gtgcaggcgt cggagggcga ggtcctgccg 117600  
ctgctgaccg accgggtgag tatcgccgcg atcaacggtc cgcagtcggt cgtgatcgcg 117660  
ggtgacgagg ccgacgcggc cgcgatcgtg gagtcttct cggaccgcaa gtccaagcgg 117720  
ctcacgggtga gccacgcgtt cactcgcgcg cacatggacg gcatgttgga cgacttccgg 117780  
gccgtggcgg aaggcctgtc ctacggggcc ccgcgcaccc cggtcgtttc gaacctcacc 117840  
ggggccctgg tctcgatga gatgggttcg gcggacttct gggtcgggca cgtccgtgag 117900  
gccgttcgct tcctggatgg catccgcgcc ctggaggccg cgggcgtcac gacatacatc 117960  
gagctggggc ccgacggcat cctgtcggcg atggcccagg agtgcacac cggcgaggg 118020  
gcggccttcg cgcccgtcct gcggggcgga cgcgacgagg ccgagacggg gctctccgcg 118080  
ctcgcgggcg ctcacgtccg cggcgttccc gtcgactggc aggccttcta cgccccggcc 118140  
ggagcacagc gcgtgcccct gccgacgtac gccttcacg gctccgtcta ctggctggac 118200

gcggggccggg cacaggggtga catcgccctcc gctgggactcg gcgcgacgga ccatccgctg 118260  
ctcagcgccg cggtcgaact gcccgactcg gacggtttcc tcttcaccgg ccgcctgtcg 118320  
ctggccaccc acccgtaggt cgccgaccac gcggtcctgg gctccgtact ccttccgggt 118380  
acggctttcg tcgaactcgc gctgcggggc ggtgaccagg tcggctgcga cctgatcgac 118440  
gaactcactc tcgaagcacc gctgggtgctg ccccgccacg gaggcgtcca gctgcggctc 118500  
gccgtcgcgg ccgcccgcgc gacgggtcgg cgccacctgg cgttccactc ccggagcgag 118560  
gacgcggacg ccgggacgcc gtggaccgtg cagccctccg gtgtactcgc ggtcggggcc 118620  
gagcggactc cgcagagcct caccgagtgg ccgcccacg gggccgaatc cgtaccggtg 118680  
gacgggctgt acgagggcct ggccgaatcc ggcttcggat acggtccggt cttccagggc 118740  
ctgcgtgccg cctggcggcg cgacggcgag tactacgccg aggtcgccct gcccgagggc 118800  
acggaggacg aggccggacg cttcggcctc caccggccc tgctcgacgc ggcgtgcac 118860  
gcgctgggtc tgggcagcac ggacaccgaa ggcggcgaag gacggctgcc gttctcctgg 118920  
tccggtgtgc acctgcacgc cgtcgggtgc tccgcgctgc gcgtacgtct caccacgtcc 118980  
cgaagcgggtg aggtggcgct gaccatcgcc gacgcggccg gagagccggt cgcgaccgtg 119040  
gccggcctcg cgctgcgggc cgtgagccgc gagcagctga gcacggcacg ggacctcacg 119100  
cgtgacgcgc tgttccgggt ggactggact gcgttgctcg cgggcgggtgc cgtggggctg 119160  
ctggacgact ggatgttgtt gggtagcgggt tcgcaggtgt atgcggatct ggcggggctg 119220  
gggtgtggctg ttgcggaggg tggtaggatt ccggcggcgt tggtaggtgcc ggtttcggag 119280  
cctgatgcgg agtctgctgc gggtaggtgt gcgggtacgg tgcacgcggc tgttgagcgt 119340  
gcgctgtctc tggtagcagg gtggtgtgcg gacgagcgggt tcgcggatgc gcgtctggtg 119400  
ttcctgacgc ggggtgcgggt ggctgcgcgg gccggggaca cggttccggg gctgggtgcag 119460  
gccgctgtgt ggggtctggt gcgctcggcg cagtcggaga atccgggtcg ttccgctctg 119520  
atcgatgtcg acggcgacgg cgacggtgac ggtgaagtgg acggggacgt gctgtcggcc 119580  
gcgctcgcca ccggtgagcc tgagctggcg gtccgtgaag gggctttgct cgtgccgcgc 119640  
cttgcccgcg ccgctgtcgt tgaggggtgc ggtcgtgaac tggatgtcga cggcaccgtg 119700  
ttggtcacgg gtgcgagcgg caccctgggt ggcttggtcg ccgctcatct ggtgggtgag 119760  
cgtggtgtgc ggcggctgct gttggtcagt cgtcgtggcg aggctgcgga aggtgctgct 119820  
gaactgggcg ccgaactcac ggagctgggt gctgatgtgc ggtgggcggc gtgtgatgtg 119880  
gccgaccgcg atgcgcttga ggctgtcctg gccgggattc ctgctgagta tccgttgtcg 119940  
gggtgtggtc atacggctgg tgtgctggac gacggtgtgg tgcgtccct gaccccgag 120000  
cgctctcgg cggtgctgcg tccgaagggt gatgcggcat ggaatctgca tgagctgacc 120060

cgcggttttg atctgtcgct gttcgtgttg ttctcttcgg ctgccggagt gttcggcggt 120120  
gcgggtcagg cgaactatgc ggcggcgaat gtgttccttg acgctctggc ccagcaccgc 120180  
agggcccagg gcctggccgc gacctccctt gcctggggtc tgtggggccgg tgtggggcggc 120240  
atgggcgggtg agctgacgga atccgaccgc gagcgcatca accgcggcgg catcaccgct 120300  
cttgagcccc agaccggtct cgccctcttc gacgcggcac agcgaccac cgacgcactg 120360  
ctcgtcccc tcccgtcga cctggccgcc ctgcgcgtcc aggcgggcag cggaatgctt 120420  
ccggacctgc tgcgcggcct ggtccgcgta ccggtgcgcc gggcgggcgg gcagggaagc 120480  
gcggccgggg gcgggtcggt actccgtacc cgactggctg cgatgcccgc cgatgagcgg 120540  
gacgcggccc tgctggacct ggtccgggcc gaggtggcgg ccgtactcgg ccacgcgtcg 120600  
accgacgagg taccggccga ccgggcgttc aaggagctcg gcttcgactc gctgacctcg 120660  
gtcgagctgc gcaaccgcct cggcgccacc acgggtgaac ggctctccgc caccctcgtc 120720  
ttcgactacc cgaccccgca cgcgctcgcc gagttcctgc gcaccgaggt gctgggcctg 120780  
gacgagccga cggatacggc cacgaccgcc cccacgcacc tcgggacatc gctcgacgac 120840  
gacccgatcg cgatcgtcgg catgagctgc cggatcccc gcggggtcga gaccccgag 120900  
gacctctggc gcctgggtgg gggtgggcgc gacgccatct cggagttccc gcagggaagc 120960  
ggctgggacc ttgagtcgct ctacgaccgc gaccggacg gcaagggcac cagctacacc 121020  
cggtcgggtg gcttcctgca cgacgcgggc cggttcgacc cggcgttctt cgggatctcg 121080  
ccgcgcgagg ccgtggcgat ggacccgcag cagcggctgc tcctcgaaac ctctgaggag 121140  
gcgttcgagc gggccgggat cgacccggcc tcgatgcgcg gcagccggac cggtgtcttc 121200  
gcgggcatca tgtaccagca ctacgcgacc cggatcacct ccgttcggga cggggtcgag 121260  
ggctacctcg gcaccgaaa ctccggcagc atcgctccg gccgcgtctc gtacgccttc 121320  
ggcctggagg gcccggcggc caccgtcgac agggcctgct cgtcctcgct cgtcgccctg 121380  
cactgggcga tccaggcgct gcgcaacggc gagtgcacga tggcgctggc cggcggtgtc 121440  
accgtcatgt cgacgccggg caccttcacc gagttcagcc gccagcgcg cctggccgcc 121500  
gacggccgca tcaagtcctt cgcggccgcg gccgacggca ccagctgggc cgaaggcgcg 121560  
ggcatgctgc tcgtagagcg gctgtcggag gcgcgggcca agggccaccc ggtcctggcg 121620  
atcgtgcggg gctcggcgat caaccaggac ggtgcgagca acggcctgac cgctccgaac 121680  
ggtccctcgc agcagcgggt gatccgccag gccctcgcg gggcccggt gaccagtgc 121740  
cagatcgacg tgggtggaggc gcacggcacg ggcaccaccc tcggcgaccc gatcgaggcg 121800  
caggcgctcc tggccacgta cggccgcgag cgcgaggcgg accagccgct gtggctgggc 121860  
tcgatcaagt ccaacatggg tcacacgcag gcggccgccg gtgtcgcggg catcatcaag 121920  
atgatcatgg ccatccggca cggtgtgctg ccgaagaccc tgcacgtcga cgagccgact 121980

ccgcatgtgg actgggagggc cgggtgcggtc tcgctcctca ccgagtccgt cccgtggccg 122040  
gagacggggc gtccgcgccg cgccggtgtg tcgtcgttcg gtatcagcgg caccaacgcg 122100  
cacacgatca tcgagcaggg gccggaggag ttctgtcccg tccgtgtgac cgagtcgcag 122160  
acgccggggc cgggttcgcg agtgctgccg ttctgtttgt ccgcgaagtc ggccgggggcg 122220  
ttgcgtggtc aggcggtgcg tctgaaggcg catgtggagg cttcgccgga ggtgtctgga 122280  
gccggggccg ttgatgtggc gtattcgctg gcgacgcggc gtgcgggtctt cgaccaccgt 122340  
gcgggtggtg tggccgggtga ccgcgaggag ttgctgcgtt ctctggctgc tgtggagtcg 122400  
gagggcgccg cggtctggtg gaccctgggg gccgtgggtg gcggaaagct tgccttcctg 122460  
ttcacggggc aggggagcca gcggctcggg atggggccgtg agctgtacga gacgtatccc 122520  
gtcttcgcgc gggctctgga cgcggcgtgt gctcgtcttg aactgccgt gaaggatgcg 122580  
ctgttcggca ccgatgcggg tctgtcgggc gagacggcgt acaccagcc ggctctcttc 122640  
gcggctgagg tggcgttgtt ccgactgctg gagagctggg gtgtgaggcc ggacttcctg 122700  
gcgggtcatt cgatcgggtga gatcgcggcc gccatgtgg ccggggtgct ctccctcgat 122760  
gacgcctgcg cactggtcga ggcgcgtggt cgtctgatgc aggcgctgcc gaccggtggc 122820  
gtgatgatcg ccgtccaggc gtctgaggct gaagtcctgc cgctgctgac cgaccgcgtg 122880  
agtatcgccg cgatcaacgg tccgcagtcg gtcgtgatcg cgggtgacga ggccgacgcg 122940  
gtggcgatcg tggagtcctt ctcgggccgc aagtccaagc ggctcacggt cagtcacgcg 123000  
ttccactcgc cgcacatgga cggcatgctg gctggcttcc gcaagggtggc ggagagcctg 123060  
tcgtacgagg ctccgcgcgt cccggtcgtc tcgaacctca ccggggccct ggtcaccgac 123120  
gagatgggtt cggccgactt ctgggtgcgg cacgtccgcg aggcgtccg cttcctggac 123180  
ggtatccga ccctggaagc cgcaggcgtc gcgacgtacg tcgaactcgg ccccgatggc 123240  
gtcctgtcgg cgatggccca ggactgcgtc accggcgagg gtgcggcctt cgcgcccgc 123300  
ctccgcaagg gccgccccga gaccgagacg atcaccaggg ccctcgccct tgcacagcc 123360  
cacggcacgt ccgtcgactg ggagacgtac ttccgggga ccggcgccca gggcgtcgag 123420  
ctgccgacct acgccttcca gcgtgactgg tactgggtga actcggccgt ggtgcaggcc 123480  
ggtccggggc acgcgagcgg attcgggctc ggccgcgaccg atcaccctt gctcgacgcg 123540  
accatcgaac tgcggactc ggacggcttc ctgttcacca gcaggctgtc cctcgacacg 123600  
cagccgtggc tcgcggacca cgcgtcctg ggtcgggtcc tcctccggg cacggccttc 123660  
gtggaaatcg ccgtacgggc aggtgaccag gtcggttgcg acgtactgga agagctgacg 123720  
ctggaggcac cgctgggtgt gcccgagcgg ggccggtgtc agctgcggct caccgtcgcc 123780  
gccgcccagc agtcgggacg gcgaggtctg tcgctgtact cccgcgacga ggacgtccc 123840

gccgacgagc cgtggacgcg ccacgccagc ggcgtgctcg ccaccggcgc ggcggcccc 123900  
gacttcgacc tcgccgcctg gccccggcc ggagccgaac cggtcgacat cgacggcctg 123960  
tacgaggggc tggccgcggc cgggttcgac tacgggtccgg ccttcaggg cctgcgcacg 124020  
gcatggctgc acggcgacgc ggtgtacgcc gaggtgagcc tggacgagga gtccgcggaa 124080  
tcggcggaat ggttcgggct gcacccggcc ctctggagc cgacgctgca cgcgcggggt 124140  
ctcggcggtc tcgtggagag caccggccag ggacggcttc cgttcgcctg gagcaatgtg 124200  
tcctgcacg cgccggcgc gtccgcggta cgggtccggc tggccccggc cgcccgtagc 124260  
gcggtgtctc tgcagctcgc cgacgcggcg ggcgcaccgg tcgcctcggc cgaatcgctg 124320  
gtgctgcggg cggctctcgc cgaccagatc ggcgcggcgc gcggcgcccg tcacgagtcg 124380  
ctcttcgaga tcgactgggc cgccctcccg ctgcgccggc tgtccgctgc cgaacagcgc 124440  
ccctgggcgc tgcgtggcgga cgacgggtcc ggccacgcgg gactcgaagc cgtgggtgtc 124500  
cgtcacgagg cccacaccgg actcgcggcg ctgcgcgaca ccggacgggc gatccccgag 124560  
gtcgtgtgcg tcccgcctgc tgcggcgaac tcccaggacc tggcggtgc ggggtgcggtg 124620  
cacgcggctg tggagcgtgc gctgggtctg gtgcaggagt ggttgtcgga cgagcggctc 124680  
gcggatgcgc gtctggtgtt cctgacgcgc ggtgcggtgt ccgcggtgcc gggcgaggac 124740  
gtgaccgata tgggtccacgc tccggtgtgg ggtctggtgc gttccgcgca gtccgagaac 124800  
ccgggcccgt tcgtcctggc cgacaccgac ggcaccgacg cctcctaccg tgccctgacg 124860  
gccgcgctcg cctcgggcga gccggagttc acggtgcggg gcggcgcggt acgggtgccc 124920  
aggctgacgc gctccactgc tgcgctgtg gaggtgtgtc ccgaactcgg ttcggacggc 124980  
acgggtgttg tgacgggtgc gagtggcacg ttgggtggtt tgttcgcccg ccatttggtg 125040  
gttgagcgtg gtgtgcggcg cctgctgttg gtgagtcgtc gtggtggggc tgcggagggt 125100  
gctgctgaac tgggcgccga actcacggag ctgggtgctg atgtgcggtg ggcggcgtgt 125160  
gatgtggccg accgtgatgc gcttgagtcc gtcctggccg ggattcctgc tgagtatccg 125220  
ttgtcgggtg tgggtcatac ggctggtgtg ctggacgacg gtgtggtgtc gtccctgacc 125280  
ccggagcgcc tctcggcggt gctgcgtccg aagggtgatg cggcatgaa cctgcacgag 125340  
ctgacccgcg gtttgatct gtcgttcttc ctgttgttct cgtcggctgc cgggtgtgtc 125400  
ggtggtgccg gtcaggcgaa ctatgcggcg gcgaatgtgt tcctggacgc tctggcccag 125460  
caccgcaggg ccagggcct ggccgcgacc tcccttgctg ggggtctgtg ggctgagccg 125520  
gggggcatgg cgggcgcgct ggacgctgat gatgtgtcgc gtctgggccg tggcggtgtc 125580  
agcgggctct ccgcgcagga ggggtgtggc ttgttcgacg cggcgtccgc ctccgaacag 125640  
gccctgttcg tcccgtgaa gctggacctg gccgccctgc gcgccagggc gggtagcggc 125700  
atgcttcgc cgctgctcag cggctctgtc cgtaccccca ccgcgcgcgc cgcgggcacc 125760

ggcggcaccg gagacaccgg cacggacggt gggaccgcgc tgcgggagcg cctggccggg 125820  
ctcgcaccgg ccgcgcggga cgaagcgctg ctggagctcg tctgcacgta cgtcgcggcg 125880  
gtgctcggct tcgccgggccc cgaggcggtc gatccggcgc ggtcgttcag cgaggtcggc 125940  
ttcgactcgc tgaccgccgt cgagctgcgc aacaggctcg gcgccgcgac cggcgtagcg 126000  
ctccccgcca cctcgtctt cgactaccgg acaccggacg cgtcgttgga gtacctgcgc 126060  
gacgaactct ggcaggacgg cgccgcggcg gtacccccgc tgctcgccga actcgaccgg 126120  
ctggagaaga cgctcgtggc gtccgtgccc gacgacgacg gccgcacccg catcaccgag 126180  
cggctgcagg cctcgtcggc cgcctggagc gaggccggcg aatcaacgga caccgccgac 126240  
gccgatgtgg ccgaggcgct tgagaccggc accgacgatg acctcttcga cttcatcggc 126300  
aaggagtctg ggatctcgtg atgcgaaggc ccggtccgc cctttccgac ggctctgtct 126360  
ttctggcttc tgtacgaggg atgcacgcat gaatgaggaa aaactccggt acttcctgaa 126420  
gcgggtgacg gccgatctcc acgagacgcg ccggcgctct caggaggctc agtcggagga 126480  
gcaggagccg atcgcgatcg tcgggatgag ctgccgctac ccgggagacg tcgagtcgcc 126540  
cgaggacctg tggcggctgg tgtccgagga gaccgacgcc atctccccct tccccaccga 126600  
ccggggctgg gacatggggc ggctcttcga cggggacccc gacggggcgg gcacgagcta 126660  
tgtgcaggaa ggcggcttcc tgcactccgc caaccggttc gaccggcggt tcttcgggat 126720  
ctcgcgcgcg gaggccgtgg cgatggaccc gcagcagcgg ctgctcctcg aaacctcgtg 126780  
ggaggcgctc gagcggggcc ggatcgaccc gacctcgtc cgcggcagcc ggaccggcgt 126840  
cttcgcgggc gtcatgtacc acgactacgc ctcgcggctg cgtgccgtcc cggaggaggt 126900  
cgagggttac ctcggcaccg gcggctccag cagcatcgcc tcgggccggg tctcgtacac 126960  
cttcggcctg gaggggcccg cgctcaccgt cgacacggcc tgctcgtcct cctcgtcac 127020  
gctgcacctg gccatgcagg cgctccgcaa gggcgagtgc tcgctcgccc tcgcgggcgg 127080  
tgtcaccgtg atggcgacac cgggcacctt cacggagtcc agccgccagc gcggtctgtc 127140  
cttcgacggc cgctgcaagt ccttcgcgga ctccgcggac ggcaccggct gggccgaggg 127200  
cgcgggcatg ctctcgtgg agcggctctc ggacgcccgt aagaacggcc atacggtact 127260  
cgccgtggtc cggggctcgg ccgtcaacca ggacgggtgcc agcaacggcc tgaccgcccc 127320  
gaacggcccc tcccagcagc gggtcattcc gcaggccctg gccgacgcc gcctcacggc 127380  
ggccgacgtc gacgtcgtgg aggcacacgg caccggcacc acctcgggtg acccgatcga 127440  
ggcgcaggcc ctgctcgcca cgtacggccg ggaacacacc gaggacagcc cgctgtggct 127500  
cggctcggtc aagtcgaacc tcggtcacac ccaggcggcc gcgggcgtcg ccggcatcat 127560  
caagatggtc atggcgatcc gccacggccg gatccccaag acgctgcatg tcgacgagcc 127620



gtcgaccaac gtcgactggt cggcggggcgc cgtctcgctg ctgcgggagt ccgtgggagt 127680  
gccggagacc ggccgccccgc gccgcgcggc gatctcttcc ttcggcatca gcggcactaa 127740  
tgcgcacacg atcatcgagc aggctccgct gccggaggcc gagaccgaaa ccgagccgac 127800  
cggcgacgag acggacggct ctgagagcac ggcgggggca gaggggacag aggggacaga 127860  
gggcgcgggg gtgcggccccg tgtccgtgcc tcccgtcctt ccgtggccccg tctcggccccg 127920  
tacggaggag gccctgcacg cccaggcgga acgcctgctg gccacgtgc ggaccaaccc 127980  
ggaccaggcc ccggtggggcg tcgctctctc cctggccaca gggcgcgccg cgctggaaca 128040  
ccgcgccggt gtcgtcgcca ccgaccggga aaccgccctc gccgacctcg ccgactggc 128100  
gtccggcgag acctcggcgc gcgtcgctgt cggcgagccg ggagcgcggg gcaagaccgc 128160  
gttcctgttc acggggcagg ggagtcagcg gctggggatg gggcgcgagc tgtacgagga 128220  
gtatcccgtc ttcgcggatg cgctggacgc ggtgtgtgcc cgtcttgaac tgcctctgaa 128280  
ggatgtgttg ttcggggcg atgcgcgtct gctggacgag accgcttata cgcaaccggc 128340  
gctcttcgcc gttgaggtgg cgttgttccg gttggtggag agctggggtc tgaagcccga 128400  
cttcctggcc gggcattcga tcggcgagat cgccgccgcg cacgtcgcgg ggggtgttctc 128460  
gctggaggat gcttgcgcgc tgggtgtcggc tcgtggccgg ttgatgggtg ccctgcctgc 128520  
gggtggcggt atgatcgcg tgcaggcgct ggaggacgag gttctgccgc tgctgacggc 128580  
ccgggtgagc attgccgcga tcaatggtcc gcagtcgggt gtgatcgcg gtgacgaggc 128640  
cgacgcggtc gcgatcgtgg agtccttcac ggggcgtaag tcgaagcggc ttacggtcag 128700  
tcacgcgttc cattcgccgc acatggacgg gatgttgaa gacttcggg tcgtggcgga 128760  
ggggctgtcg tacgaggctc cgcgcattcc cgtcgtttcg aacctcaccg gggccctggg 128820  
ctcggatgag atgggttcgg cggacttctg ggtccggcac gtccgtgagg ccgttcgctt 128880  
cctggatggc atccggggcc tggaggccgc gggcgtcacg acgtacgtcg aactcgggcc 128940  
cgacgggtgtc ctgtcggcga tggcccaggc atgcgtgacc ggcgagaact ccgtcttcgt 129000  
gccggtcctg cgctcgggtc gctccgaggc ggagagcgtc accacggccc ttgcccaggc 129060  
gcatgtccgc gggatcgccg tggactggca ggcctacttc gccggtaccg gtgccgagcg 129120  
cgtcgacctg cccacctacg cttccagcg cgaccactac tggctcgacg ccggaacgct 129180  
cggcgagac gtgaccagcg cgggccttcg atccgccgat caccctctgc tcggcgccctc 129240  
tgtggctctg gcggatgcgg agggccttct cctcaccggc cggctctcgc tcgacacca 129300  
cccgtggctc gccgaccacg ctgtggcggg gacggctcctg ctgcccggtg cggcggttcgt 129360  
cgaactcgcg ctgcggggcg gtgaccaggt cggctgcgac ctgatcgacg aactcaccct 129420  
cgcgggcgccg ctggtgctgc ccgagcaggg tggagtcgaa ctccagatca ccgtcgcggc 129480  
ccccgacgaa tcggggccgc ggtccgtcgc cttccactcg cgcgccgaca gcgcccgga 129540

cgacgaggcg tgggtccggc acgcgaccgc agtactggcc gagggcgcg acacccccgt 129600  
gttcgacttc ggcgtctggc cgccgaccgg ggctgaatcc gtaccgggtg acgggctcta 129660  
cgaggggctc gcgcactccg gattcggcta cgggtcccgtg ttccaggggc tgcgtgccgc 129720  
ctggcgccag ggcgaggacg tggtcgccga agtgagcctc ggggacgggg tcgagcccgg 129780  
agcagcgcac ttcaccgtgc acccggccct gtcgactcc gccctgcacg ccatcaacct 129840  
cggcaccctc gtcgaggaca ccggccaggg gcgactgccg ttcgcatgga gcggggctgc 129900  
ggttcacgcc gtggggggcg acaccctgcg cgtacggctc tcccgggccg gtcaggacgc 129960  
ggtggccctg gagatcgcg acgcggacgg cgcgcccgtc gcttccgtac gcagcctggc 130020  
cctgcgcgcc ttctcacccg accagctgac cgggccggac ggcgccggtc acggcgacgc 130080  
gctgttccgg gtggactggg cggcggttgc tgcgggcggt gcggtcgggt cgctggacga 130140  
ctggatgttg ttgggtgctg gttcgcaggt gtatgcggat ctggcggggt tgggtgtggc 130200  
tgttgccgag ggtgggtggg ttccggcggc gttggtggtg ccggtttcgg agcctgatgc 130260  
ggagtctgct gcgggtggtg tggcggtg gcgtgcatgc gctgttgagc gtgcgctggg 130320  
tctggtgcag gagtgggtgt cggatgagcg gttcgcggat gcgcgtctgg tgttcttgac 130380  
gcgggggtgc gcggctgcgc gggccgggga cacggttccc gggctggtgc aggcggccgt 130440  
gcgggggtctg gtgcgctcgg cgcagtcgga gaacccgggc cgtttcgtc tgatcgatgt 130500  
cgacggcgat ggtgaagtgg atgcggaggt gctgtcggcc gcgcttgcta cgggtgagcc 130560  
cgagctggca gtccgtgaag cggccttgct cgtgccgcgc cttgcccggt ccgctgtcgc 130620  
ggtggagcct gcgcccgaac tcggttcgga tggcacgggt ttggtgacgg gtgcgagtgg 130680  
cacgttgggt ggtttgttcg cccggcattt ggtggttgag cgtggtgtgc ggcggtgct 130740  
gttggtcagt cgtcgtggtg aggctgcgga aggtgctgct gaactgggcg ccgaactgac 130800  
tgggttgggt gctgatgtgc ggtgggcggc gtgtgatgtg gccgaccgtg aggcgcttga 130860  
gtcggtcctg gccgggattc ctgccagta tccgttgctg ggtgtggtgc ataccgctgg 130920  
tgtgctcgt gacggtgtgg tgcgtcgt gactgccgag cgtgtgtcgg cggtagctgc 130980  
tccgaagggt gacgcggcgt ggaacctgca cgagctgacc cgtggcctgg atctctcgt 131040  
cttcgtgttg ttctcgtcgg ctgccggtgt gttcgggtgg gccggtcagg cgaactatgc 131100  
ggcggcgaat gtgtttcttg acgctctggc ccagcaccgc agggcccagg gtctggccgc 131160  
gacctctctt gcgtggggtc tgtgggatga gccggggggc atggcgggcg cgctggacgc 131220  
tgatgatgtg tcgctctg ggcgtggtg tgtcagcgga ctctccgcg gggagggtgt 131280  
ggcgttgttc gacgctgcgt ccgctccga acaggccttg ttcgttccgg tgaagctgga 131340  
cctggccgcc ctgcgtgcc aggcgggcag tgggatgttg ccgccgctgc tcagcggctc 131400

tgtccgtacc cccacccgcc gcgccgcccg gggcggttcg gccgcggggg gaacgttcgc 131460  
ccggaagctg gccggcctcg cgggtggacca gcggtccgca gccgtgatgg agctcgtgcg 131520  
tgctcaggtc gcagccgtgc tcggccttgc cgggcccga gcggtagacc cggcacggtc 131580  
gttcagcgag gtcggcttcg actcgtgac cgccgtcgag ctgcgcaaca ggctcggcgc 131640  
cgcgaccggt gtacgcctcc ccgccaccct cgtcttcgac tacccgacct ccctcgccct 131700  
cgccgacttc ctgggtggcg aactgctcgg cggtcaggaa gcggcagcag ccccgacggc 131760  
cttcacggcc cgggacgacg agccgatcgc gatcgtggcg atgtcttgcc gtttcccccg 131820  
cggcgtgcgg tcgcccgagg atctgtgggg gctggtcctg gacggccggg atgccatctc 131880  
ggacatgccg gacgaccgcg gctgggacgt cgagggaactc ttcgaccccg accccgaccg 131940  
cccgggcacc agctacagca gggcggggcg gttcctgcac gacgcccacc acttcgacct 132000  
gacgttcttc gggatctcgc cgcgcgaggc cctcgccacc gacccccagc agcggctgct 132060  
cctcgaaacc tcgtgggagg cgttcgagcg ggccgggatc gatccggcca ccgtacgcgg 132120  
cagccggacc ggcgtcttcg cgggcgtcat gtacaacgac tacggcacc tctgcaccg 132180  
cgccccggag ggctcgaag gctatatggg cacctccagc tcgggcagcg tcgcctcggg 132240  
ccgggtctcg tacaccttcg gtctggaggg cccggcggtc accgtcgaca cggcctgctc 132300  
gtcctcgctc gtcacctgc acctcgccgt gcaggccctg cgcaacggcg agtgcgacct 132360  
cgcgctggcc ggcggtgtca cggtgatggc cagccccggt acgttcgtcg cgttcagccg 132420  
tcagcgcggc ctcgcgagt acggccgctg caagccgttc gccgcggccg ccgacggtag 132480  
ggcgtggggc gagggcgctg gcatgctgct cgtcgagcgc ctgtcggacg ctcgggccaa 132540  
gggcccaccg gtgctcgcg tggtccgtgg ctcggcgatc aaccaggacg gtgccagcaa 132600  
tggcctgacg gctccgaacg gtccctcgca gcagcgggtg atccgccagg cgctggccag 132660  
tgccggtctg tcggcgggcg atgtggacgt agtggaggcg cacggcaccg gcaccacct 132720  
gggcgaccg atcgaggcg aggcaactct cgccacctac ggtcaggagc acacggacga 132780  
cagcccgtg tggctggggg ccatcaagtc caacttcggt cacacgcagg ccgctgccgg 132840  
tgtcgcgggc atcatcaaga tgggtgcagg gatgcaccac ggggtcgtcc ccaagacgct 132900  
gcacgtggac gagccgtccc cgcacgtgga ctggtcggcg ggcgcggtct cgctcctcac 132960  
cgagcagatg gcctggcccc aaaccggccg tccccgccgc gcggcgattt cttccttcgg 133020  
tatcagcggg accaacgcgc acacgatcat cgagcaggcg ccggaggagt tcgctccggg 133080  
ccgtccggtc cgtgtgatcg agccggaggc ggtgggtgcg ggttcgcggg tgctgccgtt 133140  
cgtgttgtcc gcgaagtcgg cggggggcgtt gcgtggtcag gcggtgcgtc tgaaggcgca 133200  
tgtggaggct tcgccggagg tgtcgggggc cggggctgct gatgtggcgt attcgctggc 133260  
gacgcggcgt gcggtcttcg accaccgtgc ggtgggtggtg gccggtgacc gtgaggagct 133320

gttgctgtgt ctggctgtgt tggagtctga gggcacggcg gctggtgtga cccgtgggac 133380  
ggcgggtggc ggaaagcttg ccttcctgtt cacgggccag gggagccagc ggctggggat 133440  
ggggcgtgag ctgtacgaga cctatcccgt cttcgcgcgg gctctggacg cggcgtgtgc 133500  
tggctctgaa ctgccgtga aggatgcgct gttcggcgcc gatgcgggtc tgctggacga 133560  
gacggcgtac acccagcccc ctctcttcgc ggtcgagggt gcgttgttcc gactgctgga 133620  
gagctgggggt gtgaggcccg acttcctggc cgggcactcg atcggtgaga tcgcggccgc 133680  
gcatgtggcc ggggtgctgt ccctggacga cgcctgtgcg ctggtcgcgg cccgcggccg 133740  
gctcatgcag gcgctgcca ccggcggtgt gatgatcgcc gtccaggcgt cggaggacga 133800  
ggtcctgccg ctgctgaccg accgggtgag catcgccgcg atcaacggtc cgcagtcggg 133860  
cgtgatcgcg ggcgacgagg ccgacgcggg ggcgatcgtg gagtcccttct cgggccgcaa 133920  
gtccaagcgg ctcacggtca gtcatgcgtt ccactcgccg cacatggacg gcatgctggc 133980  
tggcttccgc aagggtggcg agagcctgtc gtacgaggct ccgcgcatcc cggtcgtctc 134040  
gaacctcacc ggggccctgg tcaccgacga gatgggttcg gccgacttct gggtcgggca 134100  
cgttcgcgag gcggtccgtt tcctggacgg tatccggggc ctggaggccg cgggcgtgac 134160  
ggcgtacgtc gaactcggtc ccgacggtgt tctgtcggcg ttggcccagg agtgctcac 134220  
cggcgaggggt gcggccttcg cggccgccct ccgcaagggc cggcccagg cggagacgat 134280  
cacaacggcc ctgcgccctg ccacaaacca cggcacgtcc gtcgactggg agacgtactt 134340  
ctccgggacc ggcgcccagc gcgtcgacct gccacctac gccttcagc gcgagcgcta 134400  
ctggatcgac gtgcccgtcc actccgtcgg cgacgtggcc tccgccggac tcggtgcggc 134460  
ggagcaccgc ctgctgggcg cggccgtcga actgcccagc tccgacgggc tgctgctcac 134520  
cggtcggctg tcgctcctgt cgcaccctg gctggccgat cagccgctc cgggcaccgt 134580  
tctgctcccc gggaccgcct tcgtggagct ggcgctccac gccgggcagc ggggtggcag 134640  
tggcctgctc gaagagctga ccctggaggc gccgctggtg cttcccagc gcggggcgct 134700  
ccagctgcgg gtgtccgtgg ccgcgcccga cgaggcgggg cgtcgtgcgc tgcacgtgca 134760  
ctcgcgtccc gaggacctgg gcggcgagga ccgtacgggg cagaggtgc cgtggacgcg 134820  
gcacgccggc ggtgtgctcg ccgcgccgga ggcggccggg gccgcgccgg aggagtccgg 134880  
cctggacgtc tggccgcccg cggacgccga accgctcgat gccggcgacc tgtacgaccg 134940  
gttcgccgag ggcgggttcg cgtacgggtc tgtcttcgc aacctgcgc ctgcctggcg 135000  
gcgcggcgac gagctgttcg ccgaactgct cctgcccag gggcagctcg cccaggccgg 135060  
ccacttcggg gtgcaccggc cgctgctgga cgcgggtctg cagggcctcg cgctcggctc 135120  
gttccatgac ggtgcggacg aggaccccc gatccggctc ccgttctcct tcagcgggtg 135180

cgctctgcac tcggtcggcg cgggctcgtt gcgcgtacgg ctcgccccgg ccgggtccgg 135240  
cgcggtgtcg ctcgcggcct tcgacgagca gggcgaccgg gtcgtgtcgg tggaatcact 135300  
gctgctgcgg gcggtggatc cggcacggct gaaggccgcg gaacagccgg tgttccacga 135360  
gtcgctcttc cggctggagt ggccggcgct ggccgcgggc ccgcgtacgg acaacgcccc 135420  
cggggacggc ggccggtggg ccgtggtcgg ggccgactcg ctcggccttg aggccgggct 135480  
gcgggcggac ggcgtcgccg tcgacgggta cgcggaacctg tccgcgctcg ccggagtcgt 135540  
ggccgcgggc aagccgcagc cggacacggg gctggtctcg tacgcctcct cgggtccccg 135600  
catcaggacg gcggacgccg ttcggcaggc ggctcacgac gcgctggagc tgggtccagg 135660  
ctggctcgcc gaggagtgcg tcgccgggtc acgactggtc gtggtcaccg gcggcgcggt 135720  
cgaggcgcgg cccggcgagg gcgtgcccga tctggcgcac gcggcggtgt ggggcctgct 135780  
gcgggtccg cgagtcgaga accccgggcg gttcgtactg ctcgacctcg acgcggaaga 135840  
cgcgagggtc ctggctccgc tgatggccgc cgctgtggcg agcggggaac ccagctcgc 135900  
cgcccgcgag ggcgtcctgc atgccgcgag gctggcacgg gttcccgcgg cccccaccgc 135960  
ggtggcgggc acggagcgcg cgcccgccct cgaccccgac ggtacgggtc tcatcaccgg 136020  
cggcaccgga tcgctcggca gcctgctggc ccgccacctg gtcgtggagc acggcgtagc 136080  
gcacctgctg ctgaccagcc ggcgcggtgc cgcccgcgag ggcgccccgg aactcgctgc 136140  
cgcaactggc gaactgggcg ccgagggcgac cgtcgcccgc tgtgacggcg ccgaccggga 136200  
ggcgctggcc gcgctgctgg ccggcattec ggccgcgcac cccctcacgg ccgtcgctca 136260  
cacggcgggc cggtcgacg acgggctcct gggtcgctc agcccgagc ggatcgacac 136320  
ggtgctgctg cccaaggccg acggggcgct gcactctgac gagctgacct gcgggctgga 136380  
cctcgccgcg ttcgtcctgt tctcctccgc ggccgggaacc ctcggaacc ccggccaggc 136440  
caactacgcg gcggccaacg ccttcctgga cgccctggca cagcaccggc gcgcggcggg 136500  
gctgcccggg gtgtcgctgg cctgggggct gtgggagcag cgagcgcgga tgaccggagc 136560  
gctgtcggac gcggacgtcc agcggtggc acgcgcggga ctcgcgcccc tctcctcggc 136620  
ggagggcctg gccctcttcg acacggcggt cgccctcgcg ccggtgggcg ccacggagac 136680  
cgccaccggc gacggagcgt tcgtcgccat gcggctggac accgcgcccc tgcggggcca 136740  
ggcggaacgc ggagcccttc cggcggtctt ccgcgggctg gtgcgcggag gtcctcgag 136800  
ggccgcccga catcaggccg ccgattcggc ggcattcact gccgcgcgaa agctcgcggg 136860  
cctgtccggg ctgccgcagg acgagcagga gcgcgtgctg ctcgacctgg tgcgcgcca 136920  
ggtggccgccc gtactcgctt atccgtcgcc ggacgcgggtg ggggagtcgc aggagtctct 136980  
ggagctgggt ctggactcgc tgaccgccgt cgagctgcgc aaccagctga acgcggcgac 137040  
cggcctgagg ctgcccgcca ccctgctctt cgaccacccc actcccgcg tggtcgccga 137100

gcggctgcgc gccgaactcg ccggagcctc cggcccggcg gcggtccggg agggcgcggc 137160  
ggacagcggc gcggagggct ccgcgggtgt cttcggggcc atgctccacg aggccggaac 137220  
gcaggggtgcg tccgggcagt tcatggagct gctcatgcag gcgtcgcggt tccggccgtc 137280  
gttcgcctcg gcggccgagc tgcgcaaggc gccgagcctc gtgcggctct cccgcgggtga 137340  
caccgggccg ggactgggtct gtttctcctc gatcctgtcg atctcgggcc cgcaccagta 137400  
cgcgcgcttc gcctccgcgt tccggggccg ccgggacgtg cacgcgctcg gtgcccccg 137460  
cttctcgcg ggcgagcagc tgccctcggc caccgacgcg gtgatcgagg cccaggcgga 137520  
ggccgtgctc cggcacgcgg acgggtgcgc gttcgtcctc ctcgccact cctcggggcg 137580  
catgctcgcc cacgcgggtg ccgggaggct ggagagcgag ggggtcttcc cccaggcgct 137640  
ggtgatgatc gacatctact cgcacgacga cgacgcgatc atcggcatcc agcccggcct 137700  
ctccgagggg atggacgagc ggcaggacac ctacgtaccg gtcgacgaca accggctgct 137760  
ggcgatgggc gcgtacttcc ggctgttcgg aggctggaag cccgaggtgg tgaagacgcc 137820  
gaccctgctg gtccgggcgg gtgagcgggt cttcgactgg acccgggtcca cggacggcga 137880  
ctggcgttcg tactgggacc tggaccacac ggccctggac gtgccgggca accacttcac 137940  
catgatggag gagcacgctc cgacgaccgc acaggccgtc gaggggtggc tggacacgac 138000  
cggctgacac caccggctga cggcgccgga cagcgacatg gccgggcgtc aagcgtcaga 138060  
cgtcaggcga cgcgcttctc acgctcgcgg gagcgcttct tcggcagccc caccgtcacg 138120  
acctcgaagc tgtccttggg gaggtcgagg cgggtggaaga ggttgtcggg cccggtcacg 138180  
cacaccgtgc ccacgccgag ccccttgagg gactccacca cgcccgcca gtggacgggc 138240  
cggtcgaagg tgtccagcat catcgtgcgc atcccggcg cgccccggac gaccccgccg 138300  
tcctggtcgt tgaccacggg cagggtgggg tcggccagtt cgtacgcggc gaagacctct 138360  
tcctccgctc tgccggcgag cgccgagaag gccgcgcgt gcacgggcgg gcgcacgag 138420  
tacatggagt agccgccgac cgcgtgatg cccgccttca gcccgccag ctcttctcc 138480  
tgtacggaca ccatgtggaa agcggcgctc agccgcccgg agatgtcgta ccaggcaccg 138540  
cggtcgtcga agccggccag gatctcgtcc agccggctct gcgggggtgcg gacgaagcag 138600  
tgcgtagcga cgtcctggta cgcgtcggcg aagtactcct cctcgcagcg ggccagctcc 138660  
gcggtagacc ggacgacgtc cgcgaagggc agcgaccca cgaaagcgga ggcggccttc 138720  
tgcccgaaac tcgggcccgc gcagacggtg ggagagatgc cgagcgcgtc caccgcccgg 138780  
tcggccatag ccatcgaatt caccaggaag gcgatctgcg aatagaccga gtagtcgtcc 138840  
tcggaggtgc ggaaacggtc gaacaccgaa tatccgagcg cctcgtctgc ctccgcgagg 138900  
cgccggcgcg cgtaagggtc gagcagcagg aactttccga cctccgcgaa ggacgagggg 138960

cccataaccgg gaaagacgat cgccgtctcg gtcgagggag tctgctcgga gtcgaagccg 139020  
gagttgaagc cggagtcgga gccggaacgg gagtcggaac gggaatcaga agtgggtcatg 139080  
atccgtgaat gcctttgctt ccggggacgg caccggcagg cacctgccgc cgtcacgaac 139140  
gtaggaacgg ccccgacccc ggccggacgc gaatgcgccg agccggggcac gaggccagga 139200  
gggacgagag gggggagacg agagagggga gaccagacgg ggcagcgcgc gctcagtcct 139260  
gcgcctcagt cctgcgccct gcggtggaac cccttgatgc cgatcagccc gaagaccacg 139320  
atcgccccgc tcagggcgag cagatcgatc cacagcggaa tcgagccggg gccgcccggc 139380  
ggcagcagca gggcgcggtat cccctcgctg acgtaggatca gcgggttgat ggcgcacagc 139440  
acctggaacc agcggatgtc cgccaggctg tgccagggga actgggtgca gccggtgaac 139500  
atcagcgggg tcagcgtcac ggcgaagatg acgctgatgt gccgcggcgg gccagcgtg 139560  
ccgatggtca gaccacccgt gctgcccgc agcgcgcccg tcagcagcac gccagcgtg 139620  
ggcaggaagc tgtccatcgg ccaggacacg tcgtcgagga tcaggaagcc gacggggatc 139680  
atcaccagtg aggcgatgat gccgcgcagc gccccgaaga ccagcttctc gacggccacc 139740  
aggctggtgg ggatgggagc gaggagccgg tcctcgatct ccttggtcca ggagaagtcg 139800  
atgaccaggg gcagcgcggt gttctgcagg ctgaccagga agctggtgag cgcgaccacg 139860  
cccgaggagca ggatctgctg gaacccgcgg ccggtgtaac cgagtctgcc gaggaacctg 139920  
ccgaagacga acaggatgaa gaacggttcc acgagcacct gggcgaggaa cgggcccagt 139980  
tcgcggccgg tgacgaagat gtcccgccac aggatgaaga agaacgtgcg ggtcgcggtg 140040  
cgcacgtcgg tgcgcgcggg ccgcagttcg gccgggaagt cggtgaccgg gtcgggtgcg 140100  
gtcaggggtg ccgtcatcgc agtcccggc cggtgagctt gatgaagacg tcctccaggg 140160  
tcgcggttcc gacgctcacg tccttgatgt cgtgactcgc ttccgtcagg gccgtgatgg 140220  
cggtcggcag caccgcgccg gacggcgctg cgtgtagag gcggagccgt accggcgcg 140280  
gcgcgcgcc ctgctccttg gcgtgttct ggtgtgccag ctcgaccgcg tcgaccgtct 140340  
cgatccgctc cagcaggcgt acgacgctct cggcgtcgtg ccccgcgggc tggacggtga 140400  
gggtgagggc ggtgctgctc aggctccggg tcagcgccctg cggggtgctg agggccagca 140460  
gtcggccgtg gtcgacgatg ccgacgcggt cgcagagctt ggcggcttcg tccatgtcgt 140520  
gcgtggtcag cacggtggtc accccgcgt tgctcagctc ggccacgcgc tcgtggatga 140580  
acagccgtgc ctgcggatcg agtccgggtg cgggctcgtc gaggaagagc acgtcggggc 140640  
ggtgcatcag ggcccgggag atcatcacgc gctgggcctg gccgcggag agttcgtcgc 140700  
cgcgggcctt gcccgggtcg gcgagacca cccactccag gcaactcgtc gcgagccgtc 140760  
cgcgttcgga gcggctcatg ccgtgatagc cggcgtggaa ggtcaggttc tgccggaggg 140820  
tcagcgaccg gtcgaggttg ttgcgctgcg gtacgacggc gaaggcccgg cgcgcctggg 140880

cggggtgggc cacgacgtcg acgccctgga cgaacgctcg ccccgccgtg ggggccacgc 140940  
gggtggtgag gatgccgatg gtcgtcgtct tccccgcccc gttcgggccg aggaatccga 141000  
agacctcgcc cctgcggacc gagaagctca ggtcgtccac cgctggtcgg tcgcggctcc 141060  
ggtactttctt gactagtccg tcgaccacga cggcggaatc cacgggtcgt tcagagttca 141120  
tttacgcctg cgaatcaagc gggacgcggc gacggcagtc cgggggattc gcacaggaat 141180  
gtcgcgtgac cggccgcgcg tcgagcgcgc actgaatagg gcataggagt ggtgcggaat 141240  
ctttctagcg cgcaggacgg cgcgttgccc caactggcca atcggttagg gggagatgcg 141300  
gaatcctagg gggggatagg gggtagggcg gcgaatcggg gccatttggg ggtgctggtc 141360  
ggacaacccc tattcgaaag gatccggggg ggcgagtgtt gcggttccgt cgaatgtcct 141420  
catagcatcg gcgcgtgatc gcgccgaatt attcttcgca aaaaagagcg tcggcgggtc 141480  
gtgtgtccgc gggctttggg gtggaacccg ggtcgcgtcg gtggatggtg atcggcgcga 141540  
cgggcatgct cggcggcgaa gtggccgccc agctcacggc ccggggcgcc gacccggtgg 141600  
gggtcggcag tgcggatctg gacctaccg acccgcaggc ggtcgcgcg gccgtggccg 141660  
acggcggccc cgatgtcgtc gtcaactgcg ccgcctggac cgccgtggac ctggccgaga 141720  
ccgaggagga ggcggccctc gccgtcaacg ggacgggagc gggccacctc gcccgggcct 141780  
gcgccgccac cggcagccgg ctctccacg tctccaccga ctacgtcttc cgaggtgccc 141840  
cggccgatgc cggacacccc tatgcggagg acgccgaacc cgaccccgcc accgcgtacg 141900  
gacgcaccaa gtcgtcggc gagcgcgcg tcctcgccga actccccgcc accgctgccg 141960  
tggtgcgcac gtcctggctg tacggacgcg acaacggcgg cttcgtgcac accatggccc 142020  
ggctcgcgcg cgagccggga cgcaccgtgg acgtggtcga cgaccagcac ggacagccga 142080  
gctggacccc cgatgtcgcg gcccgatca tcgagctcgc cgccctgccc gccgaccggg 142140  
cgcacggcgt cttccatgcc accggcgggg gccgcaccac ctggtacgac ctggcccgcg 142200  
aggtgttccg gctgaccggc caggaccgg accgggtccg gcgcatcgac agtccgggc 142260  
tgcgacgggc ggcggtccgc ccggcatgga gcgttctggg ccatgaccgc tgggccgcca 142320  
cggggctcgc cccgatgct cactggcgca cggccctcgc ggacgccctc atgggagacc 142380  
ccgtgggcga ccgacttccc gagagtgtga actccccgg cccgaaaggc tggtgaaggg 142440  
tgaaatccct gtcgatagag ggcgcctggc tctatgagcc gctgctccac gacgatgagc 142500  
gcggcacgtt cctggaggtg ttccagagcc aggccttcga gctggccacc ggccgccgcc 142560  
tcgaactggc ccaggtcaac tgctccgtgt cccgcgcgg cgctcgtcgc ggctccact 142620  
tcgccgactt accgcccggc caggccaagt acgtcacctg cgtacgcggc gcggtgcgcg 142680  
atgtgatcgt ggacctgcgc accggctcgc ccacctaccg cgcctgggag gccgtcgaac 142740



tcgacgaccg cgaccggcgg gcggtcttcc tctccgaggg cctcggccac gccttccagg 142800  
cgatcaccga cgacgccacc gtcgtctacc tgaccacctc gggctacgcc cccggccgtg 142860  
agcacggcgt ccaccgctc gaccgggagc tgggcatcac ctggcttccc ggcattggaac 142920  
cgctgctgtc cccgaaggac gctgtcgccc ccaccctcgc ggtggccgag gccagggtc 142980  
tgctgccccg gtacgaggac tgcgtacggc acgtgtcctc gctcgccaca ccaactcagcg 143040  
aggagacccc gtgaaggcac tcgtcctggc ggggggatcc ggcacccgcc tgcgccccct 143100  
gaccacacc tcggcgaagc aactcgtgcc cgggtggcaa caaacccatc ctcttctacg 143160  
tcctggaagg gatcgccgac gcgggcgtca ccgatgtcgg catcatcgtc ggcgacacgg 143220  
ccgacgagat cagggcgggc gtcggcgacg gctcccgctt cggcatcagc gtcacctaca 143280  
tcccgcagca ccagccgctc ggcctggccc acgccgtgcg catcgacagg gactggctcg 143340  
gcgaggacga ctctgtgatg tacctggggc acaacttctt gctcggcggg atcagcgagc 143400  
agctggagga gttccgcacc cggcgggccc ccgcgcagat catgctcacc cgggtccccg 143460  
atccctccgc ctctggcgctc gtcaccctcg acgaggcggg ccgggtcacc ggcctggagg 143520  
agaagccgaa gttccccaag agcgatctcg cgttggtcgg cgtgtacttc ttcaccgccg 143580  
ccgtgcacga cgccgtggac gccatccagc cctccgcccc cggcgagctg gagatcaccg 143640  
aggccctcca gtggctcctc gacaagggcc tcggcatcgc gtcctccacg gtcaacggct 143700  
actggaagga caccggcaac gccaccgaca tgctggaggc caaccgcacg gtgctcgaca 143760  
ggctgacccc gtactgcgac ggctccgtcg acggcgagag cgaactggtc ggccgggtcg 143820  
tcgtcgagga cggcgcggtg atcaccgct cccggatcgt gggccccgcc atcatcggcc 143880  
gcggcaccgc cgtcgagggc tcctacatcg gccogttcac ctccgtcggg gcggactgcg 143940  
tggtcgtcga cagcgagatc gactactcca tcgtgctggc cggcgcgggc atcgacggcg 144000  
tcggccggat cgaggcgctc atgatcggc gtcaggcgca ggtaaccccc gcgccccgca 144060  
cgccccaggc ccaccgtctg atcctcggcg accacagcaa ggtgcagatc cgttcatgaa 144120  
catcctgac acgggagcgg ccggcttcat cggctcccac ctcgtaacga cgatcctggg 144180  
cccggacaaa ccgctegggc acgacgtccg cgtcaccgtc ctggacgcgc tgacctacgc 144240  
gggcaaccgc gcctccctcg ccgcgctga ggacgaaccg ggcttcacct tcgtgcacgg 144300  
cgacatcacc gacgcgctgc tgggtggacc cctggtggcg gccacgacg ccgtgggtgca 144360  
cctggccgcc gagtcgcacg tcgaccgttc gatctggcgg gccgacgcgt tcgtacgcac 144420  
caatgtgctc ggcaccacaca ccctgtgga ggccgcgctg cggcacggca ccggcccgtt 144480  
cgtgcacgtg tcgaccgacg aggtgtacgg ctcggtcccc gtcggctcgt ccgtcgagag 144540  
cgacccgctg acgcccagct cgcctactc cgcgtccaag gcgtccagt atctgctggc 144600  
cctggccctac caccacaccc acggactcga cctggcggtg acgcgctgct ccaacaacta 144660